var images_info;if (!images_info) images_info =[]; images_info["71"]={"71000":{"type":"graphic_figure","displayName":"Etiologies of angioedema in referral populations","title":"Etiologies of angioedema in referral populations","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Etiologies of angioedema in referral populations</div><div class=\"cntnt\"><img style=\"width:512px; height:514px;\" src=\"images/ALLRG/71000_Etiologies_of_AE_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE inhibitor: angiotensin-converting enzyme inhibitor.</div><div class=\"graphic_reference\">Data from: Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175:1065.</div><div id=\"graphicVersion\">Graphic 71000 Version 5.0</div></div></div>"},"71002":{"type":"graphic_diagnosticimage","displayName":"Intraoperative cholangiogram of possible bile duct injury","title":"Intraoperative cholangiogram of possible bile duct injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraoperative cholangiogram of possible bile duct injury</div><div class=\"cntnt\"><img style=\"width:286px; height:432px;\" src=\"images/SURG/71002_Intraop_cholangiogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative cholangiogram shows filling of distal bile duct with flow into the duodenum. The lack of retrograde flow into the proximal biliary tree is concerning. A clip may be present occluding the bile duct proximally.</div><div id=\"graphicVersion\">Graphic 71002 Version 3.0</div></div></div>"},"71003":{"type":"graphic_table","displayName":"JSGE classification of endoluminal cancers","title":"Japanese Society for Gastroenterological Endoscopy classification system of early endoluminal cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Japanese Society for Gastroenterological Endoscopy classification system of early endoluminal cancers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Subclasses</td> </tr> <tr> <td rowspan=\"3\"><strong>I: Polypoid/protuberant</strong></td> <td>Ip: Pedunculated</td> </tr> <tr> <td>Ips/sp: Subpedunculated</td> </tr> <tr> <td>Is: Sessile</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>II: Flat</strong></td> <td>IIa: Superficial elevated</td> </tr> <tr> <td>IIb: Flat</td> </tr> <tr> <td>IIc: Flat depressed</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>III: Ulcerated</strong></td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>IV: Lateral spreading tumor</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer 1998; 1:10.</div><div id=\"graphicVersion\">Graphic 71003 Version 2.0</div></div></div>"},"71005":{"type":"graphic_figure","displayName":"Impaired bilirubin excretion","title":"Diseases and their histopathologic sites of interference with hepatobiliary excretion of bilirubin","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Diseases and their histopathologic sites of interference with hepatobiliary excretion of bilirubin</div><div class=\"cntnt\"><img style=\"width:544px; height:453px;\" src=\"images/GAST/71005_Impaired_bilirubin_excretio.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71005 Version 2.0</div></div></div>"},"71008":{"type":"graphic_diagnosticimage","displayName":"Mixed type2 CPAM","title":"Mixed Type II CPAM at 21 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Mixed Type II CPAM at 21 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:478px; height:441px;\" src=\"images/OBGYN/71008_Mixed_type2_CPAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and sagittal (B) ultrasound images of the chest demonstrate a large right chest mass containing multiple macro and microcysts displacing the heart to the left (arrow) and everting the diaphragm inferiorly. Axial (C) MR image demonstrates marked deviation of the heart to the left (arrow). Coronal (D) MRI demonstrates minimal residual normal lung in the left upper lobe (arrow). No systemic feeding vessel and no hydrops appreciated. CVR was 2.4, consistent with high risk for hydrops.</div><div class=\"graphic_footnotes\">CPAM: congenital pulmonary airway malformation; MRI: magnetic resonance image; CVR: congenital pulmonary airway malformation volume ratio.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 71008 Version 3.0</div></div></div>"},"71010":{"type":"graphic_picture","displayName":"Pleomorphic adenoma Light","title":"Pleomorphic adenoma of salivary gland","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Pleomorphic adenoma of salivary gland</div><div class=\"cntnt\"><img style=\"width:565px; height:265px;\" src=\"images/ONC/71010_Pleomorphic_adenoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel demonstrates a low power view of a well circumscribed tumor surrounded by a fibrous capsule and adjacent serous salivary gland. The right panel demonstrates the epithelial and myoepithelial components. The myxoid stroma (arrow) contains myoepithelial cells that have separated from the main epithelial nests. Occasional chondroid metaplasia may be seen in the stroma.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 71010 Version 4.0</div></div></div>"},"71011":{"type":"graphic_diagnosticimage","displayName":"Anterior anal sphincter damage","title":"Anterior anal sphincter damage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior anal sphincter damage</div><div class=\"cntnt\"><img style=\"width:360px; height:342px;\" src=\"images/GAST/71011_Obstetrical_damage_anal_sph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anal ultrasound scan of a woman with anterior sphincter damage due to obstetrical complications. The top of the figure is anterior. There is disruption of the muscles of both the internal anal sphincter (small arrows) and the external anal sphincter (large arrows).</div><div id=\"graphicVersion\">Graphic 71011 Version 2.0</div></div></div>"},"71013":{"type":"graphic_diagnosticimage","displayName":"RML atelectasis CT","title":"CT scan of right middle lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of right middle lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:429px; height:288px;\" src=\"images/PULM/71013_RML_atelectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The collapsed right middle lobe has a characteristic configuration on CT scan: it has the shape of a triangle abutting the right aspect of the cardiac silhouette (arrow). The appearance has been compared to an ice cream cone, the collapsed lobe representing the cone and the cardiac silhouette the ice cream.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71013 Version 3.0</div></div></div>"},"71014":{"type":"graphic_figure","displayName":"Estimated mortality rate from fire","title":"Estimated mortality rates from fire-related injuries in 2010 by development category and income","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Estimated mortality rates from fire-related injuries in 2010 by development category and income</div><div class=\"cntnt\"><img style=\"width:510px; height:434px;\" src=\"images/SURG/71014_Burns_epi_mort_IC.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Graph based on data from the Global Burden of Disease 2010 study. Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington, 2012. Available at: <a href=\"http://viz.healthmetricsandevaluation.org/gbd-compare/\" target=\"_blank\">http://viz.healthmetricsandevaluation.org/gbd-compare/</a> (Accessed on July 1, 2013). Copyright &copy; 2012. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 71014 Version 2.0</div></div></div>"},"71015":{"type":"graphic_diagnosticimage","displayName":"Humerus fracture","title":"Humerus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Humerus fracture</div><div class=\"cntnt\"><img style=\"width:349px; height:576px;\" src=\"images/SURG/71015_Humerus_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of a comminuted humerus fracture.</div><div id=\"graphicVersion\">Graphic 71015 Version 3.0</div></div></div>"},"71016":{"type":"graphic_figure","displayName":"Ileocolic anastomosis and linear cutting stapler","title":"Ileocolic functional end-to-end anastomosis and linear cutting stapler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolic functional end-to-end anastomosis and linear cutting stapler</div><div class=\"cntnt\"><img style=\"width:377px; height:370px;\" src=\"images/SURG/71016_Ileocolic-anastomosis-linear-cutting-stapler.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71016 Version 2.0</div></div></div>"},"71018":{"type":"graphic_algorithm","displayName":"Approach to metabolic myopathy","title":"Algorithm for the diagnosis of metabolic myopathies","html":"<div class=\"graphic\"><div style=\"width: 1290px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of metabolic myopathies</div><div class=\"cntnt\"><img style=\"width:1270px; height:846px;\" src=\"images/PEDS/71018_Approach_metabolic_myopathy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with signs that raise the possibility of a metabolic myopathy, the constellation of clinical and laboratory features and the type of exercise inducing the symptoms may indicate the nature of the underlying biochemical defect and thus narrow down the laboratory investigation.</div><div class=\"graphic_footnotes\">CNS: central nervous system; PNS: peripheral nervous system; NGS: next-generation sequencing.</div><div id=\"graphicVersion\">Graphic 71018 Version 4.0</div></div></div>"},"71019":{"type":"graphic_algorithm","displayName":"Ischemic preconditioning","title":"Ischemic preconditioning","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Ischemic preconditioning</div><div class=\"cntnt\"><img style=\"width:529px; height:475px;\" src=\"images/CARD/71019_Ischemic_precondition.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The schematic provides a simplified overview of the potential mechanistic pathways underlying ischemic preconditioning (IPC) and postconditioning (IPost) which link the sarcolemma to the inhibition of the mitochondrial permeability transition pore (MPTP): (1) Indirect MPTP inhibition (shaded or blue): include those mechanisms that result in MPTP inhibition as an indirect effect of IPC and IPost on factors known to induce MPTP opening at the time of myocardial reperfusion, such as attenuating detrimental reactive oxygen species (ROS) production, preserving ATP levels, delaying pH correction at reperfusion and delaying restoration of physiological pH at reperfusion, and reducing mitochondrial and cytosolic calcium loading: and (2) Direct mPTP inhibition (unshaded or beige): those mechanisms that depend on a signal transduction pathway that begins at the cardiomyocyte plasma membrane with the activation of the G-protein coupled receptor by an autocoid such as adenosine, bradykinin, or opioids, which result in the recruitment of complex signal transduction pathways (for the sake of clarity only PI3K-Akt and MEK1/2-Erk1/2 pathways are shown on this diagram although a number of different signaling pathways have been implicated in both IPC and IPost) which terminate on the mitochondria and involve in some cases the translocation of protein kinases to the mitochondria. Clearly, there is a degree of overlap between these two groups- for example; both PKG and PI3K-Akt have been reported to influence intracellular calcium regulation by promoting the uptake of calcium via SERCA into the sarcoplasmic reticulum.</div><div class=\"graphic_reference\">Reproduced from: Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009; 104:189; with kind permission from Springer Science + Business Media B.V. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 71019 Version 3.0</div></div></div>"},"71020":{"type":"graphic_picture","displayName":"Venous stasis ulcer","title":"Venous stasis ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Venous stasis ulcer</div><div class=\"cntnt\"><img style=\"width:214px; height:271px;\" src=\"images/PC/71020_Venous_stasis_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large venous ulcer on the medial ankle in a patient with chronic venous stasis. The ulcer is shallow and red-based with irregular borders.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 71020 Version 1.0</div></div></div>"},"71021":{"type":"graphic_table","displayName":"Dx asbestos disease B","title":"Criteria for diagnosis of nonmalignant lung disease related to asbestos","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for diagnosis of nonmalignant lung disease related to asbestos</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">1986 Guidelines</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Rule out other causes of interstitial fibrosis or obstructive disease</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>\"Evidence of abnormal test\"</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Crackles, bilateral, not cleared by cough</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Restrictive disease</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Reduced diffusing capacity</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">2004 Guidelines</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Exclusion of alternative diagnoses</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Evidence of functional impairment, as demonstrated by one or more of the of following:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Signs and symptoms (including crackles)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Change in ventilatory function (restrictive, obstructive patterns in context or disease history)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Impaired gas exchange (eg, reduced diffusing capacity)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Inflammation (eg, by bronchoalveolar lavage)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Exercise testing</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Comparison and notes</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>The 1986 guidelines primarily addressed asbestosis but mentioned smoking as a cause of obstructive disease. Implicit in the article, however, is that nonmalignant diseases presenting similarly to asbestos-related disease should also be ruled out.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Functional assessment is not required for diagnosis but is part of a complete evaluation. It contributes to diagnosis in defining the activity of disease and the resulting impairment.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Signs and symptoms are not specific for diagnosis but are valuable in assessing impairment.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>The 1986 criteria admitted the possibility of obstructive disease; the 2004 criteria address this specifically.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>The 1986 guidelines noted possible utility of bronchoalveolar lavage and gallium scanning but considered them to be experimental techniques. The 2004 guidelines exclude gallium scanning, suggest that additional indicators of active inflammation may become useful in future.</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 71021 Version 1.0</div></div></div>"},"71022":{"type":"graphic_figure","displayName":"Hemorrhage during extraction","title":"Potential complications of foreign body extraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential complications of foreign body extraction</div><div class=\"cntnt\"><img style=\"width:314px; height:296px;\" src=\"images/PULM/71022_Hemorrhage_during_extractio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhage complicating the extraction of a foreign body encased in bulky and friable inflammatory tissue.</div><div id=\"graphicVersion\">Graphic 71022 Version 1.0</div></div></div>"},"71024":{"type":"graphic_table","displayName":"Chronic HBV dose adjustment","title":"Adjustment of adult dose of nucleos(t)ide analogues for treatment of chronic hepatitis B in accordance with creatinine clearance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjustment of adult dose of nucleos(t)ide analogues for treatment of chronic hepatitis B in accordance with creatinine clearance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Creatinine clearance (mL/min)*</td> <td class=\"subtitle1\">Recommended oral dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Entecavir<sup>&#182;</sup> (nucleoside)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>NA treatment na&#239;ve</strong></td> </tr> <tr> <td class=\"indent2\">&#8805;50</td> <td>0.5 mg daily</td> </tr> <tr> <td class=\"indent2\">30 to 49</td> <td>0.25 mg daily or 0.5 mg every 48 hours</td> </tr> <tr> <td class=\"indent2\">10 to 29</td> <td>0.15 mg daily or 0.5 mg every 72 hours</td> </tr> <tr> <td class=\"indent2\">&#60;10 or hemodialysis<sup>&#916;</sup> or continuous ambulatory peritoneal dialysis</td> <td>0.05 mg daily or 0.5 mg every 7 days</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Lamivudine refractory/resistant</strong></td> </tr> <tr> <td class=\"indent2\">&#8805;50</td> <td>1 mg daily</td> </tr> <tr> <td class=\"indent2\">30 to 49</td> <td>0.5 mg daily or 1 mg every 48 hours</td> </tr> <tr> <td class=\"indent2\">10 to 29</td> <td>0.3 mg daily or 1 mg every 72 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">&#60;10 or hemodialysis<sup>&#916;</sup> or continuous ambulatory peritoneal dialysis</td> <td>0.1 mg daily or 1 mg every 7 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tenofovir disoproxil fumarate (TDF, nucleotide)</td> </tr> <tr> <td class=\"indent1\">&#8805;50</td> <td>300 mg daily</td> </tr> <tr> <td class=\"indent1\">30 to 49</td> <td>300 mg every 48 hours</td> </tr> <tr> <td class=\"indent1\">10 to 29</td> <td>300 mg every 72 to 96 hours</td> </tr> <tr> <td class=\"indent1\">&#60;10 with hemodialysis<sup>&#916;</sup></td> <td>300 mg once a week or after a total of approximately 12 hours of dialysis</td> </tr> <tr> <td class=\"indent1\">&#60;10 without dialysis</td> <td>Insufficient data; no recommendation<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Continuous ambulatory peritoneal dialysis</td> <td>Insufficient data; no recommendation<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tenofovir alafenamide (TAF, nucleotide)</td> </tr> <tr> <td class=\"indent1\">&#62;15</td> <td>25 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#60;15 or end-stage renal disease or dialysis</td> <td>Insufficient data; no recommendation<sup>​&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lamivudine (3TC, nucleoside)</td> </tr> <tr> <td class=\"indent1\">&#8805;50</td> <td>100 mg daily</td> </tr> <tr> <td class=\"indent1\">30 to 49</td> <td>100 mg first dose, then 50 mg daily</td> </tr> <tr> <td class=\"indent1\">15 to 29</td> <td>100 mg first dose, then 25 mg daily</td> </tr> <tr> <td class=\"indent1\">5 to 14</td> <td>35 mg first dose, then 15 mg daily</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#60;5 or hemodialysis<sup>&#916;</sup>&nbsp;or continuous ambulatory peritoneal dialysis</td> <td>35 mg first dose, then 10 mg daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Adefovir dipivoxil (nucleotide)</td> </tr> <tr> <td class=\"indent1\">&#8805;50</td> <td>10 mg daily</td> </tr> <tr> <td class=\"indent1\">30 to 49</td> <td>10 mg every 48 hours</td> </tr> <tr> <td class=\"indent1\">10 to 29</td> <td>10 mg every 72 hours</td> </tr> <tr> <td class=\"indent1\">&#60;10 (not receiving hemodialysis)</td> <td>Insufficient data; no recommendation<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Hemodialysis</td> <td>10 mg every&nbsp;seven days following dialysis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Continuous ambulatory peritoneal dialysis</td> <td>Insufficient data; no recommendation<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Telbivudine (LdT, nucleoside)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">&#8805;50</td> <td>600 mg daily</td> </tr> <tr> <td class=\"indent1\">30 to 49</td> <td>600 hours mg every 48 hours</td> </tr> <tr> <td class=\"indent1\">10 to 29 (not receiving hemodialysis)</td> <td>600 mg every 72 hours</td> </tr> <tr> <td class=\"indent1\">Hemodialysis</td> <td>600 mg every 96 hours following dialysis<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Continuous ambulatory peritoneal dialysis</td> <td>Insufficient data; no recommendation<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses are for patients without HIV coinfection.</div><div class=\"graphic_footnotes\">NA: nucleoside or nucleotide analogue.<br />* Can be estimated by using the Cockroft-Gault equation. Separate calculators for creatinine clearance using conventional and SI units are available in UpToDate.<br />¶ For doses &lt;0.5 mg, entecavir oral solution is recommended.<br />Δ Administer after intermittent hemodialysis.<br /><FONT class=lozenge>◊</FONT> Data establishing the safety, efficacy, and optimal dosing in end-stage renal disease (with or without dialysis) are not available.<br />§ Discontinued in the United States; may be available in other countries.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan; 63:261.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 71024 Version 19.0</div></div></div>"},"71028":{"type":"graphic_table","displayName":"Travel tips PI","title":"Tips to avoid lower leg swelling and deep vein thrombosis during prolonged travel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips to avoid lower leg swelling and deep vein thrombosis during prolonged travel</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">All travelers should consider the following recommendations for flights longer than six to eight hours:</td> </tr> <tr> <td> <ul> <li>Stand up and walk around every hour or two </li> </ul> </td> </tr> <tr> <td> <ul> <li>Wear loose-fitting, comfortable clothing </li> </ul> </td> </tr> <tr> <td> <ul> <li>Flex and extend the ankles and knees periodically, avoid crossing the legs, and change positions frequently while seated </li> </ul> </td> </tr> <tr> <td> <ul> <li>Consider wearing knee-high compression stockings </li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid medications (eg, sedatives, sleeping pills) or alcohol, which could impair your ability to get up and move around </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71028 Version 7.0</div></div></div>"},"71031":{"type":"graphic_picture","displayName":"Normal physiologic cupping","title":"Normal physiologic cupping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal physiologic cupping</div><div class=\"cntnt\"><img style=\"width:360px; height:285px;\" src=\"images/PEDS/71031_Normal_physiologic_cupping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal physiologic cupping in a large optic disc. Cup:disc ratio is 0.6.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 71031 Version 1.0</div></div></div>"},"71032":{"type":"graphic_table","displayName":"WHO vitamin mix","title":"Composition of vitamin mix","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of vitamin mix</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vitamin</td> <td class=\"subtitle1\">Amount per litre of liquid diet</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Water-soluble</td> </tr> <tr> <td class=\"indent1\">Thiamine (vitamin B1)</td> <td>0.7 mg</td> </tr> <tr> <td class=\"indent1\">Riboflavin (vitamin B2)</td> <td>2 mg</td> </tr> <tr> <td class=\"indent1\">Nicotinic acid</td> <td>10 mg</td> </tr> <tr> <td class=\"indent1\">Pyridoxine (vitamin B6)</td> <td>0.7 mg</td> </tr> <tr> <td class=\"indent1\">Cyanocobalamin (vitamin B12)</td> <td>1 mcg</td> </tr> <tr> <td class=\"indent1\">Folic acid</td> <td>0.35 mg</td> </tr> <tr> <td class=\"indent1\">Ascorbic acid (vitamin C)</td> <td>100 mg</td> </tr> <tr> <td class=\"indent1\">Pantothenic acid (vitamin B5)</td> <td>3 mg</td> </tr> <tr> <td class=\"indent1\">Biotin</td> <td>0.1 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fat-soluble</td> </tr> <tr> <td class=\"indent1\">Retinol (vitamin A)</td> <td>1.5 mg</td> </tr> <tr> <td class=\"indent1\">Calciferol (vitamin D)</td> <td>30 mcg</td> </tr> <tr> <td class=\"indent1\">alpha-Tocopherol (vitamin E)</td> <td>22 mg</td> </tr> <tr> <td class=\"indent1\">Vitamin K</td> <td>40 mcg</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57039&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright © 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 71032 Version 3.0</div></div></div>"},"71037":{"type":"graphic_table","displayName":"Complications of sclerotherapy","title":"Complications in patients undergoing emergent or elective sclerotherapy for variceal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications in patients undergoing emergent or elective sclerotherapy for variceal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Local complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ulcers</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bleeding</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stricture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Esophageal dysmotility</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Odynophagia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Laceration</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Regional</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Esophageal perforation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mediastinitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pleural effusions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute gastric dilation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Systemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sepsis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aspiration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spontaneous bacterial peritonitis and candidemia</td>\n\n    </tr>\n\n\n    <tr class=\"indent1 indent1\">\n\n      <td>Ventilation-perfusion mismatch (hypoxia)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adult respiratory distress syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Portal vein thrombosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Complications to physician</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sclerotherapist's eye</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Sanyal AJ. Semin Liver Dis 1993; 13:4.</div><div id=\"graphicVersion\">Graphic 71037 Version 3.0</div></div></div>"},"71038":{"type":"graphic_table","displayName":"Signs and symptoms of SBP","title":"Signs and symptoms at the time of diagnosis in 489 patients with spontaneous bacterial peritonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms at the time of diagnosis in 489 patients with spontaneous bacterial peritonitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Clinical feature</td>\n<td class=\"subtitle1\">Percent with sign or symptom</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>69</td>\n</tr>\n<tr>\n<td>Abdominal pain</td>\n<td>59</td>\n</tr>\n<tr>\n<td>Altered mental status</td>\n<td>54</td>\n</tr>\n<tr>\n<td>Abdominal tenderness</td>\n<td>49</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>32</td>\n</tr>\n<tr>\n<td>Paralytic ileus</td>\n<td>30</td>\n</tr>\n<tr>\n<td>Hypotension</td>\n<td>21</td>\n</tr>\n<tr>\n<td>Hypothermia</td>\n<td>17</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Gastrointestinal and Hepatic Infections, Surawicz CM, Owen RL (Eds), WB Saunders Company, Philadelphia 1994. p.455.</div><div id=\"graphicVersion\">Graphic 71038 Version 2.0</div></div></div>"},"71039":{"type":"graphic_picture","displayName":"Elevated papules","title":"Higher power view demonstrates the elevated papules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Higher power view demonstrates the elevated papules</div><div class=\"cntnt\"><img style=\"width:396px; height:331px;\" src=\"images/NEPH/71039_Elevated_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright © 2004 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 71039 Version 2.0</div></div></div>"},"71042":{"type":"graphic_picture","displayName":"Normal bone marrow child","title":"Normal bone marrow of a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal bone marrow of a child</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/71042_Normal_bone_marrow_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Min Xu, MD, PhD.</div><div id=\"graphicVersion\">Graphic 71042 Version 1.0</div></div></div>"},"71043":{"type":"graphic_figure","displayName":"Trichostrongylosis life cycle","title":"Trichostrongylosis life cycle","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Trichostrongylosis life cycle</div><div class=\"cntnt\"><img style=\"width:595px; height:451px;\" src=\"images/ID/71043_Trichostrongylos_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eggs are passed in the stool of the definitive host (usually a herbivorous mammal) <STRONG>(1)</STRONG>, and, under favorable conditions (moisture, warmth, shade), larvae hatch within several days. The released rhabditiform larvae grow in the soil or on vegetation <STRONG>(2)</STRONG>, and, after 5 to 10 days (and two molts), they become filariform (third-stage) larvae that are infective <STRONG>(3)</STRONG>. Infection of the human host occurs upon ingestion of these filariform larvae <STRONG>(4)</STRONG>. The larvae reach the small intestine, where they reside and mature into adults. Adult worms inhabit the digestive tract of their definitive hosts and may occur as incidental infections in humans <STRONG>(5)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Trichostrongylosis. Available at: <a href=\"http://www.cdc.gov/dpdx/trichostrongylosis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/trichostrongylosis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 71043 Version 5.0</div></div></div>"},"71044":{"type":"graphic_algorithm","displayName":"Neck stiffness without fever in children","title":"Neck stiffness or torticollis without fever in children","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Neck stiffness or torticollis without fever in children</div><div class=\"cntnt\"><img style=\"width:531px; height:401px;\" src=\"images/EM/71044_Neck_stiff_no_fever_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCM: sternocleidomastoid muscle; TB: tuberculosis.</div><div id=\"graphicVersion\">Graphic 71044 Version 8.0</div></div></div>"},"71045":{"type":"graphic_picture","displayName":"AML FAB M4EO","title":"Acute myelomonocytic leukemia (M4EO)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myelomonocytic leukemia (M4EO)</div><div class=\"cntnt\"><img style=\"width:389px; height:288px;\" src=\"images/HEME/71045_AML_FAB_M4EO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a patient with acute myelomonocytic leukemia with increased marrow eosinophils (FAB classification M4EO) and an associated inv(16) chromosome abnormality. (Wright-Giemsa stain). The two eosinophilic precursors in this field (arrows) show prominent basophilic-staining granules.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 71045 Version 1.0</div></div></div>"},"71046":{"type":"graphic_table","displayName":"Web resources diabetes child","title":"Useful resources on diabetes for parents and caregivers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Useful resources on diabetes for parents and caregivers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <p>Chase HP and Maahs D. Understanding Diabetes, 12th edition (in English&nbsp;or Spanish)</p> <p>Available from the University of Colorado Barbara Davis Center for Diabetes, (www.ucdenver.edu/academics/colleges/medicalschool/centers/BarbaraDavis/OnlineBooks/Pages/default.aspx), or from the Children's Diabetes Foundation.</p> </td> </tr> <tr> <td> <p>Chase HP and Messer L. Understanding insulin pumps and continuous glucose monitors. &nbsp;</p> <p>Available from the University of Colorado Barbara Davis Center for Diabetes, (www.ucdenver.edu/academics/colleges/medicalschool/centers/BarbaraDavis/OnlineBooks/Pages/default.aspx), or from the Children's Diabetes Foundation.</p> </td> </tr> <tr> <td> <p>Travis LB. An Instructional Aid on Diabetes, 12th edition, (in English&nbsp;or Spanish)</p> <p>Available from Designer's Ink, http://www.designersink.com/Diabetes/diabetes.htm</p> </td> </tr> <tr> <td> <p>Hendel E.&nbsp;A Child in Your Care Has Diabetes: A Collection of Information, Third Edition, (in English or English-Spanish)</p> <p>Hen House Press, 2005.</p> </td> </tr> <tr> <td class=\"sublist1_start\">Other Web sites</td> </tr> <tr> <td class=\"sublist1\">http://www.childrenwithdiabetes.com </td> </tr> <tr> <td class=\"sublist1\">http://www.ndep.nih.gov</td> </tr> <tr> <td class=\"sublist1\">http://www.diabetes.org</td> </tr> <tr> <td class=\"sublist1\">http://www.jdrf.org</td> </tr> <tr> <td class=\"sublist1\">http://www.childrensdiabetesfdn.org/publications.html </td> </tr> <tr> <td class=\"sublist1\">http://www.diabetes.ca/ (Canadian Diabetes Association for information in French)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71046 Version 3.0</div></div></div>"},"71048":{"type":"graphic_figure","displayName":"Interstitial pulmonary edema","title":"Pleural fluid accumulation in interstitial pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Pleural fluid accumulation in interstitial pulmonary edema</div><div class=\"cntnt\"><img style=\"width:463px; height:298px;\" src=\"images/PULM/71048_Interstitial_pulmonary_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the mechanism of pleural fluid accumulation in interstitial pulmonary edema. Lung interstitial liquid can move into the pleural space along a pressure gradient and across leaky pleural membranes (heavy solid arrow). Lymphatic fluid removal is able to increase, but not sufficiently to prevent fluid accumulation in the pleura.</div><div id=\"graphicVersion\">Graphic 71048 Version 2.0</div></div></div>"},"71049":{"type":"graphic_figure","displayName":"Retrieval of histology specimen","title":"Retrieval of histology specimens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retrieval of histology specimens</div><div class=\"cntnt\"><img style=\"width:373px; height:263px;\" src=\"images/PULM/71049_Retrieval_of_histology_spec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation shows histology specimen retrieval by 19-gauge TBNA. The 19-gauge needle is advanced over the 21-gauge needle, which is used as an obturator.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 71049 Version 1.0</div></div></div>"},"71051":{"type":"graphic_diagnosticimage","displayName":"TEE vena cavae bicaval view","title":"Inferior and superior vena cavae, right atrium, and right atrial appendage on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Inferior and superior vena cavae, right atrium, and right atrial appendage on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:490px; height:186px;\" src=\"images/CARD/71051_TEE_vena_cavae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using a vertical (90L) imaging plane, the superior vena cava (SVC), inferior vena cava (IVC), right atrial appendage (RAA), body of the right atrium (RA), interatrial septum, and left atrium (LA) are visualized (panel A). Panel B is a similar orientation during injection of agitated saline through the right antecubital vein. There is early appearance of contrast filling the superior vena cava and superior half of the right atrium.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 71051 Version 4.0</div></div></div>"},"71053":{"type":"graphic_picture","displayName":"Malassezia furfur histology","title":"Pityriasis versicolor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis versicolor</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/ID/71053_Malassezia_furfur_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Malassezia furfur</EM>. Cluster of yeast cells in skin scraping. Periodic acid Schiff x630.</div><div class=\"graphic_reference\">Courtesy of www.doctorfungus.org ©2006. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 71053 Version 3.0</div></div></div>"},"71057":{"type":"graphic_picture","displayName":"Squamous cell carcinoma MRI","title":"Squamous cell carcinoma of the right lower lobe","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma of the right lower lobe</div><div class=\"cntnt\"><img style=\"width:495px; height:260px;\" src=\"images/PULM/71057_Squamous_cell_carcinoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Coronal&nbsp;magnetic resonance imaging&nbsp;demonstrates transdiaphragmatic extension of a right lower lobe squamous cell carcinoma into the liver. This is a T4 tumor. Right panel: Sagittal sequence demonstrates transdiaphragmatic extension into the liver and a small pleural effusion (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71057 Version 2.0</div></div></div>"},"71059":{"type":"graphic_table","displayName":"How to perform nasal irrigation","title":"How to perform nasal irrigation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to perform nasal irrigation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Buffered normal saline nasal irrigation</td> </tr> <tr> <td class=\"subtitle2_single\">The benefits</td> </tr> <tr> <td class=\"indent1\">1. Saline (saltwater) washes the mucus and irritants from your nose.</td> </tr> <tr> <td class=\"indent1\">2. The sinus passages are moisturized.</td> </tr> <tr> <td class=\"indent1\">3. Studies have also shown that a nasal irrigation improves cell function (the cells that move the mucus work better).</td> </tr> <tr> <td class=\"subtitle2_single\">The recipe</td> </tr> <tr> <td class=\"indent1\">Use a one-quart glass jar that is thoroughly cleansed.</td> </tr> <tr> <td class=\"indent1\">You may use a large medical syringe (30 cc), water pick with an irrigation tip (preferred method), squeeze bottle, or Neti pot. Do not use a baby bulb syringe. The syringe or pick should be sterilized frequently or replaced every two to three weeks to avoid contamination and infection.</td> </tr> <tr> <td class=\"indent1\">Fill with water that has been distilled, previously boiled, or otherwise sterilized. Plain tap water is not recommended, because it is not necessarily sterile.</td> </tr> <tr> <td class=\"indent1\">Add 1 to 1&#189; heaping teaspoons of pickling/canning salt. Do&nbsp;<strong>not</strong> use table salt, because it contains a large number of additives.</td> </tr> <tr> <td class=\"indent1\">Add 1 teaspoon of baking soda (pure bicarbonate).</td> </tr> <tr> <td class=\"indent1\">Mix ingredients together, and store at room temperature. Discard after one week.</td> </tr> <tr> <td class=\"indent1\">You may also make up a solution from premixed packets that are commercially prepared specifically for nasal irrigation.</td> </tr> <tr> <td class=\"subtitle2_single\">The instructions</td> </tr> <tr> <td class=\"indent1\">Irrigate your nose with saline one to two times per day.</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If you have been told to use nasal medication, you should always use your saline solution first. The nasal medication is much more effective when sprayed onto clean nasal membranes, and the spray will reach deeper into the nose. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pour the amount of fluid you plan to use into a clean bowl. Do&nbsp;<strong>not</strong> put your used syringe back into the storage container, because it contaminates your solution. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>You may warm the solution slightly in the microwave, but be sure that the solution is <strong>not hot</strong>. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Bend over the sink (some people do this in the shower) and squirt the solution into each side of your nose, aiming the stream toward the back of your head,&nbsp;<strong>not</strong> the top of your head. The solution should flow into one nostril and out of the other, but it will not harm you if you swallow a little. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Some people experience a little burning sensation the first few times they use buffered saline solution, but this usually goes away after they adapt to it. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Diseases of the Sinuses: Diagnosis and Management. Kennedy DW, Bolger WE, Zinreich SJ (Eds), BC Decker, Hamilton, Ontario 2001. Copyright &copy; Kennedy DW, Zinreich SJ.</div><div id=\"graphicVersion\">Graphic 71059 Version 12.0</div></div></div>"},"71060":{"type":"graphic_table","displayName":"Ascitic fluid tests AASLD","title":"Ascitic fluid laboratory data","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ascitic fluid laboratory data</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"container\">\n\t<table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_single\">Routine</td>\n\t\t\t</tr>\n\t\t\t<tr>\t\n\t\t\t\t<td>Cell count and differential</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Albumin</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Total protein</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table>\n</td>\n<td class=\"container\">\n\t<table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_single\">Optional</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Culture in blood culture bottles</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Glucose</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Lactate dehydrogenase</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Amylase</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Gram's stain</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table>\n</td>\n<td class=\"container\">\n\t<table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_single\">Unusual</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>AFB smear and culture</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Cytology</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Triglyceride</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Bilirubin</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table>\n</td>\n<td class=\"container\">\n\t<table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_single\">Unhelpful</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>pH</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Lactate</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Cholesterol</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Fibronectin</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Glycosaminoglycans</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table>\n</td>\n</tr>\n\n\n\n\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">AFB: acid-fast bacteria.</div><div class=\"graphic_reference\">Reproduced with permission from: The American Association for the Study of Liver Diseases. Hepatology 2004; 39:841.</div><div id=\"graphicVersion\">Graphic 71060 Version 1.0</div></div></div>"},"71061":{"type":"graphic_diagnosticimage","displayName":"Transmural balloon dilation","title":"EUS-guided pancreatic pseudocyst drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS-guided pancreatic pseudocyst drainage</div><div class=\"cntnt\"><img style=\"width:360px; height:370px;\" src=\"images/GAST/71061_Transmural_balloon_dilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image demonstrating balloon dilatation of fistulous tract between gastric wall and the adjacent pseudocyst.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 71061 Version 2.0</div></div></div>"},"71063":{"type":"graphic_picture","displayName":"Three piece penile prosthesis","title":"Three piece penile prosthesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three piece penile prosthesis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/71063_Penile_implant_three_piece.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of American Medical Systems, Minnetonka, Minnesota. www.AmericanMedicalSystems.com.</div><div id=\"graphicVersion\">Graphic 71063 Version 5.0</div></div></div>"},"71065":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram short axis with RV pressure overload","title":"Echocardiogram short axis showing RV pressure overload in advanced pulmonary hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram short axis showing RV pressure overload in advanced pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:286px; height:246px;\" src=\"images/CARD/71065_Short_axis_pulmonary_hypert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view at the level of the mitral chordae from a patient with advanced pulmonary hypertension shows substantial morphologic changes, including severe hypertrophy of the right ventricular (RV) wall, dilation of the RV chamber and hypertrophy of the right side of the septum. The septum is flattened, strongly suggesting pressure overload in the RV; this septal shape imparts a &quot;D shape&quot; to the left ventricle (LV) which has relatively thin walls.</div><div id=\"graphicVersion\">Graphic 71065 Version 4.0</div></div></div>"},"71066":{"type":"graphic_table","displayName":"Biodegradable soft tissue fillers","title":"Examples of biodegradable filling agents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of biodegradable filling agents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Filler type</td> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Properties</td> <td class=\"subtitle1\">Uses</td> <td class=\"subtitle1\">Duration<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"6\">Hyaluronic acid (HA)</td> <td> <p>Restylane<br /> Restylane-L</p> <p>&nbsp;</p> <p>Perlane<br /> Perlane-L</p> <p>&nbsp;</p> <p>Restylane Silk</p> </td> <td>Non-animal HA; cross-linked with BDDE</td> <td> <p>Restylane, Restylane-L: Correction of moderate to severe wrinkles and folds (eg, nasolabial folds) and lip augmentation</p> <p>&nbsp;</p> <p>Perlane and Perlane-L: Correction of moderate to severe wrinkles and folds (eg, nasolabial folds) </p> <p>&nbsp;</p> <p>Restylane Silk: Lip augmentation and correction of perioral wrinkles</p> </td> <td>Six&nbsp;months</td> </tr> <tr> <td> <p>Juv&#233;derm Ultra<br /> Juv&#233;derm Ultra XC<br /> Juv&#233;derm Ultra Plus<br /> Juv&#233;derm Ultra Plus XC</p> <p>&nbsp;</p> <p>Juv&#233;derm Voluma XC</p> <p>&nbsp;</p> <p>Juv&#233;derm Volbella XC</p> <p>&nbsp;</p> <p>Juv&#233;derm Volift</p> </td> <td>Non-animal, cross-linked HA; XC formulations contain lidocaine</td> <td> <p>Juv&#233;derm Ultra, Juv&#233;derm Ultra XC, Juv&#233;derm Ultra Plus, Juv&#233;derm Ultra Plus XC: Correction of moderate to severe wrinkles and folds (eg, nasolabial folds) </p> <p>&nbsp;</p> <p>Juv&#233;derm Voluma XC: Correction of&nbsp;volume deficits in the midface</p> <p>&nbsp;</p> <p>Juv&#233;derm Volbella XC: Lip augmentation and correction of perioral rhytides</p> <p>&nbsp;</p> <p>Juv&#233;derm Volift: Facial contouring and the treatment of deep skin depressions</p> </td> <td>6 to 12 months</td> </tr> <tr> <td>Elevess</td> <td>Non-animal HA + lidocaine; cross-linked with BCDI, sodium metabisulfite preservative</td> <td>Correction of moderate to severe wrinkles and folds (eg, nasolabial folds)</td> <td>12 months</td> </tr> <tr> <td>Prevelle Silk</td> <td>Non-animal HA + lidocaine</td> <td>Correction of moderate to severe wrinkles and folds (eg, nasolabial folds)</td> <td>Six&nbsp;months</td> </tr> <tr> <td>Teosyal</td> <td>Non-animal HA, cross-linked with BDDE; reduced protein and bacterial endotoxin level, no lidocaine</td> <td>Correction of fine lines to deeper rhytides and facial sculpting</td> <td>6 to 12 months</td> </tr> <tr> <td>Revanesse Ultra</td> <td>Non-animal HA, cross-linked with BDDE</td> <td>Correction of moderate to deep rhytides, as well as lipoatrophy and facial wasting</td> <td>6 to 12 months</td> </tr> <tr class=\"divider_top\"> <td>Calcium hydroxylapatite microspheres (CaHA)</td> <td>Radiesse</td> <td>Synthetic CaHA microspheres (25-45 mcm) suspended in an aqueous carboxymethylcellulose gel carrier</td> <td>For correction of moderate-to-severe facial wrinkles and folds (eg, nasolabial folds); for the correction of facial lipoatrophy</td> <td>12 months</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Poly-L-lactic acid (PLLA)</td> <td>Sculptra</td> <td rowspan=\"2\">Microparticles of PLLA induce fibroblastic activity; PLLA particles are eventually metabolized</td> <td>For restoration and/or correction of facial lipoatrophy</td> <td rowspan=\"2\">12 to 24 months</td> </tr> <tr> <td>Sculptra Aesthetic</td> <td>For correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles</td> </tr> <tr class=\"divider_top\"> <td>Autologous fat</td> <td>n/a</td> <td>Harvesting and reinjection of fat</td> <td>Dermal/lip augmentation</td> <td>Months to years</td> </tr> <tr class=\"divider_top\"> <td>Platelet-rich fibrin matrices (PRFM)</td> <td>SELPHYL System</td> <td>PRFM generated through collection and centrifugation of blood; stimulates cell proliferation and skin rejuvenation over time</td> <td>Glabellar lines, nasolabial folds, acne or post-operative scars, full-face contouring, and other dermal defects</td> <td>Three&nbsp;months to years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BDDE: butanediol diglycidyl ether; BCDI: biscarbodiimide.<br />* Collagen-based filling agents are additional biodegradable fillers.<br />¶&nbsp;The duration of filler effect tends to be longer in the upper face and mid face than in the perioral region.<br /></div><div id=\"graphicVersion\">Graphic 71066 Version 10.0</div></div></div>"},"71067":{"type":"graphic_picture","displayName":"Tinea cruris 3","title":"Tinea cruris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea cruris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71067_Tinea_cruris_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and scaly plaque with ring-like, raised borders in the groin, characteristic of tinea cruris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71067 Version 6.0</div></div></div>"},"71068":{"type":"graphic_table","displayName":"Dx intrahepatic cholestasis","title":"Differential diagnosis of cholestatic jaundice: Intrahepatic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of cholestatic jaundice: Intrahepatic</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute hepatocellular</td> </tr> <tr> <td class=\"indent1\">Viral hepatitis</td> </tr> <tr> <td class=\"indent1\">Alcoholic fatty liver and/or hepatitis</td> </tr> <tr> <td class=\"indent1\">Non-alcoholic steatohepatitis</td> </tr> <tr> <td class=\"indent1\">Drugs</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic hepatocellular</td> </tr> <tr> <td class=\"indent1\">Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis</td> </tr> <tr> <td class=\"indent1\">Drugs</td> </tr> <tr> <td class=\"indent1\">Hepatitis (viral, alcohol, autoimmune)</td> </tr> <tr> <td class=\"indent1\">Cirrhosis of any cause</td> </tr> <tr> <td class=\"subtitle1_single\">Multifactorial</td> </tr> <tr> <td class=\"indent1\">Total parental nutrition</td> </tr> <tr> <td class=\"indent1\">Systemic infection</td> </tr> <tr> <td class=\"indent1\">Postoperative</td> </tr> <tr> <td class=\"indent1\">Sickle cell disease/crisis</td> </tr> <tr> <td class=\"indent1\">Organ transplantation (rejection; graft-versus-host disease; venoocclusive disease)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Hypotension/hypoxemia/HF</td> </tr> <tr> <td class=\"indent1\">Budd-Chiari syndrome</td> </tr> <tr> <td class=\"indent1\">Parasitic infection (<em>Clonorchis sinensis</em>; <em>Fasciola hepatica</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Inherited/endocrine</td> </tr> <tr> <td class=\"indent1\">Benign recurrent intrahepatic cholestasis (BRIC)</td> </tr> <tr> <td class=\"indent1\">Progressive familial intrahepatic cholestasis (PFIC)</td> </tr> <tr> <td class=\"indent1\">Low phospholipid-associated cholestasis (LPAC)</td> </tr> <tr> <td class=\"indent1\">Thyrotoxicosis</td> </tr> <tr> <td class=\"indent1\">Alagille syndrome</td> </tr> <tr> <td class=\"indent1\">Disorders of carbohydrate, lipid, or bile acid metabolism</td> </tr> <tr> <td class=\"indent1\">Caroli's disease</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Protoporphyria</td> </tr> <tr> <td class=\"subtitle1_single\">Infiltrative/granulomatous</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> </tr> <tr> <td class=\"indent1\">Lymphoma*</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Rarely patients with lymphoma may have hyperbilirubinemia (direct) in the absence of tumor involvement of the liver or extrahepatic obstruction.</div><div id=\"graphicVersion\">Graphic 71068 Version 4.0</div></div></div>"},"71072":{"type":"graphic_figure","displayName":"Edge detection angiography","title":"Edge detection on quantitative coronary angiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Edge detection on quantitative coronary angiography</div><div class=\"cntnt\"><img style=\"width:366px; height:213px;\" src=\"images/CARD/71072_Edge_detection_angiography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using the image obtained from the contrast angiogram, the minimal luminal diameter is measured and compared to the diameter of the &quot;normal&quot; vessel immediately adjacent which serves as the reference diameter. The percent stenosis can then be calculated.</div><div id=\"graphicVersion\">Graphic 71072 Version 1.0</div></div></div>"},"71073":{"type":"graphic_table","displayName":"Causes localized lymphadenopathy in children","title":"Causes of localized lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of localized lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lymph node group</td> <td class=\"subtitle1\">Area of drainage</td> <td class=\"subtitle1\">Causes</td> </tr> <tr class=\"divider_bottom\"> <td>Occipital</td> <td>Posterior scalp, neck</td> <td> <p>Common: Scalp infections (including tinea capitis, lice); insect bites; seborrhea; roseola (human herpesvirus 6 [HHV6])</p> Less common: Rubella; acute lymphoblastic leukemia</td> </tr> <tr class=\"divider_bottom\"> <td>Posterior auricular</td> <td>Temporal and parietal scalp</td> <td>Rubella; roseola (HHV6, HHV7)</td> </tr> <tr class=\"divider_bottom\"> <td>Anterior auricular (preauricular)</td> <td>Anterior and temporal scalp, anterior ear canal and pinna, lateral conjunctiva and eyelids</td> <td> <p>Common: Eye or conjunctival infections (eg, adenovirus, oculoglandular syndrome)</p> Less common: Cat scratch disease; tularemia; listeriosis</td> </tr> <tr class=\"divider_bottom\"> <td>Submental</td> <td>Central lower lip, floor of mouth</td> <td>Tongue, gum, buccal mucosal, and dental infections (eg, gingivostomatitis); group B streptococcal infection (in infants &#60;2 months of age)</td> </tr> <tr class=\"divider_bottom\"> <td>Submaxillary (submandibular)</td> <td>Cheek, nose, lips, anterior tongue, submandibular gland, buccal mucosa</td> <td>Tongue, gum, buccal mucosal, and dental infections; dental caries; chronically cracked lips</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cervical</td> <td class=\"divider_bottom\" rowspan=\"2\">Cranium, neck, oropharynx</td> <td> <p><strong>Anterior:</strong> Common: Viral upper respiratory infections; infections of pharynx, oral cavity, or head and neck; primary bacterial adenitis; tuberculosis; Epstein-Barr virus; cytomegalovirus; cat scratch disease; nontuberculous mycobacterium</p> Less common: Tularemia; toxoplasmosis; diphtheria; noninfectious causes (eg, Kawasaki disease, Hodgkin lymphoma, lymphosarcoma, neuroblastoma, rhabdomyosarcoma, sarcoidosis)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Posterior:</strong> Toxoplasmosis; Epstein-Barr virus; rubella</td> </tr> <tr class=\"divider_bottom\"> <td>Supraclavicular</td> <td> <p>Right: Inferior neck and mediastinum</p> Left: Inferior neck, mediastinum, and upper abdomen</td> <td>Malignancy (lymphoma or metastatic disease)</td> </tr> <tr class=\"divider_bottom\"> <td>Axillary</td> <td>Greater part of arm, shoulder, superficial anterior and lateral thoracic and upper abdominal wall</td> <td> <p>Common: Cat scratch disease; pyogenic infections of upper arms; reactive response to disruption in skin integrity</p> Less common: Brucellosis; <em>Yersinia pestis</em>; rat-bite fever; toxoplasmosis; filariasis; rheumatologic disease of the hand or wrist</td> </tr> <tr class=\"divider_bottom\"> <td>Epitrochlear</td> <td>Hand, forearm, elbow</td> <td> <p>Common: Viral diseases; sarcoidosis;infection of hands</p> Less common: Cat scratch disease; tularemia; secondary syphilis; rheumatologic disease of the hand or wrist</td> </tr> <tr class=\"divider_bottom\"> <td>Inguinal</td> <td>Leg and genitalia</td> <td> <p>Common: Genital herpes, primary; syphilis; gonococcal infection; lymphoma</p> Less common: <em>Yersinia pestis</em>; chancroid; lymphogranuloma venereum; filariasis; cat scratch disease</td> </tr> <tr> <td>Popliteal</td> <td>Posterior leg and knee</td> <td>Local infection</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Segal GB, Hall CB. Lymphadenopathy. In: Primary Pediatric Care, 4<SUP>th</SUP> ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1192. </LI>&#xD;&#xA;<LI>Perkins SL, Segal GH, Kjeldsberg CR. Work-up of lymphadenopathy in children. Semin Diagn Pathol 1995; 12:284. </LI>&#xD;&#xA;<LI>Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5<SUP>th</SUP> ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.421. </LI></OL></div><div id=\"graphicVersion\">Graphic 71073 Version 10.0</div></div></div>"},"71075":{"type":"graphic_algorithm","displayName":"Treatment algorithm for nociceptive pain","title":"Nociceptive pain: Pharmacologic approach","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Nociceptive pain: Pharmacologic approach</div><div class=\"cntnt\"><img style=\"width:456px; height:626px;\" src=\"images/PC/71075_Tx_algo_nocicept_pain_edit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Risk factors:</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>Chronic kidney disease, advanced age - avoid NSAIDs and COX-2 inhibitors.</li>&#xD;&#xA;    <li>Peptic ulcer disease, glucocorticoid use - avoid NSAIDs.</li>&#xD;&#xA;    <li>Hepatic disease - avoid NSAIDs, COX-2 inhibitors, and acetaminophen (APAP); use TCAs or duloxetine first line.</li>&#xD;&#xA;    <li>Cardiovascular disease or risk - use lowest effective dose of NSAIDs; in patients who require treatment, suggest naproxen.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug; COX-2: cyclooxygenase 2 inhibitor; APAP: acetaminophen/paracetamol; TCA: tricyclic antidepressant; PPI: proton pump inhibitor.</div><div id=\"graphicVersion\">Graphic 71075 Version 2.0</div></div></div>"},"71081":{"type":"graphic_table","displayName":"Zoonoses","title":"Infections associated with animal exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections associated with animal exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Animal </td> <td class=\"subtitle1\">Infection </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cats </td> </tr> <tr> <td class=\"indent1\">Saliva </td> <td><em>Bartonella henselae</em>, tularemia, <em>Pasteurella multocida</em>, rabies, <em>Capnocytophaga</em></td> </tr> <tr> <td class=\"indent1\">Feces </td> <td><em>Salmonella</em>, <em>Campylobacter</em>, <em>Cryptosporidium</em>, <em>Giardia lamblia</em>, <em>Toxoplasma gondii</em>, <em>Toxocara cati</em>, <em>Echinococcus</em>, <em>Ancylostoma braziliense</em>, <em>Dipylidium caninum</em></td> </tr> <tr> <td class=\"indent1\">Urine </td> <td>Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Tick or flea bites </td> <td>Lyme disease, human ehrlichiosis or anaplasmosis, babesiosis, <em>Yersinia pestis</em></td> </tr> <tr> <td class=\"indent1\">Direct contact </td> <td><em>Sporothrix schenckii</em>, <em>Microsporum canis</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Dogs </td> </tr> <tr> <td class=\"indent1\">Saliva </td> <td>Rabies, <em>Brucella</em>, <em>Pasteurella multocida</em>, <em>Capnocytophaga</em></td> </tr> <tr> <td class=\"indent1\">Feces </td> <td><em>Salmonella</em>, <em>Campylobacter</em>, <em>Giardia lamblia</em>, <em>Toxocara canis</em>, <em>Ancylostoma caninum</em>, <em>Echinococcus</em>, <em>Dipylidium caninum</em></td> </tr> <tr> <td class=\"indent1\">Urine </td> <td>Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Insect bites (fleas, ticks, mosquitoes, sand flies) </td> <td>Tularemia, Lyme disease, Rocky Mountain spotted fever, human ehrlichiosis or anaplasmosis, babesiosis, <em>Yersinia pestis</em>, <em>Dirofilaria immitis</em>, <em>Leishmania</em></td> </tr> <tr> <td class=\"indent1\">Direct contact </td> <td>Methicillin-resistant <em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Horses </td> </tr> <tr> <td class=\"indent1\">Saliva </td> <td>Rabies</td> </tr> <tr> <td class=\"indent1\">Feces </td> <td><em>Salmonella</em>, <em>Campylobacter</em>, <em>Cryptosporidium</em>, <em>Giardia lamblia</em>, <em>Clostridium difficile</em></td> </tr> <tr> <td class=\"indent1\">Mosquito bites </td> <td>Equine encephalitis</td> </tr> <tr> <td class=\"indent1\">Aerosol </td> <td><em>Brucella</em>, <em>Rhodococcus equi</em>, <em>Coxiella burnetii</em></td> </tr> <tr> <td><strong>Rabbits</strong> (domestic or wild)</td> <td><em>Salmonella</em>, tularemia, <em>Yersinia</em>, <em>Cryptosporidium</em>, <em>Trichophyton</em>, <em>Pasteurella multocida</em>, rabies, babesiosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pet rodents </td> </tr> <tr> <td class=\"indent1\">Saliva </td> <td>Tularemia, rat bite fever, rabies</td> </tr> <tr> <td class=\"indent1\">Feces </td> <td>Salmonellosis</td> </tr> <tr> <td class=\"indent1\">Direct contact or aerosol </td> <td>Lymphocytic choriomeningitis virus, monkeypox, <em>Trichophyton</em></td> </tr> <tr> <td><strong>Wild rodents</strong></td> <td>Hantavirus, tularemia</td> </tr> <tr> <td><strong>Bird feces</strong></td> <td>Psittacosis, <em>Cryptococcus</em>, Histoplasmosis</td> </tr> <tr> <td><strong>Wild and pet birds</strong></td> <td>Avian influenza, West Nile virus, <em>Chlamydia </em></td> </tr> <tr> <td><strong>Fish</strong></td> <td><em>Mycobacterium marinum</em></td> </tr> <tr> <td><strong>Pet reptiles</strong></td> <td><em>Salmonella</em>, <em>Edwardsiella tarda</em>, <em>Plesiomonas</em></td> </tr> <tr> <td><strong>Wild reptiles</strong></td> <td>Pentastomiasis</td> </tr> <tr> <td><strong>Ferrets</strong></td> <td><em>Salmonella</em>, <em>Campylobacter</em>, cryptosporidiosis, toxocariasis, tuberculosis, leptospirosis, listeriosis, influenza, <em>Giardia</em>, <em>Mycobacterium microti</em>, rabies</td> </tr> <tr> <td><strong>Flying squirrels</strong></td> <td><em>Toxoplasma gondii</em>, Staphylococci, <em>Rickettsia prowazekii</em></td> </tr> <tr> <td><strong>Monkeys</strong></td> <td>B-virus (Cercopithecine herpesvirus 1) infection</td> </tr> <tr> <td><strong>Cattle, sheep, goats</strong></td> <td><em>Escherichia coli</em>, <em>Campylobacter</em>, <em>Salmonella</em>, <em>Cryptosporidium</em>, <em>Brucella</em>, <em>Coxiella burnetii</em>, tularemia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71081 Version 4.0</div></div></div>"},"71082":{"type":"graphic_picture","displayName":"Aphakic spectacles","title":"Aphakic spectacles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aphakic spectacles</div><div class=\"cntnt\"><img style=\"width:287px; height:181px;\" src=\"images/PC/71082_Aphakic_spectacles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aphakic spectacles have optical features or artifacts that cause peripheral distortion and cause images to &quot;jump&quot; into the field of view.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 71082 Version 1.0</div></div></div>"},"71083":{"type":"graphic_picture","displayName":"Subperiosteal xanthomata","title":"Subperiosteal xanthomata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subperiosteal xanthomata</div><div class=\"cntnt\"><img style=\"width:266px; height:386px;\" src=\"images/PC/71083_Subperiosteal_xanthomata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subperiosteal xanthomata in a patient with heterozygous familial hypercholesterolemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 71083 Version 2.0</div></div></div>"},"71086":{"type":"graphic_picture","displayName":"An adult female Amblyomma americanum (lone star tick)","title":"An adult female <EM>Amblyomma americanum</EM> (lone star tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female <EM>Amblyomma americanum</EM> (lone star tick)</div><div class=\"cntnt\"><img style=\"width:180px; height:181px;\" src=\"images/ID/71086_Lone_star_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 71086 Version 4.0</div></div></div>"},"71087":{"type":"graphic_movie","displayName":"Aortic stenosis short axis echocardiogram","title":"Calcific aortic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcific aortic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71087_aosshtecconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:314px; height:235px;\" src=\"images/CARD/71087_aosshtec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view of 2-D echocardiogram showing echo dense calcified aortic valve.</div><div id=\"graphicVersion\">Graphic 71087 Version 2.0</div></div></div>"},"71088":{"type":"graphic_picture","displayName":"LCDD in liver Light","title":"Light chain deposition disease in the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light chain deposition disease in the liver</div><div class=\"cntnt\"><img style=\"width:394px; height:252px;\" src=\"images/NEPH/71088_LCDD_in_liver_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of an immunoperoxidase stain of a liver biopsy shows kappa light chain deposition in a patient with light chain deposition disease. A stain for lambda light chains was negative.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 71088 Version 1.0</div></div></div>"},"71091":{"type":"graphic_picture","displayName":"Patho nerve sheath C","title":"Intradural nerve sheath tumor: Wavy spindle cells that may be seen in schwannoma or neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Intradural nerve sheath tumor: Wavy spindle cells that may be seen in schwannoma or neurofibroma</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/ONC/71091_Patho_nerve_sheath_C.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71091 Version 2.0</div></div></div>"},"71092":{"type":"graphic_picture","displayName":"Carolis disease MRCP","title":"Caroli's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Caroli's disease</div><div class=\"cntnt\"><img style=\"width:305px; height:335px;\" src=\"images/GAST/71092_Carolis_disease_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiography in an infant with Caroli's disease. There is biliary ectasia throughout the liver and saccular dilatation of bile ducts in the left lobe (arrow). The kidneys show typical changes of autosomal recessive polycystic kidney disease with massive enlargement due to fusiform dilatation of the collecting ducts.</div><div class=\"graphic_reference\">Courtesy of Frederick J Suchy, MD.</div><div id=\"graphicVersion\">Graphic 71092 Version 1.0</div></div></div>"},"71093":{"type":"graphic_table","displayName":"Sx GI endocrine neoplasms","title":"Symptoms of gastrointestinal endocrine neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of gastrointestinal endocrine neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Syndrome </td>\n\n      <td class=\"subtitle1\">Peptide</td>\n\n      <td class=\"subtitle1\">Symptoms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Zollinger-Ellison</td>\n\n      <td>Gastrin</td>\n\n      <td>Ulcers, diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carcinoid</td>\n\n      <td>Serotonin</td>\n\n      <td>Flushing, diarrhea, bronchospasm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Verner-Morrison (VIPoma)</td>\n\n      <td>Vasoactive intestinal peptide</td>\n\n      <td>Voluminous watery diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Insulinoma</td>\n\n      <td>Insulin</td>\n\n      <td>Hypoglycemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glucagonoma</td>\n\n      <td>Glucagon</td>\n\n      <td>Diabetes, migratory necrolytic erythema</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Somatostatinoma</td>\n\n      <td>Somatostatin</td>\n\n      <td>Cholelithiasis, diabetes, steatorrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>PP-oma</td>\n\n      <td>Pancreatic polypeptide</td>\n\n      <td>No significant phenotype other than mass effect</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71093 Version 1.0</div></div></div>"},"71095":{"type":"graphic_table","displayName":"Assessment of older drivers","title":"Functional assessment of older drivers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional assessment of older drivers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Function</td>\n<td class=\"subtitle1\">Test</td>\n<td class=\"subtitle1\">Acceptable findings</td>\n</tr>\n<tr>\n<td>Muscle strength, grip strength</td>\n<td>Dynamometer for hand grip</td>\n<td>&#62;35 lb grip strength in dominant hand</td>\n</tr>\n<tr>\n<td>Mobility</td>\n<td>Get up and go test; functional reach test; range of motion in shoulder, neck, and wrist</td>\n<td>15 seconds; reach 6 inches from starting point; watch rise from chair, turn and use of arms, height of steps</td>\n</tr>\n<tr>\n<td>Hearing</td>\n<td>Whisper test</td>\n<td>Able to distinguish sounds</td>\n</tr>\n<tr>\n<td>Visual acuity and attention, peripheral vision</td>\n<td>Snellen eye chart or Rosenbaum pocket vision card; useful field of view (UFOV); visual fields</td>\n<td>20/40 in better eye; &#62;120 degrees</td>\n</tr>\n<tr>\n<td>Cognitive function, judgement, attention, visual-spatial</td>\n<td>Mini mental state exam (MMSE); hexagon drawing on MMSE</td>\n<td>23 out of 30, &#60;23 stop driving until further testing done; copy design with sides intersecting</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Abrams, WB, Beers, MH, Berkow, R, The Merck Manual of Geriatrics, Second Edition, 1995, Whitehouse Station, NJ.</div><div id=\"graphicVersion\">Graphic 71095 Version 1.0</div></div></div>"},"71096":{"type":"graphic_table","displayName":"Family history-based estimation of risk","title":"Family history-based estimate of risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Family history-based estimate of risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Average risk </td> <td class=\"subtitle1\">Moderate risk </td> <td class=\"subtitle1\">High risk </td> </tr> <tr> <td> <p>&#8226; No known family history, <strong>OR</strong></p> <p>&#8226; Only one second-degree relative (or more distantly related relative) affected</p> </td> <td> <p>&#8226; One first-degree relative with disease onset at an average age, <strong>OR</strong></p> <p>&#8226; Two affected second-degree relatives on the same side of the family</p> </td> <td> <p>&#8226; Premature disease or unusual presentation in a first-degree relative, <strong>OR</strong></p> <p>&#8226;&nbsp;Two or more first-degree relatives on the same side of the family affected, <strong>OR</strong></p> <p>&#8226; Two or more second-degree relatives on the same side of the family affected, with at least one having premature disease onset, <strong>OR</strong></p> <p>&#8226;&nbsp;Three&nbsp;or more&nbsp;affected on the same side of the family,<strong> OR</strong></p> <p>&#8226; Moderate-risk status on both sides of the family</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This risk estimation applies to common, autosomal dominant&nbsp;conditions in adults. Estimations for autosomal recessive and X-linked conditions differ. Refer to UpToDate&nbsp;topics on genetic counseling, genetic&nbsp;testing, and specific&nbsp;conditions for further information and risks&nbsp;associated with&nbsp;those conditions.</div><div id=\"graphicVersion\">Graphic 71096 Version 4.0</div></div></div>"},"71097":{"type":"graphic_picture","displayName":"Steatocystoma multiplex","title":"Steatocystoma multiplex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Steatocystoma multiplex</div><div class=\"cntnt\"><img style=\"width:432px; height:248px;\" src=\"images/DERM/71097_Steatocystoma_multiplex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy 25-year-old man complained of increasing numbers of firm cream-colored papules and nodules on his chest.</div><div class=\"graphic_reference\">Copyright © Mary Tonsager, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 71097 Version 7.0</div></div></div>"},"71098":{"type":"graphic_diagnosticimage","displayName":"Cystic fibrosis PA","title":"Chest radiograph of a patient with advanced cystic fibrosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a patient with advanced cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:311px; height:328px;\" src=\"images/PULM/71098_Cystic_fibrosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of an adult with advanced cystic fibrosis (CF) lung disease. The diaphragms are flattened, and the cardiac silhouette appears small due to the extreme hyperinflation of the lungs. This patient also has an acute right pneumothorax, a common complication of advanced CF.</div><div class=\"graphic_reference\">Courtesy of Julie P Katkin, MD.</div><div id=\"graphicVersion\">Graphic 71098 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"71099":{"type":"graphic_table","displayName":"Suggested measures to reduce indoor fungal exposure","title":"Suggested measures to reduce indoor fungal exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested measures to reduce indoor fungal exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Measure*</td> </tr> <tr> <td>Reduce indoor relative humidity &#8804;50%</td> </tr> <tr> <td>Repair water leaks</td> </tr> <tr> <td>Treat washable surfaces with detergent and water and then allow to dry completely</td> </tr> <tr> <td>Remove contaminated carpets, wallpaper, and woodwork</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Level of evidence is largely based on expert opinion.</div><div class=\"graphic_reference\">Courtesy of Robert Bush, MD.</div><div id=\"graphicVersion\">Graphic 71099 Version 4.0</div></div></div>"},"71100":{"type":"graphic_table","displayName":"Phadia IgE immunoassay classes","title":"Phadia IgE immunoassay classes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phadia IgE immunoassay classes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">IgE class (by Phadia)</td> <td class=\"subtitle1\">IgE concentration (kIU/L)</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">&#60;0.35</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">0.35 to 0.7</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">0.7 to 3.5</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">3.5 to 17.5</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">17.5 to 50</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">50 to 100</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">&#62;100</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; kIU/L: kilo international units/liter (= IU/mL).</div><div id=\"graphicVersion\">Graphic 71100 Version 3.0</div></div></div>"},"71102":{"type":"graphic_movie","displayName":"Bicuspid aortic valve short axis echocardiogram 2","title":"Bicuspid aortic valve short axis echocardiogram ","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bicuspid aortic valve short axis echocardiogram </div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71102_biav2saxconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:289px; height:467px;\" src=\"images/CARD/71102_biav2sax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view of a 2-D echocardiogram shows a bicuspid aortic valve with two leaflets that move normally.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 71102 Version 3.0</div></div></div>"},"71104":{"type":"graphic_table","displayName":"Pain synd cancer","title":"Acute pain syndromes directly related to cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute pain syndromes directly related to cancer</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acute pain syndromes directly related to cancer:\n   </td>\n   </tr>\n   <tr>\n   <td>Rupture of hepatocellular carcinoma</td>\n   </tr>\n   <tr>\n   <td>Pathologic fractures from bone metastases (vertebral or long bones)</td>\n   </tr>\n   <tr>\n   <td>Acute intestinal/biliary/ureteric obstruction or perforation</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acute pain syndromes associated with infections:\n   </td>\n   </tr>\n   <tr>\n   <td>Herpes zoster and postherpetic neuralgia</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acute pain syndromes associated with thrombotic events:\n   </td>\n   </tr>\n   <tr>\n   <td>Deep vein thrombosis (upper and lower extremities)</td>\n   </tr>\n   <tr>\n   <td>Superior vena cava obstruction</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 71104 Version 1.0</div></div></div>"},"71107":{"type":"graphic_diagnosticimage","displayName":"Lumbar hernia inf triangle","title":"Lumbar hernia through the inferior triangle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbar hernia through the inferior triangle</div><div class=\"cntnt\"><img style=\"width:400px; height:290px;\" src=\"images/SURG/71107_Lumbar_hernia_inf_triangle.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71107 Version 2.0</div></div></div>"},"71108":{"type":"graphic_picture","displayName":"Digital tourniquet","title":"Digital tourniquet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digital tourniquet</div><div class=\"cntnt\"><img style=\"width:266px; height:331px;\" src=\"images/EM/71108_Digital_tourniquet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A digital tourniquet provides hemostasis and a bloodless field for repair of a fingertip injury. A Penrose drain that is secured with a hemostat may also be used.</div><div class=\"graphic_reference\">Courtesy of Richard A Saladino, MD.</div><div id=\"graphicVersion\">Graphic 71108 Version 2.0</div></div></div>"},"71110":{"type":"graphic_figure","displayName":"Organization of Ig lambda light chain locus","title":"Organization of immunoglobulin lambda light chain locus","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Organization of immunoglobulin lambda light chain locus</div><div class=\"cntnt\"><img style=\"width:528px; height:68px;\" src=\"images/ALLRG/71110_Organization_Ig_lamda.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright © 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 71110 Version 4.0</div></div></div>"},"71111":{"type":"graphic_table","displayName":"Diseases with manometric findings of achalasia","title":"Diseases with manometric findings of achalasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases with manometric findings of achalasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Malignancy, especially gastric carcinoma</td> </tr> <tr> <td>Chagas disease</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Neurofibromatosis</td> </tr> <tr> <td>Eosinophilic esophagitis</td> </tr> <tr> <td>Multiple endocrine neoplasia, type 2B</td> </tr> <tr> <td>Juvenile Sj&#246;gren's syndrome with achalasia and gastric hypersecretion</td> </tr> <tr> <td>Chronic idiopathic intestinal pseudo-obstruction</td> </tr> <tr> <td>Anderson-Fabry disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71111 Version 3.0</div></div></div>"},"71115":{"type":"graphic_picture","displayName":"Echinacea","title":"Echinacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echinacea</div><div class=\"cntnt\"><img style=\"width:324px; height:486px;\" src=\"images/PC/71115_Echinacea.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Martin Wall/herbslides.com.</div><div id=\"graphicVersion\">Graphic 71115 Version 1.0</div></div></div>"},"71116":{"type":"graphic_table","displayName":"Rules for good sleep","title":"Sleep hygiene: Basic rules for a good night's sleep","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sleep hygiene: Basic rules for a good night's sleep</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sleep only as much as you need to feel rested and then get out of bed</td> </tr> <tr> <td>Keep a regular sleep schedule</td> </tr> <tr> <td>Do not try to sleep unless you feel sleepy</td> </tr> <tr> <td>Exercise regularly, preferably at least&nbsp;4 to 5 hours before bedtime</td> </tr> <tr> <td>Avoid caffeinated beverages after lunch</td> </tr> <tr> <td>Avoid alcohol near bedtime: no \"night cap\"</td> </tr> <tr> <td>Avoid smoking, especially in the evening</td> </tr> <tr> <td>Do not go to bed hungry</td> </tr> <tr> <td>Make the bedroom environment conducive to sleep</td> </tr> <tr> <td>Avoid prolonged use of light-emitting screens before bedtime&nbsp;</td> </tr> <tr> <td>Deal with your worries before bedtime</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71116 Version 4.0</div></div></div>"},"71117":{"type":"graphic_figure","displayName":"HLA class I diagram","title":"HLA class I molecule","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">HLA class I molecule</div><div class=\"cntnt\"><img style=\"width:502px; height:313px;\" src=\"images/RHEUM/71117_HLAclassIdiagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel:&nbsp;A ribbon diagram of the classical structure of HLA class I complex of alpha chain and beta-2-microglobulin is presented. The alpha chain is represented in blue and the noncovalently bonded beta-2-microglobulin in red.<br />Right panel:&nbsp;A schematic representation of the class I complex is shown, which indicates that the peptide binding region is comprised of portions of the alpha-1 and alpha-2 domains of the molecule. The alpha-3 domain is illustrated as being closely associated with beta-2-microglobulin. An extension from the alpha-3 domain penetrates the cell membrane and has a short cytoplasmic region.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Reproduced with permission from: Lopez-Larrea C, Gonzalez S, Martinez-Borra J. Molecular Medicine Today 1998; 4:450. Copyright © 1998 Elsevier Science. AND Copyright © 1999 From: Janeway C (Ed), Immunobiology: The Immune System in Health and Disease, Garland Publishing, Elsevier Science, 1999. Reproduced with permission of Routledge, Inc., part of the Taylor &amp;Francis Group.</div><div id=\"graphicVersion\">Graphic 71117 Version 4.0</div></div></div>"},"71118":{"type":"graphic_figure","displayName":"Myomectomy tourniquet and clamps","title":"Abdominal myomectomy: Use of a uterine artery tourniquet and ovarian artery clamps","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Abdominal myomectomy: Use of a uterine artery tourniquet and ovarian artery clamps</div><div class=\"cntnt\"><img style=\"width:463px; height:550px;\" src=\"images/OBGYN/71118_Myomectomy_tourniquet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myomectomy, controlling blood flow. The blood supply to the uterus is controlled by the use of a rubber tourniquet and by Statinsky vascular clamps which are applied to the ovarian vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright © 2010 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71118 Version 2.0</div></div></div>"},"71119":{"type":"graphic_table","displayName":"Outcome of endometrial ablation","title":"Outcome of endometrial ablation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcome of endometrial ablation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Outcome</td> <td class=\"subtitle1\" colspan=\"2\">Type of endometrial ablation</td> </tr> <tr> <td class=\"subtitle2\">Non-resectoscopic* (percent of procedures)</td> <td class=\"subtitle2\">Resectoscopic<sup>&#182;</sup> (percent of procedures)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Perioperative outcomes</td> </tr> <tr> <td class=\"indent1\">Equipment failure<sup>&#916;</sup></td> <td>9.1</td> <td>1.6</td> </tr> <tr> <td class=\"indent1\">Irrigation fluid overload<sup>&#916;</sup></td> <td>0</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\">Hemorrhage</td> <td>1.2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Uterine perforation</td> <td>0.3</td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>1</td> <td>1.1</td> </tr> <tr> <td class=\"indent1\">Endometritis</td> <td>2</td> <td>1.4</td> </tr> <tr> <td class=\"indent1\">Cervical laceration<sup>&#916;</sup></td> <td>0.2</td> <td>2.2</td> </tr> <tr> <td class=\"indent1\">Hematometra<sup>&#916;</sup></td> <td>0.9</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">Uterine cramping<sup>&#916;</sup></td> <td>38</td> <td>33</td> </tr> <tr> <td class=\"indent1\">Severe pelvic pain</td> <td>1.1</td> <td>2.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nausea/vomiting<sup>&#916;</sup></td> <td>19</td> <td>7.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Postoperative outcomes</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Amenorrhea</td> </tr> <tr> <td class=\"sublist2\">at 1 year postoperatively</td> <td class=\"sublist_other\">37</td> <td class=\"sublist_other\">38</td> </tr> <tr> <td class=\"sublist2\">at 2 to 5 years</td> <td class=\"sublist_other\">53</td> <td class=\"sublist_other\">48</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Patient satisfaction</td> </tr> <tr> <td class=\"sublist2\">at 1 year postoperatively</td> <td class=\"sublist_other\">91</td> <td class=\"sublist_other\">88</td> </tr> <tr> <td class=\"sublist2\">at 2 to 5 years</td> <td class=\"sublist_other\">93</td> <td class=\"sublist_other\">87</td> </tr> <tr> <td class=\"indent1\">Additional surgery within 2 to 5 years (including hysterectomy)</td> <td>21</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Hysterectomy within 2 to 5 years</td> <td>14</td> <td>19</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Bipolar radiofrequency, microwave, circulating hot water, thermal balloon, cryotherapy.<br />¶ Laser or roller ball ablation, wire loop resection.<br />Δ Difference between types of ablation is statistically significant.</div><div class=\"graphic_reference\">Data from: Lethaby, A, et al. Endometrial resection/ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2009; CD001501.</div><div id=\"graphicVersion\">Graphic 71119 Version 2.0</div></div></div>"},"71120":{"type":"graphic_table","displayName":"Tumor cell escape","title":"Some mechanisms of tumor cell escape from immunologic recognition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some mechanisms of tumor cell escape from immunologic recognition</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">T cells</td>\n</tr>\n<tr>\n<td>Lack of tumor-specific molecules or peptide presentation</td>\n</tr>\n<tr>\n<td>Downregulation of HLA-class I molecules</td>\n</tr>\n<tr>\n<td>Lack of costimulation</td>\n</tr>\n<tr>\n<td>Functional defects in T cells</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">NK cells</td>\n</tr>\n<tr>\n<td>Appropriate expression of self HLA class I</td>\n</tr>\n<tr>\n<td>Soluble inhibitors of NK cell function</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Both</td>\n</tr>\n<tr>\n<td>Fas ligand expression</td>\n</tr>\n<tr>\n<td>Heterogeneity and mutations</td>\n</tr>\n<tr>\n<td>Resistance to apoptosis</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71120 Version 2.0</div></div></div>"},"71121":{"type":"graphic_figure","displayName":"Heart attack medicines PI","title":"How medicines help prevent heart attacks","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">How medicines help prevent heart attacks</div><div class=\"cntnt\"><img style=\"width:531px; height:340px;\" src=\"images/PI/71121_Heartattackmedicines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In people with coronary heart disease, fatty deposits called plaques form inside the arteries that supply the heart with blood. Most heart attacks happen when these plaques break open or rupture. If a plaque ruptures, blood clots form around the rupture point, blocking the flow of blood to the heart muscle. The medicines that help prevent heart attack work on different parts of this process.</div><div id=\"graphicVersion\">Graphic 71121 Version 2.0</div></div></div>"},"71122":{"type":"graphic_picture","displayName":"Glabellar rhytides at rest and contraction","title":"Glabellar rhytides","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glabellar rhytides</div><div class=\"cntnt\"><img style=\"width:412px; height:512px;\" src=\"images/DERM/71122_Glabellar_rhytides_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical lines consistent with glabellar rhytides are present between the eyebrows. This patient has rhytides that are visible at rest (top). The rhytides are more prominent when she attempts a strong frown (bottom).</div><div id=\"graphicVersion\">Graphic 71122 Version 2.0</div></div></div>"},"71123":{"type":"graphic_diagnosticimage","displayName":"CT of temporal skull fracture","title":"Temporal skull fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temporal skull fracture</div><div class=\"cntnt\"><img style=\"width:332px; height:396px;\" src=\"images/EM/71123_Skull_fx_temp_CT_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The same skull fracture in the left temporal region seen with bone windows in a slightly more caudad slice (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169; 2008.</div><div id=\"graphicVersion\">Graphic 71123 Version 2.0</div></div></div>"},"71124":{"type":"graphic_table","displayName":"Respiratory reactions during oral challenge with aspirin","title":"Criteria for respiratory reactions during oral challenge with aspirin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for respiratory reactions during oral challenge with aspirin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">ASA-induced:</td> <td class=\"subtitle1\">Events during reaction:</td> </tr> <tr> <td>Rhinitis, conjunctivitis, and bronchospasm (classic reaction)</td> <td>Naso-ocular reaction and &#62;15% decline in FEV<sub>1</sub> compared with patient's baseline</td> </tr> <tr> <td>Bronchospasm alone (lower respiratory)</td> <td>No naso-ocular reaction, but &#62;20% decline in FEV<sub>1</sub> compared with patient's baseline</td> </tr> <tr> <td>Rhinitis and conjunctivitis (upper respiratory)</td> <td>Naso-ocular reactions and &#60;15% decline in FEV<sub>1</sub> compared with patient's baseline</td> </tr> <tr> <td>Laryngeal spasm</td> <td>Crowing sounds over trachea with an amputated inspiratory loop in the flow/volume curve</td> </tr> <tr> <td>Systemic response</td> <td>Gastrointestinal pain, flushing, urticaria, and rarely, hypotension</td> </tr> <tr> <td>Negative</td> <td>No reaction</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with AERD are usually premedicated with leukotriene-modifying agents prior to challenge. In the absence of this premedication, a spectrum of reactions to aspirin challenge are observed. With premedication, the changes in FEV<SUB>1</SUB> are dramatically reduced and/or eliminated, while nasal and ocular symptoms remain.</div><div class=\"graphic_footnotes\">ASA: aspirin; FEV<SUB>1</SUB>: forced expiratory volume in one second; AERD: aspirin-exacerbated respiratory disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Stevenson DD, Simon RA, Zuraw BL. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs. In: Middleton's Allergy: Principles and Practice, 6th Ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1695. Copyright &copy; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 71124 Version 6.0</div></div></div>"},"71125":{"type":"graphic_figure","displayName":"Bone markers and bone loss","title":"High bone turnover is predictive of rapid bone loss","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">High bone turnover is predictive of rapid bone loss</div><div class=\"cntnt\"><img style=\"width:480px; height:358px;\" src=\"images/ENDO/71125_Bone_markers_and_bone_loss.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The probability of rapid loss was calculated from the corresponding logistic regression equation for each marker. At each level, from left to right, the markers were: BALP (red bars), OC (blue bars), DPD (gray bars), and PYD (orange bars). The means and SDs were based on all 199 samples.</div><div class=\"graphic_footnotes\">SD: standard deviation; BALP: bone-specific alkaline phosphatase; OC: osteocalcin; DPD: free deoxypyridinoline; PYD: free pyridinolines.</div><div class=\"graphic_reference\">Reproduced with permission from: Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998; 13:297. Copyright &copy;1998 American Society for Bone and Mineral Research.</div><div id=\"graphicVersion\">Graphic 71125 Version 4.0</div></div></div>"},"71131":{"type":"graphic_diagnosticimage","displayName":"Intracardiac KCl","title":"Induced fetal demise: Intracardiac potassium chloride injection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Induced fetal demise: Intracardiac potassium chloride injection</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/71131_Intracardiac_KCl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The needle is seen within the fetal heart.</div><div id=\"graphicVersion\">Graphic 71131 Version 3.0</div></div></div>"},"71132":{"type":"graphic_table","displayName":"CRC chemo elderly guide","title":"Guidelines for evaluating the suitability of chemotherapy in elderly patients with CRC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for evaluating the suitability of chemotherapy in elderly patients with CRC</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Fitness category\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Criteria\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Suitability of chemotherapy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Group I: fit\r\n  \r\n   </td>\r\n  \r\n   <td>Totally independent</td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Full-dose treatment, assuming life expectancy is longer than the life expectancy from cancer\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No serious comorbidity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Group II: intermediate</td>\r\n  \r\n   <td>Dependent in one or more IADLs or with some comorbidity</td>\r\n  \r\n   <td>Consideration of chemotherapy dose reduction for first administration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Group III: frail\r\n  \r\n   </td>\r\n  \r\n   <td>Dependence in one or more ADLs</td>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Not suitable for chemotherapy; supportive care recommended\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Three or more comorbid conditions</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>One or more geriatric syndromes</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">ADLs: activities of daily living (eg, transferring, grooming, continence, using the toilet, dressing, feeding); IADLs: instrumental activities of daily living (eg, transportation, money management, shopping, taking medications, preparing meals).</div><div class=\"graphic_reference\">Reproduced with permission from: Kohne CH, Folprecht G, Goldberg RM, et al. Chemotherapy in Elderly Patients with Colorectal Cancer. The Oncologist 2008; 13:390. Copyright &#169; 2008 AlphaMed Press.</div><div id=\"graphicVersion\">Graphic 71132 Version 2.0</div></div></div>"},"71133":{"type":"graphic_waveform","displayName":"AF via multiple AV connections","title":"Preexcited tachycardia during atrial fibrillation","html":"<div class=\"graphic normal\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Preexcited tachycardia during atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/CARD/71133_AF_via_multiple_AV_connecti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ventricular rate in this irregularly irregular arrhythmia is extremely rapid, approaching 500 beats/minute. The QRS complexes are wide or aberrant and have variable morphologies, suggesting that there are multiple accessory atrioventricular connections. At electrophysiologic study, left posterior and left lateral pathways were identified and successfully ablated.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 71133 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"71134":{"type":"graphic_figure","displayName":"Incisions for skin sparing mastectomy","title":"Incisions for skin sparing mastectomy","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Incisions for skin sparing mastectomy</div><div class=\"cntnt\"><img style=\"width:588px; height:480px;\" src=\"images/SURG/71134_Incisionsskinsparingmast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A variety of skin-sparing incisions have been described. Three incision types more frequently used include the (A) periareolar, (B) tennis racket, and (C) teardrop. Tennis racket or teardrop incisions are used to obtain better access to the axilla, especially if the patient has a small breast.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71134 Version 7.0</div></div></div>"},"71135":{"type":"graphic_picture","displayName":"Scapular strength W PI","title":"Scapular strengthening exercise - \"W\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular strengthening exercise - \"W\"</div><div class=\"cntnt\"><img style=\"width:345px; height:441px;\" src=\"images/PI/71135_Scapular_strength_W_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Position the arms to form a \"W.\" Hold the arms bent with elbows pointed towards the feet and hands pointed towards the head.<br />(B) Squeeze the shoulder blades (arrows) and raise the arms until they are parallel with the floor, hold for a second or two, then return arms to the starting position; repeat 10 to 15 times.</div><div id=\"graphicVersion\">Graphic 71135 Version 4.0</div></div></div>"},"71136":{"type":"graphic_picture","displayName":"Peritoneal endometriosis light","title":"Peritoneal endometriosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peritoneal endometriosis</div><div class=\"cntnt\"><img style=\"width:395px; height:244px;\" src=\"images/ENDO/71136_Peritoneal_endometriosis_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of peritoneal endometriotic implant shows endometrial glandular epithelium (arrow) and surrounding stroma.</div><div class=\"graphic_reference\">Courtesy of Robert Schenken, MD.</div><div id=\"graphicVersion\">Graphic 71136 Version 2.0</div></div></div>"},"71141":{"type":"graphic_table","displayName":"Uses of noninvasive ventilation","title":"Common uses of noninvasive ventilatory support","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common uses of noninvasive ventilatory support</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Ventilator</td> <td class=\"subtitle1\" colspan=\"2\">Typical settings</td> <td class=\"subtitle1\" rowspan=\"2\">Applications</td> </tr> <tr> <td class=\"subtitle2\">Rate/min</td> <td class=\"subtitle2\">Pressures, cm H<sub>2</sub>O</td> </tr> <tr> <td>Positive pressure</td> <td>12-22</td> <td>10 to 20 inspiratory; &#62;4 expiratory to a volume of 12 to 15 mL/kg</td> <td>Mode of first choice. Nasal route preferred, oronasal or mouthpiece if nasal unsuccessful.</td> </tr> <tr> <td class=\"sublist1_start\">Negative pressure</td> <td class=\"sublist1_start\">&nbsp;</td> <td class=\"sublist1_start\">&nbsp;</td> <td class=\"sublist1_start\">Rarely applied as a last resort</td> </tr> <tr> <td class=\"indent1\">Iron lung</td> <td>12-14</td> <td>&ndash;12 to &ndash;25</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Wrap</td> <td>14-18</td> <td>&ndash;20 to &ndash;40</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Shell or cuirass</td> <td>14-18</td> <td>&ndash;20 to &ndash;40</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Abdominal ventilator</td> <td class=\"sublist1_start\">&nbsp;</td> <td class=\"sublist1_start\">&nbsp;</td> <td class=\"sublist1_start\">Rarely applied as a last resort</td> </tr> <tr> <td class=\"indent1\">Pneumobelt</td> <td>16-22</td> <td>35 to 50</td> <td>Diaphragm paralysis mainly for daytime use</td> </tr> <tr> <td class=\"indent1\">Rocking bed</td> <td>12-16</td> <td>&nbsp;</td> <td>Diaphragm paralysis for nocturnal use</td> </tr> <tr> <td>Glossopharyngeal breathing</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Respiratory muscle weakness, but upper airway function intact; post-polio and muscular dystrophy patients</td> </tr> <tr> <td>Diaphragm pacing</td> <td>12-14</td> <td>&nbsp;</td> <td>Intact phrenic nerve and diaphragm muscle; high cord lesion and central hypoventilation</td> </tr> <tr> <td>Expiratory aids</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>To augment peak cough flows in patients with weakened expiratory muscles</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71141 Version 3.0</div></div></div>"},"71142":{"type":"graphic_figure","displayName":"Surface contour leg muscles","title":"Surface contours of the lower leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surface contours of the lower leg</div><div class=\"cntnt\"><img style=\"width:368px; height:358px;\" src=\"images/EM/71142_Srfc_cntr_lg_mscl.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71142 Version 6.0</div></div></div>"},"71143":{"type":"graphic_diagnosticimage","displayName":"B lines","title":"B lines on thoracic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">B lines on thoracic ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:312px;\" src=\"images/PULM/71143_B_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleural ultrasound image depicting B lines (\"comet tail artifact\"), which are seen in acute pulmonary edema and acute respiratory distress syndrome. The presence of B lines would provide an alternate explanation for increased density seen on the chest radiograph, other than pleural fluid.</div><div id=\"graphicVersion\">Graphic 71143 Version 3.0</div></div></div>"},"71144":{"type":"graphic_figure","displayName":"Three types of TRAb","title":"Three types of thyrotropin receptor antibodies","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Three types of thyrotropin receptor antibodies</div><div class=\"cntnt\"><img style=\"width:473px; height:284px;\" src=\"images/ENDO/71144_Three_types_TSHR_abs3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the three types of TRAb present in autoimmune thyroid disease: stimulating, blocking, and neutral.</div><div class=\"graphic_footnotes\">TRAb: thyrotropin receptor antibody.</div><div class=\"graphic_reference\">Adapted from: Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. 2009; 38:319.</div><div id=\"graphicVersion\">Graphic 71144 Version 4.0</div></div></div>"},"71145":{"type":"graphic_picture","displayName":"Inframammary Candida intertrigo","title":"Inframammary candidal intertrigo","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Inframammary candidal intertrigo</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/DERM/71145_Inframamm_candid_intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inframammary erythema in an obese, diabetic woman with candidal intertrigo.</div><div class=\"graphic_reference\">Reproduced with permission from Ted Rosen, MD.</div><div id=\"graphicVersion\">Graphic 71145 Version 5.0</div></div></div>"},"71147":{"type":"graphic_table","displayName":"Contact collision sports","title":"Contact or collision sports","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contact or collision sports</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Basketball</td> </tr> <tr> <td>Boxing*</td> </tr> <tr> <td>Diving</td> </tr> <tr> <td>Field hockey</td> </tr> <tr> <td>Football (tackle)</td> </tr> <tr> <td>Ice hockey<sup>&#182;</sup></td> </tr> <tr> <td>Lacrosse</td> </tr> <tr> <td>Martial arts</td> </tr> <tr> <td>Rodeo</td> </tr> <tr> <td>Rugby</td> </tr> <tr> <td>Ski jumping</td> </tr> <tr> <td>Soccer</td> </tr> <tr> <td>Team handball</td> </tr> <tr> <td>Water polo</td> </tr> <tr> <td>Wrestling</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Participation not recommended by the American Academy of Pediatrics (AAP).<br />¶ To reduce injuries, the AAP recommends limiting the amount of body-checking permitted for hockey players ≤15 years.</div><div class=\"graphic_reference\">Adapted from: American Academy of Pediatrics. Medical conditions affecting sports participation (RE0046). Pediatrics 2001; 107:1205.</div><div id=\"graphicVersion\">Graphic 71147 Version 2.0</div></div></div>"},"71149":{"type":"graphic_picture","displayName":"Neuroretinitis","title":"Neuroretinitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuroretinitis</div><div class=\"cntnt\"><img style=\"width:354px; height:287px;\" src=\"images/PEDS/71149_Neuroretinitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Optic disc swelling and a star of exudate surrounds the macula in this patient with cat scratch disease.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 71149 Version 1.0</div></div></div>"},"71150":{"type":"graphic_table","displayName":"Bladder retraining instructions","title":"Bladder training instructions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bladder training instructions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">These methods are to help you regain bladder control. Think of it as \"mind over bladder.\"</td> </tr> <tr> <td> <ol> <li>Start by going to the toilet and trying to urinate as often as your shortest voiding interval (the length of time between trips to the bathroom) based on your voiding diary. For example, go every&nbsp;hour if that is what your bladder diary indicates is the shortest interval of time between visits to urinate. Make these regular trips to the toilet while you are awake. You do not have to get up during the night! </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>You must try to urinate whether you feel the need or not. You must try to urinate even if you have just been incontinent. </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>If you get a strong urge to go to the bathroom before your scheduled time, use distraction or relaxation: <ul> <li>Stop, do not run to the bathroom! </li> <li>Stand still or sit down if you can. </li> <li>RELAX. Take a deep breath and let it out slowly. </li> <li>Concentrate on making the urge decrease or even go away anyway you can (imagine the pressure becoming less and less). You can also try doing quick contractions of your pelvic floor muscles. </li> <li>DISTRACT yourself, for example by doing math problems in your head. </li> <li>When you feel IN CONTROL OF YOUR BLADDER, walk slowly to the bathroom, and then go. </li> </ul> </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>Keep this schedule until you can go&nbsp;one day without urine leakage. Then, increase the time between scheduled trips to the toilet by 15 minutes. When you can go one&nbsp;day on this new schedule without urine leakage, extend the time between bathroom trips again by 15 minutes. </li> </ol> </td> </tr> <tr> <td> <ol start=\"5\"> <li>Keep this up until you can go four hours between trips to the toilet (which is NORMAL), or until you are comfortable with a shorter time interval. This may take several weeks. </li> </ol> </td> </tr> <tr> <td> <ol start=\"6\"> <li>DO NOT GET DISCOURAGED! Bladder training takes time and effort, but it is an effective way to get rid of incontinence without medication or surgery. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Information from: &#xD;&#xA;<OL>&#xD;&#xA;<LI><A href=\"http://www.oabcentral.org/resources/AUGS_Voiding_Diary.pdf\" target=_blank>http://www.oabcentral.org/resources/AUGS_Voiding_Diary.pdf</A> (Accessed on November 10, 2017).</LI>&#xD;&#xA;<LI>Dumoulin C, Hay-Smith EJC, Mac Habée-Séguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews 2014; (5):CD005654.</LI></OL></div><div id=\"graphicVersion\">Graphic 71150 Version 5.0</div></div></div>"},"71152":{"type":"graphic_figure","displayName":"Osmolytes and hyponatremia","title":"Cerebral osmotic adaptation to severe hyponatremia","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Cerebral osmotic adaptation to severe hyponatremia</div><div class=\"cntnt\"><img style=\"width:496px; height:222px;\" src=\"images/NEPH/71152_Osmolytes_and_hyponatremia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in brain water, sodium-plus-potassium (Na + K)&nbsp;content, and three organic solutes&nbsp;– inositol, glutamine, and taurine&nbsp;– two and seven days after the onset of severe hyponatremia (plasma sodium concentration of&nbsp;less than 110 meq/L). The numbers at the bottom represent the baseline values. The return of brain water toward normal at day 7 is due to loss of sodium, potassium, and the organic solutes (called osmolytes). Although the absolute osmolyte loss is less than that of sodium plus potassium, the fractional loss is much greater&nbsp;– 36 of 60 or 60 percent versus 60 of 670 or less than 10 percent. Preferential osmolyte loss has the added advantage of not interfering with protein function within the cells.</div><div class=\"graphic_reference\">Data from Verbalis, JG, Gullans, SR, Brain Res 1991; 567:274.</div><div id=\"graphicVersion\">Graphic 71152 Version 3.0</div></div></div>"},"71153":{"type":"graphic_diagnosticimage","displayName":"Anencephaly 2","title":"Anencephaly at 12<sup>1/7th</sup> weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Anencephaly at 12<sup>1/7th</sup> weeks of gestation</div><div class=\"cntnt\"><img style=\"width:515px; height:220px;\" src=\"images/OBGYN/71153_Anencephaly_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Sagittal view of the fetus. Note the unusual shape of the fetal head and the lack of surrounding cranium. B) Transverse section showing the abnormal shape of the head, with some dysmorphic brain tissue 'hanging' from the side of the head. The orbits are prominent. The amniotic fluid is echogenic as compared with the surrounding extraembryonic space; this is due to tissue debris from the disintegrating brain. C) Three-dimensional ultrasound reconstruction of the fetus demonstrating the abnormal head shape. Arrows in each image point to the fetal head.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 71153 Version 3.0</div></div></div>"},"71155":{"type":"graphic_figure","displayName":"Breathing forces on pharynx","title":"Sagittal section of the upper airway, showing collapsing and dilating forces exerted on the pharynx during normal breathing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sagittal section of the upper airway, showing collapsing and dilating forces exerted on the pharynx during normal breathing</div><div class=\"cntnt\"><img style=\"width:386px; height:327px;\" src=\"images/PEDS/71155_Breathing_forces_on_pharynx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Martin RJ, Miller MJ, Carlo WA, J Pediatr 1986; 109:733.</div><div id=\"graphicVersion\">Graphic 71155 Version 2.0</div></div></div>"},"71156":{"type":"graphic_picture","displayName":"Direct versus indirect ophthalmoscopy","title":"Direct versus indirect ophthalmoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Direct versus indirect ophthalmoscopy</div><div class=\"cntnt\"><img style=\"width:288px; height:404px;\" src=\"images/PEDS/71156_Directindirectopthalmosco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of same fundus through (A) direct and (B) indirect ophthalmoscopes. Hemorrhage is not visible with the smaller field. Indirect ophthalmoscopy permits visualization of the optic nerve (asterisk), the fovea (arrow), the macula (within circle), and the periphery.</div><div class=\"graphic_reference\">Reproduced with permission from: Kivlin, JD. Ophthalmic manifestations of shaken baby syndrome. Journal of Aggression, Maltreatment and Trauma 2001; 5:137. Copyright ©2001 The Haworth Press, Inc.</div><div id=\"graphicVersion\">Graphic 71156 Version 3.0</div></div></div>"},"71157":{"type":"graphic_table","displayName":"Ichthyoses","title":"The ichthyoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The ichthyoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Inheritance and pathogenesis</td> <td class=\"subtitle1\">Key clinical features</td> </tr> <tr> <td rowspan=\"3\"><strong>Icthyosis vulgaris</strong></td> <td>Autosomal dominant</td> <td rowspan=\"3\">Relatively common (1:250 to 1:300). Fine, white translucent scales predominantly on extensor surfaces of extremities with sparing of flexures, palms, soles, and face. Hyperlinear palms. Often associated with keratosis pilaris and atopy including eczema. Onset during childhood. Typically improves with age.</td> </tr> <tr> <td>Fillagrin defect resulting in a retention hyperkeratoses</td> </tr> <tr> <td>(Normal epithelial turnover)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>X-linked ichthyosis (steroid sulfatase deficiency)</strong></td> <td>X-linked recessive</td> <td rowspan=\"3\">1:6000 men. Failure to progress in labor in mother of affected fetus (placental sulfatase deficiency). Large brown \"dirty\" adherent scales with relative sparing of flexures, palms, soles, and face. Asymptomatic corneal opacities (50 percent of adult males). 12 to 15 percent incidence of cryptorchidism and independently increased risk of testicular cancer. Onset at two to six weeks. Gradually worsens with age.</td> </tr> <tr> <td>Steroid sulfatase deficiency results in cholesterol sulfate accumulation and a retention hyperkeratoses</td> </tr> <tr> <td>(Normal epithelial turnover)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Lamellar ichthyosis </strong></td> <td>Autosomal recessive</td> <td rowspan=\"3\">1:300,000 live births. \"Collodion baby\" at birth (translucent taut parchment-like membrane encasing infant, ectropion, eclabium, generalized erythroderma; complications include sepsis, protein loss, and electrolyte abnormalities). Children and adults develop large brown polygonal scales involving entire body surface, with increased involvement in flexural folds. Palmoplantar keratoderma, scarring alopecia, nail dystrophy, and hypohidrosis with heat intolerance frequently seen. Ectropion is also almost always present.</td> </tr> <tr> <td>Transglutaminase deficiency</td> </tr> <tr> <td>(Increased epithelial turnover)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Congenital ichthyosiform erythroderma </strong></td> <td>Autosomal recessive</td> <td rowspan=\"2\">\"Collodion baby\" at birth (see above). Children and adults develop generalized erythroderma with fine white scaling. Palmoplantar keratoderma, scarring alopecia, and persistent ectropion may also be seen.</td> </tr> <tr> <td>(Increased epithelial turnover) </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Epidermolytic hichtyosis (epidermolytic&nbsp;hyperkeratosis or&nbsp;bullous congenital ichthyosiform erythroderma)</strong></td> <td>Autosomal dominant</td> <td rowspan=\"3\">Neonatal period with widespread blistering and erythema. Later infancy and adulthood characterized by generalized hyperkeratosis with dark scales and spiny ridges especially pronounced flexurally. Denuded areas of skin where scales shed with full thickness stratum corneum also seen. Focal bullae due to secondary infection may also develop.</td> </tr> <tr> <td>50 percent due to spontaneous mutations of keratins 1 and 10</td> </tr> <tr> <td>(Increased epithelial turnover)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Harlequin ichthyosis</strong></td> <td>Autosomal recessive</td> <td rowspan=\"2\">Massive armor-like plates of scale with deep fissures encasing fetus. Severe ectropion, eclabium, deformed or absent ears, nose, fingers, toes. Infants are born stillborn or generally die shortly after birth due to respiratory and feeding compromise due to constriction.</td> </tr> <tr> <td>(Increased epithelial turnover)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71157 Version 5.0</div></div></div>"},"71158":{"type":"graphic_picture","displayName":"Anterior exenteration specimen","title":"Anterior exenteration specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior exenteration specimen</div><div class=\"cntnt\"><img style=\"width:389px; height:259px;\" src=\"images/OBGYN/71158_Anterior_exenteration_speci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross fixed specimen from anterior exenteration.</div><div id=\"graphicVersion\">Graphic 71158 Version 1.0</div></div></div>"},"71159":{"type":"graphic_table","displayName":"FA clinical findings","title":"Common clinical findings in Fanconi anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common clinical findings in Fanconi anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anomaly</td> <td class=\"subtitle1\">Frequency (percent)</td> </tr> <tr> <td>Any physical abnormality</td> <td>60 to 75%</td> </tr> <tr> <td>Skin&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Generalized hyperpigmentation; hypopigmented areas; large freckles, caf&#233;-au-lait spots</td> <td>40 to 60%</td> </tr> <tr> <td>Short stature, delicate features</td> <td>40 to 60%</td> </tr> <tr> <td>Upper limbs&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Absent or hypoplastic thumb, supernumerary, bifid, clinodactyly</td> <td>35 to 50%</td> </tr> <tr> <td>Gonads&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Hypogenitalia, undescended/absent testes, hypospadias; bicornuate or malpositioned uterus</td> <td> <p>25% (males)</p> <p>&#60;5%&nbsp;(females)</p> </td> </tr> <tr> <td>Head&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Microcephaly or hydrocephaly; birdlike face, mid-face hypoplasia, Sprengel's deformity of neck</td> <td>20 to 25%</td> </tr> <tr> <td>Eyes&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Microphthalmia, ptosis, epicanthal folds, strabismus</td> <td>20 to 40%</td> </tr> <tr> <td>Kidney&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Abnormal, ectopic, horseshoe, hypoplastic, or absent kidney; hydronephrosis</td> <td>20 to 30%</td> </tr> <tr> <td>Ears&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Deafness (usually conductive); low set ears, abnormal shape, narrow canal</td> <td>10 to 20%</td> </tr> <tr> <td>Developmental delay</td> <td>10%</td> </tr> <tr> <td>Cardiopulmonary anomalies&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Congenital heart disease (patent ductus arteriosus, atrial or ventricular septal defects, coarctation, situs inversus)</td> <td>6%</td> </tr> <tr> <td>Gastrointestinal anomalies&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> Atresias, imperforate anus, tracheoesophageal fistula, malrotation</td> <td>5%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for details. These frequencies were derived from studies of patients with classic presentations and&nbsp;may be an underestimate. Individuals with more subtle findings may be identified from genetic sequencing.</div><div class=\"graphic_footnotes\">FA: Fanconi anemia.</div><div class=\"graphic_reference\">Adapted&nbsp;from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Alter BP, Young NS. Bone marrow failure syndromes. In: Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.238.</LI>&#xD;&#xA;<LI>Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Reviews 2010; 24:101.</LI></OL></div><div id=\"graphicVersion\">Graphic 71159 Version 6.0</div></div></div>"},"71161":{"type":"graphic_picture","displayName":"Keratic precipitates","title":"Keratic precipitates in granulomatous uveitis","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Keratic precipitates in granulomatous uveitis</div><div class=\"cntnt\"><img style=\"width:462px; height:303px;\" src=\"images/RHEUM/71161_Keratic_precipitates_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratic precipitates are deposits of leukocytes on the corneal endothelium. The cellular concretions in this picture are large. This indicates a granulomatous type inflammation, although the cellular collections are not granulomas histologically.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 71161 Version 4.0</div></div></div>"},"71162":{"type":"graphic_picture","displayName":"Botulinum toxin injection forehead","title":"Botulinum toxin injection for forehead rhytides","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection for forehead rhytides</div><div class=\"cntnt\"><img style=\"width:586px; height:156px;\" src=\"images/DERM/71162_Bot_tox_inject_forehead2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient in this image attempted to raise the eyebrows before (A) and after (B) treatment with botulinum toxin.</div><div id=\"graphicVersion\">Graphic 71162 Version 2.0</div></div></div>"},"71163":{"type":"graphic_movie","displayName":"Membranous VSD long axis color","title":"Membranous VSD long axis color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD long axis color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71163_MembranousVSDlongmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:546px; height:336px;\" src=\"images/CARD/71163_MembranousVSDlongposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This movie clip from a transthoracic echocardiogram shows the systolic left-to-right flow at the membranous ventricular septal defect (VSD) with color flow mapping (left hand frame). Color flow mapping also shows antegrade flow across the mitral valve (red) and the aortic valve (blue).</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; RV: right ventricle; AO: aorta; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 71163 Version 5.0</div></div></div>"},"71164":{"type":"graphic_figure","displayName":"Anatomy of hypothalamus","title":"Anatomy of the hypothalamic-pituitary region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the hypothalamic-pituitary region</div><div class=\"cntnt\"><img style=\"width:424px; height:254px;\" src=\"images/ENDO/71164_Anatomy_of_hypothalamus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the brain showing the relationship of the hypothalamus to the median eminence and the pituitary gland.</div><div class=\"graphic_reference\">Adapted from Krieger DT, in: Neuroendocrinology, Krieger DT, Hughes JC (Eds), Sinauer Associates, Sunderland, MA, 1980, p. 4.</div><div id=\"graphicVersion\">Graphic 71164 Version 2.0</div></div></div>"},"71165":{"type":"graphic_table","displayName":"Causes acute flaccid paralysis","title":"Common causes of acute flaccid paralysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of acute flaccid paralysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Vaccine-associated paralytic polio</td> </tr> <tr> <td class=\"indent1\">Vaccine-derived poliomyelitis</td> </tr> <tr> <td class=\"indent1\">Nonpolio enteroviruses</td> </tr> <tr> <td class=\"indent1\">West Nile virus</td> </tr> <tr> <td class=\"indent1\">Diphtheria</td> </tr> <tr> <td class=\"subtitle1_single\">Spinal cord disorders</td> </tr> <tr> <td class=\"indent1\">Transverse myelitis</td> </tr> <tr> <td class=\"indent1\">Infarction</td> </tr> <tr> <td class=\"indent1\">Compression</td> </tr> <tr> <td class=\"subtitle1_single\">Peripheral neuropathy</td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome</td> </tr> <tr> <td class=\"indent1\">Mononeuritis multiplex</td> </tr> <tr> <td class=\"indent1\">Acute intermittent porphyria</td> </tr> <tr> <td class=\"indent1\">Toxic</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of neuromuscular transmission</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">Botulism</td> </tr> <tr> <td class=\"indent1\">Tick paralysis</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of muscle</td> </tr> <tr> <td class=\"indent1\">Inflammatory myopathy</td> </tr> <tr> <td class=\"indent1\">Rhabdomyolysis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71165 Version 4.0</div></div></div>"},"71166":{"type":"graphic_picture","displayName":"HS granuloma inguinale","title":"Indolent ulcers of granuloma inguinale mimicking hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Indolent ulcers of granuloma inguinale mimicking hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:323px; height:385px;\" src=\"images/OBGYN/71166_HS_granuloma_inguinale.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&#160;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 71166 Version 2.0</div></div></div>"},"71167":{"type":"graphic_picture","displayName":"Nasal embryology","title":"Nasal embryology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal embryology</div><div class=\"cntnt\"><img style=\"width:339px; height:336px;\" src=\"images/PEDS/71167_Nasal_embryology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The developing nose in a 30-day-old embryo. Note the nasal pits (n) and primitive mouth (m).</div><div id=\"graphicVersion\">Graphic 71167 Version 5.0</div></div></div>"},"71168":{"type":"graphic_algorithm","displayName":"Treatment of PH","title":"Treatment of pulmonary arterial hypertension algorithm","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">Treatment of pulmonary arterial hypertension algorithm</div><div class=\"cntnt\"><img style=\"width:820px; height:496px;\" src=\"images/PULM/71168_TreatmentofPHedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If no improvement or patients progress, therapy should be escalated according to WHO functional symptoms. For patients on medications for other conditions, specific drug interactions and management suggestions may be determined by using Lexi-Interact, the drug interactions program included with UpToDate.</div><div class=\"graphic_footnotes\">WHO: World Health Organization; IV: intravenous; SC: subcutaneous; INH: inhaled.<br />* Endothelin receptor antagonist-phosphodiesterase-5 inhibitor combination is preferred by some experts. Combining phosphodiesterase-5 inhibitors and guanylate cyclase stimulants (riociguat) should be avoided due to the high risk of hypotension.<br />&para; Options for agents include ambrisentan, bosentan, macitentan, sildenafil, tadalafil, or riociguat. Riociguat is best studied in patients with chronic thromboembolic pulmonary hypertension.<br />&Delta; These agents are not approved for this use by regulatory agencies.<br /><span class=\"lozenge\">&loz;</span> Some experts use initial combination therapy with a prostanoid and a phosphodiesterase-5 inhibitor.</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Barst RJ, Gibbs US, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S78. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71168 Version 13.0</div></div></div>"},"71169":{"type":"graphic_picture","displayName":"Hereditary angioedema","title":"Hereditary angioedema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hereditary angioedema</div><div class=\"cntnt\"><img style=\"width:360px; height:549px;\" src=\"images/ALLRG/71169_Hereditary_angioedema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top) Severe angioedema of the face during a cutaneous attack of hereditary angioedema. Bottom) The same patient's normal appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al. (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright © 1997 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 71169 Version 2.0</div></div></div>"},"71170":{"type":"graphic_picture","displayName":"Pediculosis pubis louse","title":"Pthirus pubis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pthirus pubis</div><div class=\"cntnt\"><img style=\"width:380px; height:283px;\" src=\"images/DERM/71170_Pediculosis_pubis_louse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pubic louse.</div><div class=\"graphic_reference\">Reproduced with permission from: Koneman's Color Atlas and Textbook of Diagnostic Microbiology, Fifth Edition, Lippincott-Raven, Philadelphia 1997. Copyright &#169; 1997 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71170 Version 1.0</div></div></div>"},"71171":{"type":"graphic_figure","displayName":"Pelvic somatic nerves","title":"Somatic nerves of the pelvis","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Somatic nerves of the pelvis</div><div class=\"cntnt\"><img style=\"width:537px; height:471px;\" src=\"images/EM/71171_Pelvicsomaticnerves.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71171 Version 10.0</div></div></div>"},"71172":{"type":"graphic_diagnosticimage","displayName":"Radiocapitellar radiograph","title":"Radiocapitellar radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiocapitellar radiograph</div><div class=\"cntnt\"><img style=\"width:328px; height:589px;\" src=\"images/EM/71172_Radiocapitellar_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic and radiograph demonstrating the radial head-capitellum view.</div><div class=\"graphic_reference\">Reproduced with permission from: Greenspan, A. Orthopedic Imaging. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71172 Version 3.0</div></div></div>"},"71174":{"type":"graphic_picture","displayName":"Brown recluse spider bite","title":"Verified bite of brown recluse spider (Loxosceles reclusa)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verified bite of brown recluse spider (Loxosceles reclusa)</div><div class=\"cntnt\"><img style=\"width:400px; height:304px;\" src=\"images/EM/71174_Brown_recluse_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from&nbsp;William Stoecker, MD.</div><div id=\"graphicVersion\">Graphic 71174 Version 12.0</div></div></div>"},"71178":{"type":"graphic_figure","displayName":"Cardinal movements of birth process","title":"Cardinal movements of birth process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardinal movements of birth process</div><div class=\"cntnt\"><img style=\"width:433px; height:540px;\" src=\"images/OBGYN/71178_Birth_diagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cardinal movements (or mechanisms) of delivery.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 71178 Version 3.0</div></div></div>"},"71179":{"type":"graphic_table","displayName":"Supports of pt relationship","title":"Areas of knowledge, skills and values that support the patient-practitioner relationship","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Areas of knowledge, skills and values that support the patient-practitioner relationship</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Area</td> <td class=\"subtitle1\">Knowledge</td> <td class=\"subtitle1\">Skills</td> <td class=\"subtitle1\">Values</td> </tr> <tr> <td>Self-awareness</td> <td> <p>Knowledge of self</p> <p>Understanding self as a resource to others</p> </td> <td>Reflect on self and work</td> <td>Importance of self-awareness, self-care, self-growth</td> </tr> <tr> <td>Patient experience of health and illness</td> <td> <p>Role of family, culture, community in development</p> <p>Multiple components of health</p> <p>Multiple threats and contributors to health as dimensions of one's reality</p> </td> <td> <p>Recognize patient's life story and its meaning</p> <p>View health and illness as part of human development</p> </td> <td> <p>Appreciation of the patient as a whole person</p> <p>Appreciation of the patient's life story and the meaning of the health-illness condition</p> </td> </tr> <tr> <td>Developing and maintaining caring relationships</td> <td> <p>Understanding of threats to the integrity of the relationship (eg, power inequalities)</p> <p>Understanding of potential for conflict and abuse</p> </td> <td> <p>Attend fully to the patient</p> <p>Accept and respond to distress in patient and self</p> <p>Respond to moral and ethical challenges</p> <p>Facilitate hope, trust, and faith</p> </td> <td> <p>Respect for patient's dignity, uniqueness, and integrity (mind-body-spirit unity)</p> <p>Respect for self-determination</p> <p>Respect for person's own power and self-healing processes</p> </td> </tr> <tr> <td>Effective communication</td> <td>Elements of effective communication</td> <td> <p>Listen; learn</p> <p>Impart information</p> <p>Facilitate the learning of others</p> <p>Promote and accept patient's emotions</p> </td> <td>Importance of being open and nonjudgemental</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Tresoloni CP, Pew-Fetzer Task Force on Advancing Psychosocial Health Education, Pew Health Professions Commission, San Francisco 1994. p. 30.</div><div id=\"graphicVersion\">Graphic 71179 Version 2.0</div></div></div>"},"71181":{"type":"graphic_table","displayName":"Initiating Rx 5 to 11 years","title":"Classifying asthma severity and initiating treatment in children 5 to 11 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifying asthma severity and initiating treatment in children 5 to 11 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\" colspan=\"2\">Components of severity</td> <td class=\"subtitle1\" colspan=\"4\">Classification of asthma severity (5 to 11 years of age)</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Intermittent</td> <td class=\"subtitle2\" colspan=\"4\">Persistent</td> </tr> <tr> <td class=\"subtitle3\">Mild</td> <td class=\"subtitle3\">Moderate</td> <td class=\"subtitle3\">Severe</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;2 times/month</td> <td>3 to 4 times/month</td> <td>&#62;1 time/week but not nightly</td> <td>Often 7 times/week</td> </tr> <tr> <td>Short-acting beta<sub>2 </sub>agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week but not daily</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr class=\"divider_bottom\"> <td>Lung function</td> <td> <ul> <li>Normal FEV<sub>1</sub> between exacerbations </li> <li>FEV<sub>1</sub> &#62;80 percent predicted </li> <li>FEV<sub>1</sub>/FVC &#62;85 percent </li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> &#8805;80 percent predicted </li> <li>FEV<sub>1</sub>/FVC &#62;80 percent </li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> = 60 to 80 percent predicted </li> <li>FEV<sub>1</sub>/FVC = 75 to 80 percent </li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> &#60;60 percent predicted </li> <li>FEV<sub>1</sub>/FVC &#60;75 percent </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Risk</td> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year (see footnote)</strong></td> <td colspan=\"3\"><strong>&#8805;2/year (see footnote)</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Frequency and severity may fluctuate over time for patients in any severity category</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Relative annual risk of exacerbations may be related to FEV<sub>1</sub></strong></td> </tr> <tr> <td rowspan=\"3\" colspan=\"2\">Recommended step for initiating treatment</td> <td rowspan=\"2\">Step 1</td> <td rowspan=\"2\">Step 2</td> <td>Step 3, medium dose-inhaled glucocorticoids option</td> <td>Step 3, medium dose-inhaled glucocorticoids option, or Step 4</td> </tr> <tr> <td colspan=\"2\">And consider short course of oral systemic glucocorticoids</td> </tr> <tr> <td colspan=\"4\">In two to six weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Assessing severity and initiating therapy in children who are not currently taking long-term control medication.</strong> The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous two to four weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm; FEV<sub>1</sub>: forced expiratory volume in one second; FVC: forced vital capacity; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 71181 Version 9.0</div></div></div>"},"71182":{"type":"graphic_figure","displayName":"Antineutrophil antibody assay","title":"Antineutrophil antibody assay","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Antineutrophil antibody assay</div><div class=\"cntnt\"><img style=\"width:526px; height:272px;\" src=\"images/HEME/71182_Antineutrophil_antibody_ass.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the indirect method used to assay for antineutrophil antibodies in a patient with suspected drug-associated immune neutropenia.</div><div class=\"graphic_reference\">Adapted from Young, NS, JAMA 1994; 271:935.</div><div id=\"graphicVersion\">Graphic 71182 Version 1.0</div></div></div>"},"71183":{"type":"graphic_diagnosticimage","displayName":"Orbital floor fracture","title":"Orbital floor fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Orbital floor fracture</div><div class=\"cntnt\"><img style=\"width:385px; height:226px;\" src=\"images/EM/71183_Orbital_floor_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a fracture in the floor of the left orbit with a large fragment of bone (arrow) in the maxillary sinus. The left maxillary sinus is filled with blood.</div><div class=\"graphic_reference\">Courtesy of Richard G Bachur, MD.</div><div id=\"graphicVersion\">Graphic 71183 Version 3.0</div></div></div>"},"71184":{"type":"graphic_figure","displayName":"Spinal BMD with IHH","title":"Reduced spinal (trabecular) bone density in idiopathic hypogonadotropic hypogonadism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reduced spinal (trabecular) bone density in idiopathic hypogonadotropic hypogonadism</div><div class=\"cntnt\"><img style=\"width:374px; height:288px;\" src=\"images/ENDO/71184_Spinal_BMD_with_IHH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trabecular bone density as measured by quantitative computed tomography is plotted against age in 23 men with idiopathic hypogonadotropic hypogonadism. The closed circles refer to men in whom the epiphyses were fused (Group I) and the open circles to men in whom the epiphyses were open (Group II). The lines indicate the mean (± SD) spinal bone density in normal men. The stippled bar indicates the fracture threshold. Osteopenia is equally severe in those with immature and mature bone ages, suggesting that abnormal bone development plays an important role in the osteopenia of men with idiopathic hypogonadotropic hypogonadism.</div><div class=\"graphic_reference\">Reproduced with permission from: Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.&nbsp;Ann Intern Med 1987; 106:354.</div><div id=\"graphicVersion\">Graphic 71184 Version 2.0</div></div></div>"},"71185":{"type":"graphic_figure","displayName":"Liver and small bowel transplantation","title":"Liver and small bowel transplantation","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Liver and small bowel transplantation</div><div class=\"cntnt\"><img style=\"width:534px; height:529px;\" src=\"images/GAST/71185_Liver_sm-bowel_transplant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Khan FA, Tzakis AG. Intestinal and multivisceral transplantation. In: Transplantation, Ginnis LC, Cosmi AB, and Morris PJ (Eds), Blackwell, Malden 1999. p.422.</div><div id=\"graphicVersion\">Graphic 71185 Version 2.0</div></div></div>"},"71187":{"type":"graphic_picture","displayName":"Polyp on virtual colonoscopy","title":"Colonic polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic polyp</div><div class=\"cntnt\"><img style=\"width:194px; height:287px;\" src=\"images/GAST/71187_Polyp_on_virtual_colonoscop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Virtual colonoscopy shows a small polyp (arrow) in the transverse colon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 71187 Version 1.0</div></div></div>"},"71188":{"type":"graphic_table","displayName":"Strategies to control the rate of high order multiple gestations","title":"Strategies to control the high order multiple pregnancy rate with IVF - 2004 data","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to control the high order multiple pregnancy rate with IVF - 2004 data</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Strategy\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Country\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Rate of delivery per embryo transfer\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Rate of high order multiples per delivery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Laws to limit the number of embryos cultured</td>\r\n  \r\n   <td>Germany</td>\r\n  \r\n   <td>18.6</td>\r\n  \r\n   <td>1.1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Laws to limit the number of embryos transferred\r\n  \r\n   </td>\r\n  \r\n   <td>United Kingdom</td>\r\n  \r\n   <td>25.8</td>\r\n  \r\n   <td>0.3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Norway</td>\r\n  \r\n   <td>24.2</td>\r\n  \r\n   <td>0.3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sweden</td>\r\n  \r\n   <td>24.9</td>\r\n  \r\n   <td>0.0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Guidelines for number of embryos to transfer</td>\r\n  \r\n   <td>United States*</td>\r\n  \r\n   <td>34.0</td>\r\n  \r\n   <td>2.1</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">* Data from: Anderson, AN, et al. Hum Reprod 2008; 23:756.</div><div class=\"graphic_reference\">Data from: CDC/SART Registry, 2004.</div><div id=\"graphicVersion\">Graphic 71188 Version 2.0</div></div></div>"},"71190":{"type":"graphic_figure","displayName":"Burn classification in adults and children","title":"Modified Lund-Browder chart","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Modified Lund-Browder chart</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/71190_Burn_class_adult_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numbers refer to the percentage body surface area burned.</div><div id=\"graphicVersion\">Graphic 71190 Version 4.0</div></div></div>"},"71191":{"type":"graphic_figure","displayName":"Vaginal epithelium in menopause","title":"Changes in the vaginal epithelium with menopause","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Changes in the vaginal epithelium with menopause</div><div class=\"cntnt\"><img style=\"width:452px; height:276px;\" src=\"images/OBGYN/71191_Vaginal_epithel_menopause.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in the vaginal epithelium from the reproductive years (right) to menopause (left).</div><div class=\"graphic_reference\">Reproduced with permission from: the Anatomical Chart Company. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71191 Version 1.0</div></div></div>"},"71192":{"type":"graphic_figure","displayName":"Technique of hip disarticulation","title":"Technique of hip disarticulation","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Technique of hip disarticulation</div><div class=\"cntnt\"><img style=\"width:518px; height:671px;\" src=\"images/SURG/71192_Hip-disarticulation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71192 Version 1.0</div></div></div>"},"71193":{"type":"graphic_table","displayName":"Patch test relevance","title":"Clinical relevance of patch test reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical relevance of patch test reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td>Definite</td> <td>Allergen found in patient's products/environment, dermatitis corresponds to point of contact with allergen, use test is positive or patch test positive to product, dermatitis improved&nbsp;with removal of&nbsp;the allergen or recurred with rechallenge (provocative use test)</td> </tr> <tr> <td>Probable</td> <td>Allergen present in products/environment and clinical presentation consistent with allergy</td> </tr> <tr> <td>Possible</td> <td>Patient was likely exposed to allergen in products/environment </td> </tr> <tr> <td>Unknown</td> <td>No evidence of current or past exposure</td> </tr> <tr> <td>Past</td> <td>Allergen found in past environment and patient had reaction to allergen in the past</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71193 Version 6.0</div></div></div>"},"71194":{"type":"graphic_figure","displayName":"tPA versus streptokinase in MI","title":"tPA is superior to streptokinase for acute MI","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">tPA is superior to streptokinase for acute MI</div><div class=\"cntnt\"><img style=\"width:502px; height:274px;\" src=\"images/CARD/71194_tPA_versus_streptokinase_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-day mortality in acute MI with four different thrombolytic regimens: streptokinase (with subcutaneous heparin or intravenous heparin), accelerated tPA and intravenous heparin, and combination therapy with streptokinase, tPA, and IV heparin. There was a significant 1 percent absolute reduction in mortality with tPA (6.3 versus pooled value of 7.3 percent with the other regimens).</div><div class=\"graphic_reference\">Data from The GUSTO Investigators, N Engl J Med 1993; 329:673.</div><div id=\"graphicVersion\">Graphic 71194 Version 2.0</div></div></div>"},"71198":{"type":"graphic_diagnosticimage","displayName":"Gestational sac and embryo","title":"Measurement of embryo in gestational sac","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Measurement of embryo in gestational sac</div><div class=\"cntnt\"><img style=\"width:452px; height:515px;\" src=\"images/OBGYN/71198_Gestational_sac_and_embryo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image of an early gestational sac demonstrating the early embryo. Calipers are placed at both ends of the embryo measuring the longest length from the \"crown to the rump\" giving the crown-rump length. This measurement is used for dating the pregnancy. Surrounding the embryo is the developing amnion as shown by the hyperechoic circular line.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 71198 Version 3.0</div></div></div>"},"71199":{"type":"graphic_table","displayName":"Old single agts chemo","title":"Studies evaluating old single agents for chemotherapy in locally advanced and metastatic esophageal and gastric cancers*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies evaluating old single agents&nbsp;for&nbsp;chemotherapy in locally advanced and metastatic esophageal and gastric cancers*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Cancer type </td> <td class=\"subtitle1\">Author </td> <td class=\"subtitle1\">N </td> <td class=\"subtitle1\">RR (percent) </td> </tr> <tr> <td rowspan=\"2\">Fluorouracil</td> <td>Esophageal</td> <td>Ezdinli E; 1980</td> <td>23</td> <td>17</td> </tr> <tr> <td>Gastric</td> <td>Earl H; 1984</td> <td>457</td> <td>20</td> </tr> <tr> <td rowspan=\"2\">Mitomycin </td> <td>Esophageal</td> <td>Whittington R; 1970</td> <td>31</td> <td>35</td> </tr> <tr> <td>Gastric</td> <td>Earl H; 1984</td> <td>189</td> <td>29</td> </tr> <tr> <td rowspan=\"2\">Doxorubicin </td> <td>Esophageal</td> <td>Ezdinli E; 1980</td> <td>16</td> <td>0</td> </tr> <tr> <td>Gastric</td> <td>Earl H; 1984</td> <td>180</td> <td>17</td> </tr> <tr> <td rowspan=\"2\">Cisplatin </td> <td>Esophageal</td> <td>Bleiberg H; 1997</td> <td>37</td> <td>19</td> </tr> <tr> <td>Gastric</td> <td>Beer M; 1983</td> <td>20</td> <td>22</td> </tr> <tr> <td rowspan=\"2\">Methotrexate </td> <td>Esophageal</td> <td>Ezdinli E; 1980</td> <td>24</td> <td>13</td> </tr> <tr> <td>Gastric</td> <td>Bruckner H; 1982</td> <td>28</td> <td>11</td> </tr> <tr> <td rowspan=\"2\">Bleomycin </td> <td>Esophageal</td> <td>Br Med J; 1970</td> <td>8</td> <td>50</td> </tr> <tr> <td>Gastric</td> <td>Br Med J; 1970</td> <td>4</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">*In many cases, response rates were not determined by modern computed tomography (CT)-based criteria.</div><div class=\"graphic_footnotes\">N: number of patients; RR: objective response rate.</div><div class=\"graphic_reference\">Courtesy of Fidias P, El-Karak FR.</div><div id=\"graphicVersion\">Graphic 71199 Version 4.0</div></div></div>"},"71200":{"type":"graphic_table","displayName":"Haddon model firearm injuries","title":"Haddon injury control model for firearm injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Haddon injury control model for firearm injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Event stages</td> <td class=\"subtitle1\" colspan=\"4\">Epidemiologic factors</td> </tr> <tr> <td class=\"subtitle2\">Human factor</td> <td class=\"subtitle2\">Agent or vehicle</td> <td class=\"subtitle2\">Physical environment and medical resources</td> <td class=\"subtitle2\">Sociocultural/political environment</td> </tr> <tr> <td>Pre-event</td> <td> <p>Gun safety programs for children</p> <p>Family counseling</p> </td> <td> <p>Remove firearms from home</p> <p>Loaded chamber indicator</p> <p>Magazine disconnect device</p> <p>Trigger locks</p> <p>Personalized gun</p> </td> <td> <p>Lock boxes</p> <p>Store ammunition separately</p> </td> <td> <p>Regulation of handguns and assault weapons</p> <p>Regulation of firearms as a consumer product</p> </td> </tr> <tr> <td>Event</td> <td>Bulletproof vest</td> <td>Safer bullet</td> <td>Safe firearm practice ranges</td> <td>&nbsp;</td> </tr> <tr> <td>Post-event</td> <td>---</td> <td>---</td> <td>Improved children's emergency systems and rehabilitation</td> <td>Surveillance and analysis of firearm injuries to identify risk factors, causes, and possible prevention strategies</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71200 Version 2.0</div></div></div>"},"71203":{"type":"graphic_diagnosticimage","displayName":"Calcified gallstones KUB","title":"Calcified gallstones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified gallstones</div><div class=\"cntnt\"><img style=\"width:267px; height:382px;\" src=\"images/GAST/71203_CalcifiedgallstonesKUB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain abdominal x-ray showing calcified gallstones in the gallbladder (GB), cystic duct (CD) and common bile duct (CBD).</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP, AGAF.</div><div id=\"graphicVersion\">Graphic 71203 Version 3.0</div></div></div>"},"71204":{"type":"graphic_figure","displayName":"Laparoscopic oophorectomy","title":"Laparoscopic oophorectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic oophorectomy</div><div class=\"cntnt\"><img style=\"width:382px; height:310px;\" src=\"images/OBGYN/71204_Laparoscopic_oophorectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two to three loops are placed around the ovary and cinched down across the ovarian vessels and the utero-ovarian ligament. The ovary is then excised distal to the last loop.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 71204 Version 1.0</div></div></div>"},"71205":{"type":"graphic_table","displayName":"LMWH versus oral anticoagulants hip","title":"Clinical trials comparing low molecular weight heparin with oral anticoagulants in hip replacement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical trials comparing low molecular weight heparin with oral anticoagulants in hip replacement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Regimens</td> <td class=\"subtitle1\">All DVT, n/n<br /> (percent)</td> <td class=\"subtitle1\">Proximal DVT*, n/n<br /> (percent)</td> <td class=\"subtitle1\">Occurrence of major bleeding, n/n<br /> (percent)</td> </tr> <tr> <td rowspan=\"2\">N Engl J Med 1993; 329:1370</td> <td rowspan=\"2\">Randomized double-blind; bilateral venogram</td> <td>Tinzaparin 75 Xa units/kg sc once daily vs</td> <td>69/332 (21)</td> <td>16/332 (5)</td> <td>11/398 (2.8)</td> </tr> <tr> <td>Warfarin sodium (INR 2.0-3.0)</td> <td>79/340 (23)</td> <td>13/340 (4)</td> <td>6/397 (1.5)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Thromb Haemost 1995; 74:1428</td> <td rowspan=\"2\">Randomized single-blind; bilateral venogram</td> <td>Nadroparin 60 Xa units/kg sc once daily vs</td> <td>27/195 (14)</td> <td>12/195 (6)</td> <td>3/195 (1)</td> </tr> <tr> <td>Acenocoumarol (INR 2.0-3.0)</td> <td>27/196 (14)</td> <td>9/196 (5)</td> <td>7/196 (3.6)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">J Bone Joint Surg Am 1997; 79:1365</td> <td rowspan=\"2\">Randomized single-blind; bilateral venography</td> <td>Dalteparin 2500&nbsp;international units&nbsp;pre- and post-surgery then 5000&nbsp;international units&nbsp;sc once daily vs</td> <td>28/192 (15)</td> <td>10/192 (5)</td> <td>6/271 (2)</td> </tr> <tr> <td>Warfarin sodium (INR 2.5) begun pre-surgery</td> <td>49/190 (26)</td> <td>16/190 (8)</td> <td>4/279 (1)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Arch Intern Med 2000; 160:2199</td> <td rowspan=\"3\">Randomized double-blind; bilateral venography</td> <td>Dalteparin 2500&nbsp;international units pre- and post-surgery, then 5000&nbsp;international units qd vs</td> <td>37/337 (11)</td> <td>3/354 (0.8)</td> <td>10/496 (2)</td> </tr> <tr> <td>Dalteparin 2500&nbsp;international units post-surgery, then 5000&nbsp;international units qd vs</td> <td>44/336 (13)</td> <td>3/358 (0.8)</td> <td>5/487 (1)</td> </tr> <tr> <td>Warfarin sodium (INR 2.0-3.0) begun post-surgery</td> <td>81/338 (24)</td> <td>11/363 (3)</td> <td>8/489 (1.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis; INR: international normalized ratio; sc: subcutaneously.<br> * Popliteal, femoral, or iliac vein thrombosis.</div><div id=\"graphicVersion\">Graphic 71205 Version 4.0</div></div></div>"},"71206":{"type":"graphic_diagnosticimage","displayName":"PVOD CT image","title":"Computed tomographic (CT) image of pulmonary veno-occlusive disease (PVOD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomographic (CT) image of pulmonary veno-occlusive disease (PVOD)</div><div class=\"cntnt\"><img style=\"width:352px; height:291px;\" src=\"images/PULM/71206_PVOD_CT_image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lung base shows numerous thickened septal lines (arrow) and patchy foci of ground glass attenuation (large arrow). The arteries are enlarged relative to bronchi (thick arrow), whereas pulmonary veins appear of normal caliber (small arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Mandel J, Mark E, Hales C. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964. Official Journal of the American Thoracic Society &copy; American Lung Association.</div><div id=\"graphicVersion\">Graphic 71206 Version 4.0</div></div></div>"},"71208":{"type":"graphic_diagnosticimage","displayName":"MRI of fetal Chiari II malformation","title":"Diagnosis of Chairi II malformation by fetal MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnosis of Chairi II malformation by fetal MRI</div><div class=\"cntnt\"><img style=\"width:383px; height:504px;\" src=\"images/NEURO/71208_Chiari_II_fetal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagnosis of a Chiari II malformation can be made in utero by fetal MRI, which demonstrates the lumbar myelomeningocele (arrows) and cerebral Chiari II malformation (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 71208 Version 7.0</div></div></div>"},"71209":{"type":"graphic_diagnosticimage","displayName":"Post-traumatic arthritis of the AC joint","title":"Post-traumatic arthritis of the AC joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-traumatic arthritis of the AC joint</div><div class=\"cntnt\"><img style=\"width:432px; height:363px;\" src=\"images/EM/71209_AC_joint_OA_post_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph above shows degeneration of the acromioclavicular (AC) joint that developed following trauma. Note the widened joint space and lucent distal clavicle.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 71209 Version 3.0</div></div></div>"},"71210":{"type":"graphic_picture","displayName":"Pityriasis lichenoides chronica","title":"Pityriasis lichenoides chronica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides chronica</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71210_Pityriasis_lichen_chronica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small papules with adherent scale are present in this patient with pityriasis lichenoides chronica.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71210 Version 3.0</div></div></div>"},"71211":{"type":"graphic_table","displayName":"Mohs versus standard excision","title":"Mohs surgery versus standard excision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mohs surgery versus standard excision</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mohs</td> <td class=\"subtitle1\">Standard excision</td> </tr> <tr> <td><strong>Tissue excision</strong></td> <td>Initial narrow margin</td> <td>Wider margin</td> </tr> <tr> <td><strong>Tissue grossing</strong></td> <td>On site (oriented/inked/mapped)</td> <td>Sent to pathology</td> </tr> <tr> <td><strong>Tissue sectioning</strong></td> <td>Oblique/horizontal</td> <td>Vertical (\"bread-loafing\")</td> </tr> <tr> <td><strong>Margin evaluation</strong></td> <td>Total margin (lateral and deep)</td> <td>Small percentage of true margin sampled</td> </tr> <tr> <td><strong>Histologic evaluation</strong></td> <td>Mohs surgeon</td> <td>Pathologist</td> </tr> <tr> <td><strong>Tumor assessment</strong></td> <td>Tumor mapped/immediate excision</td> <td>Tumor presence communicated</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71211 Version 3.0</div></div></div>"},"71213":{"type":"graphic_diagnosticimage","displayName":"PDA before after indomethacin","title":"Patent ductus arteriosus in preterm infant before and after indomethacin therapy","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Patent ductus arteriosus in preterm infant before and after indomethacin therapy</div><div class=\"cntnt\"><img style=\"width:525px; height:214px;\" src=\"images/PEDS/71213_PDA_before_after_indomethac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs from a premature infant with a symptomatic patent ductus arteriosus (PDA) before (left panel) and after (right panel) the administration of indomethacin. Prior to therapy, the lungs are opacified due to pulmonary edema resulting from increased blood flow through the PDA; the heart is also mildly enlarged. After therapy, the lung fields are clear and heart size is smaller.</div><div class=\"graphic_reference\">Courtesy of Stephen E Welty, MD.</div><div id=\"graphicVersion\">Graphic 71213 Version 3.0</div></div></div>"},"71214":{"type":"graphic_figure","displayName":"Depression prevalence","title":"Prevalence of depressive disorders in various patient populations","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Prevalence of depressive disorders in various patient populations</div><div class=\"cntnt\"><img style=\"width:535px; height:368px;\" src=\"images/PC/71214_Depression_prevalence.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Prevalence range varies according to study.</div><div class=\"graphic_reference\">Data from Birrer, RB, Vemuri, SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Physician 2004; 69:2375</div><div id=\"graphicVersion\">Graphic 71214 Version 1.0</div></div></div>"},"71217":{"type":"graphic_diagnosticimage","displayName":"Empyema after liver biopsy CT","title":"Empyema after liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Empyema after liver biopsy</div><div class=\"cntnt\"><img style=\"width:374px; height:300px;\" src=\"images/PULM/71217_Empyema_after_liver_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior accumulation of low attenuation pleural effusion and the compressed atelectatic right lower lobe, forming a higher attenuation wedge-shaped structure. Note the right middle lobe bronchus pointing ventrally and the superior segmental bronchus of the right lower lobe pointing dorsally towards the collapsed lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71217 Version 2.0</div></div></div>"},"71221":{"type":"graphic_table","displayName":"Chemical quality standards","title":"Chemical quality standards for water used in hemodialysis applications in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemical quality standards for water used in hemodialysis applications in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Contaminant</td> <td class=\"subtitle1\">Maximum concentration (mg/L)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Substances normally included in dialysate</td> </tr> <tr> <td class=\"indent1\">Calcium</td> <td>2 (0.1 mEq/L)</td> </tr> <tr> <td class=\"indent1\">Magnesium</td> <td>4 (0.3 mEq/L)</td> </tr> <tr> <td class=\"indent1\">Potassium</td> <td>8 (0.2 mEq/L)</td> </tr> <tr> <td class=\"indent1\">Sodium</td> <td>70 (3.0 mEq/L)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Substances regulated by the Safe Water Drinking Act</td> </tr> <tr> <td class=\"indent1\">Antimony</td> <td>0.006</td> </tr> <tr> <td class=\"indent1\">Arsenic</td> <td>0.005</td> </tr> <tr> <td class=\"indent1\">Barium</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">Beryllium</td> <td>0.0004</td> </tr> <tr> <td class=\"indent1\">Cadmium</td> <td>0.001</td> </tr> <tr> <td class=\"indent1\">Chromium</td> <td>0.014</td> </tr> <tr> <td class=\"indent1\">Mercury</td> <td>0.0002</td> </tr> <tr> <td class=\"indent1\">Selenium</td> <td>0.09</td> </tr> <tr> <td class=\"indent1\">Silver</td> <td>0.005</td> </tr> <tr> <td class=\"indent1\">Thallium</td> <td>0.002</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Substances known to be toxic in hemodialysis</td> </tr> <tr> <td class=\"indent1\">Aluminum</td> <td>0.01</td> </tr> <tr> <td class=\"indent1\">Total chlorine*</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">Copper</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">Fluoride</td> <td>0.2</td> </tr> <tr> <td class=\"indent1\">Lead</td> <td>0.005</td> </tr> <tr> <td class=\"indent1\">Nitrate (as N)</td> <td>2.0</td> </tr> <tr> <td class=\"indent1\">Sulfate</td> <td>100</td> </tr> <tr> <td class=\"indent1\">Zinc</td> <td>0.1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">AAMI: Association for the Advancement of Medical Instrumentation.</div><div class=\"graphic_footnotes\">* A maximum allowable level for total chlorine of 0.1 mg/L replaces the separate maximum allowable levels for free chlorine and chloramine included in versions of the AAMI water quality standard published before 2011.</div><div class=\"graphic_reference\">Data from: Association for the Advancement of Medical Instrumentation. Water for Hemodialysis and Related Therapies, ANSI/AAMI/ISO 13959:2009, Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.</div><div id=\"graphicVersion\">Graphic 71221 Version 7.0</div></div></div>"},"71222":{"type":"graphic_picture","displayName":"Lichen sclerosus with squamous cell carcinoma 1","title":"Lichen sclerosus and squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus and squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:255px; height:360px;\" src=\"images/OBGYN/71222_LS_SCC_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severely itchy vulvar&nbsp;lichen sclerosus&nbsp;with scarring, loss of vulvar architecture, and thick indurated areas of squamous cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 71222 Version 5.0</div></div></div>"},"71225":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/71225_Erythrodermic_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythrodermic psoriasis may be acute or chronic. It is characterized by generalized erythema and scaling from head to toe. Patients are at high risk for complications related to loss of adequate barrier protection such as infection (including sepsis) and electrolyte abnormalities secondary to fluid loss.</div><div id=\"graphicVersion\">Graphic 71225 Version 1.0</div></div></div>"},"71226":{"type":"graphic_picture","displayName":"Tinea corporis","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:274px; height:168px;\" src=\"images/PC/71226_Tinea_corporis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea corporis caused by <em>Microsporum canis</em>. The patient also has gray patch tinea capitis (not shown).</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 71226 Version 2.0</div></div></div>"},"71227":{"type":"graphic_figure","displayName":"Mobilization and transection of the esophagus","title":"Mobilization and transection of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Mobilization and transection of the esophagus</div><div class=\"cntnt\"><img style=\"width:470px; height:712px;\" src=\"images/SURG/71227_Esophagus_mobilized.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The esophagus is encircled with a penrose drain and the crus of the diaphragm is taken down bilaterally. Following skeletonization of the distal esophagus, four stay sutures of 2-0 Prolene are placed circumferentially in the esophagus approximately 2 cm proximal to the presumed gastroesophageal junction. An automatic pursestringer and circular stapling device and knife are used to transect the distal esophagus.</div><div id=\"graphicVersion\">Graphic 71227 Version 3.0</div></div></div>"},"71228":{"type":"graphic_diagnosticimage","displayName":"Aspergillus brain abscesses","title":"<em>Aspergillus</em> brain abscesses","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\"><em>Aspergillus</em> brain abscesses</div><div class=\"cntnt\"><img style=\"width:451px; height:250px;\" src=\"images/ID/71228_Asper_brain_abscesses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 44-year-old man with hairy-cell leukemia and biopsy-proved cerebral aspergillosis.<br />(A) Computed tomography scan obtained after injection of contrast material shows multiple ring-enhancing lesions with surrounding edema and mass effect.<br />(B) T2-weighted&nbsp;magnetic resonance image (at slightly lower level than A) shows mutiple hypointense rings (arrows) with surrounding edema in right cerebral hemisphere. Rings are irregular and relatively poorly formed.</div><div class=\"graphic_reference\">From: Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155. Reprinted with permission from: the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 71228 Version 11.0</div></div></div>"},"71229":{"type":"graphic_picture","displayName":"Chronic GVHD nail dystrophy","title":"Chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71229_Chronic_GVHD_nail_dystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dystrophic nails are present in this patient with chronic graft-versus-host disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71229 Version 3.0</div></div></div>"},"71234":{"type":"graphic_figure","displayName":"Angle anatomy","title":"Glaucoma: Angle anatomy of the eye","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Glaucoma: Angle anatomy of the eye</div><div class=\"cntnt\"><img style=\"width:476px; height:203px;\" src=\"images/PEDS/71234_Angle_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The angle is the recess formed by the irido-corneal juncture. The scleral spur, trabecular meshwork, and Schwalbe's line lie within this angle. The trabecular meshwork is a fenestrated structure that transmits aqueous fluid to Schlemm's canal, from which it drains into the venous system. The normal flow of aqueous is demonstrated here.</div><div class=\"graphic_reference\">Reproduced with permission from Trobe JD. The Physician's Guide to Eye Care. Foundation of the American Academy of Ophthalmology, San Francisco, 2001. p.158. Copyright © American Academy of Ophthalmology.</div><div id=\"graphicVersion\">Graphic 71234 Version 3.0</div></div></div>"},"71235":{"type":"graphic_figure","displayName":"Heart conduction system PI","title":"The conduction system of the heart","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">The conduction system of the heart</div><div class=\"cntnt\"><img style=\"width:524px; height:342px;\" src=\"images/PI/71235_Heart_conduction_system_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart has its own built-in electrical system, called the conduction system. The conduction system sends electrical signals throughout the heart that determine the timing of the heartbeat and cause the heart to beat in a coordinated, rhythmic pattern. The electrical signals, or impulses, of the heart are generated by a clump of specialized tissue called the sinus node. Each time the sinus node generates a new electrical impulse, that impulse spreads out through the heart's upper chambers, called the right atrium and the left atrium. This electrical impulse, as it spreads across the two atria, stimulates them to contract, pumping blood into the right and left ventricles. The electrical impulse then spreads to the atrioventricular (AV) node, which is another clump of specialized tissue located between the atria and the ventricles. The AV node momentarily slows down the spread of the electrical impulse, to allow the left and right atria to finish contracting. From the AV node, the impulse spreads into a system of specialized fibers called the His bundle and the right and left bundle branches. These fibers distribute the electrical impulse rapidly to all areas of the right and left ventricles, stimulating them to contract in a coordinated way. With this contraction, blood is pumped from the right ventricle to the lungs, and from the left ventricle throughout the body.</div><div id=\"graphicVersion\">Graphic 71235 Version 3.0</div></div></div>"},"71236":{"type":"graphic_figure","displayName":"Stenting versus PTCA in CAD","title":"Stenting improves outcome after angioplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stenting improves outcome after angioplasty</div><div class=\"cntnt\"><img style=\"width:345px; height:247px;\" src=\"images/CARD/71236_Stenting_versus_PTCA_in_CAD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of major clinical end points after percutaneous transluminal coronary angioplasty (PTCA) with (dashed line) or without (solid line) insertion of a balloon-expandable stent in 528 patients with stable angina and a single coronary lesion. Stenting was associated with a statistically significant reduction in major end points, which included restenosis requiring intervention with surgery or repeat PTCA (which accounted for the majority of events), myocardial infarction, death, or a cerebrovascular accident.</div><div class=\"graphic_reference\">Data from Serruys, PW, de Jaegere, P, Kiemeneij, F, et al, N Engl J Med 1994; 331:489.</div><div id=\"graphicVersion\">Graphic 71236 Version 1.0</div></div></div>"},"71237":{"type":"graphic_table","displayName":"Biologic agents in IBD","title":"Biological agents associated with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biological agents associated with inflammatory bowel disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Growth factors</td> </tr> <tr> <td class=\"indent1\">Platelet-activating factor</td> </tr> <tr> <td class=\"indent1\">Keratinocyte growth factor</td> </tr> <tr> <td class=\"indent1\">Trefoil peptides</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory cytokines</td> </tr> <tr> <td class=\"indent1\">IL-1-beta</td> </tr> <tr> <td class=\"indent1\">IL-2</td> </tr> <tr> <td class=\"indent1\">IL-6</td> </tr> <tr> <td class=\"indent1\">IL-9</td> </tr> <tr> <td class=\"indent1\">IL-12</td> </tr> <tr> <td class=\"indent1\">IL-17</td> </tr> <tr> <td class=\"indent1\">IL-18</td> </tr> <tr> <td class=\"indent1\">IL-21</td> </tr> <tr> <td class=\"indent1\">IL-23</td> </tr> <tr> <td class=\"indent1\">IL-32</td> </tr> <tr> <td class=\"indent1\">IL-33</td> </tr> <tr> <td class=\"indent1\">TNF-alpha</td> </tr> <tr> <td class=\"indent1\">TNFSF15 (TL1A)</td> </tr> <tr> <td class=\"indent1\">IFN-gamma</td> </tr> <tr> <td class=\"subtitle1_single\">Reactive metabolites</td> </tr> <tr> <td class=\"indent1\">Reactive oxygen species</td> </tr> <tr> <td class=\"indent1\">Nitric oxide</td> </tr> <tr> <td class=\"subtitle1_single\">Arachidonic acid metabolites</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Immunoregulatory cytokines</td> </tr> <tr> <td class=\"indent1\">IL-1 receptor antagonist</td> </tr> <tr> <td class=\"indent1\">IL-4</td> </tr> <tr> <td class=\"indent1\">IL-5</td> </tr> <tr> <td class=\"indent1\">IL-10</td> </tr> <tr> <td class=\"indent1\">IL-13</td> </tr> <tr> <td class=\"indent1\">IL-22</td> </tr> <tr> <td class=\"indent1\">IL-27</td> </tr> <tr> <td class=\"indent1\">IL-35</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">TGF-beta</span></td> </tr> <tr> <td class=\"subtitle1_single\">Chemokines</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">CCL2</span></td> </tr> <tr> <td class=\"indent1\">CCL20</td> </tr> <tr> <td class=\"indent1\">CCL25</td> </tr> <tr> <td class=\"indent1\">CXCL9&nbsp;</td> </tr> <tr> <td class=\"indent1\">CXCL10</td> </tr> <tr> <td class=\"indent1\">CXCL11&nbsp;</td> </tr> <tr> <td class=\"indent1\">IL-8</td> </tr> <tr> <td class=\"subtitle1_single\">Cell adhesion molecules</td> </tr> <tr> <td class=\"indent1\">ICAM-1;LFA-1</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">MAdCAM-1:</span>Alpha4 beta7</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">VCAM-1:Alpha4 beta1</span></td> </tr> <tr> <td class=\"subtitle1_single\">Short chain fatty acids</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IL: interleukin.</div><div id=\"graphicVersion\">Graphic 71237 Version 5.0</div></div></div>"},"71241":{"type":"graphic_table","displayName":"Grading of ERCP complications","title":"Grading system for the major complications of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading system for the major complications of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td><strong>Pancreatitis</strong></td> <td>Amylase at least three times normal at more than 24 hours after the procedure, requiring admission or prolongation of planned admission to two to three days</td> <td>Hospitalization of 4 to 10 days</td> <td>Hospitalization of more than ten days, hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery)</td> </tr> <tr> <td><strong>Bleeding</strong></td> <td>Clinical (not just endoscopic) evidence of bleeding, hemoglobin drop &#60;3 g, and no need for transfusion</td> <td>Transfusion (four units or less), no angiographic intervention or surgery</td> <td>Transfusion (five units or more) or intervention (angiographic or surgical)</td> </tr> <tr> <td><strong>Cholangitis</strong></td> <td>Temperature of &#62;38&#176;C for 24 to 48 hours</td> <td>Febrile or septic illness requiring more than three days of hospital treatment or endoscopic or percutaneous intervention</td> <td>Septic shock or surgery</td> </tr> <tr> <td><strong>Perforation</strong></td> <td>Possible, or only very slight leak of fluid or contrast, treatable by fluids and suction for three days or less</td> <td>Any definite perforation treated medically for 4 to 10 days</td> <td>Medical treatment for more than 10 days, or intervention (percutaneous or surgical)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Cotton PB, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc 1991; 37:383.</div><div id=\"graphicVersion\">Graphic 71241 Version 7.0</div></div></div>"},"71243":{"type":"graphic_table","displayName":"Characteristics of ehrlichial infections of humans","title":"Characteristics of ehrlichial infections of humans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of ehrlichial infections of humans</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"6\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Genus/species</td> <td class=\"subtitle1\">Natural host</td> <td class=\"subtitle1\">Disease(s)</td> <td class=\"subtitle1\">Human disease</td> <td class=\"subtitle1\"><em>In vivo</em>-infected cells</td> <td class=\"subtitle1\">Vector</td> <td class=\"subtitle1\">Geographic distribution</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\"><em>Ehrlichia</em></td> </tr> <tr> <td class=\"indent1\"><em>E. chaffeensis</em></td> <td>Deer, dogs</td> <td>Human monocytic ehrlichiosis</td> <td>Yes</td> <td>Monocytes macrophages</td> <td><em>Amblyomma americanum</em><br /> (lone star ticks)</td> <td>United States, South America</td> </tr> <tr> <td class=\"indent1\"><em>E. ewingii</em></td> <td>Dogs</td> <td><em>E. ewingii</em> ehrlichiosis</td> <td>Yes</td> <td>Granulocytes</td> <td><em>Amblyomma americanum</em><br /> (lone star ticks)</td> <td>United States, South America</td> </tr> <tr> <td class=\"indent1\"><em>E. canis</em></td> <td>Dogs</td> <td>Canine monocytic ehrlichiosis</td> <td>Yes</td> <td>Monocytes macrophages</td> <td><em>Rhipicephalus sanguineus</em><br /> (brown dog tick)</td> <td>Worldwide</td> </tr> <tr> <td class=\"indent1\"><em>E. muris</em>,<br /> <em>E. muris eauclairensis</em></td> <td>Small mammals</td> <td><em>E. muris eauclairensis</em> ehrlichiosis</td> <td>Yes</td> <td>Monocytes macrophages endothelial cells</td> <td><em>Ixodes ovatus</em>,<br /> <em>I. persulcatus</em>,<br /> <em>I. scapularis</em><br /> (black legged or deer tick)</td> <td>Japan, Russia, Wisconsin, and Minnesota</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>E. ruminantium</em>,<br /> Panola Mountain <em>ehrlichia</em></td> <td>Ruminants, deer</td> <td>Heartwater, Panola Mountain ehrlichiosis</td> <td>Yes</td> <td>Monocytes macrophages endothelial cells</td> <td><em>Amblyomma</em> species ticks</td> <td>Sub-Saharan Africa, Caribbean, Southeast and south-central United States</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\"><em>Anaplasma</em></td> </tr> <tr> <td class=\"indent1\"><em>A. phagocytophilum</em></td> <td>Small mammals, deer</td> <td>Human/equine/canine granulocytic anaplasmosis, tick-borne fever (cattle/sheep)</td> <td>Yes</td> <td>Granulocytes</td> <td><em>Ixodes scapularis </em>(black legged or deer tick),<br /> <em>I. pacificus</em>,<br /> <em>I. ricinus</em>,<br /> <em>I. persulcatus</em>,<br /> <em>Haemaphysalis concinna</em></td> <td>Worldwide</td> </tr> <tr> <td class=\"indent1\"><em>A. capra</em></td> <td>Goats</td> <td><em>A. capra</em> anaplasmosis</td> <td>Yes</td> <td>Unknown</td> <td><em>Ixodes persulcatus</em></td> <td>China, Japan</td> </tr> <tr> <td class=\"indent1\"><em>A. ovis</em></td> <td>Sheep, goats, wild ruminants</td> <td>Anaplasmosis</td> <td>Yes (Europe)</td> <td>Erythrocytes</td> <td><em>Rhipicephalus bursa</em>,<br /> <em>Dermacentor andersoni</em></td> <td>Worldwide</td> </tr> <tr> <td class=\"indent1\"><em>A. marginale</em></td> <td>Ruminants</td> <td>Bovine anaplasmosis</td> <td>No</td> <td>Erythrocytes</td> <td><em>Rhipicephalus microplus</em>,<br /> <em>Dermacentor andersoni</em></td> <td>Worldwide</td> </tr> <tr> <td class=\"indent1\"><em>A. centrale</em></td> <td>Ruminants</td> <td>Bovine anaplasmosis</td> <td>No</td> <td>Erythrocytes</td> <td><em>Rhipicephalus microplus</em>,<br /> <em>Dermacentor andersoni</em></td> <td>Worldwide</td> </tr> <tr> <td class=\"indent1\"><em>A. bovis</em></td> <td>Ruminants</td> <td>Ruminant anaplasmosis</td> <td>No</td> <td>Monocytes</td> <td><em>Haemaphysalis</em> spp.</td> <td>Worldwide</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Aegyptianella pullorum</em></td> <td>Birds, amphibians, reptiles</td> <td>Aegyptianellosis</td> <td>No</td> <td>Nucleated erythrocytes</td> <td><em>Argas</em> spp.</td> <td>Worldwide</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\"><em>Candidatus</em> neoehrlichia</td> </tr> <tr> <td class=\"indent1\">N. mikurensis</td> <td>Small mammals</td> <td>Neoehrlichiosis</td> <td>Yes</td> <td>Endothelial cells</td> <td><em>Ixodes ricinus</em>,<br /> <em>Ixodes species</em>,<br /> <em>Haemaphysalis concinna</em></td> <td>Europe, Asia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N. lotoris</td> <td>Raccoons, white-nosed coati</td> <td>No disease recognized</td> <td>No</td> <td>Unknown</td> <td>Unknown</td> <td>Southeast United States, Central America</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\"><em>Neorickettsia</em></td> </tr> <tr> <td class=\"indent1\"><em>N. sennetsu</em></td> <td>Snails, fish</td> <td>Sennetsu fever</td> <td>Yes</td> <td>Monocytes macrophages</td> <td>Trematodes</td> <td>Southeast Asia, Japan</td> </tr> <tr> <td class=\"indent1\"><em>N. risticii</em></td> <td>Snails, insects</td> <td>Potomac horse fever</td> <td>No</td> <td>Monocytes macrophages intestinal epithelial cells</td> <td>Digenean trematodes insects</td> <td>Worldwide</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>N. helminthoeca</em></td> <td>Snails , fish</td> <td>Salmon poisoning disease</td> <td>No</td> <td>Monocytes macrophages</td> <td>Trematodes</td> <td>Pacific northwest United States, Brazil</td> </tr> <tr> <td><strong><em>Wolbachia</em></strong></td> <td>Insects, chelicerates, nematodes, crustaceans</td> <td>&nbsp;</td> <td>Complicates human filariasis</td> <td>Mammalian cells not infected</td> <td>Insects, chelicerates, nematodes, crustaceans</td> <td>Worldwide</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71243 Version 2.0</div></div></div>"},"71244":{"type":"graphic_table","displayName":"Conditions associated with secondary immunodeficiency","title":"Conditions associated with secondary immunodeficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with secondary immunodeficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Immunosuppressive therapy</td> </tr> <tr> <td>Cytotoxic chemotherapy for malignancy</td> </tr> <tr> <td>Treatment of autoimmune disease</td> </tr> <tr> <td>Bone marrow ablation prior to transplantation</td> </tr> <tr> <td>Treatment or prophylaxis of graft-versus-host disease following bone marrow transplantation</td> </tr> <tr> <td>Treatment of rejection following solid organ transplantation</td> </tr> <tr> <td class=\"subtitle1_single\">Microbial infection</td> </tr> <tr> <td class=\"sublist1_start\">Viral infection</td> </tr> <tr> <td class=\"sublist1\">HIV, AIDS</td> </tr> <tr> <td class=\"sublist1\">Measles</td> </tr> <tr> <td class=\"sublist1\">Herpes group viruses (HSV 1 or 2, EBV, CMV, VZV)</td> </tr> <tr> <td>Bacterial infection (superantigens)</td> </tr> <tr> <td>Mycobacterial infection</td> </tr> <tr> <td>Parasitic infestation</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Hodgkin disease</td> </tr> <tr> <td>Chronic lymphocytic leukemia</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Solid tumors</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of biochemical homeostasis</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Renal insufficiency/dialysis</td> </tr> <tr> <td>Hepatic insufficiency/cirrhosis</td> </tr> <tr> <td>Malnutrition</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune disease</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td>Burns</td> </tr> <tr> <td class=\"subtitle1_single\">Environmental exposure</td> </tr> <tr> <td class=\"sublist1_start\">Radiation</td> </tr> <tr> <td class=\"sublist1\">Ionizing</td> </tr> <tr> <td class=\"sublist1\">Ultraviolet</td> </tr> <tr> <td>Toxic chemicals</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Stress*</td> </tr> <tr> <td>Asplenia/hyposplenism</td> </tr> <tr> <td>Allogeneic blood transfusion</td> </tr> <tr> <td>Aging<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; HSV 1/2: herpes simplex viruses 1 or 2; EBV: Epstein-Barr virus; CMV: cytomegalovirus;&nbsp;VZV: varicella-zoster virus.<br />* Stress has been associated with an increased risk of infection, perhaps due to the effects of the endogenous stress cortisol response on the immune system.<br />¶ Aging has been associated with relative immunodeficiency,&nbsp;with&nbsp;reductions in cellular and humoral adaptive immune responses.&nbsp;Refer to the&nbsp;UpToDate topic on immune function in older adults. </div><div id=\"graphicVersion\">Graphic 71244 Version 7.0</div></div></div>"},"71248":{"type":"graphic_diagnosticimage","displayName":"Membranous VSD subcostal parasagittal 2D still frame","title":"Membranous VSD subcostal parasagittal 2D still frame","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Membranous VSD subcostal parasagittal 2D still frame</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/CARD/71248_Membr_VSD_subcost_parasagit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal parasagittal image illustrating the position of the ventricular septal defect in this echocardiographic window (arrow). The defect is immediately below the aortic valve and adjacent to the septal leaflet of the tricuspid valve.</div><div class=\"graphic_footnotes\">2D: two-dimensional; PA: pulmonary artery; AO: aorta; LA: left atrium; RV: right ventricle; TV: tricuspid valve; RA: right atrium; IVC: inferior vena cava.</div><div id=\"graphicVersion\">Graphic 71248 Version 4.0</div></div></div>"},"71249":{"type":"graphic_picture","displayName":"Bullous pemphigoid on lower legs","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71249_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tense bullae on the anterior tibial and ankle skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71249 Version 5.0</div></div></div>"},"71250":{"type":"graphic_picture","displayName":"Irritant contact dermatitis 2","title":"Irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:392px;\" src=\"images/DERM/71250_Irrit_cont_derm_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Localized erythema due to irritation from benzoyl peroxide.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71250 Version 1.0</div></div></div>"},"71251":{"type":"graphic_picture","displayName":"Infantile myofibroma head","title":"Infantile myofibromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile myofibromatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71251_Infantile_myofibroma_head.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, firm nodule is present on the forehead.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71251 Version 4.0</div></div></div>"},"71252":{"type":"graphic_diagnosticimage","displayName":"Distal humeral physis","title":"Distal humeral physis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal humeral physis</div><div class=\"cntnt\"><img style=\"width:425px; height:223px;\" src=\"images/EM/71252_Distalhumeralphysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) At 5 months of age, the metaphysis has advanced only to the supracondylar ridges. Panel B) By 4 years of age, the edge of the metaphysis has advanced well into the area of the epicondyles.</div><div class=\"graphic_reference\">Reproduced with permission from: Glotzbecker MP, Kasser JR. Distal Humeral Physeal, Medial Condyle, Lateral Epicondylar, and Other Uncommon Elbow Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins.&nbsp;<A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71252 Version 13.0</div></div></div>"},"71253":{"type":"graphic_table","displayName":"Comp oral lavage solutions","title":"Composition of oral polyethylene glycol-electrolyte solutions for gastrointestinal lavage*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of oral polyethylene glycol-electrolyte solutions for gastrointestinal lavage*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"6\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Colytely</td> <td class=\"subtitle1\">GoLytely</td> <td class=\"subtitle1\">MoviPrep</td> <td class=\"subtitle1\">NuLytely</td> <td class=\"subtitle1\">TriLyte</td> </tr> <tr> <td><strong>Na+ (mEq/L, mmol/L)</strong></td> <td class=\"centered\">125</td> <td class=\"centered\">125</td> <td class=\"centered\">182</td> <td class=\"centered\">65</td> <td class=\"centered\">65</td> </tr> <tr> <td><strong>K+ (mEq/L, mmol/L)</strong></td> <td class=\"centered\">10</td> <td class=\"centered\">10</td> <td class=\"centered\">14</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> </tr> <tr> <td><strong>Cl&ndash; (mEq/L, mmol/L)</strong></td> <td class=\"centered\">35</td> <td class=\"centered\">35</td> <td class=\"centered\">60</td> <td class=\"centered\">53</td> <td class=\"centered\">53</td> </tr> <tr> <td><strong>HC0<sub>3</sub><sup>&ndash;</sup> (mEq/L, mmol/L)</strong></td> <td class=\"centered\">20</td> <td class=\"centered\">20</td> <td class=\"centered\">0</td> <td class=\"centered\">17</td> <td class=\"centered\">17</td> </tr> <tr> <td><strong>S0<sub>4</sub><sup>&ndash;&ndash;</sup> (mmol/L)</strong></td> <td class=\"centered\">80</td> <td class=\"centered\">40</td> <td class=\"centered\">53</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> <tr> <td><strong>PEG</strong><sup>&#182;</sup> <strong>(grams/L)</strong></td> <td class=\"centered\">60</td> <td class=\"centered\">60</td> <td class=\"centered\">100</td> <td class=\"centered\">105</td> <td class=\"centered\">105</td> </tr> <tr> <td><strong>Osmolarity (average)</strong></td> <td class=\"centered\">280</td> <td class=\"centered\">280</td> <td class=\"centered\">560</td> <td class=\"centered\">288</td> <td class=\"centered\">288</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Over-the-counter (non-prescription) PEG 3350 (eg, MiraLax, GlycoLax) mixed in 2 liters of fluid (often a sports drink or sugar-free powdered drink) has been used as an alternative to balanced electrolyte solutions containing PEG. The electrolyte composition of the solution will depend on what fluid the PEG 3350 is mixed in. PEG 3350 without balanced electrolytes is not approved by the US Food &amp; Drug Administration for use as a bowel preparation prior to colonoscopy.</div><div class=\"graphic_footnotes\">* Composition is for solutions reconstituted with appropriate volume of water according to the US product information. Check local prescribing information for product specific detail. Trade names shown are for products available in the US and in some other countries.<br />&#182; PEG 3350: Polyethylene glycol (macrogol) 3350 (average molecular weight).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Keefe EB. Colonoscopy preps: What's best? Gastrointest Enclosc 1996; 43:524.</li>&#xD;&#xA;    <li>Sharara AI, Abou Mrad RR. The modern bowel preparation in colonoscopy. Gastroenterol Clin North Am 2013; 42:577.</li>&#xD;&#xA;    <li>United States product information available at <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a> (accessed October 3, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71253 Version 6.0</div></div></div>"},"71258":{"type":"graphic_table","displayName":"ECG findings Brugada syndrome","title":"Patterns of ST abnormalities in leads V1 to V3 in Brugada syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patterns of ST abnormalities in leads V1 to V3 in Brugada syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Type 1</td> <td class=\"subtitle1\">Type 2</td> </tr> <tr> <td>J wave amplitude</td> <td>&#8805;2 mm</td> <td>&#8805;2 mm</td> </tr> <tr> <td>T wave</td> <td>Negative</td> <td>Positive or biphasic</td> </tr> <tr> <td>ST-T configuration</td> <td>Coved type</td> <td>Saddle back</td> </tr> <tr> <td>ST segment (terminal portion)</td> <td>Gradually descending</td> <td>Elevated &#8805;1 mm</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002; 23:1648. Copyright © 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 71258 Version 5.0</div></div></div>"},"71259":{"type":"graphic_picture","displayName":"Heparin necrosis purpura","title":"Heparin necrosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Heparin necrosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71259_Heparin_necrosis_purpura_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric lesions and skin necrosis are present in this patient with heparin necrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71259 Version 3.0</div></div></div>"},"71260":{"type":"graphic_algorithm","displayName":"Approach to anisocoria","title":"Flowchart explaining the approach to a patient with anisocoria","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Flowchart explaining the approach to a patient with anisocoria</div><div class=\"cntnt\"><img style=\"width:604px; height:664px;\" src=\"images/NEURO/71260_Approach_anisocoria_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71260 Version 3.0</div></div></div>"},"71261":{"type":"graphic_table","displayName":"Spetzler Martin grading scale","title":"Spetzler-Martin Intracranial AVM grading scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spetzler-Martin Intracranial AVM grading scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Size</td> </tr> <tr> <td class=\"indent1\">0 to 3 cm</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">3.1 to 6.0 cm</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">&#62;6 cm</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Location</td> </tr> <tr> <td class=\"indent1\">Noneloquent brain area</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Eloquent brain area*</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Deep venous drainage</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Present</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Score = sum of all categories, with lesions graded I to V based upon total sum (eg, grade I = 1 point).</div><div class=\"graphic_footnotes\">* Associated with significant neurologic impairment (eg, language area, motor cortex, others).</div><div class=\"graphic_reference\">From: Spetzler RF, Martin NA, J Neurosurg 1986; 65:476.</div><div id=\"graphicVersion\">Graphic 71261 Version 3.0</div></div></div>"},"71262":{"type":"graphic_figure","displayName":"Removal scutum","title":"Removal of the scutum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removal of the scutum</div><div class=\"cntnt\"><img style=\"width:392px; height:424px;\" src=\"images/PEDS/71262_Removal_scutum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When a cholesteatoma has extended beyond the accessible confines of the middle ear, it is necessary to remove cranial bone to reach the temporal bone spaces above and behind the middle ear. In the above figure, the scutum (the thin bony plate separating the upper part of the middle ear from the mastoid cells) has been drilled away to expose the cholesteatoma in the space just superior to the middle ear (ie, the attic or epitympanum).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 71262 Version 3.0</div></div></div>"},"71263":{"type":"graphic_table","displayName":"Uncommon causes pneumonia","title":"Less common etiologic agents of pediatric pneumonia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Less common etiologic agents of pediatric pneumonia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Microbial agent</td> <td class=\"subtitle1\">Susceptible hosts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em> (typeable and nontypeable)</td> <td>Unimmunized (<em>H. influenzae</em> type b)</td> </tr> <tr> <td class=\"indent1\"><em>Moraxella catarrhalis</em></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Neisseria meningitidis</em> (often group Y)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em> spp</td> <td>Immunocompromised hosts, nosocomial pathogen</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> <td>Immunocompromised hosts, nosocomial pathogen</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter</em> spp</td> <td>Immunocompromised hosts, nosocomial pathogen</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>Immunocompromised hosts, nosocomial pathogen, cystic fibrosis</td> </tr> <tr> <td class=\"indent1\"><em>Burkholderia cepacia</em></td> <td>Cystic fibrosis patients</td> </tr> <tr> <td class=\"indent1\"><em>Achromobacter xylosoxidans</em></td> <td>Cystic fibrosis patients, nosocomial pathogen</td> </tr> <tr> <td class=\"indent1\"><em>Stenotrophomonas maltophilia</em></td> <td>Cystic fibrosis patients, nosocomial pathogen</td> </tr> <tr> <td class=\"indent1\"><em>Legionella pneumophila</em></td> <td>Immunocompromised hosts</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas pseudomallei</em></td> <td>Travelers to or residents of endemic areas</td> </tr> <tr> <td class=\"indent1\"><em>Francisella tularensis</em></td> <td>Exposure to a particular animal reservoir (rabbits) or insect vector; bioterrorist activity</td> </tr> <tr> <td class=\"indent1\"><em>Brucella abortus</em></td> <td>Exposure to a particular animal reservoir (cattle, goats)</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia psittaci</em></td> <td>Exposure to a particular animal reservoir (psittacines - parrots, parakeets, macaws, and virtually all domestic and wild birds)</td> </tr> <tr> <td class=\"indent1\"><em>Leptospira</em> spp</td> <td>Exposure to a particular animal reservoir</td> </tr> <tr> <td class=\"indent1\"><em>Yersinia pestis</em></td> <td>Exposure to a particular animal reservoir or insect vector (rats); bioterrorist activity</td> </tr> <tr> <td class=\"indent1\">Anaerobic mouth flora (<em>Prevotella</em> spp, Fusobacterium, <em>Bacteroides</em> spp)</td> <td>Aspiration</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em></td> <td>Travelers to or residents of endemic areas, contact with known TB, homeless, recent immigrants from endemic areas, prisoners, and HIV-infected individuals</td> </tr> <tr> <td class=\"indent1\">Nontuberculous mycobacterium</td> <td>Cystic fibrosis patients, immunocompromised hosts</td> </tr> <tr> <td class=\"indent1\"><em>Bordetella pertussis</em></td> <td>Infants, exposure to adult with a cough illness</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fungi</td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides immitis</em></td> <td>Travelers to or residents of endemic areas (southwest United States)</td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma capsulatum</em></td> <td>Travelers to or residents of endemic areas (Ohio, Mississippi, and Missouri River valleys)</td> </tr> <tr> <td class=\"indent1\"><em>Blastomyces dermatitidis</em></td> <td>Travelers to or residents of endemic areas (Ohio and Mississippi River valleys)</td> </tr> <tr> <td class=\"indent1\"><em>Candida</em> spp</td> <td>Nosocomial pathogen, immunocompromised hosts, cystic fibrosis</td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus</em> spp</td> <td>Nosocomial pathogen, immunocompromised hosts, cystic fibrosis</td> </tr> <tr> <td class=\"indent1\"><em>Pneumocystis jiroveci</em> (formerly <em>carinii</em>)</td> <td>Immunocompromised hosts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rickettsiae</td> </tr> <tr> <td class=\"indent1\"><em>Coxiella burnetii</em></td> <td>Exposure to a particular animal reservoir (sheep)</td> </tr> <tr> <td class=\"indent1\"><em>Rickettsia rickettsii</em></td> <td>Exposure to a particular insect vector</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Viruses</td> </tr> <tr> <td class=\"indent1\">Rubeola</td> <td>Travelers to or residents of endemic areas</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>Neonates and immunocompromised hosts</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> <td>Immunocompromised hosts, first 3 months of life</td> </tr> <tr> <td class=\"indent1\">Epstein Barr virus</td> <td>Immunocompromised hosts</td> </tr> <tr> <td class=\"indent1\">Varicella zoster virus</td> <td>Immunocompromised hosts</td> </tr> <tr> <td class=\"indent1\">Coronavirus</td> <td>SARS and MERS (travel to or exposure to travelers from endemic areas)</td> </tr> <tr> <td class=\"indent1\">Enterovirus</td> <td>Asthmatics (enterovirus D68)</td> </tr> <tr> <td class=\"indent1\">Rubella</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hantavirus</td> <td>Travelers to or residents of endemic areas, exposure to a particular animal reservoir (mouse droppings)</td> </tr> <tr> <td class=\"indent1\">HIV</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Mumps</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bocavirus</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Parechovirus</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Avian influenza</td> <td>Exposure to birds; travel to affected area</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis; HIV: human immunodeficiency virus; SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome.<br />* Excluding neonatal pneumonia (in infants &lt;28 days of age).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Diseases, Feigin BD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004.</li>&#xD;&#xA;    <li>Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.</li>&#xD;&#xA;    <li>Klein JO. Bacterial pneumonias. In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004. </li>&#xD;&#xA;    <li>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429. </li>&#xD;&#xA;    <li>Sandora T, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71263 Version 15.0</div></div></div>"},"71264":{"type":"graphic_figure","displayName":"TAPP hernia reduction","title":"TAPP hernia reduction","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">TAPP hernia reduction</div><div class=\"cntnt\"><img style=\"width:474px; height:411px;\" src=\"images/SURG/71264_TAPP_hernia_reduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Maithel SK, Schneider BE. Atlas of minimally invasive surgery. Ciné-Med, Woodbury, CT 2006. Copyright © 2006 Ciné-Med, Inc.</div><div id=\"graphicVersion\">Graphic 71264 Version 10.0</div></div></div>"},"71265":{"type":"graphic_table","displayName":"Meningococcal vaccination indications in the US","title":"Meningococcal vaccination recommendations in the United States by age and/or risk factor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Meningococcal vaccination recommendations in the United States by age and/or risk factor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Targeted group by age and/or risk factor</td> <td class=\"subtitle1\">Primary dose(s)</td> <td class=\"subtitle1\">Booster dose(s)</td> </tr> <tr> <td class=\"divider_bottom\"><strong>For ages 11 through 18 years</strong></td> <td class=\"divider_bottom\"> <p>Give one dose of Menactra or Menveo, preferably at age 11 or 12 years.</p> Discuss serogroup B meningococcus vaccination (Trumenba or Bexsero)*, which may be administered to adolescents and young adults 16 through 23 years of age; the preferred age for vaccination is 16 through 18 years of age (perhaps at the time of Menactra or Menveo booster).</td> <td class=\"divider_bottom\">If primary dose was given at age &#8804;12 years, give Menactra or Menveo booster at age 16 years. If primary dose was given at age 13 to 15 years, give Menactra or Menveo booster at age 16 to 18 years<sup>&#182;</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>For individuals ages 19 through 21 years who are first year college students living in residence halls</strong></td> <td> <p>If not yet received a dose of vaccine, give one dose of Menactra or Menveo.</p> Discuss serogroup B meningococcus vaccination (Trumenba or Bexsero)*, which may be administered to adolescents and young adults 16 through 23 years of age; the preferred age for vaccination is 16 through 18 years of age.</td> <td>Give Menactra or Menveo booster if previous dose given at age younger than 16 years.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Patients with HIV infection</td> </tr> <tr> <td class=\"indent1\">For age &#60;2 years</td> <td>Give four doses of Menveo (at ages 2, 4, 6, and 12 to 15 months) or give two doses of Menactra<sup>&#916;</sup> (at age 9 to 23 months, 12 weeks apart).</td> <td>Give additional dose of Menveo or Menactra&nbsp;three years after primary series. Booster doses should be repeated every&nbsp;five years thereafter. </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For age &#8805;2 years</td> <td>Give two doses of Menveo or Menactra 8 to 12 weeks apart.</td> <td> <p>For individuals age &#60;7 years at previous dose, give additional dose of Menveo or Menactra&nbsp;three years after primary series. If the most recent dose was received before age 7 years, a booster dose should be readministered&nbsp;three years later. Booster doses should be repeated every&nbsp;five years thereafter.&nbsp;</p> <p>For individuals age &#8805;7 years at previous dose, give additional dose of Menveo or Menactra&nbsp;five years after primary series; booster doses should be repeated every&nbsp;five years thereafter.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">For age 2 months through 18 months</td> <td>Give Menveo at ages 2, 4, 6, and 12 to 15 months.</td> <td rowspan=\"2\">If risk continues, give initial booster after&nbsp;three years followed by boosters every five years.</td> </tr> <tr> <td class=\"indent1\">For children age 7 months through 23 months who have not initiated a series of Menveo</td> <td>Give Menveo (if age 7 to 23 months)<sup>&#167; </sup>or Menactra (if age 9 to 23 months); administer two doses separated by&nbsp;three months<sup>&#165;</sup>.</td> </tr> <tr> <td class=\"indent1\">For age 2 years through 55 years</td> <td>Give one dose of Menactra or Menveo.</td> <td>Boost every five years with Menactra or Menveo<sup>&#135;,&#134;</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For age 56 years and older</td> <td>Give one dose of Menactra or Menveo**.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#134;</sup>.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">People with prolonged increased risk for exposure (eg, military recruits, microbiologists routinely working with <em>Neisseria meningitidis</em>)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For age&nbsp;10 years and older</td> <td> <p>Give one dose of Menactra or Menveo**<sup>,&#182;&#182;</sup>.</p> Give either Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#134;</sup>.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">People present during outbreaks caused by a meningococcal vaccine serogroup<sup>&#182;&#182;,&#916;&#916;</sup></td> </tr> <tr> <td class=\"indent1\">For age 2 months through 18 months</td> <td>Give Menveo at ages 2, 4, 6, and 12 to 15 months.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">For children age 7 months through 23 months who have not initiated a series of Menveo</td> <td>Give Menveo (if age 7 to 23 months)<sup>&#167;</sup> or Menactra (if age 9 to 23 months); administer two doses separated by 3 months<sup>&#165;</sup>.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">For age 2 years&nbsp;through 9 years</td> <td>Give one dose of Menactra or Menveo.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">For age 10 years&nbsp;through 55 years</td> <td> <p>Give one dose of Menactra or Menveo<sup>&#182;&#182;</sup>.</p> Give either Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For age 56 years and older</td> <td> <p>Give one dose of Menactra or Menveo**<sup>,</sup><sup>&#182;&#182;</sup>.</p> Give either Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">People with persistent complement component deficiencies<sup>&#9674;&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">For age 2 months through 18 months</td> <td>Give Menveo at ages 2, 4, 6, and 12 to 15 months.</td> <td>Give Menactra or Menveo booster after&nbsp;three years followed by boosters every&nbsp;five years thereafter.</td> </tr> <tr> <td class=\"indent1\">For children age 7 months&nbsp;through 23 months who have not initiated a series of Menveo</td> <td>Give Menveo (if age 7 to 23 months)<sup>&#167;</sup> or Menactra (if age 9 to 23 months); administer two doses separated by&nbsp;three months.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">For age 2 years through 9 years</td> <td>Give two doses of Menactra or Menveo&nbsp;two months apart.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#135;,&#167;&#167;</sup>.</td> </tr> <tr> <td class=\"indent1\">For age 10 years through 55 years</td> <td>Give two doses of Menactra or Menveo two months apart <strong>and either</strong> Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#135;,&#167;&#167;</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For age 56 years and older</td> <td>Give two doses of Menactra or Menveo&nbsp;two months apart** <strong>and either</strong> Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#167;&#167;</sup>.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">People with functional or anatomic asplenia, including sickle cell disease</td> </tr> <tr> <td class=\"indent1\">For age 2 months through 18 months</td> <td>Give Menveo at ages 2, 4, 6, and 12 months.</td> <td rowspan=\"2\">Give Menactra or Menveo booster after&nbsp;three years followed by boosters every&nbsp;five years thereafter.</td> </tr> <tr> <td class=\"indent1\">For children age 19 months&nbsp;through 23 months who have not initiated a series of Menveo</td> <td>Give two doses of Menveo&nbsp;three months apart.</td> </tr> <tr> <td class=\"indent1\">For age 2 years&nbsp;through 9 years</td> <td>Give two doses of Menactra or Menveo&nbsp;two months apart<sup>&#165;&#165;</sup>.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#135;,&#167;&#167;</sup>.</td> </tr> <tr> <td class=\"indent1\">For age 10 years&nbsp;through 55 years</td> <td>Give two doses of Menactra or Menveo&nbsp;two months apart<sup>&#165;&#165;</sup> <strong>and either</strong> Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#135;,&#167;&#167;</sup>.</td> </tr> <tr> <td class=\"indent1\">For age 56 years and older</td> <td>Give two doses of Menactra or Menveo&nbsp;two months apart** <strong>and either</strong> Trumenba (three doses administered at 0, 1 to 2, and 6 months) or Bexsero (two doses administered at least one month apart)<sup>&#182;&#182;</sup>.</td> <td>Boost every&nbsp;five years with Menactra or Menveo<sup>&#167;&#167;</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table was adapted from the recommendations of the United States Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) for the use of meningococcal vaccines<SUP>[1-7]</SUP>.<br />The quadrivalent meningococcal conjugate vaccines (MenACWY) are Menactra (MenACWY-DT) and Menveo (MenACWY-CRM); these have replaced the quadrivalent meningococcal polysaccharide vaccine Menomune (MPSV4). MenHibrix (HibMenCY), a combination conjugate vaccine against meningococcus serogroups C and Y and <EM>Haemophilus influenzae</EM> type b, was discontinued in 2017. Trumenba (MenB-FHbp) and Bexsero (MenB-4C) are meningococcus serogroup B vaccines.</div><div class=\"graphic_footnotes\">* Trumenba (two-dose series; second dose given six months after first dose; if the second dose is administered earlier than six months after the first dose, a third dose should be administered at least four months after the second dose) or Bexsero (two-dose series; second dose given at least one month after the first dose) may be given concomitantly with quadrivalent meningococcal conjugate vaccines but at different anatomic sites if feasible. The same meningococcus serogroup B vaccine should be given for all doses.<br />¶ The minimum interval between doses of Menactra or Menveo is eight weeks.<br />Δ If Menactra is used, it should be administered at least four weeks after completion of all pneumococcal conjugate vaccine doses and either before or concomitantly with DTaP.<br /><FONT class=lozenge>◊</FONT> Prior receipt of MenHibrix is not sufficient for children traveling to the Hajj or African meningitis belt as it doesn't provide protection against serogroups A or W135.<br />§&nbsp;If using Menveo, dose 2 should be given no younger than age 12 months.<br />¥ If a child age 7 through 23 months will enter an endemic area in less than three months, give doses as close as two months apart.<br />‡&nbsp;If primary dose(s) given when younger than age 7 years, give initial booster after three years, followed by boosters every five years.<br />†&nbsp;Booster doses are recommended if the person remains at increased risk.<br />** Only the quadrivalent meningococcal polysaccharide vaccine (Menomune; MPSV4) has been approved by the US Food and Drug Administration for individuals ≥56 years of age; however, the quadrivalent meningococcal polysaccharide vaccine was discontinued in 2017. In addition, a quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) is preferred by the ACIP for individuals in this age group who are expected to require revaccination, since limited data demonstrate a higher antibody response after a subsequent dose of a quadrivalent meningococcal conjugate vaccine compared with a subsequent dose of the quadrivalent meningococcal polysaccharide vaccine. Refer to the associated UpToDate topic review for additional details.<br />¶¶ During outbreaks, seek advice of local public health authorities to determine if vaccination is recommended and to determine which formulation(s) should be given.<br />ΔΔ Given the outbreak of meningococcal disease (first reported in 2012) in men who have sex with men (MSM) in New York City and Los Angeles, we recommend meningococcal vaccination with Menactra or Menveo for MSM, if their residence, travel, or social interactions put them in close contact with other MSM from New York City or Los Angeles<SUP>[8-12]</SUP>.<br />◊◊ Patients with persistent complement component deficiencies include those with the following deficiencies: C3, C5 to C9, properdin, factor H, and factor D as well as those receiving eculizumab (a monoclonal antibody used for treatment of complement-mediated hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria). Patients warranting treatment with eculizumab should be immunized with meningococcal vaccines (both ACYW135 and serogroup B) at least two weeks prior to administering the first dose of eculizumab, if feasible.<br />§§ If the person received a one-dose primary series, give booster at the earliest opportunity, then boost every five years.<br />¥¥&nbsp;Individuals with functional or anatomic asplenia should complete an age-appropriate series of the pneumococcal conjugate vaccine (PCV13) before vaccination with Menactra. Menactra should not be administered until two years of age and for at least four weeks after the completion of all pneumococcal conjugate vaccine doses; otherwise it may interfere with the protection by the pneumococcal conjugate vaccine. Menveo may be given at any time before or after PCV13.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</li>&#xD;&#xA;    <li>Strikas RA. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:93.</li>&#xD;&#xA;    <li>Kim DK, Riley LE, Harriman KH et al. Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med 2017; 166:209.</li>&#xD;&#xA;    <li>Committee on Infectious Diseases. Updated recommendations on the use of meningococcal vaccines. Pediatrics 2014; 134:400.</li>&#xD;&#xA;    <li>Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged &ge;10 years at increased risk for serogroup b meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608.</li>&#xD;&#xA;    <li>MacNeil JR, Rubin LG, Patton M, et al. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2016 Nov 4;65(43):1189-1194.</li>&#xD;&#xA;    <li>ACIP endorses individual choice on meningitis B vaccine. http://www.cidrap.umn.edu/news-perspective/2015/06/acip-endorses-individual-choice-meningitis-b-vaccine (Accessed June 25, 2015).</li>&#xD;&#xA;    <li>Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men - New York City, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 61:1048.</li>&#xD;&#xA;    <li>New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. http://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).</li>&#xD;&#xA;    <li>Commonwealth of Massachusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012. http://www.mass.gov/eohhs/docs/dph/cdc/immunization/alerts-meningococcal-msm.pdf (Accessed on October 26, 2012).</li>&#xD;&#xA;    <li>NYC Health. 2014 Alert #28 - Update: Invasive meningococcal disease in men who have sex with men. https://a816-health29ssl.nyc.gov/sites/NYCHAN/Lists/AlertUpdateAdvisoryDocuments/HAN%20IMD%20in%20MSM%20Sept%202014.pdf (Accessed on April 13, 2015).</li>&#xD;&#xA;    <li>County of Los Angeles Public Health. Public Health issues new vaccination recommendations for men who have sex with men (MSM) at-risk for invasive meningococcal disease http://www.publichealth.lacounty.gov/docs/PressReleaseIMDRecommend-4-2-14.pdf (Accessed on April 15, 2015).</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from the Immunization Action Coalition (www.immunize.org).</div><div id=\"graphicVersion\">Graphic 71265 Version 72.0</div></div></div>"},"71266":{"type":"graphic_diagnosticimage","displayName":"Brain MRI four-year-old with Krabbe disease","title":"Brain MRI of a four-year-old girl with Krabbe disease","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a four-year-old girl with Krabbe disease</div><div class=\"cntnt\"><img style=\"width:584px; height:243px;\" src=\"images/NEURO/71266_Brain_MRI_4yr_Krabbe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal (B) fluid-attenuated inversion recovery brain MRI scans show bilateral symmetric hyperintense signal changes involving the corticospinal tracts. (C) Sagittal T2-weighted MRI shows the hyperintense signal along the corticospinal tract from the cortical area extending into the internal capsule.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Sehgal R, Sharma S, Sankhyan N, et al. Selective corticospinal tract involvement in late-onset Krabbe disease. Neurology 2011; 77:e20. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71266 Version 7.0</div></div></div>"},"71267":{"type":"graphic_picture","displayName":"Lipoma trunk","title":"Multiple lipomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple lipomas</div><div class=\"cntnt\"><img style=\"width:336px; height:367px;\" src=\"images/DERM/71267_Lipoma_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has multiple soft, flesh-colored nodules consistent with lipomas. Scars are present at sites of previous excisions.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71267 Version 2.0</div></div></div>"},"71268":{"type":"graphic_table","displayName":"Common poisoning syndromes - toxidromes","title":"Common poisoning syndromes (toxidromes)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common poisoning syndromes (toxidromes)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Toxidrome</td> <td class=\"subtitle1\">Mental status</td> <td class=\"subtitle1\">Pupils</td> <td class=\"subtitle1\">Vital signs</td> <td class=\"subtitle1\">Other manifestations</td> <td class=\"subtitle1\">Examples of toxic agents</td> </tr> <tr> <td>Sympathomimetic</td> <td>Hyperalert, agitation, hallucinations, paranoia</td> <td>Mydriasis</td> <td>Hyperthermia, tachycardia, hypertension, widened pulse pressure, tachypnea, hyperpnea</td> <td>Diaphoresis, tremors, hyperreflexia, seizures</td> <td>Cocaine, amphetamines, cathinones, ephedrine, pseudoephedrine, phenylpropanolamine, theophylline, caffeine</td> </tr> <tr> <td>Anticholinergic</td> <td>Hypervigilance, agitation, hallucinations, delirium with mumbling speech, coma</td> <td>Mydriasis</td> <td>Hyperthermia, tachycardia, hypertension, tachypnea</td> <td>Dry flushed skin, dry mucous membranes, decreased bowel sounds, urinary retention, myoclonus, choreoathetosis, picking behavior, seizures (rare)</td> <td>Antihistamines, tricyclic antidepressants, cyclobenzaprine, orphenadrine, antiparkinson agents, antispasmodics, phenothiazines, atropine, scopolamine, belladonna alkaloids (eg, Jimson Weed)</td> </tr> <tr> <td>Hallucinogenic</td> <td>Hallucinations, perceptual distortions, depersonalization, synesthesia, agitation</td> <td>Mydriasis (usually)</td> <td>Hyperthermia, tachycardia, hypertension, tachypnea</td> <td>Nystagmus</td> <td>Phencyclidine, LSD, mescaline, psilocybin, designer amphetamines (eg, MDMA [\"Ecstasy\"], MDEA)</td> </tr> <tr> <td>Opioid</td> <td>CNS depression, coma</td> <td>Miosis</td> <td>Bradypnea, apnea characteristic; May develop: hypothermia, bradycardia, hypotension</td> <td>Hyporeflexia, pulmonary edema, needle marks</td> <td>Opioids (eg, heroin, morphine, methadone, oxycodone, hydromorphone), diphenoxylate</td> </tr> <tr> <td>Sedative-hypnotic</td> <td>CNS depression, confusion, stupor, coma</td> <td>Variable</td> <td>Often normal, but may develop: hypothermia, bradycardia, hypotension, apnea, bradypnea</td> <td>Hyporeflexia</td> <td>Benzodiazepines, barbiturates, carisoprodol, meprobamate, glutethimide, alcohols, zolpidem</td> </tr> <tr> <td>Cholinergic</td> <td>Confusion, coma</td> <td>Miosis</td> <td>Bradycardia, hypertension or hypotension, tachypnea or bradypnea</td> <td>Salivation, urinary and fecal incontinence, diarrhea, emesis, diaphoresis, lacrimation, GI cramps, bronchoconstriction, muscle fasciculations and weakness, seizures</td> <td>Organophosphate and carbamate insecticides, nerve agents, nicotine, pilocarpine, physostigmine, edrophonium, bethanechol, urecholine</td> </tr> <tr> <td>Serotonin syndrome</td> <td>Confusion, agitation, coma</td> <td>Mydriasis</td> <td>Hyperthermia, tachycardia, hypertension, tachypnea</td> <td>Tremor, myoclonus, hyperreflexia, clonus, diaphoresis, flushing, trismus, rigidity, diarrhea</td> <td>MAOIs alone or with: SSRIs, meperidine, dextromethorphan, TCAs, L-tryptophan</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LSD: lysergic acid diethylamide; MDMA: 3,4-methylenedioxymethamphetamine; MDEA: methylenedioxymethamphetamine; CNS: central nervous system; GI: gastrointestinal; MAOI: monoamine oxidase inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant.</div><div id=\"graphicVersion\">Graphic 71268 Version 18.0</div></div></div>"},"71269":{"type":"graphic_picture","displayName":"Esophageal squamous ca Lugols","title":"Chromoendoscopy of esophageal squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromoendoscopy of esophageal squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:307px; height:330px;\" src=\"images/GAST/71269_Esophageal_squamous_ca_Lugo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the esophagus following staining with Lugol's iodine solution showing squamous cell carcinoma, which appears as an unstained plaque (arrow). The dark brown areas are normal squamous mucosa.</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 71269 Version 2.0</div></div></div>"},"71271":{"type":"graphic_table","displayName":"Skin disorders associated with celiac disease","title":"Skin disorders associated with celiac disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skin disorders associated with celiac disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Acquired ichthyosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cutaneous amyloid</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cutaneous vasculitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dermatitis herpetiformis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Eczema</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Epidermal necrolysis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Nodular prurigo</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pityriasis rubra pilara</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pustular dermatitis</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 71271 Version 3.0</div></div></div>"},"71274":{"type":"graphic_table","displayName":"Antiseizure drug mechanisms","title":"Common mechanisms of antiseizure drug action","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common mechanisms of antiseizure drug action</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Na+ channels</td> <td class=\"subtitle1\">Ca+ channels</td> <td class=\"subtitle1\">K+ channels</td> <td class=\"subtitle1\">Inhibitory transmission</td> <td class=\"subtitle1\">Excitatory transmission</td> <td class=\"subtitle1\">SV2A binding&nbsp;</td> </tr> <tr> <td>Benzodiazepines</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Brivaracetam&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;+++</td> </tr> <tr> <td>Carbamazepine</td> <td>+++</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Clobazam</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Ethosuximide</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Felbamate</td> <td>++</td> <td>+</td> <td>&nbsp;</td> <td>++</td> <td>++</td> <td>&nbsp;</td> </tr> <tr> <td>Gabapentin</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Lacosamide</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Lamotrigine</td> <td>+++</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Levetiracetam</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+++&nbsp;</td> </tr> <tr> <td>Oxcarbazepine</td> <td>+++</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Perampanel&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+++&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Phenobarbital</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>+++</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Phenytoin</td> <td>+++</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Rufinamide</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Tiagabine</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Topiramate</td> <td>++</td> <td>++</td> <td>&nbsp;</td> <td>++</td> <td>++</td> <td>&nbsp;</td> </tr> <tr> <td>Valproate</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>++</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Vigabatrin</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Zonisamide</td> <td>++</td> <td>++</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">+++: primary action; ++: probable action; +: possible action.<br />SV2A: synaptic vesicle protein 2A.</div><div class=\"graphic_reference\">Adapted with permission from: Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71274 Version 15.0</div></div></div>"},"71276":{"type":"graphic_figure","displayName":"Prop gen model cen chondro","title":"Proposed multistep genetic model for central chondrosarcoma development and candidates for targeted treatment","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Proposed multistep genetic model for central chondrosarcoma development and candidates for targeted treatment</div><div class=\"cntnt\"><img style=\"width:536px; height:444px;\" src=\"images/ONC/71276_Prop_gen_mod_cen_chon_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows show candidate adjuvant treatment strategies based on identification of molecular changes during chondrosarcoma progression. Candidate targets based on single immunohistochemical studies (COX2, matrix metalloproteinases [MMP], cathepsin, and platelet-derived growth factor receptor [PDGFR]) are also shown. These should be confirmed in larger series in the different subtypes of conventional chondrosarcoma by use of additional techniques.</div><div class=\"graphic_footnotes\">IDH: isocitrate dehydrogenase.</div><div class=\"graphic_reference\">Modified from: Bov&#233;e JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2006; 6:599. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71276 Version 2.0</div></div></div>"},"71277":{"type":"graphic_table","displayName":"Toxicity adjuvant IFN alfa","title":"Toxicity profile of high-dose interferon-alfa in patients with melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicity profile of high-dose interferon-alfa in patients with melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Adverse event</td> <td class=\"subtitle1\" colspan=\"2\">Patients, percent</td> </tr> <tr> <td class=\"subtitle2\">All grades* (n = 143)</td> <td class=\"subtitle2\">Grade 3/4<sup>&#182;</sup> (range)</td> </tr> <tr> <td>Fatigue</td> <td>96</td> <td>21-24</td> </tr> <tr> <td>Fever</td> <td>81</td> <td>18</td> </tr> <tr> <td>Myalgia</td> <td>75</td> <td>4-17</td> </tr> <tr> <td>Nausea</td> <td>66</td> <td>5-9</td> </tr> <tr> <td>Vomiting</td> <td>66</td> <td>5</td> </tr> <tr> <td>Myelosuppression</td> <td>92</td> <td>26-60</td> </tr> <tr> <td>Increased AST</td> <td>63</td> <td>14-29</td> </tr> <tr> <td>Depression/neuropsychiatric/neuropsychologic</td> <td>40</td> <td>2-10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AST: aspartate aminotransferase.<br />* Based upon data from 143 patients treated with high-dose interferon-alfa in ECOG trial 1684.<br />¶ Based upon combined data from ECOG 1684, 1690, and 1694.</div><div class=\"graphic_reference\">Reproduced with permission from: Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon of alfa-2b therapy. J Clin Oncol 2002; 20:3703. Copyright ©2002 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 71277 Version 3.0</div></div></div>"},"71280":{"type":"graphic_picture","displayName":"Skin findings Wiskott-Aldrich syndrome","title":"Skin findings in Wiskott-Aldrich syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin findings in Wiskott-Aldrich syndrome</div><div class=\"cntnt\"><img style=\"width:300px; height:341px;\" src=\"images/PEDS/71280_Skin_findings_Wiskott_Aldri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eczema and petechiae in a child with Wiskott-Aldrich sydrome.</div><div class=\"graphic_reference\">Courtesy of Douglas J Barrett, MD.</div><div id=\"graphicVersion\">Graphic 71280 Version 3.0</div></div></div>"},"71281":{"type":"graphic_table","displayName":"Adverse drug events","title":"Frequency of adverse drug events and preventable adverse drug events by drug class","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of adverse drug events and preventable adverse drug events by drug class</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug class</td>\n<td class=\"subtitle1\">Total adverse drug events (n = 815) N (percent)</td>\n<td class=\"subtitle1\">Preventable adverse drug events (n = 338) N (percent)</td>\n</tr>\n<tr>\n<td>Warfarin</td>\n<td>121 (15)</td>\n<td>42 (12)</td>\n</tr>\n<tr>\n<td>Atypical antipsychotics</td>\n<td>92 (11)</td>\n<td>42 (12)</td>\n</tr>\n<tr>\n<td>Loop diuretics </td>\n<td>69 (8)</td>\n<td>33 (10)</td>\n</tr>\n<tr>\n<td>Opioids</td>\n<td>51 (6)</td>\n<td>26 (8)</td>\n</tr>\n<tr>\n<td>Antiplatelets</td>\n<td>46 (6)</td>\n<td>23 (7)</td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>45 (6)</td>\n<td>27 (8)</td>\n</tr>\n<tr>\n<td>Antidepressants</td>\n<td>43 (5)</td>\n<td>25 (7)</td>\n</tr>\n<tr>\n<td>Laxatives</td>\n<td>43 (5)</td>\n<td>16 (5)</td>\n</tr>\n<tr>\n<td>Benzodiazepines (intermediate acting)</td>\n<td>39 (5)</td>\n<td>30 (9)</td>\n</tr>\n<tr>\n<td>Insulins</td>\n<td>37 (5)</td>\n<td>18 (5)</td>\n</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">3/14/2006 perm requested should be no fee 4/14/2006 granted</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57270&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Adverse_drug_events.htm</title></head></div><div class=\"graphic_lgnd\">Only drug classes with the frequency of adverse drug events of 5 percent and more are presented. Some adverse drug events were associated with more than one drug class.</div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Adapted with permission from: Gurwitz, MD, Field, T, Judge, J, Rochon, P, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251. Copyright © 2005 Excerpta Media.</div><div id=\"graphicVersion\">Graphic 71281 Version 2.0</div></div></div>"},"71284":{"type":"graphic_table","displayName":"Periop factors aggravating OSA","title":"Factors contributing to acute perioperative aggravation of obstructive sleep apnea (OSA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors contributing to acute perioperative aggravation of obstructive sleep apnea (OSA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Depressant influences of anesthetics/sedatives/analgesics on central respiratory drive, upper airway protective reflexes, and arousal responses</td> </tr> <tr> <td>Intraluminal upper airway narrowing due to post-endotracheal intubation edema, nasal packings, nasal tubes, or hematomas</td> </tr> <tr> <td>Forced supine positioning</td> </tr> <tr> <td>Sleep deprivation </td> </tr> <tr> <td>Intense rapid eye movement (REM) rebound </td> </tr> <tr> <td>Temporary suspension of continuous positive airway pressure (CPAP) therapy due to pain, anxiety, nausea, restlessness, presence of a nasogastric tube, failure to bring the equipment to the hospital, or lack of planning for postoperative application.</td> </tr> <tr> <td>&nbsp;Rostral fluid shift</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71284 Version 3.0</div></div></div>"},"71285":{"type":"graphic_diagnosticimage","displayName":"FNH CT MRI Sulfur colloid","title":"Focal nodular hyperplasia of the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal nodular hyperplasia of the liver</div><div class=\"cntnt\"><img style=\"width:323px; height:317px;\" src=\"images/GAST/71285_FNH_CT_MRI_Sulfur_colloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiologic findings of focal nodal hyperplasia in an asymptomatic 47-year-old woman. Panel A: Contrast-enhanced computed tomography (CT) scan shows an area of slight heterogeneity (arrow) in the right lobe of the liver, but a discrete mass is difficult to identify. Panel B: Technetium-99 sulfur colloid scan shows uptake in the mass (arrow) similar to the rest of the liver. This finding is diagnostic of focal nodular hyperplasia. Panel C: T2-weighted magnetic resonance (MR) image shows the mass (arrow) as slightly increased signal intensity. Panel D: Arterial-phase dynamic gadolinium chelate-enhanced T1-weighted gradient-echo MR image shows rapid intense enhancement of the mass (arrow), typical of focal nodular hyperplasia.</div><div class=\"graphic_reference\">Courtesy of Eric Outwater, MD.</div><div id=\"graphicVersion\">Graphic 71285 Version 4.0</div></div></div>"},"71289":{"type":"graphic_table","displayName":"CytoredsurgIPchem app muc tum","title":"Contemporary series of cytoreductive surgery and perioperative intraperitoneal chemotherapy for mucinous appendiceal tumors with peritoneal dissemination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contemporary series of cytoreductive surgery and perioperative intraperitoneal chemotherapy for mucinous appendiceal tumors with peritoneal dissemination</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author; year</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" rowspan=\"2\">IP chemo</td> <td class=\"subtitle1\" rowspan=\"2\">Perioperative morbidity, percent</td> <td class=\"subtitle1\" rowspan=\"2\">Perioperative mortality, percent</td> <td class=\"subtitle1\" colspan=\"2\">Overall survival, percent</td> </tr> <tr> <td class=\"subtitle2\">3-yr</td> <td class=\"subtitle2\">5-yr</td> </tr> <tr> <td>Sugarbaker P; 1999</td> <td>385</td> <td>MMC + 5 FU</td> <td>27</td> <td>2.7</td> <td>74</td> <td>63</td> </tr> <tr> <td>Loungnarath R; 2005</td> <td>27</td> <td>MMC</td> <td>44</td> <td>0</td> <td>80</td> <td>50</td> </tr> <tr> <td>Guner Z; 2005</td> <td>28</td> <td>Cisplatin or MMC or 5-FU</td> <td>36</td> <td>7</td> <td>NR</td> <td>75</td> </tr> <tr> <td>Moran BJ; 2006</td> <td>65</td> <td>MMC + 5 FU</td> <td>20</td> <td>6</td> <td>NR</td> <td>65</td> </tr> <tr> <td>Stewart J; 2006</td> <td>110*</td> <td>MMC</td> <td>38</td> <td>4</td> <td>59</td> <td>53</td> </tr> <tr> <td>Baratti D; 2008</td> <td>104</td> <td>MMC and cisplatin</td> <td>19</td> <td>1</td> <td>NR</td> <td>78</td> </tr> <tr> <td>Chua T; 2009</td> <td>106</td> <td>MMC + 5-FU</td> <td>49<sup>&#182;</sup></td> <td>3</td> <td>NR</td> <td>75</td> </tr> <tr> <td>Elias D; 2010</td> <td>301</td> <td>Not reported (n = 255)</td> <td>40<sup>&#182;</sup></td> <td>4.4</td> <td>85</td> <td>73</td> </tr> <tr> <td>Youssef H; 2011</td> <td>456<sup>&#916;</sup></td> <td>MMC</td> <td>&#9674;</td> <td>1.6</td> <td>NR</td> <td>69 (57 percent at 10-years)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IP chemo: intraperitoneal chemotherapy; NR: not reported; MMC: mitomycin C; 5-FU: 5-fluorouracil.<br />* Included 55 DPAM, 29 peritoneal mucinous carcinomatosis (PMCA), 18 PMCA with intermediate features and 8 high grade mucinous lesions.<br />¶ Severe (grade 3/4) morbidity.<br />Δ 289 patients (out of 456) had complete surgical cytoreduction; five and ten-year predicted survival were 87 and 74 percent, respectively.<br /><FONT class=lozenge>◊</FONT> Grade 3 or 4 complications in 7 percent of patients undergoing cytoreductive surgery; among 441 patients undergoing cytoreductive surgery or major debulking, 3.6 percent reoperation rate for bleeding, 10 percent venous thromboembolism, including 2 percent pulmonary emboli.</div><div id=\"graphicVersion\">Graphic 71289 Version 6.0</div></div></div>"},"71290":{"type":"graphic_picture","displayName":"PUNLMP","title":"Papillary urothelial neoplasm of low malignant potential (PUNLMP)","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Papillary urothelial neoplasm of low malignant potential (PUNLMP)</div><div class=\"cntnt\"><img style=\"width:515px; height:200px;\" src=\"images/ONC/71290_PUNLMP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (A, 20x), the discrete and slender papillae of PUNLMP are lined by a thickened multilayered urothelium with absent cytologic atypia. At high power (B, 40x), the cell density is increased compared to normal urothelium. The cell polarity and the umbrella cell layer are preserved.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 71290 Version 1.0</div></div></div>"},"71291":{"type":"graphic_picture","displayName":"Mulberry molar","title":"Congenital syphilis: Mulberry molar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Mulberry molar</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/PEDS/71291_Mulberry_molar_final.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &#169; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71291 Version 2.0</div></div></div>"},"71292":{"type":"graphic_figure","displayName":"Normal and abnormal plethysmographic digit waveforms","title":"Normal and abnormal plethysmographic digit waveforms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal plethysmographic digit waveforms</div><div class=\"cntnt\"><img style=\"width:438px; height:670px;\" src=\"images/SURG/71292_waveforms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With photoplethysmography (PPG), infrared light is emitted onto a defined area of skin. More or less light is absorbed depending upon changes in blood volume, which is determined by measuring the light reflected from the skin. A normal PPG waveform consists of a short rise in the upstroke during systole (A), a gradual decline during diastole (B), and a dicrotic notch in the diastolic downstroke (C). Moderate arterial obstruction results in loss of the dicrotic notch, flattening of the upstroke and downstroke, and rounding of the peaks of the waveform. Severe obstruction flattens the waveform.</div><div class=\"graphic_footnotes\">mV: millivolts; V: volts; PPG: photoplethysmography; HR: heartrate; FP: finger pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Kesselman P. Non-Invasive Arterial Vascular Testing: Providing these diagnostic services benefits both the patient and your bottom line. Podiatry Management Nov/Dec 2006. Copyright © 2006.</div><div id=\"graphicVersion\">Graphic 71292 Version 1.0</div></div></div>"},"71293":{"type":"graphic_figure","displayName":"Periphepatic packing to control bleeding from the liver","title":"Periphepatic packing to control bleeding from the liver","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Periphepatic packing to control bleeding from the liver</div><div class=\"cntnt\"><img style=\"width:534px; height:534px;\" src=\"images/SURG/71293_Liver-packing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perihepatic packing&#160;compresses the liver tissue from multiple directions by placing laparotomy pads into the space between the diaphragm and liver, between the lateral abdominal wall and liver, and between the liver and hepatic flexure of the colon. Intrahepatic packing should <strong>not</strong> be used because it can cause increased bleeding.</div><div id=\"graphicVersion\">Graphic 71293 Version 2.0</div></div></div>"},"71294":{"type":"graphic_table","displayName":"Causes of secondary dyslipidemia in children","title":"Causes of secondary dyslipidemia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary dyslipidemia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Exogenous</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td class=\"sublist1_start\">Drug therapy</td> </tr> <tr> <td class=\"sublist1\"> <p>Corticosteroids</p> <p>Isotretinoin</p> <p>Beta-blockers </p> <p>Some oral contraceptives</p> <p>Select chemotherapeutic agents</p> <p>Select antiretroviral agents</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine/Metabolic</td> </tr> <tr> <td> <p>Hypothyroidism/hypopituitarism</p> <p>Diabetes mellitus types 1 and 2</p> <p>Pregnancy</p> <p>Polycystic ovary syndrome</p> <p>Lipodystrophy</p> <p>Acute intermittent porphyria</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Renal</td> </tr> <tr> <td> <p>Chronic renal disease</p> <p>Hemolytic uremic syndrome</p> <p>Nephrotic syndrome</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td> <p>Acute viral/bacterial infection*</p> <p>Human immunodeficiency virus (HIV) infection</p> <p>Hepatitis</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Hepatic</td> </tr> <tr> <td> <p>Obstructive liver disease/cholestatic conditions</p> <p>Biliary cirrhosis</p> <p>Alagille syndrome</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory disease</td> </tr> <tr> <td> <p>Systemic lupus erythematosis</p> <p>Juvenile rheumatoid arthritis</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Storage disease</td> </tr> <tr> <td> <p>Glycogen storage disease</p> <p>Gaucher's disease</p> <p>Cystine storage disease</p> <p>Juvenile Tay-Sachs disease</p> <p>Niemann-Pick disease</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td> <p>Kawasaki disease</p> <p>Anorexia nervosa</p> <p>Solid organ transplantation</p> <p>Childhood cancer survivor</p> <p>Progeria </p> <p>Idiopathic hypercalcemia</p> <p>Klinefelter syndrome </p> <p>Werner's syndrome</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Delay measurement until ≥3 weeks postinfection.</div><div class=\"graphic_reference\">Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div><div id=\"graphicVersion\">Graphic 71294 Version 3.0</div></div></div>"},"71295":{"type":"graphic_table","displayName":"Common names and classification of select hallucinogens","title":"Common names and classification of select hallucinogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common names and classification of select hallucinogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Active ingredient</td> <td class=\"subtitle1\">Drug class</td> </tr> <tr> <td>2CB, \"Bromo\", \"Nexus\"</td> <td>25B-NBOMe</td> <td>Phenylethylamine</td> </tr> <tr> <td>2CT-7, \"Blue Mystic\"</td> <td>25C-NBOMe</td> <td>Phenylethylamine</td> </tr> <tr> <td>25I, \"N-bomb\", \"Smiles\"&nbsp;</td> <td>25I-NBOMe&nbsp;</td> <td>Phenylethylamine&nbsp;</td> </tr> <tr> <td>AMT</td> <td>&#945;-methyltryptamine</td> <td>Indolealkylamine (tryptamine)</td> </tr> <tr> <td>DMT, <em>Ayahuasca</em></td> <td>Dimethyltryptamine</td> <td>Indolealkylamine (tryptamine)</td> </tr> <tr> <td>Dextromethorphan, DXM</td> <td>Dextromethorphan</td> <td>Arylcyclohexylamine (piperidine)</td> </tr> <tr> <td>\"Foxy Methoxy\"</td> <td>5-MeO-DIPT (5-methoxydimethyl tryptamine)</td> <td>Indolealkylamine (tryptamine)</td> </tr> <tr> <td>Hawaiian baby woodrose (<em>Argyreia nervosa</em>)</td> <td>Ergine</td> <td>Lysergamide</td> </tr> <tr> <td>Ibogaine</td> <td>12-methoxybogamine</td> <td>Indolealkylamine (tryptamine)</td> </tr> <tr> <td>Ketamine, \"Special K\"</td> <td>Ketamine</td> <td>Arylcyclohexylamine (piperidine)</td> </tr> <tr> <td>LSD</td> <td>D-lysergic acid diethylamide</td> <td>Lysergamide</td> </tr> <tr> <td>Mescaline, peyote</td> <td>3,4,5-trimethoxy-phenethylamine</td> <td>Phenylethylamine</td> </tr> <tr> <td>Morning glory (<em>Ipomoea violacea</em>)</td> <td>Lysergic acid hydroxyethylamide</td> <td>Lysergamide</td> </tr> <tr> <td>PCP, \"Angel dust\"</td> <td>Phencyclidine</td> <td>Arylcyclohexylamine (piperidine)</td> </tr> <tr> <td>Psilocybin, \"Magic mushroom\"</td> <td>Psilocin (N,N-dimethyl-4-phosphoryloxytryptamine)</td> <td>Indolealkylamine (tryptamine)</td> </tr> <tr> <td><em>Salvia divinorum</em></td> <td>Salvinorin A</td> <td>Diterpene alkaloid</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71295 Version 4.0</div></div></div>"},"71296":{"type":"graphic_figure","displayName":"Prostate weight and age","title":"Age-related increase in prostate weight","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age-related increase in prostate weight</div><div class=\"cntnt\"><img style=\"width:329px; height:241px;\" src=\"images/ENDO/71296_Prostate_weight_and_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Average prostatic weights (mean &#177; standard error of the mean in gray) are presented for 10-year intervals. The prostate glands were obtained at autopsy from 925 samples collected from five separate studies.</div><div class=\"graphic_reference\">Data from Berry, SJ, Coffey, DS, Walsh, PC, et al, J Urol 1984; 132:474.</div><div id=\"graphicVersion\">Graphic 71296 Version 1.0</div></div></div>"},"71298":{"type":"graphic_picture","displayName":"Actinic keratosis eyelid","title":"Actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic keratosis</div><div class=\"cntnt\"><img style=\"width:392px; height:258px;\" src=\"images/PC/71298_Actinic_keratosis_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scaly, flat lesion is present on the lower eyelid (arrow).</div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 71298 Version 1.0</div></div></div>"},"71299":{"type":"graphic_picture","displayName":"Man of war sting","title":"Man-of-war sting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Man-of-war sting</div><div class=\"cntnt\"><img style=\"width:396px; height:262px;\" src=\"images/PC/71299_Man_of_war_sting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tentacle prints are evident on this patient who was stung by a Portuguese man-of-war. (Physalia sp., also called bluebottle jellyfish).</div><div class=\"graphic_reference\">Courtesy of Ed Lopez, MD.</div><div id=\"graphicVersion\">Graphic 71299 Version 1.0</div></div></div>"},"71301":{"type":"graphic_figure","displayName":"IMV versus PV","title":"Intermittent mandatory ventilation (IMV) versus pressure support ventilation (PSV)","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Intermittent mandatory ventilation (IMV) versus pressure support ventilation (PSV)</div><div class=\"cntnt\"><img style=\"width:564px; height:568px;\" src=\"images/PULM/71301_IMV_versus_PSV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>A)</strong> Changes in pressure-time product (PTP) per minute, <strong>B)</strong> PTP per breath, and <strong>C)</strong> frequency as intermittent mandatory ventilation (IMV) and pressure support (PS) were progressively increased. PS of 100 percent represents the level necessary to achieve a tidal volume equivalent to that during assist-control ventilation (10 mL/kg); IMV of 100 percent is the same ventilator rate as during assist-control ventilation. From zero assistance to 60 percent, decrease in PTP/min was greater with PS than with IMV. From 60 to 100 percent assistance, the opposite was observed - the decrease in PTP/min was greater with IMV than with PS. PTP per breath decreased linearly as the rate of IMV was increased to 60 percent. PTP per breath decreased linearly as the amount of PS was increased to 60 percent, but little thereafter. Frequency decreased linearly as PS was increased. In contrast, frequency changed little as the rate of IMV was increased, until a high level of assistance was provided.</div><div class=\"graphic_reference\">Reproduced with permission from: Tobin MJ, Jubran, A, Laghi, F. Patient-Ventilator Interaction. Am J Respir Crit Care Med 2001; 163:1059. Copyright &#169;2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 71301 Version 1.0</div></div></div>"},"71302":{"type":"graphic_figure","displayName":"Orthodromic AVRT","title":"Orthodromic atrioventricular reentrant tachycardia (AVRT) in the setting of an accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Orthodromic atrioventricular reentrant tachycardia (AVRT) in the setting of an accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:372px; height:262px;\" src=\"images/CARD/71302_OrthodromictachycardiaWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rhythm strip shows a sinus (S) beat that has a short PR interval and a wide QRS complex as a result of a delta wave (d). Panel A shows an atrial premature beat (APB,*) that is blocked in the accessory pathway (AP) which has a long refractory period but is conducted antegradely through the atrioventricular node (N) and the His-Purkinje system, resulting in a normal PR interval and a narrow and normal QRS complex, as seen on the rhythm strip. After normal myocardial activation, the impulse is conducted retrogradely along the AP, activating the atrium in a retrograde fashion (panel B) which results in a negative P wave. If this activation sequence repeats itself (panel C), an orthodromic atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is established.</div><div id=\"graphicVersion\">Graphic 71302 Version 6.0</div></div></div>"},"71303":{"type":"graphic_picture","displayName":"Gonococcal skin lesion","title":"Skin lesions in disseminated gonococcal infection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Skin lesions in disseminated gonococcal infection</div><div class=\"cntnt\"><img style=\"width:540px; height:351px;\" src=\"images/ID/71303_Gonococcal_skin_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical small pustular skin lesion in a patient with disseminated gonococcal infection.</div><div class=\"graphic_reference\">Courtesy of Don L Goldenberg, MD.</div><div id=\"graphicVersion\">Graphic 71303 Version 3.0</div></div></div>"},"71304":{"type":"graphic_picture","displayName":"Chagas disease Light","title":"Inflammatory response in Chagas' disease","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Inflammatory response in Chagas' disease</div><div class=\"cntnt\"><img style=\"width:543px; height:181px;\" src=\"images/CARD/71304_Chagas_disease_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrographs from an animal with experimental Chagas' disease shows lymphocytic infiltration of the myocardium (left panel) and neuronal tissue (right panel).</div><div class=\"graphic_reference\">Courtesy of Ricardo Ribeiro dos Santos, MD.</div><div id=\"graphicVersion\">Graphic 71304 Version 1.0</div></div></div>"},"71308":{"type":"graphic_picture","displayName":"Disseminated granuloma annulare - annular lesions","title":"Disseminated granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:346px;\" src=\"images/DERM/71308_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 42-year-old patient with disseminated granuloma annulare presented with 200 annular lesions ranging from 5 to 25 mm in diameter on the arms, legs, and trunk.</div><div id=\"graphicVersion\">Graphic 71308 Version 4.0</div></div></div>"},"71313":{"type":"graphic_picture","displayName":"Giant granules in Chediak-Higashi syndrome","title":"Giant neutrophil granules in Chediak-Higashi syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant neutrophil granules in Chediak-Higashi syndrome</div><div class=\"cntnt\"><img style=\"width:442px; height:288px;\" src=\"images/HEME/71313_Chediak_Higashi_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with Chediak-Higashi syndrome shows giant granules in the cytoplasm of both a neutrophil and a band form. These granules are formed by the inappropriate fusion of lysosomes and endosomes.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 71313 Version 3.0</div></div></div>"},"71314":{"type":"graphic_picture","displayName":"Hand-foot-and-mouth disease - tongue","title":"Hand-foot-and-mouth disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-foot-and-mouth disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71314_Hand_foot_mouth_dis_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small ulcers are present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71314 Version 4.0</div></div></div>"},"71315":{"type":"graphic_picture","displayName":"Deep diabetic foot ulcer involving bone","title":"Deep diabetic foot ulcer involving bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep diabetic foot ulcer involving bone</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/SURG/71315_Wagner_3_foot_ulcer_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presented with a fluctuant eschar on the plantar surface of the foot. The abscess was unroofed and drained and, following debridement, exposed bone was apparent at the base of the wound.</div><div class=\"graphic_reference\">Courtesy of Paul Thottingal, MD.</div><div id=\"graphicVersion\">Graphic 71315 Version 3.0</div></div></div>"},"71316":{"type":"graphic_figure","displayName":"Normal anatomy of the mandible","title":"Normal anatomy of the mandible","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Normal anatomy of the mandible</div><div class=\"cntnt\"><img style=\"width:505px; height:378px;\" src=\"images/ALLRG/71316_Anatomy_mandible_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71316 Version 1.0</div></div></div>"},"71322":{"type":"graphic_algorithm","displayName":"Rabies postexposure prophylaxis algorithm","title":"Rabies postexposure prophylaxis algorithm","html":"<div class=\"graphic\"><div style=\"width: 809px\" class=\"figure\"><div class=\"ttl\">Rabies postexposure prophylaxis algorithm</div><div class=\"cntnt\"><img style=\"width:789px; height:513px;\" src=\"images/ID/71322_RabiesPEPalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEP: postexposure prophylaxis.<br />* PEP should be initiated immediately in patients with severe bites to the head, neck, or trunk after an unprovoked attack from a high-risk animal. PEP can be discontinued if testing proves the animal was not rabid.<br />¶ In areas without an endemic, terrestrial strain of rabies (eg, dog, raccoon, skunk, fox, mongoose), contact local public health authorities for risk assessment. </div><div class=\"graphic_reference\">Courtesy of Alfred DeMaria Jr, MD and the Massachusetts Department of Public Health.</div><div id=\"graphicVersion\">Graphic 71322 Version 4.0</div></div></div>"},"71324":{"type":"graphic_algorithm","displayName":"Choice stress test modality","title":"Choice of exercise testing modality in different clinical settings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choice of exercise testing modality in different clinical settings</div><div class=\"cntnt\"><img style=\"width:446px; height:406px;\" src=\"images/CARD/71324_Choice_stress_test_modality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Marked baseline ECG abnormalities\" include pre-excitation (Wolff-Parkinson-White) syndrome, more than 1 mm of ST depression at rest, and patients taking digoxin or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. Evaluation of patients with left bundle branch block or paced ventricular rhythm is not included in this algorithm.</div><div id=\"graphicVersion\">Graphic 71324 Version 2.0</div></div></div>"},"71326":{"type":"graphic_table","displayName":"Difficult airway children","title":"Physical assessment to identify signs of a difficult airway in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical assessment to identify signs of a difficult airway in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Difficulty</td>\n<td class=\"subtitle1\">Signs</td>\n</tr>\n<tr>\n<td>Positioning</td>\n<td>Prominent or misshapen occiput, short neck, poor neck mobility</td>\n</tr>\n<tr>\n<td>Bag-mask ventilation</td>\n<td>Facial anomalies, facial trauma (including burns)</td>\n</tr>\n<tr>\n<td>Laryngoscopy</td>\n<td>Small mouth, small mandible, abnormal palate, large tongue</td>\n</tr>\n<tr>\n<td>Intubation</td>\n<td>Signs of upper airway obstruction (hoarseness, stridor, drooling, upright position of comfort)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71326 Version 2.0</div></div></div>"},"71327":{"type":"graphic_figure","displayName":"ACEIs in HF in blacks","title":"ACE inhibitors more effective in whites than blacks with heart failure","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">ACE inhibitors more effective in whites than blacks with heart failure</div><div class=\"cntnt\"><img style=\"width:511px; height:362px;\" src=\"images/CARD/71327_ACEIs_in_HF_in_blacks.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the rates of hospitalization for heart failure in a matched cohort analysis from the SOLVD trial comparing the responses of black and matched white patients randomly assigned to enalapril or placebo. The rate of hospitalization for heart failure was significantly higher among black than white patients whether treated with enalapril or placebo. Compared to placebo, whites but not blacks had a significant benefit from enalapril therapy.</div><div class=\"graphic_reference\">Data from Exner DV, Dries DL, Domanski MJ, Cohn JN. N Engl J Med 2001; 344:1351.</div><div id=\"graphicVersion\">Graphic 71327 Version 2.0</div></div></div>"},"71329":{"type":"graphic_picture","displayName":"Acrodermatitis enteropathica","title":"Acrodermatitis enteropathica","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Acrodermatitis enteropathica</div><div class=\"cntnt\"><img style=\"width:512px; height:224px;\" src=\"images/PEDS/71329_Acrodermatitis_entero_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acrodermatitis enteropathica in an infant. Moist erythematous plaques are present on the cheeks and buttocks. The buttock lesions are typically symmetric.</div><div class=\"graphic_reference\">(Panel A) Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.<BR>(Panel B) Courtesy of Robert Sidbury, MD.</div><div id=\"graphicVersion\">Graphic 71329 Version 6.0</div></div></div>"},"71330":{"type":"graphic_picture","displayName":"Foreign body impacted in RLL","title":"68-year-old woman with an airway foreign body who was misdiagnosed with asthma unresponsive to therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">68-year-old woman with an airway foreign body who was misdiagnosed with asthma unresponsive to therapy</div><div class=\"cntnt\"><img style=\"width:315px; height:323px;\" src=\"images/PULM/71330_Foreign_body_impacted_in_RL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view shows an oyster shell fragment impacted in the right lower lobe bronchus.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 71330 Version 4.0</div></div></div>"},"71332":{"type":"graphic_table","displayName":"Follow-up blood lead testing in infants under 6 months","title":"Schedule for follow-up blood lead testing in infants*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Schedule for follow-up blood lead testing in infants*<SUP>¶</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Venous blood lead level<br /> (BLL; &#181;g/dL)</td> <td class=\"subtitle1\">Early follow-up<br /> (first 2-4 tests after identification or until BLL begins to decline)</td> <td class=\"subtitle1\">Later follow-up<br /> (after BLL begins to decline)</td> </tr> <tr> <td>&#60;10</td> <td>According to local lead screening guidelines for children</td> <td>According to local lead screening guidelines for children</td> </tr> <tr> <td>10-14</td> <td>3 months<sup>&#916;</sup></td> <td>Within 6-9 months</td> </tr> <tr> <td>15-19</td> <td>1-3 months<sup>&#916;</sup></td> <td>Within 3-6 months</td> </tr> <tr> <td>20-24</td> <td>1-3 months<sup>&#916;</sup></td> <td>Within 1-3 months</td> </tr> <tr> <td>25-44</td> <td>2 weeks-1 month<sup>&#9674;</sup></td> <td>Within 1 month</td> </tr> <tr> <td>&#8805;45</td> <td>Within 24 hours<sup>&#9674;</sup></td> <td>As directed by clinician managing chelation treatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BLL: blood lead level.<br />* After 6 months of age, recommendations from Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention (Centers for Disease Control and Prevention 2002) should be followed.<br />¶ If infants are breastfeeding, also follow recommendations as discussed in \"Childhood lead poisoning: Management\", section on 'Breastfeeding'.<br />Δ Some case managers or primary care providers may choose to repeat blood lead tests on all new patients within a month to ensure that their BLL levels are not rising more quickly than anticipated. Seasonal variation of BLLs exists and may be more apparent in colder climate areas. Greater exposure in the summer months may necessitate more frequent follow-ups.<br /><FONT class=lozenge>◊</FONT> Consultation with a clinician experienced in the management of children with BLLs in this range is strongly advised.</div><div class=\"graphic_reference\">Reproduced from: Ettinger AS, Gurthrie Wengrovitz A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at <A href=\"http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=_blank>http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf</A>.</div><div id=\"graphicVersion\">Graphic 71332 Version 6.0</div></div></div>"},"71333":{"type":"graphic_figure","displayName":"Lentigo maligna staged excision","title":"Staged excision of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Staged excision of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:562px; height:588px;\" src=\"images/DERM/71333_Lentigomalignastgdexcsn.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71333 Version 4.0</div></div></div>"},"71334":{"type":"graphic_picture","displayName":"AAT deficiency liver Light","title":"Alpha-1 antitrypsin deficiency: Liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alpha-1 antitrypsin deficiency: Liver biopsy</div><div class=\"cntnt\"><img style=\"width:438px; height:288px;\" src=\"images/GAST/71334_AAT_deficiency_liver_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a liver biopsy from a patient with alpha-1 antitrypin deficiency shows numerous intracellular and intercellular PAS-positive granules in the periportal area.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 71334 Version 2.0</div></div></div>"},"71336":{"type":"graphic_table","displayName":"Diet and chronic kidney disease","title":"Recommended dietary intake for chronic kidney and end-stage renal disease patients*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dietary intake for chronic kidney and end-stage renal disease patients*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Chronic kidney disease<sup>&#182;</sup></td> <td class=\"subtitle1\">Maintenance hemodialysis</td> </tr> <tr> <td>Protein</td> <td>0.8 to 1.0 g/kg/day<sup>&#916;</sup> of high biological value protein</td> <td>&#62;1.2 to 1.3 g/kg/day</td> </tr> <tr> <td>Energy</td> <td colspan=\"2\">&#8805;35 kcal/kg/day; if the body weight is greater than 120 percent of normal or the patient is greater than 60 years of age a lower amount may be prescribed</td> </tr> <tr> <td>Fat, percent of total energy intake</td> <td>30 to 40</td> <td>30 to 40</td> </tr> <tr> <td>Polyunsaturated-to-saturated ratio (fatty acid ratio)</td> <td>1.0:1.0</td> <td>1.0:1.0</td> </tr> <tr> <td>Carbohydrate</td> <td colspan=\"2\">Balance of nonprotein calories</td> </tr> <tr> <td>Total fiber, g/day</td> <td>20 to 25</td> <td>20 to 25</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Minerals, range of intake</td> </tr> <tr> <td class=\"sublist1\">Sodium, mg/day</td> <td class=\"sublist_other\">&#60;2000</td> <td class=\"sublist_other\">&#60;2000</td> </tr> <tr> <td class=\"sublist1\">Potassium, meq/day</td> <td class=\"sublist_other\">40 to 70</td> <td class=\"sublist_other\">40 to 70</td> </tr> <tr> <td class=\"sublist1\">Phosphorus, mg/day</td> <td class=\"sublist_other\">600 to 800<sup>&#9674;</sup></td> <td class=\"sublist_other\">600 to 800<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist1\">Calcium, mg/day</td> <td class=\"sublist_other\">1400 to 1600</td> <td class=\"sublist_other\">1400 to 1600</td> </tr> <tr> <td class=\"sublist1\">Magnesium, mg/day</td> <td class=\"sublist_other\">200 to 300</td> <td class=\"sublist_other\">200 to 300</td> </tr> <tr> <td class=\"sublist1\">Iron, mg/day</td> <td class=\"sublist_other\">&#8805;10 to 18<sup>&#167;</sup></td> <td class=\"sublist_other\">&#8805;10 to 18<sup>&#167;</sup></td> </tr> <tr> <td class=\"sublist1\">Zinc, mg/day</td> <td class=\"sublist_other\">15</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td>Water, mL/day</td> <td>Up to 3000 as tolerated</td> <td>Usually 750 to 1500</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The nutritional intake is adjusted based upon individual needs. This is particularly important for the carbohydrate, lipid, and mineral contents of the diet.<br />¶ GFR &lt;70 mL/min/1.73 m<SUP>2</SUP> with evidence for progression.<br />Δ Some recommend 0.56 to 0.75 g/kg/day, with 0.35 g/kg/day of high biological value protein. The protein intake is increased by 1 g/day of high biological value protein for each gram per day of urinary protein loss. This is performed under close supervision and dietary counseling.<br /><FONT class=lozenge>◊</FONT> Phosphate binders often are also needed to maintain normal serum phosphorus levels.<br />§ 10 mg/day for males and nonmenstruating females, 18 mg/day for menstruating females.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ahmed K, Kopple J. Nutritional management of renal disease. In: Primer on Kidney Diseases, Greenberg A (Ed). Academic Press, San Diego, CA, 1994, p.289.</LI>&#xD;&#xA;<LI>Ikizler IA. Nutrition and kidney disease. In: Primer on Kidney Diseases, Greenberg A (Ed). Elsevier, Philadelphia, 2005, p.496.</LI></OL></div><div id=\"graphicVersion\">Graphic 71336 Version 6.0</div></div></div>"},"71338":{"type":"graphic_diagnosticimage","displayName":"Hemorrhagic venous infarct","title":"Brain MRI of hemorrhagic venous infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of hemorrhagic venous infarction</div><div class=\"cntnt\"><img style=\"width:437px; height:260px;\" src=\"images/NEURO/71338_Hemorrhagic_venous_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI showing hemorrhagic venous infarction as hyperintense on T1- and T2-weighted sequences.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 71338 Version 4.0</div></div></div>"},"71340":{"type":"graphic_diagnosticimage","displayName":"Parenchymal asymmetry","title":"Parenchymal asymmetry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parenchymal asymmetry</div><div class=\"cntnt\"><img style=\"width:240px; height:396px;\" src=\"images/PC/71340_Parenchymal_asymmetry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A focal asymmetry (arrow) is seen in the lateral aspect of the breast on the CC view. A follow up mammogram is usually obtained to assess stability.</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 71340 Version 3.0</div></div></div>"},"71341":{"type":"graphic_diagnosticimage","displayName":"Atypical pneumothorax PA","title":"Chest radiograph of an atypical pneumothorax","html":"<div class=\"graphic normal\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an atypical pneumothorax</div><div class=\"cntnt\"><img style=\"width:498px; height:264px;\" src=\"images/PULM/71341_Atypical_pneumothorax_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left inferolateral atypical pneumothorax in patient with emphysema and pleural adhesions. Left panel: Chest radiograph shows left basilar collection of pleural gas with concave visceral pleural edge toward the chest wall. At first glance, this resembles a bulla. Right panel: After drainage of the pneumothorax, no evidence of a bulla is seen.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71341 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"71344":{"type":"graphic_picture","displayName":"Erythema nodosum IBD","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:259px; height:262px;\" src=\"images/GAST/71344_Erythema_nodosum_IBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with inflammatory bowel disease with red nodular areas on the shins which are characteristic of erythema nodosum.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 71344 Version 2.0</div></div></div>"},"71345":{"type":"graphic_picture","displayName":"True knot","title":"Tight true knot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tight true knot</div><div class=\"cntnt\"><img style=\"width:432px; height:246px;\" src=\"images/OBGYN/71345_True_knot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 71345 Version 1.0</div></div></div>"},"71347":{"type":"graphic_table","displayName":"Specific treatment for osteoarticular infections in children","title":"Suggested antimicrobial regimens for the most commonly isolated pathogens causing osteoarticular infections in infants and children when results of culture and susceptibility testing are known","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested antimicrobial regimens for the most commonly isolated pathogens causing osteoarticular infections in infants and children when results of culture and susceptibility testing are known</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">Parenteral agents</td> <td class=\"subtitle1\">Oral agents</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"indent1\">Methicillin-susceptible</td> <td> <p>Cefazolin</p> <p>Nafcillin</p> <p>Oxacillin</p> </td> <td> <p>Cephalexin</p> <p>Cloxacillin (not available in the United States)</p> <p>Dicloxacillin</p> <p>Clindamycin*</p> </td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Methicillin-resistant</td> </tr> <tr> <td class=\"sublist2\">Clindamycin-susceptible</td> <td class=\"sublist_other\"> <p>Vancomycin</p> <p>Clindamycin</p> </td> <td class=\"sublist_other\">Clindamycin</td> </tr> <tr> <td class=\"sublist2\">Clindamycin-resistant<sup>&#182;</sup></td> <td class=\"sublist_other\"> <p>Vancomycin</p> <p>Linezolid</p> <p>Daptomycin<sup>&#916;</sup></p> </td> <td class=\"sublist_other\">Linezolid</td> </tr> <tr class=\"divider_top\"> <td><strong><em>Streptococcus agalactiae</em> (Group B <em>Streptococcus</em>)</strong></td> <td>Penicillin</td> <td>Oral therapy not suggested in infants</td> </tr> <tr class=\"divider_top\"> <td><strong><em>S. pyogenes</em> (Group A <em>Streptococcus</em>)</strong></td> <td> <p>Penicillin</p> <p>Ampicillin</p> </td> <td> <p>Penicillin</p> <p>Amoxicillin</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\"><em>S. pneumoniae</em> (Pneumococcus)</td> </tr> <tr> <td class=\"indent1\">Penicillin-susceptible</td> <td>Penicillin</td> <td> <p>Penicillin</p> <p>Amoxicillin</p> </td> </tr> <tr> <td class=\"indent1\">Penicillin-nonsusceptible</td> <td> <p>Cefotaxime</p> <p>Ceftriaxone</p> <p>Clindamycin*</p> <p>Linezolid</p> </td> <td> <p>Clindamycin*</p> <p>Linezolid</p> </td> </tr> <tr class=\"divider_top\"> <td><strong><em>Kingella kingae</em></strong></td> <td> <p>Penicillin</p> <p>Cefazolin</p> <p>Cefotaxime</p> <p>Ceftriaxone</p> </td> <td> <p>Penicillin</p> <p>Cephalexin</p> <p>Cefixime</p> </td> </tr> <tr class=\"divider_top\"> <td><strong><em>Haemophilus influenzae</em> type b</strong></td> <td> <p>Cefotaxime</p> <p>Ceftriaxone</p> <p>Cefuroxime</p> </td> <td> <p>Amoxicillin (if susceptible)</p> <p>Cefixime</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If isolate is clindamycin-susceptible.<br />¶&nbsp;Clindamycin should not be used even if D-test is negative.<br />Δ Daptomycin should not be used in children with concomitant pulmonary involvement. It is not approved for the treatment of osteoarticular infections in children; the appropriate dose has not been established.</div><div id=\"graphicVersion\">Graphic 71347 Version 12.0</div></div></div>"},"71349":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis periosteal elevation plain radiograph","title":"Osteomyelitis with subperiosteal abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis with subperiosteal abscess</div><div class=\"cntnt\"><img style=\"width:396px; height:404px;\" src=\"images/PEDS/71349_Osteomyelitis_periosteal_el.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain radiograph of the femur demonstrates periosteal elevation due to a subperiosteal abscess as the result of osteomyelitis.</div><div class=\"graphic_reference\">Courtesy of Marvin B Harper, MD.</div><div id=\"graphicVersion\">Graphic 71349 Version 3.0</div></div></div>"},"71353":{"type":"graphic_table","displayName":"Definitions major bleeding","title":"Definitions of major bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of major bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">TIMI<br /> (1988)</td> <td class=\"subtitle1\">GUSTO<br /> (1997)</td> <td class=\"subtitle1\">ISAR trials*<br /> (2000-05)</td> <td class=\"subtitle1\">ACUITY<br /> (2006)</td> <td class=\"subtitle1\">REPLACE-2<br /> (2007)</td> <td class=\"subtitle1\">HORIZONS AMI<br /> (2009)</td> </tr> <tr class=\"divider_bottom\"> <td>Intracranial bleed</td> <td>Intracranial bleed</td> <td>Intracranial bleed</td> <td>Intracranial or intraocular</td> <td>Intracranial, intraocular, or retroperitoneal</td> <td>Intracranial or intraocular</td> </tr> <tr class=\"divider_bottom\"> <td>Hgb &#8595; &#62;5 g/dL or Hct &#8595; &#62;15 percent</td> <td>&nbsp;</td> <td>Hgb &#8595; &#62;5 g/dL or Hct &#8595; &#62;15 percent</td> <td> <p>Hgb &#8595; &#8805;3 g/dL with overt bleeding</p> Any Hgb &#8595; &#8805;4 g/dL</td> <td> <p>Hgb &#8595; &#8805;3 g/dL with overt bleeding</p> Any Hgb &#8595; &#8805;4 g/dL</td> <td> <p>Hgb &#8595; &#8805;3 g/dL with overt bleeding</p> Any Hgb &#8595; &#8805;4 g/dL</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Any transfusion</td> <td>Transfusion &#8805;2 units of PRBCs</td> <td>Any transfusion</td> </tr> <tr> <td>&nbsp;</td> <td>Hemodynamic compromise requiring intervention</td> <td>&nbsp;</td> <td> <p>Access site bleeding requiring intervention</p> <p>Hematoma &#8805;5 cm</p> Reoperation for bleeding</td> <td>&nbsp;</td> <td> <p>Access site bleeding requiring intervention</p> <p>Hematoma &#8805;5 cm</p> Reoperation for bleeding</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">TIMI and GUSTO were trials of fibrinolytic therapy for acute myocardial infarction. The remaining studies examined adjunctive pharmacology during percutaneous coronary intervention.</div><div class=\"graphic_footnotes\">PBRC: packed red blood cell.<br />* ISAR-REACT, ISAR-SWEET, ISAR-SMART, ISAR-REACT 2.</div><div id=\"graphicVersion\">Graphic 71353 Version 3.0</div></div></div>"},"71354":{"type":"graphic_table","displayName":"Total fetal loss rate TC-CVS compared with amniocentesis","title":"Total fetal loss rate: Randomized trials of TC-CVS compared with amniocentesis ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Total fetal loss rate: Randomized trials of TC-CVS compared with amniocentesis </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study, year</td> <td class=\"subtitle1\" colspan=\"2\">Total loss rate, percent</td> <td class=\"subtitle1\" rowspan=\"2\">Difference percentage</td> <td class=\"subtitle1\" rowspan=\"2\">Relative risk, 95% CI</td> </tr> <tr> <td class=\"subtitle2\">TC-CVS</td> <td class=\"subtitle2\">Amniocentesis</td> </tr> <tr> <td>Borrell (1999)</td> <td>19.5 (83/425)</td> <td>14.0 (57/407)</td> <td>5.5</td> <td>1.4 (1.03-1.9)</td> </tr> <tr> <td>Lippman (1992)</td> <td>17.2 (232/1348)</td> <td>15.7 (208/1324)</td> <td>1.5</td> <td>1.1 (0.9-1.3)</td> </tr> <tr> <td>Smidt-Jensen (1992)</td> <td>11.9 (127/1068)</td> <td>7.0 (81/1158)</td> <td>4.9</td> <td>1.7 (1.3-2.2)</td> </tr> <tr> <td>MRC (1991)</td> <td>7.3 (29/399)</td> <td>4.0 (16/398)</td> <td>3.2</td> <td>1.8 (1.0-3.3)</td> </tr> <tr> <td>Overall</td> <td>14.5&nbsp;</td> <td>11.0&nbsp;</td> <td>3.5</td> <td>1.3 (1.2-1.5)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Total fetal loss rate&nbsp;during the time from&nbsp;randomization to the end of the pregnancy.</div><div class=\"graphic_footnotes\">TC-CVS: transcervical chorionic villus sampling; MRC: Medical Research Council; CI: confidence interval.</div><div id=\"graphicVersion\">Graphic 71354 Version 7.0</div></div></div>"},"71355":{"type":"graphic_table","displayName":"Autism screening tools","title":"Screening tools for autism spectrum disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening tools for autism spectrum disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tool</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Sensitivity/specificity</td> <td class=\"subtitle1\">Validation</td> <td class=\"subtitle1\">Comment</td> </tr> <tr class=\"divider_bottom\"> <td>M-CHAT-R/F</td> <td>16 to 30 months</td> <td> <p>20 parent-report items</p> <p>Takes approximately 5 minutes to administer and 2 minutes to score</p> Available in English, Spanish, and other languages from the <a href=\"http://www2.gsu.edu/~psydlr/M-CHAT/Official_M-CHAT_Website.html\" target=\"_blank\">Official M-CHAT Website</a></td> <td> <p>Sensitivity: 85%</p> Specificity: 99% </td> <td>&#62;15,000 children in primary care practices</td> <td>Validated as first-tier screen*. Assesses risk of ASD as low, medium, or high. Children at medium risk require structured follow-up questions for additional information before referral for diagnostic evaluation. Follow-up interview takes approximately 5 to 10 minutes.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">ESAT</td> <td class=\"divider_bottom\" rowspan=\"2\">14 to 15 months</td> <td>14-item questionnaire</td> <td>Sensitivity: 90%</td> <td> <p>478 14- to 15-month-old children from the community</p> <p>153 older children with ASD</p> 76 older children with ADHD </td> <td>The parents of the older children were instructed to answer based on their child's presentation at age 14 months.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>First stage: 4 items</p> Second stage: 14-item questionnaire </td> <td>Positive predictive value: 25%</td> <td>31,724 children in a random population</td> <td>False-positive screens included children with language disorder and intellectual disability, but no typically developing children. Children with negative screens were not systematically followed up, precluding calculation of sensitivity and specificity.</td> </tr> <tr class=\"divider_bottom\"> <td>STAT</td> <td>24 to 36 months</td> <td> <p>12 observed activities during 20-minute play session</p> Requires training for administration and scoring</td> <td> <p>Sensitivity: 92 to 95%</p> Specificity: 73 to 85% </td> <td>52 children with ASD and other developmental disorders and 71 high-risk children</td> <td>Not validated as a first-tier screen*. Language comprehension is not required.</td> </tr> <tr class=\"divider_bottom\"> <td>ITC</td> <td>6 to 24 months</td> <td>24-item questionnaire, a component of the Communication and Symbolic Behavior Scales-Developmental Profile (CSBS-DP)</td> <td>Positive predictive value: 75%</td> <td>10,479 infants screened at one-year health supervision visit</td> <td>The CSBS-DP is a broadband screen for communication delays but has not been validated as a screen for ASD.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">POSI</td> <td class=\"divider_bottom\" rowspan=\"2\">18 to 35 months</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>7-item parent-report items, a component of the Survey of Wellbeing of Young Children (SWYC)</p> Takes &#8804;5 minutes to complete</td> <td> <p>Sensitivity: 83%</p> Specificity: 74% </td> <td>232 children (16 to 36 months) from primary care and specialty clinics</td> <td class=\"divider_bottom\" rowspan=\"2\">Additional studies in community samples are necessary before the POSI can be recommended as a first-tier screen*.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Sensitivity: 89%</p> Specificity: 54% </td> <td>217 children (18 to 48 months) from specialty clinic</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">SCQ</td> <td class=\"divider_bottom\" rowspan=\"2\">4 to 40 years</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>40 parent-report items (yes/no)</p> Takes &#60;10 minutes to administer and &#60;5 minutes to score</td> <td> <p>Sensitivity: 85%</p> Specificity: 75% </td> <td>200 high-risk patients</td> <td class=\"divider_bottom\" rowspan=\"2\">Additional studies are necessary before the SCQ can be used as a first-tier screen*. Nonverbal children may require different cut-off scores.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Sensitivity: not reported</p> <p>Specificity: not reported</p> 90% of children who failed (SCQ score &#8805;15) had a neurodevelopmental disorder </td> <td>247 low-risk children from school or general population</td> </tr> <tr class=\"divider_bottom\"> <td>CAST</td> <td>4 to 11 years</td> <td>37 parent-report items</td> <td>Accuracy varied with case definition</td> <td>1925 children</td> <td>Additional studies are necessary before the CAST can be recommended as a first-tier screen*.</td> </tr> <tr class=\"divider_bottom\"> <td>ASSQ</td> <td>7 to 16 years</td> <td> <p>27-item checklist to be completed by parents or teachers</p> Takes approximately 10 minutes to complete</td> <td> <p>Varies depending upon the cut-off score:</p> <p>Sensitivity: 91%</p> <p>Specificity: 86%</p> (with cut-off score &#8805;17) </td> <td>9430 children (7 to 9 years)</td> <td>Validated as first-tier screen*. Designed as a first-tier screen for children with high-functioning ASD. Clinicians can individualize cut-off scores to meet their diagnostic needs.</td> </tr> <tr class=\"divider_bottom\"> <td>AQ-Child</td> <td>4 to 11 years</td> <td>Parent-report measure</td> <td> <p>Sensitivity: 95%</p> Specificity: 95% </td> <td>540 children with ASD, 1225 children from the general population</td> <td>Additional studies are necessary before the AQ-Child can be recommended as a first-tier screening* tool.</td> </tr> <tr class=\"divider_bottom\"> <td>DBC-ASA</td> <td>4 to 18 years</td> <td>29 parent-report items from the DBC-P</td> <td> <p>Sensitivity: 86%</p> <p>Specificity: 79%</p> (with cut-off score of 17) </td> <td>180 children with ASD and 180 controls (matched for age, sex, and IQ-range)</td> <td>For use in children with intellectual disability.</td> </tr> <tr> <td rowspan=\"2\">DBC-ES</td> <td rowspan=\"2\">18 to 48 months</td> <td rowspan=\"2\">17 parent-report items from the DBC-P</td> <td> <p>Sensitivity: 88%</p> <p>Specificity: 69%</p> (with cut-off score of &#8805;10.5)</td> <td>60 children with developmental delay and ASD and 60 controls (developmental delay without ASD)</td> <td rowspan=\"2\">For use in children with developmental delay.</td> </tr> <tr> <td> <p>Sensitivity: 83%</p> <p>Specificity: 48%</p> (with cut-off score of 11)</td> <td>207 children from the community</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">M-CHAT-R/F: Modified CHAT, Revised with Follow-Up; ASD: autism spectrum disorder; ESAT: Early Screening of Autistic Traits; ADHD: attention deficit hyperactivity disorder; STAT: Screening Tool for Autism in Toddlers and Young Children; ITC: Infant Toddler Checklist; POSI: Parent's Observations of Social Interactions; SCQ: Social Communication Questionnaire; CAST: Childhood Autism Spectrum Test; ASSQ: Autism Spectrum Screening Questionnaire; AQ-Child: Autism Spectrum Quotient-Children's Version; DBC-ASA: Developmental Behaviour Checklist-Autism Screening Algorithm; IQ: intelligence quotient;&nbsp;DBC-P: Developmental Behaviour Checklist for Pediatrics; DBC-ES: Developmental Behaviour Checklist-Early Screen.<br />* First-tier screening tools are used to identify children at risk for ASD from a general population; second-tier screening tools are used to discriminate ASD from other developmental disorders in children with developmental concerns.</div><div id=\"graphicVersion\">Graphic 71355 Version 11.0</div></div></div>"},"71356":{"type":"graphic_picture","displayName":"Hidden penis","title":"Hidden penis in a five month old infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidden penis in a five month old infant</div><div class=\"cntnt\"><img style=\"width:374px; height:243px;\" src=\"images/PEDS/71356_Hidden_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Buried penis in a five-month-old infant. Although only tip of glans is visible, the entire penis easily emerges if skin is gently pushed down under the pubic bone.</div><div class=\"graphic_reference\">Reproduced from: Eroglu E, Bastian OW, Ozcan HC, et al. Buried penis after newborn circumcision. J Urol 2009; 181:1841. Copyright © 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71356 Version 4.0</div></div></div>"},"71357":{"type":"graphic_picture","displayName":"Pancreatic tumor pancreatoscopy","title":"Pancreatoscopy showing a pancreatic tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatoscopy showing a pancreatic tumor</div><div class=\"cntnt\"><img style=\"width:338px; height:266px;\" src=\"images/GAST/71357_Pancreatic_tumor_pancreatos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Identification of the papillary projections by pancreatoscopy.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 71357 Version 3.0</div></div></div>"},"71360":{"type":"graphic_figure","displayName":"Analysis strategy for genome-wide gene expression studies","title":"Analysis strategy for genome-wide gene expression studies","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Analysis strategy for genome-wide gene expression studies</div><div class=\"cntnt\"><img style=\"width:524px; height:718px;\" src=\"images/PC/71360_Microarray_analy_strat.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71360 Version 5.0</div></div></div>"},"71362":{"type":"graphic_figure","displayName":"Single fiber and concentric needle electrodes","title":"Single fiber and concentric needle electrodes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single fiber and concentric needle electrodes</div><div class=\"cntnt\"><img style=\"width:393px; height:498px;\" src=\"images/NEURO/71362_Single-fiber-and-concentric-needle-electrodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Single fiber electrode, recording area 25 µm in diameter.<br> (B) Concentric needle electrode, recording area 580 x 150 µm.</div><div class=\"graphic_reference\">Based on information from: Stålberg E, Trontelj JV. Single fibre electromyography, The Mirvelle Press, Woking, Surrey 1979.</div><div id=\"graphicVersion\">Graphic 71362 Version 3.0</div></div></div>"},"71363":{"type":"graphic_picture","displayName":"Valved T-adaptor for nebulization during mechanical ventilation","title":"Valved T-adaptor for nebulization during mechanical ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Valved T-adaptor for nebulization during mechanical ventilation</div><div class=\"cntnt\"><img style=\"width:400px; height:338px;\" src=\"images/PULM/71363_Valved_T-adaptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The valved T-adaptor can be used as a permanent part of the ventilator tubing. A spring-loaded valve opens and closes the circuit during nebulizer insertion and removal for addition of medication.</div><div class=\"graphic_reference\">Photo reproduced with the permission of CareFusion Corporation. Copyright &#169; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71363 Version 1.0</div></div></div>"},"71367":{"type":"graphic_table","displayName":"BAL fluid in former smokers","title":"Expected values of BAL fluid constituents in healthy former smokers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected values of BAL fluid constituents in healthy former smokers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Mean &#177; SEM</td> <td class=\"subtitle1\">5th percentile*</td> <td class=\"subtitle1\">95th percentile<sup>&#182;</sup></td> </tr> <tr> <td>Percent recovery of lavagate</td> <td>62.3 &#177; 1.4</td> <td>42.6</td> <td>80.4</td> </tr> <tr> <td>Total cells, 10<sup>6</sup><sup>&#916;</sup></td> <td>20.01 &#177; 1.5</td> <td>8.7</td> <td>44.6</td> </tr> <tr> <td>Total cells/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>13.9 &#177; 1.1</td> <td>5.2</td> <td>31.4</td> </tr> <tr> <td>Macrophages, percent<sup>&#916;</sup></td> <td>86.5 &#177; 1.4</td> <td>66.6</td> <td>97</td> </tr> <tr> <td>Macrophages/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>11.9 &#177; 0.9</td> <td>4</td> <td>29</td> </tr> <tr> <td>Lymphocytes, percent<sup>&#916;</sup></td> <td>11.5 &#177; 1.2</td> <td>2</td> <td>29.3</td> </tr> <tr> <td>Lymphocytes/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>1.69 &#177; 0.31</td> <td>0.1</td> <td>5.6</td> </tr> <tr> <td>Neutrophils, percent<sup>&#916;</sup></td> <td>2.1 &#177; 0.5</td> <td>0</td> <td>8.4</td> </tr> <tr> <td>Neutrophils/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>0.27 &#177; 0.049</td> <td>0</td> <td>1</td> </tr> <tr> <td>Eosinophils, percent<sup>&#916;</sup></td> <td>0.2 &#177; 0.06</td> <td>0</td> <td>3.7</td> </tr> <tr> <td>Eosinophils/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>0.08 &#177; 0.035</td> <td>0</td> <td>0.05</td> </tr> <tr> <td>T cells, percent<sup>&#9674;</sup></td> <td>74.23 &#177; 4.31</td> <td>15.8</td> <td>96.7</td> </tr> <tr> <td>T-helper cells, percent<sup>&#9674;</sup></td> <td>46.88 &#177; 3.69</td> <td>11.2</td> <td>77.7</td> </tr> <tr> <td>T-suppressor cells, percent<sup>&#9674;</sup></td> <td>20.65 &#177; 2.14</td> <td>5.7</td> <td>44.7</td> </tr> <tr> <td>Helper/suppressor ratio<sup>&#9674;</sup></td> <td>2.78 &#177; 0.32</td> <td>0.7</td> <td>6</td> </tr> <tr> <td>B cells, percent<sup>&#9674;</sup></td> <td>3.46 &#177; 1</td> <td>0</td> <td>17.5</td> </tr> <tr> <td>IgG, mcg/mL<sup>&#167;</sup></td> <td>9.14 &#177; 0.82</td> <td>2.1</td> <td>17.7</td> </tr> <tr> <td>IgA, mcg/mL<sup>&#167;</sup></td> <td>7.63 &#177; 0.8</td> <td>2.6</td> <td>22.5</td> </tr> <tr> <td>IgM, mcg/mL<sup>&#167;</sup></td> <td>0.33 &#177; 0.06</td> <td>0.05</td> <td>1.4</td> </tr> <tr> <td>Albumin, mcg/mL<sup>&#167;</sup></td> <td>46.39 &#177; 3.82</td> <td>13.6</td> <td>84.2</td> </tr> <tr> <td>Total protein, mcg/mL<sup>&#167;</sup></td> <td>97.69 &#177; 5.78</td> <td>43.4</td> <td>171.1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.<br />* 5th percentile of the study population.<br />¶ 95th percentile of the study population.<br />Δ n = 50.<br /><FONT class=lozenge>◊</FONT> n = 26.<br />§ = 46.</div><div class=\"graphic_reference\">Data from: BAL Cooperative Group. Am Rev Respir Dis 1990; 141:S169 (BAL Cooperative Group, 1990 #261).</div><div id=\"graphicVersion\">Graphic 71367 Version 3.0</div></div></div>"},"71369":{"type":"graphic_figure","displayName":"PEEP status asthmaticus","title":"Extrinsic postive end-expiratory pressure (PEEP) reduces the work of breathing in status asthmaticus","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Extrinsic postive end-expiratory pressure (PEEP) reduces the work of breathing in status asthmaticus</div><div class=\"cntnt\"><img style=\"width:519px; height:286px;\" src=\"images/PULM/71369_PEEP_status_asthmaticus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure compares three conditions: No intrinsic or extrinsic positive end-expiratory pressure (PEEP), intrinsic PEEP only, and intrinsic plus extrinsic PEEP. When intrinsic PEEP exists, the addition of extrinsic PEEP reduces inspiratory effort (shown in red) from -11 cm H<sub>2</sub>O to -3 cm H<sub>2</sub>O. Airflow obstruction is inhomogenous, so levels of intrinsic PEEP are likely to vary from airway to airway. Thus, as a general rule, extrinsic PEEP is usually set up to, but not exceeding, 80 percent of the measured intrinsic PEEP in order to prevent regions of worsening dynamic hyperinflation.</div><div id=\"graphicVersion\">Graphic 71369 Version 2.0</div></div></div>"},"71370":{"type":"graphic_figure","displayName":"Pacemaker algorithm AV block","title":"Selection of pacemaker systems for patients with atrioventricular block","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Selection of pacemaker systems for patients with atrioventricular block</div><div class=\"cntnt\"><img style=\"width:526px; height:527px;\" src=\"images/CARD/71370_Pacemakers_AV_block.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Decisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker.</div><div class=\"graphic_footnotes\">AV: atrioventricular.</div><div class=\"graphic_reference\">Reproduced with permission from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51(21):e1-e62. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &#169; 2008 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 71370 Version 3.0</div></div></div>"},"71371":{"type":"graphic_table","displayName":"Comparison pharmacologic stress agents","title":"Comparison of major pharmacologic agents used for stress testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of major pharmacologic agents used for stress testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dipyridamole</td> <td class=\"subtitle1\">Adenosine</td> <td class=\"subtitle1\">Regadenoson</td> <td class=\"subtitle1\">Dobutamine</td> </tr> <tr> <td><strong>Chemical</strong></td> <td>Pyrimidine derivative</td> <td>Endogenous vasodilator of purine derivative</td> <td>Purine derivative</td> <td>Synthetic catecholamine</td> </tr> <tr> <td><strong>Onset and duration of action, half-life</strong></td> <td>Effect peaks at 7 to 15 minutes, half-life 30 to 45 minutes</td> <td>Immediate onset, half-life less than&nbsp;5 seconds, effects disappear rapidly after infusion</td> <td> <p>Peak 1 to 4 minutes after injection</p> Half-life of &#8773; 30 minutes</td> <td>Onset 1 to 2 minutes, half-life 2 minutes</td> </tr> <tr> <td><strong>Mechanism of action</strong></td> <td>Blocks reuptake of endogenous adenosine causing coronary vasodilation</td> <td>Stimulation of adenosine receptor A2A causing coronary vasodilation</td> <td>Stimulates A2A adenosine receptor causes coronary vasodilation</td> <td>Alpha-1, beta-1, and beta-2 stimulation increases myocardial O<sub>2</sub> demand and secondary vasodilatation</td> </tr> <tr> <td><strong>Dose</strong></td> <td>140 mcg/kg per minute for 4 minutes (maximum 0.56 mg/kg)</td> <td>140 mcg/kg per minute for 4 to 6 minutes</td> <td>Regadenoson 0.4 mg/5 mL</td> <td>5 to 40 mcg/kg per minute, depending upon heart rate response</td> </tr> <tr> <td><strong>Radionuclide injection</strong></td> <td>7 to 9 minutes after initiation of infusion</td> <td>3 minutes into infusion; infusion continued for further 1 to 3 minutes</td> <td>10 to 20 seconds after regadenoson</td> <td>At peak stress</td> </tr> <tr> <td><strong>Hemodynamics</strong></td> <td>Slight increase in heart rate and slight decrease in blood pressure (BP)</td> <td>Slight increase in heart rate and slight decrease in BP (adenosine more than dipyridamole)</td> <td>Slight increase in heart rate and slight decrease in BP</td> <td>Target heart rate 85 percent of maximum predicted heart rate</td> </tr> <tr> <td><strong>Side effects</strong></td> <td>Most common chest pain</td> <td>Same as dipyridamole but resolve rapidly; heart block more common</td> <td>Dyspnea, headache, and flushing</td> <td>Most common palpitations and chest pain, most serious nonsustained ventricular tachycardia, nonfatal myocardial infarction</td> </tr> <tr> <td><strong>Contraindications</strong></td> <td>Bronchospasm, second- or third-degree AV block or sick sinus syndrome (unless protected by a functioning pacemaker)</td> <td>Same as dipyridamole</td> <td> <p>Second- or third-degree AV block or sinus node dysfunction</p> Caution for bronchospasm</td> <td>Recent acute coronary syndrome, hemodynamic and electrophysiologic instability</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71371 Version 8.0</div></div></div>"},"71373":{"type":"graphic_picture","displayName":"Majocchi's granuloma","title":"Majocchi's granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Majocchi's granuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71373_Majocchis_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 14-year-old boy with tinea pedis developed&nbsp;a pruritic&nbsp;eruption of erythematous papules and small pustules&nbsp;on&nbsp;the leg that progressed after topical corticosteroid use.&nbsp;</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 71373 Version 8.0</div></div></div>"},"71374":{"type":"graphic_figure","displayName":"Scabies distribution","title":"Scabies distribution","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies distribution</div><div class=\"cntnt\"><img style=\"width:442px; height:551px;\" src=\"images/PC/71374_Scabies_distribution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies usually involves the sides and webs of the fingers, the flexor aspects of the wrists, the extensor aspects of the elbows, anterior and posterior axillary folds, the skin immediately adjacent to the nipples (especially in women), the periumbilical areas, waist, male genitalia (scrotum, penile shaft, and glans), the extensor surface of the knees, the lower half of the buttocks and adjacent thighs, and the lateral and posterior aspects of the feet. The back is relatively free of involvement; the head is spared except in very young children.</div><div id=\"graphicVersion\">Graphic 71374 Version 3.0</div></div></div>"},"71375":{"type":"graphic_table","displayName":"Types of allergic reactions","title":"Classification of allergic reactions (Gell and Coombs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of allergic reactions (Gell and Coombs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td> <p>I</p> <p>Immediate reaction (30 to 60 min)</p> <p>Accelerated reaction (1 to 72 hours)</p> </td> <td>Anaphylactic, immediate-type hypersensitivity</td> <td>Antigen exposure causes release of vasoactive substances, such as histamine, prostaglandins, and leukotrienes from mast cells or basophils. This response is usually, but not always, IgE-dependent.</td> <td> <p>Anaphylaxis</p> <p>Angioedema</p> <p>Bronchospasm</p> <p>Urticaria (hives)</p> </td> </tr> <tr class=\"divider_top\"> <td>II</td> <td>Antibody-dependent cytotoxicity</td> <td>An antigen or hapten that is intimately associated with a cell binds to antibody, leading to cell or tissue injury.</td> <td> <p>Hemolytic anemia</p> <p>Interstitial nephritis</p> </td> </tr> <tr class=\"divider_top\"> <td>III</td> <td>Immune complex disease</td> <td>Damage is caused by formation or deposition of antigen-antibody complexes in vessels or tissue.</td> <td>Serum sickness</td> </tr> <tr class=\"divider_top\"> <td>IV</td> <td>Cell-mediated or delayed hypersensitivity</td> <td>Antigen exposure sensitizes T cells, which then mediate tissue injury.</td> <td>Contact dermatitis</td> </tr> <tr class=\"divider_top\"> <td> <p>V</p> <p>(&#62;72 hours)</p> </td> <td>&nbsp;</td> <td>Uncertain, but probably involving T cell cytotoxicity.</td> <td>Maculopapular rash</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Adapted from: Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988; 18:515.</div><div id=\"graphicVersion\">Graphic 71375 Version 6.0</div></div></div>"},"71377":{"type":"graphic_waveform","displayName":"Advanced case 4 with answer","title":"Electrical alternans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrical alternans</div><div class=\"cntnt\"><img style=\"width:408px; height:360px;\" src=\"images/CARD/71377_Advanced_case_4_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus tachycardia with electrical alternans which is characterized by beat-to-beat alternation in the QRS appearance (best seen in leads V2 to V4). These findings are strongly suggestive of pericardial effusion, usually with tamponade. The alternating ECG pattern is related to back-and-forth swinging motion of the heart in the pericardial fluid.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 71377 Version 2.0</div></div></div>"},"71378":{"type":"graphic_picture","displayName":"Vulvar cancer 2","title":"Vulvar cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar cancer</div><div class=\"cntnt\"><img style=\"width:350px; height:466px;\" src=\"images/OBGYN/71378_Vulvar_cancer_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vulvar carcinoma in situ presenting as white or hyperpigmented lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: Scott, JR, Gibbs, RS. Danforth's Obstetrics and Gynecology, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71378 Version 1.0</div></div></div>"},"71379":{"type":"graphic_diagnosticimage","displayName":"Lymphoma liver spleen","title":"Difusely enlarged liver and spleen in patient with lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Difusely enlarged liver and spleen in patient with lymphoma</div><div class=\"cntnt\"><img style=\"width:390px; height:262px;\" src=\"images/HEME/71379_Lymphoma_liver_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography&nbsp;of the upper abdomen shows a diffusely enlarged liver and spleen. A small nodular focus can be appreciated in the posterior spleen (arrow). The patient had biopsy-proven T-cell rich, B-cell lymphoma.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 71379 Version 4.0</div></div></div>"},"71381":{"type":"graphic_diagnosticimage","displayName":"Ultrasound fetal schizencephaly","title":"Schizencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schizencephaly</div><div class=\"cntnt\"><img style=\"width:344px; height:566px;\" src=\"images/OBGYN/71381_US_fetal_schizencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Courtney Stephenson, DO.</div><div id=\"graphicVersion\">Graphic 71381 Version 3.0</div></div></div>"},"71383":{"type":"graphic_table","displayName":"RODS mnemonic for difficult extraglottic airway placement","title":"RODS mnemonic for difficult extraglottic airway placement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">RODS mnemonic for difficult extraglottic airway placement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>R</strong>estricted lungs (poor compliance)&nbsp;or mouth opening</td> </tr> <tr> <td><strong>O</strong>bstruction</td> </tr> <tr> <td><strong>D</strong>isrupted or distorted airway</td> </tr> <tr> <td><strong>S</strong>hort thyromental&nbsp;distance</td> </tr> </tbody></table></div><div class=\"graphic_reference\">© The Difficult Airway Course®: Emergency.</div><div id=\"graphicVersion\">Graphic 71383 Version 2.0</div></div></div>"},"71384":{"type":"graphic_table","displayName":"Classification lipodystrophy","title":"Classification of lipodystrophic disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of lipodystrophic disorders</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      \n<td class=\"subtitle1_single\">Familial/congenital lipodystrophy</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td>Total lipoatrophy (Berardinelli - Seip syndrome)</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist1_start\">Partial lipoatrophy</td>\n\n    </tr>\n\n    <tr>\n      \n<td class=\"sublist1\">Dunningan variety</td>\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Koeberling variety</td>\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Lipodystrophy with other dysmorphic features</td>\n    </tr>\n    <tr>\n\n      \n<td>Other varieties</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle1_single\">Aquired lipodystrophy</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td>Total lipoatrophy (Lawrence syndrome)</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist1_start\">Partial lipoatrophy</td>\n\n    </tr>\n\n    <tr>\n      \n<td class=\"sublist1\">Upper atrophy-lower hypertrophy</td>\n    </tr>\n    <tr>\n\n      \n<td class=\"sublist2\">Dermatome pattern</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td>HIV protease inhibitor-associated lipodystrophy</td>\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist1_start\">Localized lipodystrophies</td>\n\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Drug-induced </td>\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Pressure-induced </td>\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Panniculitis variety </td>\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Centrifugal variety </td>\n    </tr>\n    <tr>\n      \n<td class=\"sublist1\">Idiopathic</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71384 Version 1.0</div></div></div>"},"71385":{"type":"graphic_picture","displayName":"Papillary thyroid cancer FNA","title":"Papillary thyroid cancer: Findings on fine-needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papillary thyroid cancer: Findings on fine-needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ENDO/71385_Papillary_carcinoma_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FNA of a thyroid nodule showing papillary cancer. The cells and nuclei are large, and their cytoplasm has a \"ground glass\" appearance. Nucleoli are prominent, and the nuclei have clefts, grooves, and \"holes\" due to intranuclear cytoplasmic inclusions (\"Orphan Annie eyes\").</div><div class=\"graphic_footnotes\">FNA: fine-needle aspirate.</div><div id=\"graphicVersion\">Graphic 71385 Version 4.0</div></div></div>"},"71386":{"type":"graphic_table","displayName":"Major causes of right axis deviation","title":"Major causes of right axis deviation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of right axis deviation</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Artifactual</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Left-right arm electrode reversal (look for negative P and negative QRS in lead I)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normal variant</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Right ventricular overload</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Acute - pulmonary embolus or other causes of acute cor pulmonale</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Chronic</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2\">Chronic obstructive lung disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2\">Any cause of right ventricular hypertrophy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Lateral wall myocardial infarction</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dextrocardia, as with situs inversus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Left posterior fascicular block - must exclude other causes listed above</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 71386 Version 2.0</div></div></div>"},"71388":{"type":"graphic_table","displayName":"Resp patterns and ABG in coma","title":"Ventilatory and arterial blood gas patterns in coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ventilatory and arterial blood gas patterns in coma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Breathing pattern</td>\n<td class=\"subtitle1\">Metabolic pattern</td>\n<td class=\"subtitle1\">pH, PaCO2, HCO3</td>\n<td class=\"subtitle1\">Specific conditions</td>\n</tr>\n<tr>\n<td>Hyperventilation</td>\n<td>Metabolic acidosis</td>\n<td>pH &#60;7.3, PaCO2 &#60;30 mmHg, HCO3 &#60;17 mmol/L</td>\n<td>Uremia, diabetic ketoacidosis, lactic acidosis, salicylates, methanol, ethylene glycol</td>\n</tr>\n<tr>\n<td>Hyperventilation</td>\n<td>Respiratory alkalosis</td>\n<td>pH &#62;7.45, PaCO2 &#60;30 mmHg, HCO3 &#62;17 mmol/L</td>\n<td>Hepatic failure, acute sepsis, acute salicylate intoxication, cardiopulmonary states with hypoxemia, psychogenic causes</td>\n</tr>\n<tr>\n<td>Hypoventilation</td>\n<td>Respiratory acidosis</td>\n<td>pH &#60;7.35 (if acute), PaCO2 &#62;90 mmHg, HCO3 &#62;17 mmol/L</td>\n<td>Respiratory failure from central (eg, brain or spinal cord) or peripheral nervous system disease, chest conditions or deformities. Coma only with severe hypercarbia.</td>\n</tr>\n<tr>\n<td>Hypoventilation</td>\n<td>Metabolic alkalosis</td>\n<td>pH&#62; 7.45, PaCO2 &#62;45 mmHg, HCO3 &#62;30 mmol/L</td>\n<td>Vomiting, alkali ingestion. Usually no impairment of consciousness; if so, suspect psychogenic unresponsiveness or additional cause.</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">10.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=41385&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Resp_patterns_and_ABG_in_Co.htm</title></head></div><div id=\"graphicVersion\">Graphic 71388 Version 2.0</div></div></div>"},"71389":{"type":"graphic_table","displayName":"Findings child vasculitis","title":"Common or specific manifestations of childhood vasculitis at presentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common or specific&nbsp;manifestations of childhood vasculitis at presentation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Involved organ or system</td> <td class=\"subtitle1\">Symptom or sign</td> </tr> <tr> <td>Constitutional</td> <td>Fever, weight loss, weakness, fatigue</td> </tr> <tr> <td>Musculoskeletal</td> <td>Arthralgia, myalgia, arthritis</td> </tr> <tr> <td>Cutaneous</td> <td>Palpable purpura, nodules, urticaria, livedoreticularis, superficial phlebitis, ischemic lesions, mucositis, oral/nasal/genital ulcers</td> </tr> <tr> <td>Neurologic</td> <td>Headache, stroke, mononeuritis multiplex</td> </tr> <tr> <td>Head and neck</td> <td>Sinusitis, chondritis, otitis, iritis</td> </tr> <tr> <td>Renal</td> <td>Nephritis, hypertension</td> </tr> <tr> <td>Pulmonary</td> <td>Hemorrhage, cavities, nodules, infiltrates</td> </tr> <tr> <td>Cardiovascular</td> <td>Chest pain, heart failure, limb claudication</td> </tr> <tr> <td>Gastrointestinal</td> <td>Abdominal pain, mesenteric ischemia, gastrointestinal hemorrhage</td> </tr> <tr> <td>Laboratory</td> <td>Anemia, elevated erythrocyte sedimentation rate, abnormal liver function tests, hematuria</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data reproduced with permission from: Churg A, Churg J. Systemic Vasculitides. Igaku-Shoin Medical Publishers. New York 1991. Copyright © 1991 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 71389 Version 7.0</div></div></div>"},"71390":{"type":"graphic_figure","displayName":"Myocardial action potential","title":"Myocardial action potential","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Myocardial action potential</div><div class=\"cntnt\"><img style=\"width:468px; height:245px;\" src=\"images/CARD/71390_Myocardialactionpotential.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of an action potential in ventricular myocardial cells. An action potential is generated when the membrane potential is partially depolarized from the resting level (Em) to the threshold potential (Et). The ensuing rapid phase 0 depolarization is mediated by sodium entry into the cells due to a marked increase in the number of open sodium channels in the cell membrane. Repolarization in phases 1 and 3 results from potassium exit from the cells as the sodium channels are closed and potassium channels opened. The phase 2 plateau reflects the slow entry of calcium into the cells, which counteracts the effect of potassium exit. The membrane potential is driven closer to Em and maintained there in phase 4 by activation of an inwardly rectifying potassium current (I<SUB>K1</SUB>) </div><div id=\"graphicVersion\">Graphic 71390 Version 2.0</div></div></div>"},"71391":{"type":"graphic_figure","displayName":"AVS primary aldosteronism","title":"Adrenal vein aldosterone ratios for patients with unilateral APAs, bilateral IHA, and unilateral PAH","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Adrenal vein aldosterone ratios for patients with unilateral APAs, bilateral IHA, and unilateral PAH</div><div class=\"cntnt\"><img style=\"width:615px; height:418px;\" src=\"images/ENDO/71391_AVS_primary_aldosteronism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Between 1990 and 2003, 203 patients underwent adrenal venous sampling. Bilateral successful adrenal vein catheterization was achieved in 95.6% of the patients.&nbsp;The sensitivity and specificity of the cortisol-corrected PAC lateralization ratio &gt;4.0 for unilateral disease are 95.2 and 100%, respectively. Shaded symbols indicate the diagnosis was confirmed surgically.</div><div class=\"graphic_footnotes\">APA: aldosterone-producing adenoma; IHA: idiopathic hyperaldosteronism; PAH: primary adrenal hyperplasia; PAC: plasma aldosterone concentration.</div><div class=\"graphic_reference\">Reproduced from: Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136:1227. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71391 Version 5.0</div></div></div>"},"71392":{"type":"graphic_table","displayName":"Monitoring MTC and timing thyroidectomy in RET mutation carriers","title":"Clinical monitoring for medullary thyroid cancer and timing of thyroidectomy in carriers of a mutation in the <EM>RET</EM> gene","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical monitoring for medullary thyroid cancer and timing of thyroidectomy in carriers of a mutation in the <EM>RET</EM> gene</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\"><em>RET</em> codon mutation</td> <td class=\"subtitle1\">Recommended age to begin annual screening for MTC*</td> <td class=\"subtitle1\">Recommended timing of prophylactic thyroidectomy<sup>&#182;</sup></td> </tr> <tr> <td>Highest</td> <td>918</td> <td>Not applicable</td> <td>In the first months to year of life</td> </tr> <tr> <td>High</td> <td>634, 883</td> <td>3 years</td> <td>At or before age 5 years</td> </tr> <tr> <td>Moderate</td> <td>533, 609, 611, 618, 620, 630, 666, 768, 790, 804, 891, 912</td> <td>5 years</td> <td>Childhood or young adulthood</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Risk of MTC development in MEN2 depends on mutated <em>RET</em> codon.</div><div class=\"graphic_footnotes\">MTC: medullary thyroid cancer; MEN2: multiple endocrine neoplasia type 2.<br />* Annual physical examination, neck ultrasound, and measurement of serum calcitonin.<br />¶ Patients with MEN2 and a diagnosis of MTC (regardless of age) must have pheochromocytoma excluded prior to thyroidectomy.</div><div class=\"graphic_reference\">Data from: Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.</div><div id=\"graphicVersion\">Graphic 71392 Version 6.0</div></div></div>"},"71393":{"type":"graphic_picture","displayName":"Hemoglobin SC disease","title":"Peripheral blood smear in hemoglobin SC disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in hemoglobin SC disease</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/HEME/71393_Hemoglobin_SC_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with hemoglobin SC disease shows numerous target cells (red arrows), partially sickled &quot;canoe&quot; shaped erythrocytes (black arrows), and folded (Pita bread) red cells (blue arrows).</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 71393 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"71394":{"type":"graphic_figure","displayName":"Transcription fx myelopoiesis","title":"Transcription factors and myelopoiesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transcription factors and myelopoiesis</div><div class=\"cntnt\"><img style=\"width:443px; height:565px;\" src=\"images/HEME/71394_Transcription_fx_myelopoies.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71394 Version 1.0</div></div></div>"},"71395":{"type":"graphic_table","displayName":"Dosages of antimicrobial agents by intraventricular route","title":"Recommended dosages of antimicrobial agents administered by the intraventricular route","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dosages of antimicrobial agents administered by the intraventricular route</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial agent</td> <td class=\"subtitle1\">Daily intraventricular dose</td> </tr> <tr> <td>Amikacin</td> <td>5 to 50 mg*</td> </tr> <tr> <td>Colistin</td> <td> <p>10&nbsp;mg colistimethate sodium (CMS), which corresponds to:</p> <p>&nbsp;&nbsp; &nbsp;125,000 international units of CMS<strong> or</strong> </p> <p>&nbsp;&nbsp;&nbsp; 4.2 mg colistin base activity (approximately)<sup>&#182;</sup></p> </td> </tr> <tr> <td>Daptomycin</td> <td>2 to 5 mg<sup>&#916;</sup></td> </tr> <tr> <td>Gentamicin</td> <td> <p>1 to 2 mg<sup>&#9674;</sup> in children</p> 4 to 8 mg<sup>&#9674;</sup><sup>&#167;</sup> in adults</td> </tr> <tr> <td>Polymyxin B</td> <td> <p>2 mg in children</p> 5 mg in adults</td> </tr> <tr> <td>Quinupristin/dalfopristin</td> <td>2 to 5 mg</td> </tr> <tr> <td>Tobramycin</td> <td>5 to 20 mg</td> </tr> <tr> <td>Vancomycin</td> <td>5 to 20 mg<sup>&#9674;</sup><sup>&#167;</sup><sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There are no specific data that define the exact dose of intraventricular antimicrobial agents that should be used in cerebrospinal fluid (CSF) shunt and drain infections. Given the smaller CSF volume in infants (approximately 50 mL) compared&nbsp;with adults (approximately 125 to 150 mL), doses in infants should probably be decreased at least 60% or more compared to adults. Antibiotics given through the intrathecal or intraventricular route should be preservative free. <EM innerHtml>UpToDate Editor's Note: </EM>Pediatric data are limited; consultation with a pediatric infectious diseases specialist is advised.</div><div class=\"graphic_footnotes\">* The usual intraventricular dose is 30 mg daily.<br />¶ The formulation available in the United States is measured as colistin base activity. The total daily dose can be&nbsp;administered as one daily dose or divided into two doses given every 12 hours.<br />Δ One study used 10 mg every day for 2 days and then 10 mg every 48 hours. Another study used 5 mg or 10 mg every 72 hours. Data are based on isolated case reports.<br /><FONT class=lozenge>◊</FONT> Recommendations for frequency of administration based on external ventricular drain output over 24 hours as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>&lt;50 mL/24 hours: Every third day.</LI>&#xD;&#xA;<LI>50 to 100 mL/24 hours: Every second day.</LI>&#xD;&#xA;<LI>100 to 150 mL/24 hours: Once daily.</LI>&#xD;&#xA;<LI>150 to 200 mL/24 hours: Increase the dosage by 5 mg of vancomycin and 1 mg of gentamicin and give once daily.</LI>&#xD;&#xA;<LI>200 to 250 mL/24 hours: Increase the dosage by 10 mg of vancomycin and 2 mg of gentamicin and give once daily.</LI></UL>§ Dosage recommendations in adults based on ventricle size/volume as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Slit ventricles: 5 mg vancomycin and 2 mg gentamicin.</LI>&#xD;&#xA;<LI>Normal size: 10 mg vancomycin and 3 mg gentamicin.</LI>&#xD;&#xA;<LI>Enlarged ventricles: 15 to 20 mg vancomycin and 4 to 5 mg gentamicin.</LI></UL>¥ Most studies used a 10 mg or 20 mg dose.</div><div class=\"graphic_reference\">Reproduced from: Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 71395 Version 9.0</div></div></div>"},"71396":{"type":"graphic_picture","displayName":"Wright Giemsa stain morula","title":"Wright-Giemsa stain morula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wright-Giemsa stain morula</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ID/71396_Wright_Giemsa_stain_morula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wright-Giemsa stain of a buffy coat specimen revealed the presence of a morula, or cluster of intracellular coccobacilli, inside of a polymorphonuclear leukocyte (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Donato, AA, Chaudhary, A. Photo Quiz: A 78-Year-Old Man with the &quot;Summer Flu&quot; and Cytopenias. Clin Infect Dis 2009; 48:1433. Copyright &#169;2009 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 71396 Version 1.0</div></div></div>"},"71397":{"type":"graphic_diagnosticimage","displayName":"MRI NPH cerebral aqueduct flow void","title":"MRI NPH cerebral aqueduct flow void","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">MRI NPH cerebral aqueduct flow void</div><div class=\"cntnt\"><img style=\"width:507px; height:295px;\" src=\"images/NEURO/71397_Cerebral_aqueduct_flow_void.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T2-weighted image in a patient with normal pressure hydrocephalus shows a flow void in the cerebral aqueduct.<br />(B) Axial T2-weighted image showing normal signal (no flow void) in the cerebral aqueduct.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; NPH: normal pressure hydrocephalus. </div><div id=\"graphicVersion\">Graphic 71397 Version 4.0</div></div></div>"},"71398":{"type":"graphic_figure","displayName":"Frank breech presentation","title":"Frank breech presentation","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Frank breech presentation</div><div class=\"cntnt\"><img style=\"width:507px; height:578px;\" src=\"images/OBGYN/71398_Frank_breech_presentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both hips are flexed and both knees are extended in frank breech presentation.</div><div id=\"graphicVersion\">Graphic 71398 Version 3.0</div></div></div>"},"71399":{"type":"graphic_table","displayName":"Indications placental exam","title":"Potential indications for examination of second and third trimester placentas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications for examination of second and third trimester placentas</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Maternal medical conditions with potential fetal effects</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Preterm or postterm birth</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Peripartum fever or infection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Third trimester bleeding or postpartum hemorrhage</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Severe oligohydramnios or polyhydramnios</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Invasive procedures with suspected placental injury</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>In utero fetal therapy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Placenta previa or abruptio placentae</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Thick meconium</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>History of substance abuse or exposure to toxins</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Maternal trauma during pregnancy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Prolonged premature rupture of membranes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Stillbirth or neonatal death</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Maternal death</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Depressed neonate</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hydrops fetalis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neonatal seizures</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Multiple gestation (including vanishing twin)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Small or large for gestational age neonates</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Congenital anomaly</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Umbilical cord abnormality</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Placental abnormality</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neonatal hematologic abnormalities</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Pathological examination of the placenta can be omitted with normal delivery (vaginal or cesarean) of a healthy term infant from an uncomplicated pregnancy.</div><div class=\"graphic_reference\">Data from: Langston, C. Practice guideline for examination of the placenta. Archives of Pathology &amp; Laboratory Medicine 1997; 121:449. Khong, TY. From delivery suite to laboratory: optimizing returns from placental examination in medico-legal defense. Aust N Z J Obstet Gynaecol 1997; 37:1. Kaplan, C, Lowell, DM, Salafia, C. College of American Pathologists Conference XIX on the Examination of the Placenta: report of the Working Group on the Definition of Structural Changes Associated with Abnormal Function in the Maternal/Fetal/Placental Unit in the Second and Third Trimesters. Arch Pathol Lab Med 1991; 115:709.</div><div id=\"graphicVersion\">Graphic 71399 Version 1.0</div></div></div>"},"71400":{"type":"graphic_table","displayName":"Complications corticosteroid Rx","title":"Complications of corticosteroid therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of corticosteroid therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"subtitle2_single\">Common</td> </tr> <tr> <td class=\"indent1\">Behavioral changes, insomnia, myopathy, hallucinations, hiccups, tremor, reduced taste and smell, cerebral atrophy</td> </tr> <tr> <td class=\"subtitle2_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\">Psychosis, dementia, seizures, dependence, paraparesis (epidural lipomatosis)</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic</td> </tr> <tr> <td>Thin, fragile skin, purpura, ecchymosis, striae, hirsutism, acne, inhibition of wound healing, Kaposi sarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Rheumatologic</td> </tr> <tr> <td>Osteoporosis, avascular necrosis, growth retardation, tendinous rupture</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td>Increased appetite, abdominal bloating, gastrointestinal bleeding and perforation, pancreatitis, liver hypertrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Ophthalmologic</td> </tr> <tr> <td>Visual blurring, cataract, glaucoma, exophthalmos, uveitis</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td>Hypertension, atherosclerosis, arrhythmia (with IV push)</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td>Hyperglycemia, hypokalemia, hypophosphatemia, hypernatremia, hyperlipidemia, redistribution of body fat (centripetal obesity, buffalo hump, etc), amenorrhea</td> </tr> <tr> <td class=\"subtitle1_single\">Urogenital</td> </tr> <tr> <td>Polyuria, genital burning (with IV push)</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Opportunistic infections (including candidiasis, PCP), hypersensitivity reactions, neutrophilia, lymphopenia, night sweats</td> </tr> <tr> <td class=\"subtitle1_single\">Steroid withdrawal</td> </tr> <tr> <td>Pseudorheumatism (very common), headache, lethargy, low-grade fever, adrenal insufficiency, pseudotumor cerebri</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; PCP: <EM>Pneumocystis </EM>pneumonia.</div><div class=\"graphic_reference\">Data adapted from Delattre&nbsp;JY, Posner JB. Neurological complications of chemotherapy and radiation therapy. In: Neurology and General Medicine, Aminoff MJ (Ed), Churchill Livingstone, New York, 1994. p.421.</div><div id=\"graphicVersion\">Graphic 71400 Version 2.0</div></div></div>"},"71401":{"type":"graphic_figure","displayName":"APRV","title":"Airway pressure release ventilation (APRV)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway pressure release ventilation (APRV)</div><div class=\"cntnt\"><img style=\"width:376px; height:293px;\" src=\"images/PULM/71401_APRV.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Seymour, CW, Frazer M, Reilly, PM, Fuchs, BD. Airway pressure release and biphasic intermittent positive airway pressure ventilation: are they ready for prime time? J Trauma 2007; 62:1298.</div><div id=\"graphicVersion\">Graphic 71401 Version 1.0</div></div></div>"},"71404":{"type":"graphic_table","displayName":"Rhabdomyosarc prognos stratify","title":"Rhabdomyosarcoma prognostic stratification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rhabdomyosarcoma prognostic stratification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Prognosis (EFS) </td> <td class=\"subtitle1\">Stage </td> <td class=\"subtitle1\">Clinical group </td> <td class=\"subtitle1\">Site </td> <td class=\"subtitle1\">Size </td> <td class=\"subtitle1\">Age </td> <td class=\"subtitle1\">Histology </td> <td class=\"subtitle1\">Mets </td> <td class=\"subtitle1\">Nodes </td> </tr> <tr> <td rowspan=\"5\"> <p>Excellent (&#62;85%)</p> <p>&nbsp;</p> <p>Low risk subset A</p> </td> <td>1</td> <td>I</td> <td>Favorable</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0</td> </tr> <tr> <td>1</td> <td>II</td> <td>Favorable</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0</td> </tr> <tr> <td>1</td> <td>III</td> <td>Orbit only</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0</td> </tr> <tr> <td>2</td> <td>I</td> <td>Unfavorable</td> <td>a</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0 or NX</td> </tr> <tr> <td>1</td> <td>II</td> <td>Favorable</td> <td>a or&nbsp;b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N1&nbsp;</td> </tr> <tr> <td rowspan=\"5\"> <p>Very good (70 to 85%)</p> <p>&nbsp;</p> <p>Low risk subset B</p> <br /> <p>&nbsp;</p> </td> <td>1</td> <td>III</td> <td>Orbit only</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N1</td> </tr> <tr> <td>1</td> <td>III</td> <td>Favorable, excluding orbit</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0 or N1 or NX</td> </tr> <tr> <td>2</td> <td>II</td> <td>Unfavorable</td> <td>a</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0 or NX</td> </tr> <tr> <td>3</td> <td>I or II</td> <td>Unfavorable</td> <td>a</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N1</td> </tr> <tr> <td>3</td> <td>I or II</td> <td>Unfavorable</td> <td>b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0 or N1 or NX</td> </tr> <tr> <td rowspan=\"5\"> <p>Good (50 to 70%)</p> <p>&nbsp;</p> <p>Intermediate risk</p> </td> <td>2</td> <td>III</td> <td>Unfavorable</td> <td>a</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0 or NX</td> </tr> <tr> <td>3</td> <td>III</td> <td>Unfavorable</td> <td>a</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N1</td> </tr> <tr> <td>3</td> <td>III</td> <td>Unfavorable</td> <td>b</td> <td>&#60;21</td> <td>Fusion negative</td> <td>M0</td> <td>N0 or N1 or NX</td> </tr> <tr> <td>1, 2, 3</td> <td>I, II, III</td> <td>Favorable or unfavorable</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion positive</td> <td>M0</td> <td>N0 or N1 or NX</td> </tr> <tr> <td>4</td> <td>IV</td> <td>Favorable or unfavorable</td> <td>a or b</td> <td>&#60;10</td> <td>Fusion negative</td> <td>M1</td> <td>N0 or N1 or NX</td> </tr> <tr> <td rowspan=\"2\"> <p>Poor (&#60;30%)</p> <p>&nbsp;</p> <p>High risk</p> </td> <td>4</td> <td>IV</td> <td>Favorable or unfavorable</td> <td>a or b</td> <td>&#8805;10</td> <td>Fusion negative</td> <td>M1</td> <td>N0 or N1 or NX</td> </tr> <tr> <td>4</td> <td>IV</td> <td>Favorable or unfavorable</td> <td>a or b</td> <td>&#60;21</td> <td>Fusion positive</td> <td>M1</td> <td>N0 or N1 or NX</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The risk group descriptions in this table are based upon the results of historically completed trials using the&nbsp;EFS estimates of the individual patient groups. Current Children's Oncology Group (COG) protocols can deviate from theses definitions for protocol purposes (refer to&nbsp;text).<br /></div><div class=\"graphic_footnotes\">EFS: event-free survival; Favorable site: orbit/eyelid, head and neck (excluding parameningeal), genitourinary (not bladder or prostate), and biliary tract; Unfavorable site: bladder, prostate, extremity, parameningeal, trunk, retroperitoneal, pelvis, other; a: tumor size 5 cm in diameter; b: tumor size &gt;5 cm in diameter; N0: regional nodes clinically not involved; N2: regional nodes clinically involved; NX: node status unknown. M0: no distant metastases; M1: distant metastases present.</div><div class=\"graphic_reference\">Adapted with permission from: Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group Experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23:215. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71404 Version 15.0</div></div></div>"},"71405":{"type":"graphic_table","displayName":"Causes of stridor other than congenital anomalies","title":"Causes of stridor other than congenital anomalies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of stridor other than congenital anomalies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Acute</td> <td class=\"subtitle1\">Chronic</td> </tr> <tr> <td colspan=\"3\"><strong>Infection</strong></td> </tr> <tr> <td class=\"indent1\">Congenital</td> <td>&nbsp;</td> <td>Papilloma virus<br /> Herpes virus</td> </tr> <tr> <td class=\"indent1\">Viral</td> <td>Croup (Parainfluenza)<br /> RSV<br /> Influenza A and B<br /> Mycoplasma</td> <td>Lymphadenopathy caused by CMV and EBV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bacterial</td> <td>Epiglottitis<br /> Tracheitis<br /> Peritonsillar and retropharyngeal abscess<br /> Lateral pharyngeal space abscess<br /> Diphtheria</td> <td>Lymphadenopathy caused by tuberculosis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tumors</strong></td> <td>&nbsp;</td> <td>Encephalocele, teratoma, lymphoma, granuloma, fibroma, papilloma, neuroblastoma, hemangioma, rhabdomyosarcoma, cystic hygroma</td> </tr> <tr> <td colspan=\"3\"><strong>Trauma</strong></td> </tr> <tr> <td class=\"indent1\">Recurrent laryngeal nerve</td> <td>&nbsp;</td> <td>Post PDA repair<br /> Thyroid surgery</td> </tr> <tr> <td class=\"indent1\">Post extubation</td> <td>Edema</td> <td>Subglottic stenosis<br /> Unilateral or bilateral vocal cord paralysis</td> </tr> <tr> <td class=\"indent1\">Thermal epiglottitis</td> <td>Airway injury may be caused by exposure to hot air, liquids, solids or steam. Injury from steam inhalation may occur in the absence of oropharyngeal burns.<sup>[1]</sup></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other</td> <td>Caustic ingestion<br /> Inhalation injury<br /> Facial trauma or burn</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Allergic</strong></td> <td>Anaphylaxis<br /> Hereditary angioneurotic edema</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neurologic</strong></td> <td>&nbsp;</td> <td>CNS malformation<br /> Hypoxic encephalopathy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Metabolic</strong></td> <td>Hypocalcemia</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Other</strong></td> <td>Airway foreign body<br /> Esophageal foreign body<br /> Spasmodic croup<br /> Exercise<br /> Vocal cord dysfunction</td> <td>Gastroesophageal reflux<br /> Juvenile idiopathic arthritis (cricoarytenoid arthritis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RSV: respiratory syncytial virus; CMV: cytomegalovirus; EBV: Epstein-Barr virus; PDA: patent ductus arteriosus; CNS: central nervous system.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Kudchadkar SR, Hamrick JT, Mai CL, et al. The Heat Is on ... Thermal Epiglottitis As a Late Presentation of Airway Steam Injury. J Emerg Med 2013.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71405 Version 7.0</div></div></div>"},"71406":{"type":"graphic_table","displayName":"Decontamination supplies","title":"Supplies for radiation decontamination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supplies for radiation decontamination</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Emergency department</td>\n</tr>\n<tr>\n<td>Rolls of brown paper 3 to 4 feet wide or other disposable waterproof floor covering from the entrance of the facility to the treating area</td>\n</tr>\n<tr>\n<td>Tape to secure the floor covering and to delineate and separate treating areas</td>\n</tr>\n<tr>\n<td>Signs indicating radiation contamination</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Treatment room</td>\n</tr>\n<tr>\n<td>All necessary medical equipment</td>\n</tr>\n<tr>\n<td>Patient sheets and gowns</td>\n</tr>\n<tr>\n<td>Table with a waterproof covering (Drainage system to collect contaminated washings is ideal)</td>\n</tr>\n<tr>\n<td>Large buckets for collection of waste water</td>\n</tr>\n<tr>\n<td>Plastic bags and other containers for storage and disposal of swabs, clothing, linens, or trash</td>\n</tr>\n<tr>\n<td>Lead containers for possible radioactive foreign bodies</td>\n</tr>\n<tr>\n<td>Solutions for decontamination including saline, water, soap, cornmeal (for use as a mild abrasive), hydrogen peroxide, and soft brushes</td>\n</tr>\n<tr>\n<td>Muller-Geiger counter and alpha counter</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Personnel</td>\n</tr>\n<tr>\n<td>Scrubs</td>\n</tr>\n<tr>\n<td>Gowns, masks, foot covers, hats, and waterproof gloves</td>\n</tr>\n<tr>\n<td>Tape to secure the outer coverings</td>\n</tr>\n<tr>\n<td>Dosimeters and film badges</td>\n</tr>\n<tr>\n<td>Waterproof aprons</td>\n</tr>\n<tr>\n<td>Stickers and pens for labeling specimens</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71406 Version 1.0</div></div></div>"},"71407":{"type":"graphic_figure","displayName":"Neonatal BP birth weight","title":"Neonatal blood pressure based on birth weight","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neonatal blood pressure based on birth weight</div><div class=\"cntnt\"><img style=\"width:449px; height:588px;\" src=\"images/PEDS/71407_Neonatal_BP_birth_weight.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear regression of mean systolic and diastolic blood pressure based&nbsp;on birth weight in 329 infants admitted to the neonatal intensive care unit (NICU) on day&nbsp;one of life. The mean systolic and diastolic blood pressure and 95 percent confidence limit (CL) for incremental birth weight are plotted about the respective regression lines.</div><div class=\"graphic_reference\">Adapted with&nbsp;permission from: Macmillan Publishers Ltd. Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470. Copyright ©1995.</div><div id=\"graphicVersion\">Graphic 71407 Version 6.0</div></div></div>"},"71408":{"type":"graphic_table","displayName":"Function extraocular muscles","title":"Functions of the vertical and oblique extraocular muscles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functions of the vertical and oblique extraocular muscles</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Functions</td>\n\n      <td class=\"subtitle1\">Superior rectus</td>\n\n      <td class=\"subtitle1\">Inferior rectus</td>\n\n      <td class=\"subtitle1\">Superior oblique</td>\n\n      <td class=\"subtitle1\">Inferior oblique</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td>Primary</td>\n\n      <td>Elevation</td>\n\n      <td>Depression</td>\n\n      <td>Incyclotorsion</td>\n\n      <td>Excyclotorsion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Secondary</td>\n\n      <td>Incyclotorsion</td>\n\n      <td>Excyclotorsion</td>\n\n      <td>Depression</td>\n\n      <td>Elevation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tertiary</td>\n\n      <td>Adduction</td>\n\n      <td>Adduction</td>\n\n      <td>Abduction</td>\n\n      <td>Abduction</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71408 Version 1.0</div></div></div>"},"71410":{"type":"graphic_waveform","displayName":"ECG Antidromic AVRT","title":"12-lead electrocardiogram (ECG) showing antidromic atrioventricular reentrant tachycardia (AVRT)","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing antidromic atrioventricular reentrant tachycardia (AVRT)</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/CARD/71410_AntidromicAVRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG shows a wide complex tachycardia in a patient with Wolff-Parkinson-White syndrome and a left lateral accessory pathway. The QRS complexes are wide and have a morphology that is similar to that during sinus rhythm, confirming that this is an antidromic atrioventricular reentrant tachycardia.</div><div id=\"graphicVersion\">Graphic 71410 Version 5.0</div></div></div>"},"71411":{"type":"graphic_figure","displayName":"Exposed medial wall of orbit","title":"Medial wall of the left orbit (lateral wall removed)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Medial wall of the left orbit (lateral wall removed)</div><div class=\"cntnt\"><img style=\"width:504px; height:495px;\" src=\"images/ID/71411_Exposed_medial_wall_of_orbi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the proximity of the frontal, ethmoidal, and maxillary sinuses to the orbital space. The lamina papyracea is the thin bone wall on the surface of the ethmoid air cells.</div><div id=\"graphicVersion\">Graphic 71411 Version 5.0</div></div></div>"},"71412":{"type":"graphic_table","displayName":"Rx strep PVE II","title":"Suggested regimens for therapy of prosthetic valve endocarditis due to strains of viridans streptococci and <EM innerHtml>Streptococcus gallolyticus </EM>(<EM innerHtml>bovis</EM>) relatively or fully resistant to penicillin G (MIC >0.12 mcg/mL)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of prosthetic valve endocarditis due to strains of viridans streptococci and <EM innerHtml>Streptococcus gallolyticus </EM>(<EM innerHtml>bovis</EM>) relatively or fully resistant to penicillin G (MIC &gt;0.12 mcg/mL)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology* (ESC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric</td> <td class=\"subtitle2\">Adult&nbsp;</td> </tr> <tr> <td> <p><strong>Combination:</strong></p> <p><strong>Either</strong></p> <p>Aqueous penicillin G 24 million units per 24 hours IV either continuously or in&nbsp;four or&nbsp;six divided doses for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 2 g IV every 4 hours for six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>&#182;</sup> 2 g/24 hours IV in&nbsp;one dose for&nbsp;six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#916;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;three divided doses for two to six weeks</p> <p><strong>Monotherapy:</strong></p> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for&nbsp;six weeks</p> </td> <td> <p><strong>Combination:</strong></p> <p><strong>Either</strong></p> <p><strong></strong>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in&nbsp;six divided doses (maximum dose: 24 million units per&nbsp;24 hours)&nbsp;for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ampicillin&nbsp;200 to 300&nbsp;mg/kg per 24 hours IV divided in four&nbsp;or six divided doses&nbsp;(maximum dose: 12 g per 24 hours) for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone 100 mg/kg per 24 hours IV in two divided doses or 80 mg/kg in one daily dose (maximum&nbsp;dose: 4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours) for&nbsp;six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup><span style=\"font-size: 13px;\">&#916;</span></sup> 3 to 6 mg/kg per 24 hours IV&nbsp;in&nbsp;three divided doses for&nbsp;six weeks</p> <p><strong>Beta-lactam-intolerant patients:</strong></p> <p>Vancomycin<sup>&#9674; </sup>40 mg/kg per 24 hours IV in two or three divided doses (maximum dose: 2 g per 24 hours unless levels are inappropriately low) for six weeks&nbsp;<strong>plus</strong> gentamicin (dosing as above) for first two weeks</p> </td> <td> <p><strong>Combination:&nbsp;</strong></p> <p><strong>Either</strong></p> <p>Aqueous penicillin G 24 million units per 24 hours IV in&nbsp;four&nbsp;or six divided doses or continuously for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Amoxicillin 200 mg/kg per 24 hours IV in&nbsp;four or six divided doses for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>&#182;</sup> 2 g per 24 hours IV in one dose for six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (or 200 mg/kg per 24 hours) in&nbsp;four or six divided doses for&nbsp;six weeks</p> <p><strong>or</strong></p> <p>Vancomycin<sup>&#9674; ​</sup>30 mg/kg per 24 hours IV in&nbsp;two doses for&nbsp;six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#916;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one dose for six weeks</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the individual Lexicomp drug monographs for renal dose adjustments.<br />​Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; IV: intravenously; IM: intramuscularly.<br />* Also includes <EM>Abiotrophia dejectiva</EM>,&nbsp;<EM>Granulicatella</EM> spp, and <EM>Gemella</EM> spp. AHA adult guidelines define relatively resistant streptococcal strains as MIC &gt;0.12 mcg/mL and &lt;0.5 mcg/mL; AHA pediatric guidelines use MIC &gt;0.1 mcg/mL and &lt;0.5 mcg/mL; ESC guidelines use MIC 0.25 to 2 mcg/mL. AHA guidelines define resistant streptococcal strains as MIC ≥0.5 mcg/mL. ESC guidelines use MIC &gt;2 mcg/mL.<br />¶&nbsp;Alternative in patients with nonsevere penicillin allergy; preferred for outpatient therapy.<br />Δ In adults, aminoglycosides are dosed based on ideal body weight. Renal function and serum gentamicin concentrations should be monitored at least once per week. When given in three divided doses, pre-dose (trough) concentrations should be &lt;1 mcg/mL and post-dose (peak, one hour after infection) should be between 3 and 4 mcg/mL.&nbsp;When given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, postdose (peak, one hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing). Refer to the UpToDate topic on antimicrobial therapy of prosthetic valve endocarditis for duration of gentamicin therapy based on penicillin susceptibility or infecting species.<br />◊&nbsp;Vancomycin therapy only recommended for patients allergic to penicillin and cephalosporins. Penicillin desensitization can be attempted in stable patients. In adults, vancomycin is dosed based on actual body weight. The dose should be adjusted for trough concentration of 10 to 15 mcg/mL.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI></OL></div><div id=\"graphicVersion\">Graphic 71412 Version 8.0</div></div></div>"},"71413":{"type":"graphic_figure","displayName":"PD survival and creat clearance","title":"Graph showing predicted probability of survival among CAPD patients according to weekly creatinine clearance","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Graph showing predicted probability of survival among CAPD patients according to weekly creatinine clearance</div><div class=\"cntnt\"><img style=\"width:560px; height:383px;\" src=\"images/NEPH/71413_PDsurvivalandcreatclear.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Predicted probability of survival in patients treated with continuous peritoneal dialysis according to the weekly creatinine clearance (CCr). A progressive decline in two-year survival is noted at lower values for CCr. The values were 86% at a CCr of 95 L/week versus only 72% at a CCr of 55 L/week.</div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis; CCr: creatinine clearance.</div><div class=\"graphic_reference\">Data from CANADA-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes.&nbsp;J Am Soc Nephrol 1996; 7:198.</div><div id=\"graphicVersion\">Graphic 71413 Version 5.0</div></div></div>"},"71415":{"type":"graphic_table","displayName":"Cause pain by location","title":"Location of pain of some of the common diseases that cause acute pelvic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Location of pain of some of the common diseases that cause acute pelvic pain</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Periumbilical pain\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>All visceral diseases in their early stages</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abdominal trauma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abdominal wall hernias</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bowel obstruction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Diffuse or generalized pain\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>All visceral pathologies late in their course</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pelvic inflammatory disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Endometriosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Muscular strain or sprain</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bowel obstruction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Left lower quadrant\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adnexal torsion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Constipation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Crohn's disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diverticulitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ectopic pregnancy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Endometriosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inflammation or perforation of colonic carcinoma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Irritable bowel syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ovarian cyst or ruptured ovarian cyst</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pyelonephritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Salpingitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urinary calculi</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Right lower quadrant\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Appendicitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ectopic pregnancy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adnexal torsion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ovarian cyst or ruptured ovarian cyst</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urinary calculi</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Endometriosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pyelonephritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Meckel diverticulitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Regional enteritis (Crohn's disease)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Salpingitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Suprapubic pain\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Obstruction of the urinary bladder</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cystitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urinary calculi</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Lumbar radiation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Colonic obstruction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pyelonephritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urinary calculi</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Flank pain\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urinary calculi</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Howard, FM. Acute Abdominal Pain. In: Primary Care for Women., Leppert, PC, Peipert, P (Eds), Lippincott, Williams and Wilkins 2004. Copyright &#169;2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71415 Version 1.0</div></div></div>"},"71416":{"type":"graphic_table","displayName":"Bethesda 2001 class cervix cytol","title":"Bethesda classification of cervical cytology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bethesda classification of cervical cytology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Specimen type</td> </tr> <tr> <td>Conventional smear, liquid-based, or other technique</td> </tr> <tr> <td class=\"subtitle1_single\">Specimen adequacy</td> </tr> <tr> <td>Satisfactory for evaluation (description includes quality indicators, including endocervical/transformation zone component and obscuring blood or inflammation)</td> </tr> <tr> <td>Unsatisfactory due to... (specify reason)</td> </tr> <tr> <td class=\"subtitle1_single\">General categorization (optional)</td> </tr> <tr> <td>Negative for intraepithelial lesion or malignancy</td> </tr> <tr> <td>Epithelial cell abnormality (specify squamous or glandular)</td> </tr> <tr> <td>Other: see interpretation/result (eg, endometrial cells in woman &#8805;age 40)</td> </tr> <tr> <td class=\"subtitle1_single\">Automated review</td> </tr> <tr> <td>If examined by a device, specify device and result</td> </tr> <tr> <td class=\"subtitle1_single\">Ancillary testing</td> </tr> <tr> <td>Describe method and result (eg, molecular testing)</td> </tr> <tr> <td class=\"subtitle1_single\">Interpretation/result</td> </tr> <tr> <td class=\"subtitle2_single\">Negative for intraepithelial lesion or malignancy (when there is absence of neoplasia this should be stated specifically, regardless of other findings)</td> </tr> <tr> <td class=\"sublist2_start\">In addition describe, if present:</td> </tr> <tr> <td class=\"sublist2\">Infection (<em>Trichomonas vaginalis</em>, <em>Candida</em> spp, shift in flora consistent with bacterial vaginosis, <em>Actinomyces</em> spp, cellular changes)</td> </tr> <tr> <td class=\"sublist2_start\">Other nonneoplastic findings, such as, but not limited to:</td> </tr> <tr> <td class=\"sublist2\">Reactive cellular changes associated with inflammation/cellular repair, radiation, or an intrauterine contraceptive device</td> </tr> <tr> <td class=\"sublist2\">Glandular cells post hysterectomy</td> </tr> <tr> <td class=\"sublist2\">Atrophy</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Endometrial cells (in a woman age&nbsp;&#8805;40) and specify whether negative for squamous intraepithelial lesion</td> </tr> <tr> <td class=\"subtitle2_single\">Epithelial cell abnormalities</td> </tr> <tr> <td class=\"subtitle3_single\">Squamous cell</td> </tr> <tr> <td class=\"sublist3_start\">Atypical squamous cells (ASC)</td> </tr> <tr> <td class=\"sublist3\">of undetermined significance (ASC-US)</td> </tr> <tr> <td class=\"sublist3\">cannot exclude high-grade squamous intraepithelial lesion (HSIL; ASC-H)</td> </tr> <tr> <td class=\"indent2\">Low-grade squamous intraepithelial lesion (LSIL) cellular changes consistent with HPV, mild dysplasia, CIN 1</td> </tr> <tr> <td class=\"sublist3_start\">HSIL moderate/severe dysplasia, CIN 2, CIN 3, CIS</td> </tr> <tr> <td class=\"sublist3\">indicate if there are features suspicious for invasion (if invasion suspected)</td> </tr> <tr> <td class=\"indent2\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"subtitle3_single\">Glandular cell</td> </tr> <tr> <td class=\"sublist3_start\">Atypical</td> </tr> <tr> <td class=\"sublist3\">Endocervical cells</td> </tr> <tr> <td class=\"sublist3\">Endometrial cells</td> </tr> <tr> <td class=\"sublist3\">Not otherwise specified</td> </tr> <tr> <td class=\"sublist3_start\">Atypical, favor neoplastic</td> </tr> <tr> <td class=\"sublist3\">Endocervical cells</td> </tr> <tr> <td class=\"sublist3\">Not otherwise specified</td> </tr> <tr> <td class=\"indent2\">Endocervical adenocarcinoma in situ (AIS)</td> </tr> <tr> <td class=\"indent2\">Adenocarcinoma</td> </tr> <tr> <td class=\"subtitle2_single\">Other malignant neoplasms (specify)</td> </tr> <tr> <td class=\"subtitle1_single\">Educational notes and suggestions</td> </tr> <tr> <td>Suggestions should be concise and consistent with clinical follow-up guidelines published by professional organizations</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HPV: human papillomavirus.</div><div class=\"graphic_reference\">Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.</div><div id=\"graphicVersion\">Graphic 71416 Version 6.0</div></div></div>"},"71417":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of parathyroid adenoma","title":"Ultrasound of parathyroid adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of parathyroid adenoma</div><div class=\"cntnt\"><img style=\"width:377px; height:562px;\" src=\"images/SURG/71417_US_parathyroid_aden_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse (A) and sagittal (B) ultrasound images of the left neck demonstrate a well defined nodule (arrow) that is isoechoic to the adjacent thyroid gland (T).</div><div class=\"graphic_reference\">Courtesy of Pierre J Sasson, MD.</div><div id=\"graphicVersion\">Graphic 71417 Version 8.0</div></div></div>"},"71418":{"type":"graphic_diagnosticimage","displayName":"Hyperechoic nodule","title":"Hyperechoic nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperechoic nodule</div><div class=\"cntnt\"><img style=\"width:432px; height:326px;\" src=\"images/ENDO/71418_Hyperechoic_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of the thyroid region that shows a hyperechoic nodule (N) in the right lobe of a goiter. The tracheal cartilage (TC) is seen, as is the isthmus above that. A 14.0 MHz transducer was used.</div><div id=\"graphicVersion\">Graphic 71418 Version 2.0</div></div></div>"},"71420":{"type":"graphic_diagnosticimage","displayName":"Amebic liver abscess","title":"Amebic liver abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amebic liver abscess</div><div class=\"cntnt\"><img style=\"width:394px; height:558px;\" src=\"images/ID/71420_Amebic_liver_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 37-year-old man with amebic liver abscess.<br />(A) Sonogram shows a round mass consisting of a band of peripheral solid part (arrows), and central liquefied part showing low-level internal echoes.<br />(B) Contrast-enhanced&nbsp;computed tomography&nbsp;scan shows a peripheral solid part and central liquefied part. At surgery, the central portion was liquefied and contained \"anchovy paste.\"</div><div class=\"graphic_reference\">Reproduced from: Park MS, Kim KW, Ha HK, Lee DH. Intestinal parasitic infection. Abdom Imaging 2008; 33:166, with kind permission from Springer Science + Business Media B.V. Copyright © 2008.</div><div id=\"graphicVersion\">Graphic 71420 Version 7.0</div></div></div>"},"71421":{"type":"graphic_table","displayName":"Drugs and gynecomastia","title":"Drugs associated with gynecomastia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with gynecomastia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Antiandrogens/inhibitors of androgen synthesis</td> </tr> <tr> <td class=\"indent1\">Cyproterone acetate</td> </tr> <tr> <td class=\"indent1\">Flutamide, bicalutamide, nilutamide</td> </tr> <tr> <td class=\"indent1\">Finasteride, dutasteride</td> </tr> <tr> <td class=\"indent1\">Spironolactone</td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Lavender oil</td> </tr> <tr> <td class=\"indent1\">Tea tree oil</td> </tr> <tr> <td class=\"subtitle1_single\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Ethionamide</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> </tr> <tr> <td class=\"subtitle1_single\">Antiulcer drugs</td> </tr> <tr> <td class=\"indent1\">Cimetidine</td> </tr> <tr> <td class=\"indent1\">Ranitidine</td> </tr> <tr> <td class=\"indent1\">Omeprazole</td> </tr> <tr> <td class=\"subtitle1_single\">Cancer chemotherapeutic drugs</td> </tr> <tr> <td class=\"indent1\">Alkylating agents</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Vinca alkaloids</td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy</td> </tr> <tr> <td class=\"indent1\">Imatinib</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular drugs</td> </tr> <tr> <td class=\"indent1\">ACE inhibitors (captopril, enalapril)</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers (diltiazem, nifedipine)</td> </tr> <tr> <td class=\"indent1\">Digitoxin</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Reserpine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs of abuse</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Amphetamines</td> </tr> <tr> <td class=\"indent1\">Heroin</td> </tr> <tr> <td class=\"indent1\">Marijuana</td> </tr> <tr> <td class=\"indent1\">Methadone</td> </tr> <tr> <td class=\"subtitle1_single\">Hormones</td> </tr> <tr> <td class=\"indent1\">Androgens</td> </tr> <tr> <td class=\"indent1\">Anabolic steroids</td> </tr> <tr> <td class=\"indent1\">Chorionic gonadotropin</td> </tr> <tr> <td class=\"indent1\">Estrogens</td> </tr> <tr> <td class=\"indent1\">Growth hormone</td> </tr> <tr> <td class=\"subtitle1_single\">Psychoactive drugs</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> </tr> <tr> <td class=\"indent1\">Phenothiazines</td> </tr> <tr> <td class=\"indent1\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"indent1\">Atypical antipsychotics</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Auranofin</td> </tr> <tr> <td class=\"indent1\">Diethylproprion</td> </tr> <tr> <td class=\"indent1\">Domperidone</td> </tr> <tr> <td class=\"indent1\">Etretinate</td> </tr> <tr> <td class=\"indent1\">HAART</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Penicillamine</td> </tr> <tr> <td class=\"indent1\">Sulindac</td> </tr> <tr> <td class=\"indent1\">Theophylline</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Most of the drugs that are listed are based on anecdotal reports and do not have high-quality evidence supporting a cause-and-effect relationship.&nbsp;Using evidence-based criteria, there is good evidence of a true association with estrogens, spironolactone, cimetidine, ketoconazole, growth hormone, gonadotropins, antiandrogen therapies, and 5-alpha-reductase inhibitors.&nbsp;Drugs with fair evidence include first-generation and atypical antipsychotics in adults, calcium channel blockers, omeprazole, HIV drugs, alkylating agents, anabolic steroids, alcohol, and opioids.<SUP innerHtml>[1]</SUP>​</div><div class=\"graphic_footnotes\">HAART:&nbsp;highly active antiretroviral therapy; ACE: angiotensin-converting enzyme; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Deepinder F, Braunstein GD. Drug-induced gynecomastia: An evidence-based review. Expert Opin Drug Saf 2012; 11:779.</LI></OL></div><div id=\"graphicVersion\">Graphic 71421 Version 6.0</div></div></div>"},"71422":{"type":"graphic_picture","displayName":"Gastric xanthoma CPC Endosc","title":"Gastric xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric xanthoma</div><div class=\"cntnt\"><img style=\"width:300px; height:258px;\" src=\"images/GAST/71422_Gastric_xanthoma_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing two small 4 mm yellow nodules in the gastric fundus.</div><div class=\"graphic_reference\">Courtesy of Douglas Horst, MD and Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 71422 Version 2.0</div></div></div>"},"71423":{"type":"graphic_figure","displayName":"Nerves of the abdominal wall","title":"Nerves of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Nerves of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:542px; height:572px;\" src=\"images/SURG/71423_Nerves_abdominal_wall.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71423 Version 3.0</div></div></div>"},"71424":{"type":"graphic_table","displayName":"Palliative Prognostic Index","title":"Palliative Prognostic Index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Palliative Prognostic Index</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Prognostic domains</td> <td class=\"subtitle1\">Partial score value</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Palliative&nbsp;Performance status*</td> </tr> <tr> <td class=\"indent1\">10 to 20</td> <td class=\"centered\">4.0</td> </tr> <tr> <td class=\"indent1\">30 to 50</td> <td class=\"centered\">2.5</td> </tr> <tr> <td class=\"indent1\">&#8805;60</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical symptoms</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Oral intake</td> </tr> <tr> <td class=\"sublist2\">Moderately reduced</td> <td class=\"sublist_other_centered\">1.0</td> </tr> <tr> <td class=\"sublist2\">Severely reduced</td> <td class=\"sublist_other_centered\">2.5</td> </tr> <tr> <td class=\"sublist2\">Normal</td> <td class=\"sublist_other_centered\">0</td> </tr> <tr> <td class=\"indent1\">Edema</td> <td class=\"centered\">1.0</td> </tr> <tr> <td class=\"indent1\">Dyspnea at rest</td> <td class=\"centered\">3.5</td> </tr> <tr> <td class=\"indent1\">Delirium</td> <td class=\"centered\">4.0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Description of the components of the Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. The scores from each prognostic domain are added. A score of 0 to 2.0 was associated with a median survival of 90 days; score of 2.1 to 4.0, 61 days; score &gt;4.0, 12 days.</div><div class=\"graphic_footnotes\">* The Palliative Performance Status represents a modified version of the Karnofsky Performance Scale (KPS), which grades patients' general conditions on a scale from 0 (death) to 100 (normal).</div><div class=\"graphic_reference\">Reproduced with permission from: Morita T, Tsundoa J, Inoue S, et al. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Supportive Care Cancer 1999; 7:128. Copyright &copy; 1999 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 71424 Version 4.0</div></div></div>"},"71425":{"type":"graphic_table","displayName":"Asthma severity 12 and up","title":"Classifying asthma severity in youths greater than or equal to 12 years of age and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifying asthma severity in youths greater than or equal to 12 years of age and adults</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t\n\t<tr>\n\t\t<td class=\"subtitle1\" rowspan=\"3\" colspan=\"2\">Components of severity</td>\n\t\t<td class=\"subtitle1\" colspan=\"4\">Classification of asthma severity (youths &#8805;12 years of age and adults)</td>\n\t</tr>\n\t<tr>\n\t\t<td class=\"subtitle2\" rowspan=\"2\">Intermittent</td>\n\t\t<td class=\"subtitle2\" colspan=\"4\">Persistent</td>\n\t</tr>\n\t<tr>\n\t\t<td class=\"subtitle3\">Mild</td>\n\t\t<td class=\"subtitle3\">Moderate</td>\n\t\t<td class=\"subtitle3\">Severe</td>\n\t</tr>\n\t<tr>\n\t\t<td rowspan=\"5\"><p>Impairment</p>\n\t\t\t\t\t\t<p>Normal FEV<sub>1</sub>/FVC:</p>\n\t\t\t\t\t\t<p>8-19 yr 85 percent</p>\n\t\t\t\t\t\t<p>20-39 yr 80 percent</p>\n\t\t\t\t\t\t<p>40-59 yr 75 percent</p>\n\t\t\t\t\t\t<p>60-80 yr 70 percent</p></td>\n\t\t<td>Symptoms</td>\n\t\t<td>&#8804;2 days/week</td>\n\t\t<td>&#62;2 days/week but not daily</td>\n\t\t<td>Daily</td>\n\t\t<td>Throughout the day</td>\n\t</tr>\n\t<tr>\n\t\t<td>Nighttime awakenings</td>\n\t\t<td>&#8804;2x/month</td>\n\t\t<td>3-4x/month</td>\n\t\t<td>&#62;1x/week but not nightly</td>\n\t\t<td>Often 7x/week</td>\n\t</tr>\n\t<tr>\n\t\t<td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td>\n\t\t<td>&#8804;2 days/week</td>\n\t\t<td>&#62;2 days/week but not &#62;1x/day</td>\n\t\t<td>Daily</td>\n\t\t<td>Several times per day</td>\n\t</tr>\n\t<tr>\n\t\t<td>Interference with normal activity</td>\n\t\t<td>None</td>\n\t\t<td>Minor limitation</td>\n\t\t<td>Some limitation</td>\n\t\t<td>Extremely limited</td>\n\t</tr>\n\t<tr>\n\t\t<td>Lung function</td>\n\t\t<td><p>&#8226; Normal FEV<sub>1</sub> between exacerbations</p>\n\t\t\t<p>&#8226; FEV<sub>1</sub> &#62;80 percent predicted</p>\n\t\t\t<p>&#8226; FEV<sub>1</sub>/FVC normal</p></td>\n\t\t<td><p>&#8226; FEV<sub>1</sub> &#8805;80 percent predicted</p>\n\t\t\t<p>&#8226; FEV<sub>1</sub>/FVC normal</p></td>\n\t\t<td><p>&#8226; FEV<sub>1</sub> &#62;60 but &#60;80 percent predicted</p>\n\t\t\t<p>&#8226; FEV<sub>1</sub>/FVC reduced 5 percent</p></td>\n\t\t<td><p>&#8226; FEV<sub>1</sub> &#60;60 percent predicted</p>\n\t\t\t<p>&#8226; FEV<sub>1</sub>/FVC reduced &#62;5 percent</p></td>\n\t</tr>\n\t<tr>\n\t\t<td rowspan=\"4\">Risk</td>\n\t\t<td rowspan=\"4\"><strong>Exacerbations requiring oral systemic corticosteroids</strong></td>\n\t\t<td><strong>0-1/year (see footnote)</strong></td>\n\t\t<td colspan=\"3\"><strong>&#8805;2/year (see footnote)</strong></td>\n\t</tr>\n\t<tr>\n\t\t<td colspan=\"4\"><strong>Consider severity and interval since last exacerbation</strong></td>\n\t</tr>\n\t<tr>\n\t\t<td colspan=\"4\"><strong>Frequency and severity may fluctuate over time for patients in any severity category</strong></td>\n\t</tr>\n\t<tr>\n\t\t<td colspan=\"4\"><strong>Relative annual risk of exacerbations may be related to FEV<sub>1</sub></strong></td>\n\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\"><strong>Classifying severity for patients who are not currently taking long-term control medications.</strong> Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &#8805;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 71425 Version 1.0</div></div></div>"},"71428":{"type":"graphic_diagnosticimage","displayName":"Manubriosternal osteoarthrosis","title":"Manubriosternal osteoarthrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manubriosternal osteoarthrosis</div><div class=\"cntnt\"><img style=\"width:243px; height:342px;\" src=\"images/RHEUM/71428_Manubriosternal_osteoarthro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique view of the manubriosternal joint (arrow) in a patient with anterior chest pain demonstrating irregularity and sclerosis of the manubriosternal joint.</div><div class=\"graphic_reference\">Courtesy of Christopher Wise, MD.</div><div id=\"graphicVersion\">Graphic 71428 Version 2.0</div></div></div>"},"71429":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 2","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:371px; height:520px;\" src=\"images/OBGYN/71429_Tx_post_vaginal_wall_def_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior vaginal mucosa is undermined and a midline incision is made.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 71429 Version 2.0</div></div></div>"},"71431":{"type":"graphic_table","displayName":"Calculation of BMI","title":"Calculation of body mass index (BMI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculation of body mass index (BMI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">English formula for BMI:</td> </tr> <tr> <td>703 x Weight in pounds &#247; (Height in inches)<sup>2</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Metric formula for BMI:</td> </tr> <tr> <td>Weight in Kilograms &#247; (Height in meters)<sup>2</sup></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71431 Version 4.0</div></div></div>"},"71433":{"type":"graphic_figure","displayName":"Impaired aqueous flow","title":"Impaired aqueous flow","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Impaired aqueous flow</div><div class=\"cntnt\"><img style=\"width:496px; height:213px;\" src=\"images/PEDS/71433_Impaired_aqueous_flow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aqueous fluid normally flows through the trabecular meshwork into Schlemm's canal, from which it drains into the venous system. When the drainage of aqueous fluid from the anterior chamber is compromised, as depicted here, intraocular pressure increases.</div><div class=\"graphic_reference\">Reproduced with permission from Trobe JD. The Physician's Guide to Eye Care. Foundation of the American Academy of Ophthalmology, San Francisco, 2001. p.158. Copyright &#169; American Academy of Ophthalmology.</div><div id=\"graphicVersion\">Graphic 71433 Version 2.0</div></div></div>"},"71434":{"type":"graphic_waveform","displayName":"Intermediate case 21","title":"Intermediate case 21","html":"<div class=\"graphic normal\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Intermediate case 21</div><div class=\"cntnt\"><img style=\"width:492px; height:239px;\" src=\"images/CARD/71434_Intermediate_case_21.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71434 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"71435":{"type":"graphic_table","displayName":"Functional GI disorders child","title":"Rome IV diagnostic criteria for functional abdominal pain disorders in the child/adolescent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rome IV diagnostic criteria for functional abdominal pain disorders in the child/adolescent</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1_single\">Universal criterion: After appropriate evaluation, the symptoms cannot be fully explained by another medical condition</td> </tr> <tr> <td class=\"subtitle2_left\">Functional dyspepsia</td> </tr> <tr class=\"divider_bottom\"> <td>In addition to the universal criterion, at least two months with &#8805;1 of the following bothersome symptoms on &#8805;4 days per month: <ul class=\"decimal_heading\"> <li>Postprandial fullness </li> <li>Early satiation </li> <li>Epigastric pain or burning not associated with defecation </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Irritable bowel syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>In addition to the universal criterion, &#8805;2 months with abdominal pain associated with one of the following on &#8805;4 days per month: <ul class=\"decimal_heading\"> <li>Related to defecation </li> <li>Change in frequency of stool </li> <li>Change in form (appearance) of stool </li> </ul> In children with constipation, the pain does not resolve with the resolution of the constipation (resolution of pain indicates functional constipation)</td> </tr> <tr> <td class=\"subtitle2_left\">Abdominal migraine</td> </tr> <tr class=\"divider_bottom\"> <td>In addition to the universal criterion, all of the following: <ul class=\"decimal_heading\"> <li>Paroxysmal episodes of intense, acute, periumbilical, midline, or diffuse abdominal pain lasting &#8805;1 hour (abdominal pain is the most severe and distressing symptom) at least twice within a six month period </li> <li>Episodes are separated by weeks or months </li> <li>The pain is incapacitating and interferes with normal activities </li> <li>Stereotypical pattern and symptoms in the individual patient </li> <li>The pain is associated with &#8805;2 of the following: <ul> <li>Anorexia </li> <li>Nausea </li> <li>Vomiting </li> <li>Headache </li> <li>Photophobia </li> <li>Pallor </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Functional abdominal pain - not otherwise specified</td> </tr> <tr class=\"divider_bottom\"> <td>In addition to the universal criterion, all of the following: <ul class=\"decimal_heading\"> <li>Occurs &#8805;4 times per month for &#8805;2 months </li> <li>Episodic or continuous abdominal pain that does not occur solely during physiologic events (eg, eating, menses) </li> <li>Insufficient criteria for irritable bowel syndrome, functional dyspepsia, or abdominal migraine </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Functional constipation*</td> </tr> <tr> <td>In addition to the universal criterion, &#8805;2 of the following occurring &#8805;1 time per week for &#62;1 month with insufficient criteria for a diagnosis of irritable bowel syndrome: <ul class=\"decimal_heading\"> <li>&#8804;2 defecations in the toilet per week in a child of a developmental age of &#8805;4 years </li> <li>&#8805;1 episode of fecal incontinence per week </li> <li>History of retentive posturing or excessive volitional stool retention </li> <li>Presence of a large fecal mass in the rectum </li> <li>History of large diameter stools that can obstruct the toilet </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Functional constipation is not categorized as a functional abdominal pain disorder in the Rome IV classification. However, it is included in this table as a common cause of chronic abdominal pain in children.</div><div class=\"graphic_reference\">Adapted from: Hyams JS, Di Lorenzo C, Saps M, et al. Childhood functional gastrointestinal disorders: Child/adolescent. Gastroenterology 2016; 150:1456.</div><div id=\"graphicVersion\">Graphic 71435 Version 4.0</div></div></div>"},"71436":{"type":"graphic_table","displayName":"Differentiation between hibernation and stunning","title":"Differentiation between hibernation and stunning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiation between hibernation and stunning</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Hibernation</td>\n\n      <td class=\"subtitle1\">Stunning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Response to inotropes</td>\n\n\n      <td>&#8593; then &#8595;&#8595;</td>\n\n      <td>&#8593; then &#8595;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glycosis</td>\n\n\n      <td>&#8595;&#8595;</td>\n\n      <td>&#8595;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blood flow at rest</td>\n\n\n      <td>Slight &#8595;</td>\n\n      <td>Normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Coronary flow reserve</td>\n\n\n      <td>&#8595;&#8595;</td>\n\n      <td>&#8595;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intra/extracellur potassium ([K<sub>i</sub>]/[K<sub>o</sub>])</td>\n\n\n      <td>Normal</td>\n\n      <td>Normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Recovery following revascularization</td>\n\n\n      <td>&#8593;&#8593;</td>\n\n      <td>&#8593;&#8593;</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Redwood SR, Ferrari R, Marber MS. Heart 1998; 80:218.</div><div id=\"graphicVersion\">Graphic 71436 Version 3.0</div></div></div>"},"71437":{"type":"graphic_figure","displayName":"Cryoretinopexy spots","title":"Cryoretinopexy spots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryoretinopexy spots</div><div class=\"cntnt\"><img style=\"width:372px; height:304px;\" src=\"images/PC/71437_Cryoretinopexy_spots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cryoretinopexy probe is applied underneath the retinal break, freezing through the sclera, choroid, and retina. A number of cryoretinopexy spots are created in order to continuously surround the retinal break.</div><div class=\"graphic_reference\">Reproduced with permission from: Wilkinson CP, Rice TA. Mitchel's Retinal Detachment, 2nd ed, Mosby-Year Book, Inc., Louis 1997. Copyright © Charles P Wilkinson, MD.</div><div id=\"graphicVersion\">Graphic 71437 Version 3.0</div></div></div>"},"71440":{"type":"graphic_figure","displayName":"Neurohumoral activation HF","title":"Neurohumoral activation in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neurohumoral activation in HF</div><div class=\"cntnt\"><img style=\"width:321px; height:301px;\" src=\"images/CARD/71440_NeurohumoralactivationHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depressed ventricular contractility, induced by the underlying cardiac disease, leads to neurohumoral activation (moving clockwise) that is initially adaptive in that it maintains blood pressure and tissue perfusion. Over the long term, however, the increase in outflow resistance (afterload) hastens the rate of myocardial deterioration and worsens ventricular performance. This leads to a vicious cycle of increasing release of norepinephrine, angiotensin II, and ADH that further increases afterload.</div><div class=\"graphic_footnotes\">HF: heart failure; ADH: antidiuretic hormone.</div><div id=\"graphicVersion\">Graphic 71440 Version 3.0</div></div></div>"},"71441":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis 1","title":"Lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71441_Lymphomatoid_papulosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphomatoid papulosis lesions in different evolution stages. A regressing lesion appears as red-brown papule.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71441 Version 3.0</div></div></div>"},"71442":{"type":"graphic_algorithm","displayName":"ETT confirm colorimetry","title":"Universal tube placement confirmation with Colorimetric CO<sub>2</sub> detectors","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Universal tube placement confirmation with Colorimetric CO<sub>2</sub> detectors</div><div class=\"cntnt\"><img style=\"width:465px; height:458px;\" src=\"images/EM/71442_ETT_confirm_colorimetry.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Clinical maneuvers, such as auscultation (chest, epigastric) and direct laryngoscopy may be utilized at physician discretion, but clinicians must be aware of their limitations in discriminating between esophageal and tracheal intubation.</div><div id=\"graphicVersion\">Graphic 71442 Version 2.0</div></div></div>"},"71443":{"type":"graphic_figure","displayName":"Physeal fractures of the proximal humerus","title":"Physeal fractures of the proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Physeal fractures of the proximal humerus</div><div class=\"cntnt\"><img style=\"width:534px; height:230px;\" src=\"images/EM/71443_Physealfxhumerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Salter-Harris I. Panel B) Salter-Harris II. Panel C) Salter-Harris III. Panel D) Salter-Harris IV.</div><div class=\"graphic_reference\">Reproduced with permission from: Bae DS. Humeral Shaft and Proximal Humerus, Shoulder Dislocation. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71443 Version 13.0</div></div></div>"},"71445":{"type":"graphic_table","displayName":"ESWL clinical results","title":"Clinical results of endoscopy and ESWL for pancreatic stones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical results of endoscopy and ESWL for pancreatic stones</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author<br /> (year)</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" rowspan=\"2\">Complete or partial pain relief<br /> (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Overall increase in BW<br /> (percent)</td> <td class=\"subtitle1\" colspan=\"2\">Exocrine function</td> <td class=\"subtitle1\" colspan=\"2\">Endocrine function</td> <td class=\"subtitle1\" rowspan=\"2\">Need for surgery<br /> (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Mean follow-up<br /> (months)</td> </tr> <tr> <td class=\"subtitle2\">Improved<br /> (percent)</td> <td class=\"subtitle2\">Worsened<br /> (percent)</td> <td class=\"subtitle2\">Improved<br /> (percent)</td> <td class=\"subtitle2\">Worsened<br /> (percent)</td> </tr> <tr> <td>Delhaye 1992</td> <td>123</td> <td>85</td> <td>62</td> <td>55</td> <td>32</td> <td>10</td> <td>13</td> <td>8</td> <td>14</td> </tr> <tr> <td>Sauerbruch 1992</td> <td>24</td> <td>83</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>8</td> <td>24</td> </tr> <tr> <td>Schneider 1994</td> <td>50</td> <td>62</td> <td>54</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>12</td> <td>20</td> </tr> <tr> <td>Johanns 1996</td> <td>35</td> <td>83</td> <td>51</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>14</td> <td>23</td> </tr> <tr> <td>Ohara 1996</td> <td>32</td> <td>86</td> <td>52</td> <td>61</td> <td>&ndash;</td> <td>17</td> <td>17</td> <td>3</td> <td>44</td> </tr> <tr> <td>Costamagna 1997</td> <td>35</td> <td>72</td> <td>84</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>3</td> <td>27</td> </tr> <tr> <td>Adamek 1999</td> <td>80</td> <td>76</td> <td>&ndash;</td> <td>47</td> <td>&ndash;</td> <td>0</td> <td>&ndash;</td> <td>10</td> <td>40</td> </tr> <tr> <td>Brand 2000</td> <td>48</td> <td>82</td> <td>68</td> <td>77</td> <td>&ndash;</td> <td>15</td> <td>&ndash;</td> <td>4</td> <td>7</td> </tr> <tr> <td>Kozarek 2002</td> <td>40</td> <td>80</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>20</td> <td>29</td> </tr> <tr> <td>Inui 2005</td> <td>504</td> <td>91</td> <td>&ndash;</td> <td>38</td> <td>33</td> <td>24</td> <td>29</td> <td>4</td> <td>44</td> </tr> <tr> <td>Tadenuma 2005</td> <td>70</td> <td>70</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>1.4</td> <td>77</td> </tr> <tr> <td>Seven 2012</td> <td>120</td> <td>85</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>12</td> <td>52</td> </tr> <tr> <td>Suzuki 2013</td> <td>479</td> <td>91</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>31</td> </tr> <tr> <td>Tandan 2013</td> <td>636</td> <td>95</td> <td>&ndash;</td> <td>12</td> <td>&ndash;</td> <td>8</td> <td>10</td> <td>9</td> <td>&#8805;24</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BW: body weight.</div><div id=\"graphicVersion\">Graphic 71445 Version 6.0</div></div></div>"},"71446":{"type":"graphic_figure","displayName":"Jones metroplasty AB","title":"Jones metroplasty AB","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Jones metroplasty AB</div><div class=\"cntnt\"><img style=\"width:452px; height:628px;\" src=\"images/OBGYN/71446_Jones_metroplasty_AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In the Jones procedure, the common cavity is initially reached through a wedge resection of the septum. (B) The septum is totally removed as the two cavities are unroofed.</div><div id=\"graphicVersion\">Graphic 71446 Version 1.0</div></div></div>"},"71447":{"type":"graphic_diagnosticimage","displayName":"Pulmonary mucormycosis","title":"Pulmonary mucormycosis in a lung transplant recipient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary mucormycosis in a lung transplant recipient</div><div class=\"cntnt\"><img style=\"width:275px; height:504px;\" src=\"images/ID/71447_Pulmzygomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomography (CT) scan of lung showing pulmonary nodule and (B) fine needle aspiration of right lower lobe of lung showing aseptate hyphae (Papanicolaou stain, x400).</div><div class=\"graphic_reference\">Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71447 Version 14.0</div></div></div>"},"71448":{"type":"graphic_figure","displayName":"Extension injury to olecranon with valgus stress","title":"Extension injury to olecranon with valgus stress","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Extension injury to olecranon with valgus stress</div><div class=\"cntnt\"><img style=\"width:598px; height:371px;\" src=\"images/EM/71448_Extensinjolecranonvalgus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A fall on an outstretched hand with the elbow extended places a valgus stress on the forearm.<br> (B) This stress can cause a greenstick fracture of the olecranon with or without a radial neck fracture or medial epicondylar apophysis avulsion.<br> (C) Radiograph of a valgus extension fracture of the olecranon with an associated radial neck fracture.</div><div class=\"graphic_reference\">Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71448 Version 8.0</div></div></div>"},"71449":{"type":"graphic_table","displayName":"Medications associated with diarrhea","title":"Medications associated with diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">System targeted by drug</td> <td class=\"subtitle1\">Type of agent</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Cardiovascular</td> <td>Antiarrhythmics</td> <td>Digoxin<br /> Procainamide<br /> Quinidine</td> </tr> <tr> <td>Antihypertensives</td> <td> <p>ACE-inhibitors<br /> Angiotensin II receptor blockers*<br /> Beta-blockers<br /> Hydralazine<br /> Methyldopa</p> </td> </tr> <tr> <td>Cholesterol-lowering agents</td> <td>Clofibrate<br /> Gemfibrozil<br /> Statins</td> </tr> <tr class=\"divider_bottom\"> <td>Diuretics</td> <td>Acetazolamide<br /> Ethacrynic acid<br /> Furosemide</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Central nervous system</td> <td>Antianxiety drugs</td> <td>Alprazolam<br /> Meprobamate</td> </tr> <tr> <td>Antiparkinsonian drugs</td> <td>Levodopa</td> </tr> <tr class=\"divider_bottom\"> <td>Other agents</td> <td>Anticholinergic agents<br /> Fluoxetine<br /> Lithium<br /> Tacrine</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Endocrine</td> <td>Oral hypoglycemic agents</td> <td>Metformin</td> </tr> <tr class=\"divider_bottom\"> <td>Thyroid replacement therapy</td> <td>Synthroid</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Gastrointestinal</td> <td>Antiulcer/antacid drugs</td> <td>H2-receptor antagonists<br /> Magnesium containing antacids<br /> Misoprostol<br /> Proton pump inhibitors</td> </tr> <tr> <td>Bile acids</td> <td>Chenodeoxycholic acid<br /> Ursodeoxycholic acid</td> </tr> <tr> <td>Laxatives</td> <td>Cathartics<br /> Lactulose<br /> Sorbitol</td> </tr> <tr class=\"divider_bottom\"> <td>Treatments for inflammatory bowel disease</td> <td>5-aminosalycilates (particularly olsalazine)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Musculoskeletal</td> <td>Gold salts</td> <td>Auranofin</td> </tr> <tr> <td>Nonsteroidal antiinflammatory drugs</td> <td>Ibuprofen<br /> Mefenamic acid<br /> Naproxen<br /> Phenylbutazone</td> </tr> <tr class=\"divider_bottom\"> <td>Treatments for gout</td> <td>Colchicine</td> </tr> <tr> <td rowspan=\"4\">Other</td> <td>Antibiotics<sup>&#182;</sup></td> <td>Amoxicillin<br /> Ampicillin<br /> Cephalosporins<br /> Clindamycin<br /> Neomycin<br /> Tetracycline</td> </tr> <tr> <td>Antineoplastic agents</td> <td>Many</td> </tr> <tr> <td>Dietary</td> <td>Alcohol<br /> Sugar substitutes (eg, sorbitol)</td> </tr> <tr> <td>Vitamins</td> <td>Magnesium<br /> Vitamin C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin converting enzyme.<br />* Olmesartan has been associated with sprue-like enteropathy.<br />¶ Most antibiotics have been associated with diarrhea.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Holt PR. Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 2001; 30:427. </li>&#xD;&#xA;    <li>Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998; 13:245. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71449 Version 5.0</div></div></div>"},"71450":{"type":"graphic_movie","displayName":"Long axis tetralogy of Fallot","title":"Parasternal long axis view in tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis view in tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/71450_LongaxistetraFallot.mp4\" style=\"width:432px;height:400px\"></div><img style=\"width:451px; height:354px;\" src=\"images/PEDS/71450_LongaxistetralogyFall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiogram of the parasternal long axis view demonstrates a large malalignment ventricular septal defect (VSD, arrow) with an overriding ascending aorta in a patient with tetralogy of Fallot (TOF).</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; Ao: aorta; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 71450 Version 2.0</div></div></div>"},"71451":{"type":"graphic_picture","displayName":"St Marks deep pelvic retractor","title":"St. Mark's deep pelvic retractor","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">St. Mark's deep pelvic retractor</div><div class=\"cntnt\"><img style=\"width:451px; height:289px;\" src=\"images/SURG/71451_StMarks_deep_pelv_retrac_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">St. Mark's deep pelvic retractor.</div><div class=\"graphic_reference\">Image provided by Dr. Michael Edwards. Available at: http://www.wikisurgery.com.</div><div id=\"graphicVersion\">Graphic 71451 Version 2.0</div></div></div>"},"71453":{"type":"graphic_waveform","displayName":"Mobitz type I second degree atrioventricular block","title":"Mobitz type I second degree atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobitz type I second degree atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:358px; height:105px;\" src=\"images/CARD/71453_Mobitz_I_AV_block_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several characteristic features of Wenckebach second degree AV block are noted on this ECG (P waves are marked by arrows): 1) The PR interval after the second P wave is longer than the preceeding PR interval; the third P wave is not conducted at all. 2) The PP intervals are constant; however, the RR interval surrounding the completely blocked P wave is longer than the preceeding normal RR interval. 3) The fourth P wave (after the blocked beat) is conducted normally; this PR interval is shorter than the PR interval that immediately preceeded the pause.</div><div id=\"graphicVersion\">Graphic 71453 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"71455":{"type":"graphic_table","displayName":"Endoscopic Rx LGIB","title":"Endoscopic therapy of lower intestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic therapy of lower intestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Probe diameter<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Coaptive pressure</td> <td class=\"subtitle1\" colspan=\"2\">Electrogenerator settings*</td> <td class=\"subtitle1\" rowspan=\"2\">Desired outcome</td> <td class=\"subtitle1\" rowspan=\"2\">Special features</td> </tr> <tr> <td class=\"subtitle2\">Heater probe<sup>&#182;</sup></td> <td class=\"subtitle2\">Bipolar probe<sup>&#182;</sup></td> </tr> <tr> <td>Angiodysplasia</td> <td>Large<sup>&#916;</sup></td> <td>Light</td> <td>10-15 J</td> <td>10-15 W, 1 second pulses</td> <td>Bleeding stops/angiodysplasia obliterated</td> <td>Periphery of lesion treated before center; caution with right-sided lesions</td> </tr> <tr> <td>Diverticulosis</td> <td>Large<sup>&#916;</sup></td> <td>Light to moderate</td> <td>10-15 J</td> <td>15-20 W, 1-2 second pulses</td> <td>Bleeding stops/visible vessel flat</td> <td>Coaptive pressure may depend upon location (dome vs neck of diverticulum)</td> </tr> <tr> <td>Postpolypectomy</td> <td>Large<sup>&#916;</sup></td> <td>Light to moderate</td> <td>10-20 J</td> <td>15-20 W, 1-2 second pulses</td> <td>Bleeding stops</td> <td>Snaring (tamponade) of polyp stalk without current may be adequate for early bleeds</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">J: Joules; W: Watts<br />* Preinjection with epinephrine solution can be considered before endoscopic coagulation.<br />&para; Probe size, power settings, and coaptive pressure will necessarily vary depending on clinical experience and location of lesion. Repeated cautery to the same point increases risk of perforation.<br />&Delta; Large probe preferred if therapeutic endoscope used.</div><div class=\"graphic_reference\">Adapted with permission from: Zuckerman G, Prakash C. Gastrointest Endosc 1999; 49:231.</div><div id=\"graphicVersion\">Graphic 71455 Version 3.0</div></div></div>"},"71462":{"type":"graphic_table","displayName":"Criteria for treating ischemic stroke with tPA","title":"Eligibility criteria for the treatment of acute ischemic stroke with intravenous alteplase (recombinant tissue plasminogen activator or tPA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eligibility criteria for the treatment of acute ischemic stroke with intravenous alteplase (recombinant tissue plasminogen activator or tPA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inclusion criteria</td> </tr> <tr> <td class=\"indent1\">Clinical diagnosis of ischemic stroke causing measurable neurologic deficit</td> </tr> <tr> <td class=\"indent1\">Onset of symptoms &#60;4.5 hours before beginning treatment; if the exact time of stroke onset is not known, it is defined as the last time the patient was known to be normal or at neurologic baseline</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Age &#8805;18 years</td> </tr> <tr> <td class=\"subtitle1_single\">Exclusion criteria</td> </tr> <tr> <td class=\"indent1\"><strong>Historical</strong></td> </tr> <tr> <td class=\"indent2\">Ischemic stroke or severe head trauma in the previous three months</td> </tr> <tr> <td class=\"indent2\">Previous intracranial hemorrhage</td> </tr> <tr> <td class=\"indent2\">Intra-axial intracranial neoplasm</td> </tr> <tr> <td class=\"indent2\">Gastrointestinal malignancy or hemorrhage in the previous 21 days</td> </tr> <tr> <td class=\"indent2\">Intracranial or intraspinal surgery within the prior three months</td> </tr> <tr> <td class=\"indent1\"><strong>Clinical</strong></td> </tr> <tr> <td class=\"indent2\">Symptoms suggestive of subarachnoid hemorrhage</td> </tr> <tr> <td class=\"indent2\">Persistent blood pressure elevation (systolic &#8805;185 mmHg or diastolic &#8805;110 mmHg)</td> </tr> <tr> <td class=\"indent2\">Active internal bleeding</td> </tr> <tr> <td class=\"indent2\">Presentation consistent with infective endocarditis</td> </tr> <tr> <td class=\"indent2\">Stroke known or suspected to be associated with aortic arch dissection</td> </tr> <tr> <td class=\"indent2\">Acute bleeding diathesis, including but not limited to conditions defined in 'Hematologic'</td> </tr> <tr> <td class=\"indent1\"><strong>Hematologic</strong></td> </tr> <tr> <td class=\"indent2\">Platelet count &#60;100,000/mm<sup>3</sup>*</td> </tr> <tr> <td class=\"indent2\">Current anticoagulant use with an INR &#62;1.7 or PT &#62;15 seconds or aPTT &#62;40 seconds or PT &#62;15 seconds*</td> </tr> <tr> <td class=\"indent2\">Therapeutic doses of low molecular weight heparin received within 24 hours (eg, to treat VTE and ACS); this exclusion does not apply to prophylactic doses (eg, to prevent VTE)</td> </tr> <tr> <td class=\"indent2\">Current use of a direct thrombin inhibitor or direct factor Xa inhibitor with evidence of anticoagulant effect by laboratory tests such as aPTT, INR, ECT, TT, or appropriate factor Xa activity assays</td> </tr> <tr> <td class=\"indent1\"><strong>Head CT scan</strong></td> </tr> <tr> <td class=\"indent2\">Evidence of hemorrhage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Extensive regions of obvious hypodensity consistent with irreversible injury</td> </tr> <tr> <td class=\"subtitle1_single\">Relative exclusions/warnings<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Only minor and isolated neurologic signs or rapidly improving symptoms<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Serum glucose &#60;50 mg/dL (&#60;2.8 mmol/L)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Serious trauma in the previous 14 days<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Major surgery in the previous 14 days<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">History of gastrointestinal bleeding (remote) or genitourinary bleeding<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\">Seizure at the onset of stroke with postictal neurologic impairments<sup>&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Pregnancy**</td> </tr> <tr> <td class=\"indent1\">Arterial puncture at a noncompressible site in the previous seven days<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Large (&#8805;10 mm), untreated, unruptured intracranial aneurysm<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Untreated intracranial vascular malformation<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Additional relative exclusion criteria for treatment from 3 to 4.5 hours from symptom onset</strong><sup>&#916;&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Age &#62;80 years</td> </tr> <tr> <td class=\"indent2\">Oral anticoagulant use regardless of INR</td> </tr> <tr> <td class=\"indent2\">Severe stroke (NIHSS score &#62;25)</td> </tr> <tr> <td class=\"indent2\">Combination of both previous ischemic stroke and diabetes mellitus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; aPTT: activated partial thromboplastin time; ECT: ecarin clotting time; INR: international normalized ratio; PT: prothrombin time; NIHSS: National Institutes of Health Stroke Scale; tPA: intravenous alteplase; TT: thrombin time; VTE, venous thromboembolism.<br />* Although it is desirable to know the results of these tests, thrombolytic therapy should not be delayed while results are pending unless (1) there is clinical suspicion of a bleeding abnormality or thrombocytopenia, (2) the patient is currently on or has recently received anticoagulants (eg, heparin, warfarin, a direct thrombin inhibitor, or a direct factor Xa inhibitor), (3) use of anticoagulants is not known. For patients without recent use of oral anticoagulants or heparin, treatment with intravenous tPA can be started before availability of coagulation test results but should be discontinued if the INR, PT, or aPTT exceed the limits stated in the table.<br />¶ With careful consideration and weighting of risk-to-benefit, patients may receive intravenous alteplase despite one or more relative contraindications or warnings.<br />Δ Patients who have a persistent neurologic deficit that is potentially disabling, despite improvement of any degree, should be treated with tPA in the absence of other contraindications. Any of the following should be considered disabling deficits: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Complete hemianopsia: ≥2 on NIHSS question 3, or</LI>&#xD;&#xA;<LI>Severe aphasia: ≥2 on NIHSS question 9, or</LI>&#xD;&#xA;<LI>Visual or sensory extinction: ≥1 on NIHSS question 11, or</LI>&#xD;&#xA;<LI>Any weakness limiting sustained effort against gravity: ≥2 on NIHSS question 5 or 6, or</LI>&#xD;&#xA;<LI>Any deficits that lead to a total NIHSS &gt;5, or</LI>&#xD;&#xA;<LI>Any remaining deficit considered potentially disabling in the view of the patient and the treating practitioner using clinical judgment</LI></UL><FONT class=lozenge>◊</FONT> Patients may be treated with intravenous alteplase if glucose level is subsequently normalized.<br />§ The potential risks of bleeding with alteplase from injuries related to the trauma should be weighed against the anticipated benefits of reduced stroke-related neurologic deficits.<br />¥ The increased risk of surgical site bleeding with alteplase should be weighed against the anticipated benefits of reduced stroke-related neurologic deficits.<br />‡ There is a low increased risk of new bleeding with alteplase in the setting of past gastrointestinal or genitourinary bleeding. However, alteplase administration within 21 days of gastrointestinal bleeding is not recommended.<br />† Alteplase is reasonable in patients with a seizure at stroke onset if evidence suggests that residual impairments are secondary to acute ischemic stroke and not to a postictal phenomenon.<br />** Alteplase can be given in pregnancy when the anticipated benefits of treating moderate or severe stroke outweigh the anticipated increased risks of uterine bleeding.<br />¶¶ The safety and efficacy of administering alteplase is uncertain for these relative exclusions.<br />ΔΔ Intravenous alteplase appears to be safe and may be beneficial for patients with these relative exclusions, including patients taking oral anticoagulants with an INR &lt;1.7.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317.</li>&#xD;&#xA;    <li>Del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40:2945.</li>&#xD;&#xA;    <li>Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force:, Levine SR, Khatri P, et al. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms. Stroke 2013; 44:2500.</li>&#xD;&#xA;    <li>Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016; 47:581.</li>&#xD;&#xA;    <li>Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49:e46.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71462 Version 19.0</div></div></div>"},"71463":{"type":"graphic_figure","displayName":"Smith-Lemli-Opitz syndrome: Biosynthetic pathways","title":"Smith-Lemli-Opitz syndrome: Biosynthetic pathways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Smith-Lemli-Opitz syndrome: Biosynthetic pathways</div><div class=\"cntnt\"><img style=\"width:410px; height:340px;\" src=\"images/OBGYN/71463_SmithLemliOpitzsyndrome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of Smith-Lemli-Opitz syndrome on the biosynthesis of estriol by the fetalplacental unit A mutation of the enzyme C7-reductase in the fetus prevents the conversion of 7-dehydrocholesterol (DHC) to cholesterol. This blockade leads to impaired biosynthesis of estriol. Conversion of 7-DHC to cholesterol by the mother, who is a carrier of the mutation and is not affected, is not impaired.</div><div class=\"graphic_footnotes\">DHEAS: dehydroepiandrosterone sulfate.</div><div id=\"graphicVersion\">Graphic 71463 Version 5.0</div></div></div>"},"71466":{"type":"graphic_table","displayName":"Antihypertensive drugs for pediatric chronic hypertension","title":"Antihypertensive drugs for outpatient management of chronic hypertension for infants, children, and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antihypertensive drugs for outpatient management of chronic hypertension&nbsp;for infants,&nbsp;children, and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Initial oral dose</td> <td class=\"subtitle1\">Maximal oral&nbsp;dose per day</td> <td class=\"subtitle1\">Dosing interval</td> <td class=\"subtitle1\">Formulations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">ACE inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\"><strong>Contraindications:</strong> Pregnancy, angioedema.<br /> <strong>Common adverse effects:</strong> Cough, headache, dizziness, asthenia.<br /> <strong>Severe adverse effects:</strong> Hyperkalemia, acute kidney injury, angioedema, fetal toxicity.</td> </tr> <tr> <td class=\"indent1\">Benazepril</td> <td>&#8805;6 years*</td> <td>0.2 mg/kg per day (up to 10 mg per day)</td> <td>0.6 mg/kg (up to 40 mg)</td> <td>Daily.</td> <td> <p>Tablet: 5, 10, 20, 40 mg (generic).</p> Extemporaneous liquid: 2 mg/mL.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Captopril<sup>&#182;</sup></td> <td>Infants</td> <td>0.05 mg/kg per dose</td> <td>6 mg/kg</td> <td>Daily to 4 times a day.</td> <td rowspan=\"2\"> <p>Tablet: 12.5, 25, 50, 100 mg (generic).</p> Extemporaneous liquid: 1 mg/mL.</td> </tr> <tr> <td>Children</td> <td>0.5 mg/kg per dose</td> <td>6 mg/kg</td> <td>Three times a day.</td> </tr> <tr> <td class=\"indent1\">Enalapril</td> <td>&#8805;1 month*</td> <td>0.08 mg/kg per day (up to 5 mg per day)</td> <td>0.6 mg/kg (up to 40 mg)</td> <td>Daily to twice a day.</td> <td> <p>Tablet: 2.5, 5, 10, 20 mg (generic).</p> Solution: 1 mg/mL.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Fosinopril</td> <td>&#8805;6 years</td> <td rowspan=\"2\">0.1 mg/kg per day (up to 5 mg per day)</td> <td rowspan=\"2\">40 mg</td> <td rowspan=\"3\">Daily.</td> <td rowspan=\"3\">Tablet: 10, 20, 40 mg (generic).</td> </tr> <tr> <td>&#60;50 kg</td> </tr> <tr> <td>&#8805;50 kg*</td> <td>5 mg per day</td> <td>40 mg</td> </tr> <tr> <td class=\"indent1\">Lisinopril</td> <td>&#8805;6 years*</td> <td>0.07 mg/kg per day (up to 5 mg per day)</td> <td>0.6 mg/kg&nbsp;(up to 40 mg)</td> <td>Daily.</td> <td> <p>Tablet: 2.5, 5, 10, 20, 30, 40 mg (generic).</p> Solution: 1 mg/mL.</td> </tr> <tr> <td class=\"indent1\">Ramipril<sup>&#182;</sup></td> <td>NA</td> <td>1.6 mg/m<sup>2</sup> per day</td> <td>6 mg/m<sup>2</sup> </td> <td>Daily.</td> <td>Capsule: 1.25, 2.5, 5, 10 mg (generic).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Quinapril</td> <td>NA</td> <td>5 mg per day</td> <td>80 mg </td> <td>Daily.</td> <td>Tablet: 5, 10, 20, 40 mg (generic).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">ARBs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\"><strong>Contraindications:</strong> Pregnancy.<br /> <strong>Common adverse effects:</strong> Headache, dizziness.<br /> <strong>Severe adverse effects:</strong> Hyperkalemia, acute kidney injury, fetal toxicity.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Candesartan</td> <td>1 to 5 years*</td> <td rowspan=\"2\">0.02 mg/kg per day (up to 4 mg per day)</td> <td rowspan=\"2\">0.4 mg/kg (up to 16 mg)</td> <td rowspan=\"4\">Daily to twice a day.</td> <td rowspan=\"4\"> <p>Tablet: 4, 8, 16, 32 mg.</p> Extemporaneous liquid: 1 mg/mL.</td> </tr> <tr> <td>&#8805;6 years*</td> </tr> <tr> <td>&#60;50 kg</td> <td>4 mg per day</td> <td>16 mg </td> </tr> <tr> <td>&#8805;50 kg</td> <td>8 mg per day</td> <td>32 mg </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Irbesartan</td> <td>6 to 12 years</td> <td>75 mg per day</td> <td>150 mg </td> <td rowspan=\"2\">Daily.</td> <td rowspan=\"2\">Tablet: 75, 150, 300 mg (generic).</td> </tr> <tr> <td>&#8805;13 years</td> <td>150 mg per day</td> <td>300 mg </td> </tr> <tr> <td class=\"indent1\">Losartan</td> <td>&#8805;6 years*</td> <td>0.7 mg/kg (up to 50 mg)</td> <td>1.4 mg/kg (up to 100 mg)</td> <td>Daily.</td> <td> <p>Tablet: 25, 50, 100 mg (generic).</p> Extemporaneous liquid: 2.5 mg/mL.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Olmesartan</td> <td>&#8805;6 years*</td> <td>NA</td> <td>NA</td> <td rowspan=\"3\">Daily.</td> <td rowspan=\"3\"> <p>Tablet: 5, 20, 40 mg.</p> Extemporaneous liquid: 2 mg/mL.</td> </tr> <tr> <td>&#60;35 kg</td> <td>10 mg</td> <td>20 mg</td> </tr> <tr> <td>&#8805;35 kg</td> <td>20 mg</td> <td>40 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Valsartan</td> <td>&#8805;6 years*</td> <td>1.3 mg/kg (up to 40 mg)</td> <td>2.7 mg/kg (up to 160 mg)</td> <td>Daily.</td> <td> <p>Tablet: 40, 80, 160, 320 mg (generic).</p> Extemporaneous liquid: 4 mg/mL.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Thiazide diuretics</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\"><strong>Contraindications:</strong> Anuria.<br /> <strong>Common adverse effects:</strong> Dizziness, hypokalemia.<br /> <strong>Severe adverse effects:</strong> Cardiac dysrhythmias, cholestatic jaundice, new onset diabetes mellitus, pancreatitis.</td> </tr> <tr> <td class=\"indent1\">Chlorthalidone</td> <td>Children</td> <td>0.3 mg/kg</td> <td>2 mg/kg (50 mg)</td> <td>Daily.</td> <td>Tablet: 25, 50, 100 mg (generic).</td> </tr> <tr> <td class=\"indent1\">Chlorothiazide</td> <td>Children*</td> <td>10 mg/kg per day</td> <td>20 mg/kg (up to 375 mg per day)</td> <td>Daily to twice a day.</td> <td> <p>Tablet: 250, 500 mg (generic).</p> <p>Suspension: 250/5 mL.</p> Extemporaneous liquid: 1 mg/mL.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydrochlorothiazide</td> <td>Children*</td> <td>1 mg/kg per day</td> <td>2 mg/kg (up to 37.5 mg)</td> <td>Daily to twice a day.</td> <td>Tablet: 12.5, 25, 50 mg.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Calcium channel blockers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\"><strong>Contraindications:</strong> Hypersensitivity to CCBs.<br /> <strong>Common adverse effects:</strong> Flushing, peripheral edema, dizziness.<br /> <strong>Severe adverse effects:</strong> Angioedema.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Amlodipine</td> <td>1 to 5 years</td> <td>0.1 mg/kg</td> <td>0.6 mg/kg (up to 5 mg)</td> <td rowspan=\"2\">Daily.</td> <td rowspan=\"2\"> <p>Tablet: 2.5, 5, 10 mg.</p> Extemporaneous liquid: 1 mg/mL.</td> </tr> <tr> <td>&#8805;6 years*</td> <td>2.5 mg</td> <td>10 mg</td> </tr> <tr> <td class=\"indent1\">Felodipine</td> <td>&#8805;6 years</td> <td>2.5 mg</td> <td>10 mg</td> <td>Daily.</td> <td>Tablet (extended release): 2.5, 5, 10 mg (generic).</td> </tr> <tr> <td class=\"indent1\">Isradipine</td> <td>Children</td> <td>0.05 to 0.1 mg/kg</td> <td>0.6 mg/kg (up to 10 mg)</td> <td> <p>Capsule: Twice daily to 3 times a day.</p> Tablet (extended release): Daily.</td> <td> <p>Capsule: 2.5, 5 mg.</p> Tablet (extended release): 5, 10 mg.</td> </tr> <tr> <td class=\"indent1\">Nifedipine extended release</td> <td>Children</td> <td>0.2 to 0.5 mg/kg per day</td> <td>3 mg/kg (up to 120 mg)</td> <td>Daily to twice a day.</td> <td>Tablet (extended release): 30, 60, 90 mg (generic).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin converting enzyme; NA: not applicable; ARB: angiotensin-receptor blocker; FDA: US Food and Drug Administration.<br />* FDA pediatric labeling.<br />¶ Dose per 24 hours should not exceed the usual maximum daily dose in adults.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 140, doi: 10.1542/peds.2017-1904. Copyright &copy; 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 71466 Version 8.0</div></div></div>"},"71467":{"type":"graphic_picture","displayName":"Glaucomatous optic disc","title":"Glaucomatous optic disc cupping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glaucomatous optic disc cupping</div><div class=\"cntnt\"><img style=\"width:274px; height:371px;\" src=\"images/PEDS/71467_Glaucomatous_optic_disc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the inferior elongation of the cup. Vertical cup:disc ratio is 0.8, horizontal cup:disc ratio is 0.5.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 71467 Version 1.0</div></div></div>"},"71468":{"type":"graphic_picture","displayName":"Retinoblastoma gross path","title":"Retinoblastoma gross pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinoblastoma gross pathology</div><div class=\"cntnt\"><img style=\"width:360px; height:307px;\" src=\"images/PEDS/71468_Retinoblastoma_gross_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This surgically excised eye is almost filled by a cream-colored intraocular retinoblastoma with calcified flecks.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71468 Version 2.0</div></div></div>"},"71470":{"type":"graphic_table","displayName":"Biliary stents","title":"Biliary stents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biliary stents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stent (manufacturer)</td> <td class=\"subtitle1\">Covering</td> <td class=\"subtitle1\">Material</td> <td class=\"subtitle1\">Diameter (mm)</td> <td class=\"subtitle1\">Length (mm)</td> <td class=\"subtitle1\">Delivery system</td> </tr> <tr> <td rowspan=\"3\">Wallflex (Boston Scientific)</td> <td>Uncovered</td> <td>Platinol</td> <td>8, 10</td> <td>40, 60, 80, 100</td> <td>8.0 Fr</td> </tr> <tr> <td>Partially covered</td> <td>Platinol</td> <td>8, 10</td> <td>40(30)*, 60(50), 80(70)</td> <td>8.5 Fr</td> </tr> <tr> <td>Fully covered</td> <td>Platinol</td> <td>8, 10</td> <td>40*, 60, 80</td> <td>8.5 Fr</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Wallstent (Boston Scientific)</td> <td>Uncovered</td> <td>Nitinol</td> <td>8, 10</td> <td>40, 60 ,80, 100</td> <td>8.0 Fr</td> </tr> <tr> <td>Partially covered</td> <td>Nitinol</td> <td>8, 10</td> <td>40(30), 60(50), 80(70)</td> <td>8.0 Fr</td> </tr> <tr class=\"divider_top\"> <td>Zilver (Cook Medical Inc.)</td> <td>Uncovered</td> <td>Nitinol</td> <td>6, 8, 10</td> <td>40, 60, 80</td> <td>7.0 Fr</td> </tr> <tr class=\"divider_top\"> <td>Zilver 635 (Cook Medical inc.)</td> <td>Uncovered</td> <td>Nitinol</td> <td>6, 8, 10</td> <td>40, 60, 80</td> <td>6.0 Fr</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Viabil (Gore)</td> <td>Fully covered w/sideholes</td> <td>Nitinol</td> <td>8, 10</td> <td>60, 80, 100</td> <td>8.5 Fr</td> </tr> <tr> <td>Fully covered w/o sideholes</td> <td>Nitinol</td> <td>8, 10</td> <td>40, 60, 80, 100</td> <td>8.5 Fr</td> </tr> <tr class=\"divider_top\"> <td>FLEXXUS (ConMed)</td> <td>Uncovered</td> <td>Nitinol</td> <td>8, 10</td> <td>40, 60, 80, 100</td> <td>7.5 Fr</td> </tr> <tr class=\"divider_top\"> <td>ALIMAXX-B (MeritMedical)</td> <td>Uncovered</td> <td>Nitinol</td> <td>8, 10</td> <td>40, 60, 80</td> <td>6.5 Fr</td> </tr> <tr class=\"divider_top\"> <td>X-Suit NIR (Olympus)</td> <td>Uncovered</td> <td>Nitinol</td> <td>8, 10</td> <td>40, 60, 80, 100</td> <td>7.5 Fr</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Parentheses () indicate the covered length of the stent.</div><div class=\"graphic_footnotes\">* Only available in 10 mm diameter.</div><div class=\"graphic_reference\">Courtesy of Douglas G. Adler, MD, FACG, FASGE.</div><div id=\"graphicVersion\">Graphic 71470 Version 1.0</div></div></div>"},"71472":{"type":"graphic_table","displayName":"Migratory skin lesions","title":"Infections associated with migratory skin lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections associated with migratory skin lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infection </td> <td class=\"subtitle1\">Geographic distribution </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Cutaneous larva migrans</td> <td>Worldwide</td> <td>Creeping eruption</td> </tr> <tr> <td>Dracunculiasis</td> <td>Focal in sub-Saharan Africa</td> <td>Movement of worm just before eruption</td> </tr> <tr> <td>Fascioliasis</td> <td>Worldwide in areas where sheep and cattle are raised</td> <td>Migratory areas of inflammation</td> </tr> <tr> <td>Gnathostomiasis</td> <td>Most common in Asia but also found in other areas</td> <td>Migratory inflammatory subcutaneous swellings; urticaria</td> </tr> <tr> <td>Hookworm</td> <td>Worldwide; most common in tropical, subtropical areas&nbsp;with poor sanitation</td> <td>Itchy tracts at points of penetration of larvae through skin</td> </tr> <tr> <td>Loiasis</td> <td>Central and western Africa</td> <td>Migratory inflammatory swellings</td> </tr> <tr> <td>Paragonimiasis</td> <td>Most common in east and&nbsp;southeast Asia, Africa</td> <td>Migratory swelling or subcutaneous nodules</td> </tr> <tr> <td>Sparganosis</td> <td>Parasite found on all continents; most human cases from southeast&nbsp;Asia</td> <td>Edematous, painful migratory swellings</td> </tr> <tr> <td>Strongyloidiasis</td> <td>Most common in tropical, subtropical areas</td> <td>Itchy, papular and migratory serpiginous lesions (larva currens)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71472 Version 5.0</div></div></div>"},"71473":{"type":"graphic_movie","displayName":"Robot-assisted rad hyst 2","title":"Division of the right uterine artery during robot-assisted radical hysterectomy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Division of the right uterine artery during robot-assisted radical hysterectomy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71473_Divrightuterartconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:396px; height:303px;\" src=\"images/CARD/71473_Divisionrightuterart.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Colleen M Feltmate, MD.</div><div id=\"graphicVersion\">Graphic 71473 Version 4.0</div></div></div>"},"71475":{"type":"graphic_table","displayName":"Electrodiagnostic criteria CIDP","title":"Electrodiagnostic criteria for CIDP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electrodiagnostic criteria for CIDP</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>These criteria are applied by testing the median, ulnar (stimulated below the elbow), peroneal (stimulated below the fibular head), and tibial nerves on one side of the body. During testing, limb temperature should be no less than 33&#176;C at the palm and no less than 30&#176;C at the external malleolus.</td> </tr> <tr> <td class=\"subtitle1_single\">Definite CIDP</td> </tr> <tr> <td>At least one of the following demyelinating parameters are necessary:</td> </tr> <tr> <td class=\"indent1\">&#8805;50 percent prolongation of motor distal latency above the ULN in two nerves</td> </tr> <tr> <td class=\"indent1\">&#8805;30 percent reduction of motor conduction velocity below the LLN in two nerves</td> </tr> <tr> <td class=\"indent1\">&#8805;20 percent prolongation of F-wave latency above the ULN in two nerves, or &#62;50 percent if the amplitude of the distal negative peak CMAP is &#60;80 percent of the LLN</td> </tr> <tr> <td class=\"indent1\">Absence of F-waves in two nerves, if these nerves have amplitudes of distal negative peak CMAPs &#8805;20 percent of the LLN, plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve</td> </tr> <tr> <td class=\"indent1\">Partial motor conduction block, defined by a &#8805;50 percent amplitude reduction of the proximal negative peak CMAP relative to distal, if distal negative peak CMAP is &#8805;20 percent of the LLN, in two nerves, or in one nerve plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve</td> </tr> <tr> <td class=\"indent1\">Abnormal temporal dispersion, defined by a &#62;30 percent duration increase between the proximal and distal negative peak CMAP in at least two nerves</td> </tr> <tr> <td class=\"indent1\">Distal CMAP duration (interval between onset of the first negative peak and return to baseline of the last negative peak) increase in at least one nerve (median &#8805;6.6 ms, ulnar &#8805;6.7 ms, peroneal &#8805;7.6 ms, tibial &#8805;8.8 ms) plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve</td> </tr> <tr> <td class=\"subtitle1_single\">Probable CIDP</td> </tr> <tr> <td>&#8805;30 percent amplitude reduction of the proximal negative peak CMAP relative to the distal, excluding the posterior tibial nerve, if the distal negative peak CMAP is &#8805;20 percent of LLN, in two nerves, or in one nerve plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve</td> </tr> <tr> <td class=\"subtitle1_single\">Possible CIDP</td> </tr> <tr> <td>As in \"Definite CIDP\" but in only one nerve</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=40628&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">CIDP: chronic inflammatory demyelinating polyneuropathy; CMAP: compound muscle action potential; ULN: upper limit of normal; LLN: lower limit of normal.</div><div class=\"graphic_reference\">Adapted from: Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst 2010; 15:1.</div><div id=\"graphicVersion\">Graphic 71475 Version 7.0</div></div></div>"},"71478":{"type":"graphic_table","displayName":"Causes of vulvar contact dermatitis","title":"Causes of vulvar contact dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of vulvar contact dermatitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Irritants</td> </tr> <tr> <td>Soaps, bubble bath, shampoo</td> </tr> <tr> <td>Sanitary or incontinence pads, tampons</td> </tr> <tr> <td>Nylon underwear</td> </tr> <tr> <td>Sweat, urine</td> </tr> <tr> <td>Talcum powder</td> </tr> <tr> <td>Vaginal or vulvar medications</td> </tr> <tr> <td>Douches</td> </tr> <tr> <td>Vaginal hygiene products</td> </tr> <tr> <td>Vaginal contraceptive products</td> </tr> <tr> <td>Methylated spirits</td> </tr> <tr> <td>Tea tree oil</td> </tr> <tr> <td>Pinetarsol</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Fragrances</td> </tr> <tr> <td>Deodorants&nbsp;</td> </tr> <tr> <td>Hair conditioner</td> </tr> <tr> <td>Chemically-treated clothing, toilet paper, or water</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Allergens</td> </tr> <tr> <td>Benzocaine</td> </tr> <tr> <td>Neomycin</td> </tr> <tr> <td>Chlorhexidine (eg, in lubricants, antiseptic washes)</td> </tr> <tr> <td>Ethylene diamine (eg, hydroxyzine)</td> </tr> <tr> <td>Fragrances</td> </tr> <tr> <td>Balsam of Peru (<em>Myroxylon pereirae</em>), fragrances (eg, in soaps, feminine products)</td> </tr> <tr> <td>Propylene glycol, formaldehyde-releasing preservatives,&nbsp;and other preservatives (eg, methylchloroisothiazolinone and methylisothiazolinone in moist flushable wipes)</td> </tr> <tr> <td>Tea tree oil</td> </tr> <tr> <td>Natural rubber (latex) and synthetic rubber (nitrile)&nbsp;(eg, condoms, diaphragms)</td> </tr> <tr> <td>Semen</td> </tr> <tr> <td>Disinfectants</td> </tr> <tr> <td>Lanolin</td> </tr> <tr> <td>Dyes</td> </tr> <tr> <td>Nickel</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71478 Version 6.0</div></div></div>"},"71480":{"type":"graphic_picture","displayName":"Petechiae in immune thrombocytopenia","title":"Petechiae in Immune Thrombocytopenia (ITP)","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Petechiae in Immune Thrombocytopenia (ITP)</div><div class=\"cntnt\"><img style=\"width:467px; height:177px;\" src=\"images/HEME/71480_Petechiae_ITP_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Petechiae in a man with immune thrombocytopenia (ITP).<br />(A) Dense, cutaneous petechiae on the foot and ankle. There are no petechiae on the sole of his foot, a site at which the vessels are protected by the strong subcutaneous tissue.<br />(B) Occasional petechiae on the patient's face and large, bullous hemorrhages on the buccal mucosa, which are related to the lack of vessel protection by the submucosal tissue. Similar petechiae and hemorrhagic bullae can be seen in patients with thrombocytopenia of any cause.</div><div class=\"graphic_reference\">Reproduced with permission from: Stein JH, Internal Medicine, 5th ed, Mosby, St. Louis, 1998.</div><div id=\"graphicVersion\">Graphic 71480 Version 7.0</div></div></div>"},"71482":{"type":"graphic_figure","displayName":"Dermoscopy colors","title":"Colors seen under dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Colors seen under dermoscopy</div><div class=\"cntnt\"><img style=\"width:605px; height:263px;\" src=\"images/DERM/71482_Dermoscopy_colors_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 71482 Version 3.0</div></div></div>"},"71483":{"type":"graphic_picture","displayName":"Photoaging periocular","title":"Periorbital wrinkles in photodamaged skin","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periorbital wrinkles in photodamaged skin</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71483_Photoaging_periocular.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71483 Version 3.0</div></div></div>"},"71484":{"type":"graphic_table","displayName":"Pediatric airway equipment ","title":"Airway equipment for pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway equipment for pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n<tr>\r\n<td class=\"subtitle1_single\">Supplemental oxygen</td>\r\n</tr>\r\n<tr>\r\n<td>Nasal cannulae (infant, child, and adult)</td>\r\n</tr>\r\n<tr>\r\n<td>Clear oxygen masks (standard and nonrebreathing - infant, child, and adult)</td>\r\n</tr>\r\n<tr>\r\n<td class=\"subtitle1_single\">Suction</td>\r\n</tr>\r\n<tr>\r\n<td>Suction catheters (6 through 16 French)</td>\r\n</tr>\r\n<tr>\r\n<td>Yankauer suction tip (two sizes)</td>\r\n</tr>\r\n<tr>\r\n<td class=\"subtitle1_single\">Bag-mask ventilation</td>\r\n</tr>\r\n<tr>\r\n<td>Masks (neonate, infant, child, adult)</td>\r\n</tr>\r\n<tr>\r\n<td>Self-inflating resuscitator bag (450 and 1000 mL)</td>\r\n</tr>\r\n<tr>\r\n<td class=\"subtitle1_single\">Artificial airways</td>\r\n</tr>\r\n<tr>\r\n<td>Oropharyngeal airways (sizes 0 through 5)</td>\r\n</tr>\r\n<tr>\r\n<td>Nasopharyngeal airways (12 through 30 French)</td>\r\n</tr>\r\n<tr>\r\n<td class=\"subtitle1_single\">Intubation equipment</td>\r\n</tr>\r\n<tr>\r\n<td>Endotracheal tubes (uncuffed and cuffed, 2.5 through 8.0 mm internal diameter)</td>\r\n</tr>\r\n<tr>\r\n<td>Stylets (infant, pediatric, and adult)</td>\r\n</tr>\r\n<tr>\r\n<td>Laryngoscope handle (pediatric and adult)</td>\r\n</tr>\r\n<tr>\r\n<td>Laryngoscope blades: straight (sizes 0, 1, 2, and 1.5 Wis-Hipple) and curved (sizes 2 and 3)</td>\r\n</tr>\r\n<tr>\r\n<td class=\"subtitle1_single\">Rescue airway devices</td>\r\n</tr>\r\n<tr>\r\n<td>Laryngeal mask airway (sizes 1, 1.5, 2, 2.5, 3, 4, and 5)</td>\r\n</tr>\r\n<tr>\r\n<td>Combitube (37 and 41 French)</td>\r\n</tr>\r\n<tr>\r\n<td class=\"subtitle1_single\">Miscellaneous</td>\r\n</tr>\r\n<tr>\r\n<td>End-tidal CO2 detector</td>\r\n</tr>\r\n<tr>\r\n<td>Magill forceps (pediatric and adult)</td>\r\n</tr>\r\n<tr>\r\n<td>Bulb suction</td>\r\n</tr>\r\n</tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 71484 Version 2.0</div></div></div>"},"71485":{"type":"graphic_picture","displayName":"Stockinette folded","title":"Stockinette folded for final application of casting tape","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stockinette folded for final application of casting tape</div><div class=\"cntnt\"><img style=\"width:336px; height:468px;\" src=\"images/EM/71485_Stockinette_folded.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that one additional layer of casting tape is applied after this step.&nbsp;Although the wrist appears to be in some radial deviation in this photograph due to the way the fingers are angled, the wrist is kept neutral (ie, without radial or ulnar deviation).</div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 71485 Version 2.0</div></div></div>"},"71486":{"type":"graphic_diagnosticimage","displayName":"Substernal goiter PA","title":"Substernal goiter: Chest radiograph showing tracheal deviation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Substernal goiter: Chest&nbsp;radiograph showing tracheal deviation</div><div class=\"cntnt\"><img style=\"width:298px; height:324px;\" src=\"images/ENDO/71486_Substernal_goiter_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing a substernal goiter appearing as a paratracheal mass deviating the trachea to the right (arrow).</div><div class=\"graphic_reference\">Courtesy of Douglas S Ross, MD.</div><div id=\"graphicVersion\">Graphic 71486 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"71487":{"type":"graphic_picture","displayName":"Tampon and balloon packs","title":"Tampon and balloon packs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tampon and balloon packs</div><div class=\"cntnt\"><img style=\"width:432px; height:308px;\" src=\"images/PC/71487_Tampon_and_balloon_packs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">L-R: Merocel tampon, 6 cm; Storz T-3100 balloon packing, 12 cm; Rapid Rhino balloon pack with carboxymethylated cellulose mesh casing, 7.5 cm.</div><div id=\"graphicVersion\">Graphic 71487 Version 1.0</div></div></div>"},"71491":{"type":"graphic_figure","displayName":"Compound Z-plasty","title":"Compound Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Compound Z-plasty</div><div class=\"cntnt\"><img style=\"width:465px; height:683px;\" src=\"images/SURG/71491_Compound_z-plasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple Z-plasties are used to manage large wounds or scars not amenable to a single Z-plasty.</div><div id=\"graphicVersion\">Graphic 71491 Version 2.0</div></div></div>"},"71492":{"type":"graphic_figure","displayName":"Innervation of the adrenal glands","title":"Innervation of the adrenal glands","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Innervation of the adrenal glands</div><div class=\"cntnt\"><img style=\"width:523px; height:698px;\" src=\"images/SURG/71492_Innervation-of-the-adrenal-glands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The innervation of the adrenal glands is via visceral afferent fibers arising from the celiac, aorticorenal, and renal ganglia.These fibers connect with the posterior vagus nerve, phrenic nerve, and greater and lesser splanchnic nerves.<br> The nerve fibers provide sensory or indirect vasomotor innervation as they traverse the adrenal cortex, and terminate in the medulla as preganglionic sympathetic fibers.</div><div id=\"graphicVersion\">Graphic 71492 Version 4.0</div></div></div>"},"71493":{"type":"graphic_table","displayName":"Stage distribution for gallbladder cancer","title":"Stage distribution for 439 incidentally found gallbladder cancers in a German registry, according to type of surgery performed","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stage distribution for 439 incidentally found gallbladder cancers in a German registry, according to type of surgery performed</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Pathologic T (tumor) stage</td>\r\n            <td class=\"subtitle1\">Laparoscopic, percent<br />\r\n            (n = 239)</td>\r\n            <td class=\"subtitle1\">Open resection, percent<br />\r\n            (n = 131)</td>\r\n            <td class=\"subtitle1\">Conversion from laparoscopic to open resection*<br />\r\n            (n = 69)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>pTis</td>\r\n            <td>5</td>\r\n            <td>2</td>\r\n            <td>1</td>\r\n        </tr>\r\n        <tr>\r\n            <td>pT1</td>\r\n            <td>21</td>\r\n            <td>21</td>\r\n            <td>19</td>\r\n        </tr>\r\n        <tr>\r\n            <td>pT2</td>\r\n            <td>56</td>\r\n            <td>38</td>\r\n            <td>24</td>\r\n        </tr>\r\n        <tr>\r\n            <td>pT3</td>\r\n            <td>12</td>\r\n            <td>19</td>\r\n            <td>46</td>\r\n        </tr>\r\n        <tr>\r\n            <td>pT4</td>\r\n            <td>4</td>\r\n            <td>15</td>\r\n            <td>7</td>\r\n        </tr>\r\n        <tr>\r\n            <td>pTx</td>\r\n            <td>3</td>\r\n            <td>5</td>\r\n            <td>3</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46234&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">* Conversion to an open procedure for non-oncologic reasons.</div><div class=\"graphic_reference\">Data from: Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg 2008; 247:104.</div><div id=\"graphicVersion\">Graphic 71493 Version 4.0</div></div></div>"},"71494":{"type":"graphic_table","displayName":"Chance of pregnancy PI","title":"Probability of pregnancy after unprotected intercourse by timing of coitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of pregnancy after unprotected intercourse by timing of coitus</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_left\">\n   3 days before ovulation\n   </td>\n   <td>15 percent</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   1 or 2 days before ovulation\n   </td>\n   <td>30 percent</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   day of ovulation\n   </td>\n   <td>12 percent</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   1 or 2 days after ovulation\n   </td>\n   <td>near zero</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from: Trusell, J, et al. Contraception 1998; 57:363.</div><div id=\"graphicVersion\">Graphic 71494 Version 1.0</div></div></div>"},"71495":{"type":"graphic_diagnosticimage","displayName":"Torus (or buckle) fracture of the distal radius","title":"Torus (or buckle) fracture of the distal radius","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Torus (or buckle) fracture of the distal radius</div><div class=\"cntnt\"><img style=\"width:433px; height:288px;\" src=\"images/PEDS/71495_Distal_radius_torus_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Torus fractures of the distal radius. Torus fractures are caused by compressive forces that lead to buckling of the cortex (arrows).</div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 71495 Version 3.0</div></div></div>"},"71496":{"type":"graphic_picture","displayName":"Hyperplasia lymphoid tissue","title":"Hyperplasia of lymphoid tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperplasia of lymphoid tissue</div><div class=\"cntnt\"><img style=\"width:325px; height:315px;\" src=\"images/PEDS/71496_Hyperplasia_lymphoid_tissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperplasia of oropharyngeal lymphoid tissue in a patient with an immunodeficiency.</div><div class=\"graphic_reference\">Courtesy of Douglas J Barrett, MD.</div><div id=\"graphicVersion\">Graphic 71496 Version 2.0</div></div></div>"},"71497":{"type":"graphic_figure","displayName":"Side lying position PI","title":"Side-lying position for breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Side-lying position for breastfeeding</div><div class=\"cntnt\"><img style=\"width:480px; height:429px;\" src=\"images/PI/71497_Side_lying_position_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The side-lying hold allows the mother to nurse while lying down. When using this position, there should be no excess bedding around the infant. The side-lying hold should not be used on a waterbed, a couch, or a recliner because this poses a suffocation hazard to the infant.<br />To nurse from the left breast, the woman lies on her left side. The baby's head and body lie parallel to the woman's body, with the baby's mouth close to and facing the woman's left breast. The woman may prefer to have a pillow under her head, with her left hand between her head and the pillow. The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide-open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.</div><div id=\"graphicVersion\">Graphic 71497 Version 4.0</div></div></div>"},"71499":{"type":"graphic_table","displayName":"Alternative preparations of antiretroviral agents","title":"Antiretroviral formulations for adults unable to swallow tablets/capsules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiretroviral formulations for adults unable to swallow tablets/capsules</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Options for those unable to swallow tablets/capsules</td> <td class=\"subtitle1\">Antiretroviral agents<sup>*</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Oral liquid formulation available</td> <td>NRTI:<sup>&#182;</sup> Abacavir (20 mg/mL), emtricitabine (10 mg/mL), lamivudine (10 mg/mL), zidovudine (10 mg/mL).</td> </tr> <tr> <td>NNRTI: Nevirapine (10 mg/mL).</td> </tr> <tr> <td>PI: Darunavir (100 mg/mL), fosamprenavir (50 mg/mL), lopinavir-ritonavir (80 mg lopinavir and 20 mg ritonavir per mL)<sup>&#916;</sup>, tipranavir (100 mg/mL).</td> </tr> <tr class=\"divider_bottom\"> <td>Pharmacokinetic enhancer: Ritonavir (80 mg/mL).<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Powder packet granules, or chewable tablet formulation available</td> <td>NRTI: Tenofovir disoproxil fumarate (TDF) powder granules for mixture with soft foods (40 mg TDF per scoop; for adults, this requires 7.5 scoops per dose).</td> </tr> <tr> <td>PI: Atazanavir (50 mg oral powder for mixture with beverages or soft foods).</td> </tr> <tr class=\"divider_bottom\"> <td>INSTI: Raltegravir (chewable tablets [25 and 100 mg] and packet for oral suspension [100 mg/5 mL reconstituted).<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Tablets can be dissolved or dispersed in liquid<sup>&#167;</sup></td> <td>NNRTI: Etravirine (tablet may be dispersed in water).</td> </tr> <tr class=\"divider_bottom\"> <td>PI: Nelfinavir (tablet may be crushed or dissolved).</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Tablets can be crushed; capsules can be opened<sup>&#165;</sup></td> <td>NRTI: Emtricitabine (capsule may be opened), lamivudine (tablet may be crushed), tenofovir disoproxil fumarate (tablet may be crushed).</td> </tr> <tr> <td>NNRTI: Efavirenz (capsules may be opened).<sup>&#135;</sup></td> </tr> <tr> <td>PI: Darunavir (tablet may be crushed), nelfinavir (tablet may be crushed or dissolved), saquinavir (capsule may be opened).</td> </tr> <tr class=\"divider_bottom\"> <td>INSTI: Dolutegravir, elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Tablets can be crushed and administered via gastrostomy or nasogastric tubes<sup>&#134;</sup></td> <td>NRTI: Tenofovir disoproxil fumarate, emtricitabine.</td> </tr> <tr> <td>NNRTI: Etravirine.</td> </tr> <tr class=\"divider_bottom\"> <td>INSTI: Raltegravir, elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Tablets are very small, easy to swallow</td> <td>Rilpivirine.</td> </tr> <tr> <td>Dolutegravir.</td> </tr> <tr class=\"divider_bottom\"> <td>Tenofovir alafenamide-emtricitabine.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Tablets that should <strong>not</strong> be crushed or dissolved</td> <td>Lopinavir-ritonavir tablets.</td> </tr> <tr> <td>Efavirenz-emtricitabine-tenofovir disoproxil fumarate coformulation.</td> </tr> <tr> <td>Nevirapine extended-release.</td> </tr> <tr> <td>Ritonavir tablets.</td> </tr> <tr class=\"divider_bottom\"> <td>Darunavir-cobicistat tablets and atazanavir-cobicistat tablets.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Injectable formulations available</td> <td>Enfuvirtide (subcutaneous injection twice daily).</td> </tr> <tr class=\"divider_bottom\"> <td>Zidovudine (intravenous).</td> </tr> <tr> <td rowspan=\"7\">Components of coformulations may be available as separate drugs in liquid or powder form</td> <td>Efavirenz-emtricitabine-tenofovir disoproxil fumarate.<sup>&#135;</sup></td> </tr> <tr> <td>Rilpivirine-tenofovir disoproxil fumarate-emtricitabine: <p class=\"indent1\">Rilpivirine tablet very small, but no liquid option available.<br /> Tenofovir disoproxil fumarate powder and emtricitabine liquid available separately.</p> </td> </tr> <tr> <td>Zidovudine-lamivudine: <p class=\"indent1\">Liquid formulation for each component available separately.</p> </td> </tr> <tr> <td>Zidovudine-lamivudine-abacavir: <p class=\"indent1\">Liquid formulation for each component available separately.</p> </td> </tr> <tr> <td>Tenofovir disoproxil fumarate-emtricitabine: <p class=\"indent1\">Tenofovir powder and emtricitabine liquid available separately.</p> </td> </tr> <tr> <td>Abacavir-lamivudine: <p class=\"indent1\">Liquid formulation for each component available separately.</p> </td> </tr> <tr> <td>Lopinavir-ritonavir: <p class=\"indent1\">Coformulated liquid available.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NRTI: nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors; INSTI: integrase inhibitors.<br />* Administration detail of antiretroviral preparations listed in this table refer to products available in the United States, Canada, and some other countries. Refer to the Lexicomp individual drug monographs included within UpToDate and local product labeling for additional information.<br />¶ Didanosine and stavudine are available as powder for oral suspension; however, these agents are rarely used because of toxicity.<br />Δ Liquid formulation available but not very palatable for most adults. These formulations should not be used with polyurethane feeding tubes.<br />​<FONT class=lozenge>◊</FONT> Not bioequivalent to the adult film coated tablet. Refer to Lexicomp drug information topic for dosing.<br />§ Good instructions and relatively good bioavailability data available.<br />¥ To be prepared immediately before ingestion. Instructions available but little to no stability or bioavailability data available.<br />‡ The efavirenz capsules can be opened; however, the tablets should not be crushed.<br />† Minimal data from case reports.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nyberg CR, Patterson BY, Williams MM. When patients cannot take pills: Antiretroviral drug formulations for managing adult HIV infection topics. Top Antivir Med 2011; 19:126.</LI>&#xD;&#xA;<LI>Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations and obstacles to their development. J Infect Dis 2011; 204:669.</LI>&#xD;&#xA;<LI>Hoon M, Colbers A,Burger DM et al, et al. Pharmacokinetics of crushed elvitegravir combination tablet given with drip feed. Presented at the Conference on Retroviruses and Opportunistic Infections. Boston. 2016.</LI>&#xD;&#xA;<LI>Bristol-Myers Squibb Canada. Our Key Products. http://www.bmscanada.ca/en/products/evotaz (Accessed on May 10, 2016).</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 71499 Version 13.0</div></div></div>"},"71501":{"type":"graphic_movie","displayName":"Mitral stenosis 4 chamber view","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71501_4chechmsconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:480px;\" src=\"images/CARD/71501_4chechms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber echocardiogram shows thickened mitral valve with reduced motion and doming during diastole. Right and left atrial enlargement are also present.</div><div id=\"graphicVersion\">Graphic 71501 Version 2.0</div></div></div>"},"71502":{"type":"graphic_table","displayName":"Consensus statements on driving and epilepsy","title":"AAN, AES, and EF of America consensus on driving and epilepsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AAN, AES, and EF of America consensus on driving and epilepsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. The licensing decision should be made by the state Department of Motor Vehicles.</td> </tr> <tr> <td>2. A seizure-free interval should be stated, and three months is preferred, starting from the date of the seizure. Both favorable and unfavorable modifiers (see text) could alter the interval.</td> </tr> <tr> <td>3. Physicians should not be required to report their patients to the Department of Motor Vehicles.</td> </tr> <tr> <td>4. The patient should be responsible to self-report.</td> </tr> <tr> <td>5. Physicians should be given specific legal immunity for their patient reports and recommendations to regulators.</td> </tr> <tr> <td>6. A Medical Advisory Board or similar body composed of at least one member with expertise and experience in treating epilepsy should function in each state.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Consensus statements, sample statutory provisions, and model regulations regarding driver licensing and epilepsy. American Academy of Neurology, American Epilepsy Society, and Epilepsy Foundation of America. Epilepsia 1994; 35:696.</div><div id=\"graphicVersion\">Graphic 71502 Version 3.0</div></div></div>"},"71503":{"type":"graphic_table","displayName":"Cystic fibrosis carrier frequency in screen-negative individuals","title":"Carrier risk as a function of the proportion of detectable mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carrier risk as a function of the proportion of detectable mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Proportion of cystic fibrosis cases in the population caused by detectable mutations</td> <td class=\"subtitle1\">Carrier risk for person with negative test</td> </tr> <tr class=\"centered\"> <td>0</td> <td>1 in 25.5</td> </tr> <tr class=\"centered\"> <td>70</td> <td>1 in 82.7</td> </tr> <tr class=\"centered\"> <td>75</td> <td>1 in 99</td> </tr> <tr class=\"centered\"> <td>80</td> <td>1 in 126</td> </tr> <tr class=\"centered\"> <td>85</td> <td>1 in 165</td> </tr> <tr class=\"centered\"> <td>90</td> <td>1 in 246</td> </tr> <tr class=\"centered\"> <td>95</td> <td>1 in 491</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The degree to which the risk of being a carrier is reduced after a negative test is determined by the number of mutations screened and the proportion of cystic fibrosis (CF) attributable to those mutations. As an example, if a non-Hispanic white woman of Northern European descent does not carry the &Delta;F508 mutation (which accounts for 75 percent of all CF cases in this population), her risk of being a CF carrier is reduced from 1 in 25 (the a priori risk based solely on ethnic origin) to 1 in 99. If she does not carry any of the most common mutations causing 90 percent of CF cases in her ethnic group, her risk is reduced to 1 in 246.</div><div class=\"graphic_reference\">Reproduced with permission from: Elias S, Annas GJ, Simpson JL. Carrier screening for cystic fibrosis: Implications for obstetric and gynecologic practice. Am J Obstet Gynecol 1991; 164:1077. Copyright &copy; 1991 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 71503 Version 3.0</div></div></div>"},"71505":{"type":"graphic_diagnosticimage","displayName":"MRI cortical glioneuronal hamartomas","title":"Brain magnetic resonance imaging of cortical glioneuronal hamartomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain magnetic resonance imaging of cortical glioneuronal hamartomas</div><div class=\"cntnt\"><img style=\"width:386px; height:504px;\" src=\"images/NEURO/71505_MRI_cortical_tubers_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluid-attenuated inversion recovery image demonstrating multiple areas of high signal corresponding to cortical glioneuronal hamartomas, also known as tubers (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Crino PB, Henske EP. New developments in the neurobiology of the tuberous sclerosis complex. Neurology 1999; 53:1384. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71505 Version 6.0</div></div></div>"},"71506":{"type":"graphic_table","displayName":"Diabetes screening tests PI","title":"Diabetes screening tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diabetes screening tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Glucose level</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fasting glucose</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>70 to 99</td> </tr> <tr> <td class=\"indent1\">Pre-diabetes</td> <td>100 to 125</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> <td>126 or higher on at least 2 tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Glucose tolerance</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Below 140</td> </tr> <tr> <td class=\"indent1\">Pre-diabetes</td> <td>140 to 199</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diabetes</td> <td>200 or higher on at least 2 tests</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">A1C percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">A1C</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Below 5.7</td> </tr> <tr> <td class=\"indent1\">Pre-diabetes</td> <td>5.7 to 6.4</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> <td>6.5 or higher on at least 2 tests</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pre-diabetes is a term doctor or nurses use as a warning. People with pre-diabetes do not yet have diabetes, but they are at increased risk of getting it.</div><div id=\"graphicVersion\">Graphic 71506 Version 2.0</div></div></div>"},"71507":{"type":"graphic_picture","displayName":"Grade IV hyphema","title":"Grade IV hyphema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade IV hyphema</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/EM/71507_Hyphema_grade_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grade IV hyphema following blunt trauma.</div><div class=\"graphic_reference\">Photo courtesy of Roberto Pineda, II, MD, Massachusetts Eye and Ear Infirmary, Boston.</div><div id=\"graphicVersion\">Graphic 71507 Version 3.0</div></div></div>"},"71511":{"type":"graphic_table","displayName":"Management sexual dysfunction","title":"Second Princeton consensus panel recommendations for risk assignment for sexual activity and management of sexual dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Second Princeton consensus panel recommendations for risk assignment for sexual activity and management of sexual dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade of risk</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td rowspan=\"2\">CAVEATS </td> <td>Phosphodiesterase-5 inhibitors contraindicated with any nitrate preparation should not be taken with alpha-blocking agents</td> </tr> <tr> <td>Nitrates should not be administered within 24 hours (or longer in patients with renal or hepatic dysfunction) of sildenafil, 24 hours of vardenafil, or up to 48 hours of tadalafil</td> </tr> <tr> <td rowspan=\"9\">Low risk</td> <td>No symptoms and less than three major cardiovascular risk factors (excluding gender)</td> </tr> <tr> <td>Controlled hypertension</td> </tr> <tr> <td>Mild, stable angina</td> </tr> <tr> <td>Post-successful coronary revascularization</td> </tr> <tr> <td>Uncomplicated MI more than six to eight weeks previously in patients who do not have exercise-induced ischemia or who have undergone coronary revascularization</td> </tr> <tr> <td>Mild valvular disease</td> </tr> <tr> <td>Asymptomatic LV dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\">Management</td> </tr> <tr> <td class=\"indent1\">Patients at low risk can safely initiate or resume sexual activity and can be treated for sexual dysfunction</td> </tr> <tr> <td rowspan=\"7\">Intermediate or indeterminate risk </td> <td>No symptoms and three or more major cardiovascular risk factors (excluding gender)</td> </tr> <tr> <td>Moderate, stable angina</td> </tr> <tr> <td>Recent MI (more than two but less than six weeks previously); in patients who have not undergone revascularization, the risk can be assessed with stress testing</td> </tr> <tr> <td>Asymptomatic LV dysfunction with LV ejection fraction &#60;40 percent or NYHA class II heart failure</td> </tr> <tr> <td>Noncardiac sequelae of atherosclerotic disease, such as peripheral vascular disease or prior stroke or transient ischemic attack</td> </tr> <tr> <td class=\"subtitle2_left\">Management</td> </tr> <tr> <td class=\"indent1\">Patients at intermediate or indeterminate risk should undergo further cardiologic evaluation, such as stress testing (particularly in patients with a sedentary lifestyle), in an attempt to restratify the patient into the high risk or low risk category</td> </tr> <tr> <td rowspan=\"9\">High risk </td> <td>Unstable or refractory angina</td> </tr> <tr> <td>Uncontrolled hypertension</td> </tr> <tr> <td>NYHA class III/IV heart failure</td> </tr> <tr> <td>MI within the past two weeks</td> </tr> <tr> <td>High-risk arrhythmias</td> </tr> <tr> <td>Obstructive hypertrophic cardiomyopathy</td> </tr> <tr> <td>Moderate to severe valvular disease, particular aortic stenosis</td> </tr> <tr> <td class=\"subtitle2_left\">Management</td> </tr> <tr> <td class=\"indent1\">Patients at high risk should be stabilized by appropriate therapy before resuming sexual activity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MI: myocardial infarction; LV: left ventricular; NYHA: New York Heart Association.</div><div class=\"graphic_reference\">Adapted from Kostis B, Jackson G, Rosen R, et al. Am J Cardiol 2005; 96:313.</div><div id=\"graphicVersion\">Graphic 71511 Version 4.0</div></div></div>"},"71512":{"type":"graphic_picture","displayName":"Adeno CA lung Light I","title":"Adenocarcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:401px; height:284px;\" src=\"images/PULM/71512_Adeno_CA_lung_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-powered photomicrograph demonstrating the typical acinar pattern of glandular differentiation observed in adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 71512 Version 1.0</div></div></div>"},"71513":{"type":"graphic_figure","displayName":"Necrosis versus apoptosis","title":"Necrosis versus apoptosis","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Necrosis versus apoptosis</div><div class=\"cntnt\"><img style=\"width:484px; height:249px;\" src=\"images/RHEUM/71513_Necrosis_versus_apoptosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cells either die in an unregulated distension and protein denaturation (necrosis) or in a tightly programmed series of events (apoptosis) orchestrated by a series of capsase enzymes. Necrotic cells enlarge in the process of dying whereas in apoptosis the cell shrinks and develops surface blebs (far right picture) which contain apoptotically modified self antigens. The larger blebs contain nucleosomal DNA, Ro, La, and the small nuclear ribonucleoproteins. The cells eventually fragment and are cleared by macrophages. It is hypothesized that modified nucleoprotein complexes, which escape phagocytosis, can be taken up by antigen presenting cells with a resulting autoimmune response.</div><div class=\"graphic_reference\">Reproduced with permission from: Mixed connective tissue disease and other overlap syndromes. In: Kelley s Textbook of Rheumatology, 7th ed, Harris, ED, Budd, RC, Firestein, GS, et al (Eds), W.B. Saunders 2004. Copyright &#169; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 71513 Version 1.0</div></div></div>"},"71514":{"type":"graphic_picture","displayName":"Piebaldism - trunk and extremities","title":"Piebaldism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Piebaldism</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71514_Piebaldism_trunk_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple depigmented patches are present on the trunk and legs in this patient with piebaldism.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71514 Version 3.0</div></div></div>"},"71515":{"type":"graphic_picture","displayName":"Congenital toxoplasmosis generalized manifestations","title":"Generalized clinical manifestations of congenital toxoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized clinical manifestations of congenital toxoplasmosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/71515_Cong_toxopl_manifest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical manifestations of congenital toxoplasmosis in this infant include hepatosplenomegaly, jaundice, and thrombocytopenic purpura.</div><div class=\"graphic_reference\">Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &#169; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71515 Version 1.0</div></div></div>"},"71518":{"type":"graphic_algorithm","displayName":"Diagnosis neurosyphilis HIV infected","title":"Algorithm for the diagnosis of neurosyphilis in a patient with HIV infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of neurosyphilis in a patient with HIV infection</div><div class=\"cntnt\"><img style=\"width:306px; height:710px;\" src=\"images/NEURO/71518_Diagnosis_NS_HIV_infected.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ARV: antiretroviral drugs; CD4: cluster determinant 4 T lymphocyte; CSF: cerebrospinal fluid; EIA: syphilis enzyme immunoassay; FTA-ABS: fluorescent treponemal antibody-absorbed test; HIV: human immunodeficiency virus; LP: lumbar puncture; NS: neurosyphilis; RNA: ribonucleic acid; RPR: rapid plasma reagin test; TPPA: treponema pallidum particle agglutination test; VDRL: Venereal Disease Research Laboratory test; WBC: white blood cell count.<br />* A reactive serum EIA should be confirmed with a different treponemal test.</div><div class=\"graphic_reference\">Courtesy of Christina M Marra, MD.</div><div id=\"graphicVersion\">Graphic 71518 Version 6.0</div></div></div>"},"71519":{"type":"graphic_figure","displayName":"Chromosomal translocations","title":"Chromosomal translocations","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chromosomal translocations</div><div class=\"cntnt\"><img style=\"width:504px; height:318px;\" src=\"images/PC/71519_Chromosomal_translocations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Translocations involve rearrangement of chromosomal material. With a balanced translocation, no chromosomal material has been lost or gained. With an unbalanced translocation, there may be loss or gain of chromosomal material in one of the daughter cells. Refer to UpToDate topics on chromosomal translocations and genetic variation for further information.</div><div id=\"graphicVersion\">Graphic 71519 Version 2.0</div></div></div>"},"71521":{"type":"graphic_figure","displayName":"Vaginal hysterectomy PI","title":"Vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:544px; height:423px;\" src=\"images/PI/71521_Vaginal_hysterectomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a vaginal hysterectomy, the uterus and cervix are removed through the vagina. The top of the vagina is then sewn together. There are no visible scars. The ovaries and fallopian tubes may also be removed (called &quot;salpingo-oophorectomy&quot;) at the same time, or may be left in place.</div><div id=\"graphicVersion\">Graphic 71521 Version 4.0</div></div></div>"},"71522":{"type":"graphic_diagnosticimage","displayName":"Lateral skull of elderly woman with Paget disease","title":"Lateral skull of an elderly woman with Paget disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral skull of an elderly woman with Paget disease</div><div class=\"cntnt\"><img style=\"width:405px; height:490px;\" src=\"images/RHEUM/71522_Lat_skull_eld_wom_Paget_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral skull of an&nbsp;older adult&nbsp;woman with Paget disease. Note the thickened table of the skull, the areas of lytic mixed with sclerotic bone, and the appearance of \"cotton wool spots\" or circular densities of sclerotic bone so characteristic of Paget disease.</div><div class=\"graphic_reference\">Courtesy of Margaret Seton, MD.</div><div id=\"graphicVersion\">Graphic 71522 Version 3.0</div></div></div>"},"71525":{"type":"graphic_table","displayName":"Classification of VWD","title":"Classification of von Willebrand disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of von Willebrand disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory findings</td> <td class=\"subtitle1\">Comments on treatment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Type 1 (partial quantitative deficiency)</strong></td> <td> <ul> <li>Accounts for approximately three-fourths of patients with VWD </li> <li>Variable bleeding severity from mild to severe </li> <li>AD inheritance </li> </ul> </td> <td> <ul> <li>VWF activity and RIPA decreased </li> <li>RIPA may be normal in mild disease </li> <li>Multimer electrophoresis: All multimers present and uniformly decreased </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"4\"><strong>Type 2 (qualitative variant)</strong></td> </tr> <tr> <td class=\"indent1\">Type 2A</td> <td> <ul> <li>Accounts for approximately one-tenth to one-fifth of patients with VWD </li> <li>Moderate to severe bleeding </li> <li>AD or AR inheritance </li> </ul> </td> <td> <ul> <li>VWF activity and RIPA decreased </li> <li>Factor VIII levels may be normal or reduced </li> <li>Multimer electrophoresis: Decreased large multimers </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Type 2B</td> <td> <ul> <li>Accounts for approximately 5% of patients with VWD </li> <li>Moderate to severe bleeding </li> <li>Thrombocytopenia or giant platelets may be seen </li> <li>AD inheritance </li> </ul> </td> <td> <ul> <li>VWF activity decreased </li> <li>RIPA increased </li> <li>Factor VIII levels may be normal or reduced </li> <li>Thrombocytopenia/giant platelets </li> <li>Multimer electrophoresis: Decreased large multimers </li> </ul> </td> <td>DDAVP may be used to treat minor bleeding if a trial of DDAVP performed when the patient is not bleeding has demonstrated that the platelet count drop is temporary.</td> </tr> <tr> <td class=\"indent1\">Type 2M</td> <td> <ul> <li>Uncommon </li> <li>Moderate to severe bleeding </li> <li>AD or AR inheritance </li> </ul> </td> <td> <ul> <li>VWF activity and RIPA decreased </li> <li>Factor VIII levels may be normal or decreased </li> <li>Multimer electrophoresis: All multimers present and uniformly decreased </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Type 2N</td> <td> <ul> <li>Uncommon </li> <li>Clinically similar to hemophilia A with joint, soft tissue, urinary bleeding </li> <li>AR inheritance </li> </ul> </td> <td> <ul> <li>VWF activity and RIPA normal </li> <li>Factor VIII levels low (5 to 15%) </li> <li>Multimer electrophoresis: Normal </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td><strong>Type 3 (severe)</strong></td> <td> <ul> <li>Rare </li> <li>Clinically similar to hemophilia A with joint and soft tissue bleeding </li> <li>Severe mucosal bleeding </li> <li>AR inheritance </li> </ul> </td> <td> <ul> <li>VWF activity and RIPA absent or markedly decreased </li> <li>Factor VIII levels low (1 to 10%) </li> <li>Multimer electrophoresis: Undetectable or too faint to visualize </li> </ul> </td> <td>Do not use DDAVP to treat bleeding (will not be effective).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for additional details of the classification, presentation, diagnosis, and management of VWD.</div><div class=\"graphic_footnotes\">VWD: von Willebrand disease; VWF: von Willebrand factor; RIPA: ristocetin-induced platelet aggregation; AD: autosomal dominant; AR: autosomal recessive.</div><div class=\"graphic_reference\">Adapted from: The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.</div><div id=\"graphicVersion\">Graphic 71525 Version 6.0</div></div></div>"},"71527":{"type":"graphic_table","displayName":"Aerosol device comparison","title":"Advantages and disadvantages of various aerosol devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of various aerosol devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Jet nebulizer*</td> <td> <ul> <li>Patient coordination not required </li> <li>High doses possible </li> </ul> </td> <td> <ul> <li>May be more expensive than pressurized metered dose inhaler (pMDI) </li> <li>More time required </li> <li>Contamination possible </li> <li>Device preparation required before treatment </li> <li>Not all medications available </li> <li>Less efficient than other devices (dead volume loss) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Mesh nebulizer<br /> (eg, Aeroneb, eFlow, Omron MicroAir, I-neb)</td> <td> <ul> <li>Patient coordination not required </li> <li>High doses possible </li> <li>Quiet </li> <li>Faster delivery than jet nebulizer </li> <li>Portable, battery operated </li> </ul> </td> <td> <ul> <li>Expensive </li> <li>Contamination possible </li> <li>Device preparation required before treatment </li> <li>Cleaning required after dose </li> <li>Not all medications available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ultrasonic nebulizer<br /> (eg, OPTI-NEB, Beetle Neb, Lumiscope, MiniBreeze)</td> <td> <ul> <li>Patient coordination not required </li> <li>High doses possible </li> <li>Small dead volume </li> <li>Quiet </li> <li>No drug loss during exhalation </li> <li>Faster delivery than jet nebulizer </li> </ul> </td> <td> <ul> <li>Expensive </li> <li>Contamination possible </li> <li>Prone to malfunction </li> <li>Device preparation required before treatment </li> <li>Cannot use with medications in suspension (eg, budesonide) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Pressurized metered dose inhaler (pMDI)</td> <td> <ul> <li>Convenient </li> <li>May be less expensive than nebulizer </li> <li>Portable </li> <li>More efficient than nebulizer </li> <li>No drug preparation required </li> <li>Difficult to contaminate </li> <li>Dose counter with some devices </li> </ul> </td> <td> <ul> <li>Patient coordination essential </li> <li>Patient actuation required </li> <li>Large pharyngeal deposition </li> <li>Difficult to deliver high doses </li> <li>Not all medications available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>pMDI with holding chamber</td> <td> <ul> <li>Less patient coordination required </li> <li>Less pharyngeal deposition </li> </ul> </td> <td> <ul> <li>More expensive than pMDI alone </li> <li>Less portable than pMDI alone </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dry powder inhaler (DPI)</td> <td> <ul> <li>Less patient coordination required </li> <li>Convenient </li> <li>Propellant not required </li> <li>Portable </li> <li>Breath-actuated </li> <li>Dose counter </li> </ul> </td> <td> <ul> <li>Requires moderate to high inspiratory flow </li> <li>Some units are single dose and need daily loading&nbsp;</li> <li>Can result in high pharyngeal deposition </li> <li>Not all medications available </li> <li>Cannot be used effectively in mechanically-ventilated patients </li> </ul> </td> </tr> <tr> <td>Soft mist inhaler (SMI)</td> <td> <ul> <li>Higher lung deposition than pMDIs or jet nebulizers </li> <li>Less pharyngeal deposition than pMDIs </li> <li>Longer duration of spray </li> <li>Low risk of contamination </li> <li>Propellant not required </li> <li>Dose counter </li> </ul> </td> <td> <ul> <li>Requires actuation by patient </li> <li>Needs coordination between breathing and actuation<sup>&#182;</sup> </li> <li>Requires loading of cartridge into inhaler before first use </li> <li>Not all medications available </li> <li>Cannot be used effectively in mechanically-ventilated patients </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Many brands are commercially available in both disposable and nondisposable designs for use in the hospital and at home.<br />¶ The relatively slower moving and longer duration spray from a SMI makes it easier for a patient to coordinate breathing and actuation compared to a pMDI.</div><div class=\"graphic_reference\">Adapted from: Consensus Statement: Aerosols and Delivery Devices. Respir Care 2000; 45:589.</div><div id=\"graphicVersion\">Graphic 71527 Version 13.0</div></div></div>"},"71529":{"type":"graphic_figure","displayName":"Ventricular pacemaker tracing","title":"Cannon 'a' waves caused by ventricular pacing","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Cannon 'a' waves caused by ventricular pacing</div><div class=\"cntnt\"><img style=\"width:471px; height:269px;\" src=\"images/PULM/71529_Ventricular_pacemaker_traci.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous electrocardiographic and right atrial pressure tracings from a patient with a ventricular pacemaker. Arrows indicate underlying atrial activity. Occasional normal a and v waves are interspersed with cannon 'a' waves (ca). Cannon 'a' waves result from atrial contraction against a closed valve, and are a sign of atrioventricular dissociation.</div><div class=\"graphic_reference\">Redrawn from Schriner, DK, Crit Care Nurs Clin N America 1989; 1:563.</div><div id=\"graphicVersion\">Graphic 71529 Version 1.0</div></div></div>"},"71530":{"type":"graphic_figure","displayName":"mAb production using hybridoma technology","title":"Method of monoclonal antibody production using hybridoma technology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Method of monoclonal antibody production using hybridoma technology</div><div class=\"cntnt\"><img style=\"width:422px; height:396px;\" src=\"images/RHEUM/71530_Monoclonalantibodygenerat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this method, an animal is immunized with a protein (or antigen)&nbsp;of interest. Spleen or lymph node cells are harvested and fused with a nonsecreting myeloma cell to create a hybridoma. Successfully fused cells can be selected in specialized media that only allows the hybridomas to survive. The candidate hybridomas are grown in culture, and the&nbsp;culture supernatants are screened for antibodies that bind to the target antigen. Cells are cloned by limiting dilution to yield a homogenous population. Refer to UpToDate for details of this method and for other methods of producing therapeutic monoclonal antibodies.</div><div id=\"graphicVersion\">Graphic 71530 Version 3.0</div></div></div>"},"71531":{"type":"graphic_picture","displayName":"Eruptive syringoma - neck","title":"Eruptive syringoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eruptive syringoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/71531_Eruptive_syringoma_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple flesh-colored and erythematous small papules are present on the neck and chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71531 Version 3.0</div></div></div>"},"71532":{"type":"graphic_figure","displayName":"Pylephlebitis liver abscess","title":"Pyelphlebitis and liver abscess","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Pyelphlebitis and liver abscess</div><div class=\"cntnt\"><img style=\"width:501px; height:618px;\" src=\"images/ID/71532_Pylephlebitis_liver_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diverticulitis in the sigmoid colon can result in bacterial leakage into the portal venous system. Bacteroides species, particularly B. fragilis, have unique virulence factors that contribute to thrombosis.</div><div id=\"graphicVersion\">Graphic 71532 Version 2.0</div></div></div>"},"71534":{"type":"graphic_diagnosticimage","displayName":"Contrast enhancement CW Doppler","title":"Contrast enhancement of continuous wave Doppler tricuspid regurgitation signal","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Contrast enhancement of continuous wave Doppler tricuspid regurgitation signal</div><div class=\"cntnt\"><img style=\"width:490px; height:168px;\" src=\"images/CARD/71534_Contrast_enhancement_CW_Dop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Before enhancement the continuous wave Doppler signals are weak and complete and only a few of the signals are measurable. After enhancement with intravenous agitated saline, the signals, obtained during exercise, are clear enough to measure.</div><div id=\"graphicVersion\">Graphic 71534 Version 2.0</div></div></div>"},"71535":{"type":"graphic_table","displayName":"Comprehensive geriatric assessm","title":"Comprehensive geriatric assessment (CGA) and its implications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comprehensive geriatric assessment (CGA) and its implications</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Functional status</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Activities of daily (ADL) and instrumental activities of daily living (IADL)</td>\n\n      <td>Relation to life expectancy, functional dependence and tolerance of stress</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Comorbidity</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Number of comorbid conditions and comorbidity indices</td>\n\n      <td>Relation to life expectancy and tolerance of stress</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Mental status</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Folstein Minimental status</td>\n\n      <td>Relation to life expectancy and dependency</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Emotional conditions</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Geriatric Depression Scale (GDS)</td>\n\n      <td>Relation to survival; may indicate motivation to receive treatment</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Nutritional status</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Mininutritional assessment (MNA)</td>\n\n      <td>Reversible condition; possible relationship to survival</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"1\">Polypharmacy</td><td>Risk of drug interactions</td>\n\n\n    </tr>\n\n    \n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Geriatric syndromes</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Delirium, dementia, depression, falls, incontinence, spontaneous bone fractures. Neglect and abuse, failure to thrive.</td>\n\n      <td>Relationship to survival</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Functional dependence</td>\n\n    </tr>\n\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003; 46:212. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 71535 Version 2.0</div></div></div>"},"71537":{"type":"graphic_picture","displayName":"Sunburn back PI","title":"Sunburn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sunburn</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PI/71537_Sunburn_back_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person has a sunburn on the back. The skin that was not covered by clothes has turned red.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71537 Version 4.0</div></div></div>"},"71539":{"type":"graphic_figure","displayName":"Peritoneal dialysis PI","title":"Peritoneal dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peritoneal dialysis</div><div class=\"cntnt\"><img style=\"width:432px; height:354px;\" src=\"images/PI/71539_Peritoneal_dialysis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a person having peritoneal dialysis. The dialysis fluid (fresh dialysis solution) flows into the person's belly. It stays there for a certain amount of time, and then it drains out into the drain bag. The &quot;transfer set&quot; is the tubing that connects a thin tube (catheter) in the person's belly to the dialysis equipment.</div><div class=\"graphic_reference\">Reproduced from: Treatment Methods for Kidney Failure: Peritoneal Dialysis. National Institute of Diabetes and Digestive and Kidney Diseases. Available at: <A spellcheck=true href=\"http://www.niddk.nih.gov/health-information/health-topics/kidney-disease/treatment-methods-for-kidney-failure-peritoneal-dialysis/Pages/facts.aspx\"target=_blank>http://www.niddk.nih.gov/health-information/health-topics/kidney-disease/treatment-methods-for-kidney-failure-peritoneal-dialysis/Pages/facts.aspx</A> (Accessed on May 11, 2016).</div><div id=\"graphicVersion\">Graphic 71539 Version 4.0</div></div></div>"},"71540":{"type":"graphic_table","displayName":"Causes of congenital goiter","title":"Causes of congenital goiter","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of congenital goiter</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Inborn errors of thyroid hormone production</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Dyshormonogenesis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Transplacental passage of maternal antibodies</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>TSH-receptor blocking antibodies </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>TSH-receptor stimulating antibodies </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Maternal ingestion of antithyroid drugs and other goitrogens</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Propylthiouracil </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Methimazole or carbamazole </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Iodine and iodine-containing drugs </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Activating mutations of the TSH receptor</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Congenital nonimmune hyperthyroidism </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Activating mutations of the G protein alpha subunit</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>McCune-Albright syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Thyroid hemiagenesis</td> </tr> <tr> <td><strong>Thyroid tumors</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71540 Version 2.0</div></div></div>"},"71543":{"type":"graphic_diagnosticimage","displayName":"Crohns UGI children","title":"Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/PEDS/71543_Crohns_UGI_children.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium radiograph demonstrating Crohn disease. Note cobblestoning of the terminal ileum (arrow), narrow cecum, and separation of bowel loops. Cobblestoning should be distinguished from lymphonodularity of the terminal ileum, which is a normal finding in young children.</div><div class=\"graphic_reference\">Courtesy of Carlo Buonomo, MD.</div><div id=\"graphicVersion\">Graphic 71543 Version 4.0</div></div></div>"},"71545":{"type":"graphic_picture","displayName":"Erythrasma biopsy","title":"Erythrasma biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrasma biopsy</div><div class=\"cntnt\"><img style=\"width:396px; height:285px;\" src=\"images/PC/71545_Erythrasma_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stained slide of erythrasma. Bacteria are visible in the superficial levels of the epidermis. Special stains are often required to appreciate the bacteria in pathology sections.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. James E. Fitzpatrick.</div><div id=\"graphicVersion\">Graphic 71545 Version 1.0</div></div></div>"},"71546":{"type":"graphic_diagnosticimage","displayName":"Aneurysm and pseudoaneurysm of the left ventricular apex","title":"Aneurysm and pseudoaneurysm of the left ventricular apex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aneurysm and pseudoaneurysm of the left ventricular apex</div><div class=\"cntnt\"><img style=\"width:356px; height:288px;\" src=\"images/CARD/71546_LV_aneurysm_pseudoaneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four-chamber view in panel A shows an aneurysm (AN) of the left ventricular (LV) apex; the LV does not narrow at the opening to the aneurysm. Panel B shows a pseudoaneurysm (PAN) identified by its connection to the LV across a narrow neck (n).</div><div class=\"graphic_footnotes\">LA: left atrium.</div><div id=\"graphicVersion\">Graphic 71546 Version 5.0</div></div></div>"},"71548":{"type":"graphic_table","displayName":"Oral antibiotics for suspected cholera","title":"Oral antibiotics for suspected cholera","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antibiotics for suspected cholera</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Typical pediatric dose*</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Comment(s)</td> </tr> <tr> <td rowspan=\"2\"><strong>Tetracyclines</strong></td> <td>Doxycycline</td> <td>4-6 mg/kg (single dose)</td> <td>300 mg (single dose)</td> <td rowspan=\"2\">Antibiotic resistance to all tetracyclines is common<sup>[1]</sup>. Empiric use is appropriate in epidemics caused by documented susceptible isolates. Not recommended for pregnant women and children less than 8 years.</td> </tr> <tr> <td>Tetracycline</td> <td>50 mg/kg/day in four equally divided doses, for three days</td> <td>500 mg four times per day for three days</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Macrolides</strong></td> <td>Azithromycin</td> <td>20 mg/kg (single dose)</td> <td>1 g (single dose)</td> <td rowspan=\"2\">Single dose azithromycin is preferred therapy<sup>[2]</sup>. Rare reports of macrolide resistance.</td> </tr> <tr> <td>Erythromycin</td> <td>40 mg/kg/day in four equally divided doses, for three days</td> <td>500 mg four times per day for three days</td> </tr> <tr class=\"divider_top\"> <td><strong>Fluoroquinolones</strong></td> <td>Ciprofloxacin</td> <td>20 mg/kg (single dose)</td> <td>1 g (single dose)</td> <td>Reduced susceptibility to fluoroquinolones has been reported in Asia and Africa<sup>[2,3]</sup>. Not recommended for pregnant women and children less than 8 years.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not to exceed maximum dose.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Yamamoto T, Nair GB, Albert MJ, et al. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother 1995; 39:241. </li> <li>Saha D, Karim MM, Khan WA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006; 354:2452. </li> <li>Islam MS, Midzi SM, Charimari L, et al. Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA 2009; 302:2321. </li> </ol></div><div id=\"graphicVersion\">Graphic 71548 Version 4.0</div></div></div>"},"71549":{"type":"graphic_picture","displayName":"Primary site lesions","title":"Child, marshfield index case","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Child, marshfield index case</div><div class=\"cntnt\"><img style=\"width:468px; height:330px;\" src=\"images/ID/71549_Primary_site_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary inoculation site right index finger, 5/27/03. 14 days after prairie dog bites, 11 days after febrile illness, hospital day 5.</div><div class=\"graphic_reference\">Reproduced with permission from: Marshfield Clinic. Copyright &#169; 2005 Marshfield Clinic.</div><div id=\"graphicVersion\">Graphic 71549 Version 2.0</div></div></div>"},"71550":{"type":"graphic_movie","displayName":"Left atrial myxoma five chamber echocardiogram 2","title":"Left atrial myxoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71550_5chlamy2conv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:236px; height:372px;\" src=\"images/CARD/71550_5chlamy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The five-chamber view from a 2-D echocardiogram shows a very large atrial myxoma which adheres to the interatrial septum by a broad stalk and extends into the left ventricle during diastole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 71550 Version 3.0</div></div></div>"},"71551":{"type":"graphic_diagnosticimage","displayName":"Coronary artery fistula occluder","title":"Coronary artery fistula occluder","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Coronary artery fistula occluder</div><div class=\"cntnt\"><img style=\"width:526px; height:204px;\" src=\"images/CARD/71551_Cor_artery_fistula_occluder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selective left coronary artery angiogram shows a dilated left circumflex coronary artery (LCx) with a fistula (arrow) to the right atrium (RA). Panel B shows a selective LCx coronary angiogram via a sheath (arrow) introduced from the inferior vena cava to the LCX through the fistula. Note the patency of the last viable myocardial branch of the LCX (arrowhead). Panel C shows a selective left coronary artery angiogram after the placement of an occlusion device (arrow); there is no residual shunting to the RA through the device. Note that the last viable myocardial branch remains patent (dashed arrow) and that there is enhanced blood flow to the other coronary artery branches after elimination of the steal (arrowhead).</div><div id=\"graphicVersion\">Graphic 71551 Version 4.0</div></div></div>"},"71552":{"type":"graphic_table","displayName":"Maternal serum marker pattern in selected fetal syndromes","title":"Maternal serum marker pattern in selected fetal syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal serum marker pattern in selected fetal syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Genetic disorder</td> <td class=\"subtitle1\" colspan=\"4\">Second-trimester markers</td> <td class=\"subtitle1\" colspan=\"3\">First-trimester markers</td> </tr> <tr> <td class=\"subtitle2\">AFP</td> <td class=\"subtitle2\">uE3</td> <td class=\"subtitle2\">hCG/free beta</td> <td class=\"subtitle2\">Inhibin A</td> <td class=\"subtitle2\">NT</td> <td class=\"subtitle2\">PAPP-A</td> <td class=\"subtitle2\">hCG/free beta</td> </tr> <tr class=\"divider_bottom\"> <td>Down syndrome</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> </tr> <tr class=\"divider_bottom\"> <td>Trisomy 18</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> </tr> <tr class=\"divider_bottom\"> <td>Trisomy 13</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> </tr> <tr class=\"divider_bottom\"> <td>45X, with hydrops</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8595;</span></td> </tr> <tr class=\"divider_bottom\"> <td>45X, without hydrops</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8595;</span></td> </tr> <tr class=\"divider_bottom\"> <td>Triploidy (paternal)</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8593;</span></td> </tr> <tr class=\"divider_bottom\"> <td>Triploidy (maternal)</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8593;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> </tr> <tr class=\"divider_bottom\"> <td>Smith-Lemli-Opitz syndrome</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;&#8595;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8595;</span></td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> </tr> <tr> <td>Sex chromosome aneuploidy</td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> <td class=\"centered\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&#8596;</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&uarr;</span>: increased; <span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&darr;</span>: decreased; <span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&harr;</span>: unchanged; <span style=\"font-size: 1.4em; font-family: Cambria, 'Hoefler Text', 'Liberation Serif', Times, 'Times New Roman', 'serif'; vertical-align: middle;\">&uarr;&darr;</span>: variable; NR: not reported; AFP: alpha-fetoprotein; uE3: unconjugated estriol; hCG: human chorionic gonadotropin; NT: nuchal translucency; PAPP-A: pregnancy-associate plasma protein A.</div><div id=\"graphicVersion\">Graphic 71552 Version 6.0</div></div></div>"},"71553":{"type":"graphic_picture","displayName":"Cribriform ductal carcinoma in situ","title":"Cribriform ductal carcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cribriform ductal carcinoma in situ</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ONC/71553_Cribriform_ductal_CIS_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a lesion from the breast of a woman with cribriform ductal carcinoma in situ shows a back to back glandular growth pattern. The nuclei are well differentiated (low grade). A small calcification is noted near the center of the involved space (arrow).</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 71553 Version 3.0</div></div></div>"},"71554":{"type":"graphic_table","displayName":"Euthanasia PAS Netherlands","title":"Euthanasia and PAS practices in the Netherlands","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Euthanasia and PAS practices in the Netherlands</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">1991</td> <td class=\"subtitle1\">1995</td> <td class=\"subtitle1\">2001</td> <td class=\"subtitle1\">2005</td> <td class=\"subtitle1\">2010</td> <td class=\"subtitle1\">2015&nbsp;</td> </tr> <tr> <td>Number of deaths</td> <td>128,824</td> <td>135,675</td> <td>140,377</td> <td>136,402</td> <td>136,056</td> <td>147,134</td> </tr> <tr> <td>Estimated percent&nbsp;of deaths preceded by an&nbsp;explicit request for euthanasia or PAS</td> <td>6.9</td> <td>7.1</td> <td>6.9</td> <td>4.8</td> <td>6.5</td> <td>8.4</td> </tr> <tr> <td>Percent of deaths by euthanasia</td> <td>1.7</td> <td>2.4</td> <td>2.6</td> <td>1.7</td> <td>2.8</td> <td>4.5</td> </tr> <tr> <td>Percent of deaths by PAS</td> <td>0.2</td> <td>0.2</td> <td>0.2</td> <td>0.1</td> <td>0.1</td> <td>0.1</td> </tr> <tr> <td>Percent of&nbsp;cases in which ending of life was without request (not necessarily without consent)&nbsp;</td> <td>0.8</td> <td>0.7</td> <td>0.7</td> <td>0.4</td> <td>0.2</td> <td>0.3</td> </tr> <tr> <td>Overall percent of deaths with explicit intention of hastening death</td> <td>2.7</td> <td>3.3</td> <td>3.5</td> <td>2.2</td> <td>3.1</td> <td>4.9</td> </tr> <tr> <td>Percent of physicians who performed PAS or euthanasia</td> <td>54</td> <td>53</td> <td>57</td> <td>N/R</td> <td>N/R</td> <td>57</td> </tr> <tr> <td>Percent of physicians who performed PAS or euthanasia in last year</td> <td>24</td> <td>29</td> <td>30</td> <td>N/R</td> <td>N/R</td> <td>31</td> </tr> <tr> <td>Percent of all cancer deaths by euthanasia or PAS</td> <td>6.1</td> <td>8.0</td> <td>8.4</td> <td>N/R</td> <td>5.1</td> <td>10.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PAS: physician-assisted suicide; N/R: not reported.</div><div class=\"graphic_reference\">Data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Onwuteaka-Philipsen BD, van der Heide A, Koper D,&nbsp;et al. Euthanasia and other end-of-life decisions in the Netherlands in 1990, 1995, and 2001. Lancet 2003; 362:395.</LI>&#xD;&#xA;<LI>van der Heide A, Onwuteaka-Philipsen BD, Rurup ML, et al. End-of-life practices in the Netherlands under the Euthanasia Act. N Engl J Med 2007; 356:1957.</LI>&#xD;&#xA;<LI>Onwuteaka-Philipsen BD, Brinkman-Stoppelenburg A, Penning C, et al. Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey.&nbsp;Lancet 2012; 380:908.</LI>&#xD;&#xA;<LI>van der Heide A, van Delden JJM, Onwuteaka-Philipsen BD. End of life decisions in the Netherlands over 25 years. N Engl J Med 2017; 377:494.</LI></OL></div><div id=\"graphicVersion\">Graphic 71554 Version 10.0</div></div></div>"},"71557":{"type":"graphic_table","displayName":"Food allergy camp","title":"Guidelines for managing food allergies at camp","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for managing food allergies at camp</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Food allergies can be life-threatening. In any camp setting: day camps, residential camps, sports camps, or travel camps the risk of accidental exposure to a food allergen is present. Camp staff, physicians, parents, and campers themselves must work together to minimize the risk. There must also be medications and procedures in place to deal with accidental ingestion or contact.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Family responsibility</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Choose an appropriate camp for the child. Find out the following:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Who is the primary healthcare person and what are their credentials?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Who is responsible for their duties in this person's absence?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">How does camp communicate and monitor food allergy information? Is this sufficient for your child?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">How far is the camp from definitive care?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">What trips might the camper take that change the response time? Are you ok with this?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Notify the camp of the camper's allergies or suspected allergies.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Use the camp application and/or health form to fully describe the allergy. If necessary, attach a detailed explanation of the type of symptoms. List foods to which the camper is allergic, and the specific symptoms he or she typically experiences during an allergic reaction.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Inform the camp director of the allergy early in the process so that appropriate personnel can be hired or instructed on proper approach to the camper with food allergy.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Make personal contact with the director, counselor, or the division supervisor before the camper's arrival at the facility.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Make certain that the camp director notifies all affected personnel. Pool life guards, transportation drivers, dining hall/cafeteria workers, camp nurses, counselors, specialty area workers, and anyone else who may offer food or plan parties or events all need to be informed of the allergy. Additionally, many camps use volunteers who may only come to camp one or two days during the week. These individuals will also need to understand the camp's food allergy policy.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Provide the camp with a recent photo of the child, attached to written instructions, medical documentation, and medications as prescribed by the physician for handling accidental contact.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\"><em>Do not simply transfer school documentation.</em></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">The specific camp personnel need to be authorized and instructed on how to proceed.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">The camp may have an Allergy Action Plan, OR use the Food Allergy Action Plan from the Food Allergy &amp; Anaphylaxis Network.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Check the expiration date of all medications.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td  class=\"indent1\">Be prepared to replace any expired or unsealed, previously used medication. Review with camp director and nurse the location and storage of medications. Given the remote location of many camps, provide two (2) epinephrine auto-injectors (such as EpiPen&#174;) if prescribed.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Educate and review often with the camper the self management of his or her food allergy.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Camper should know:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Safe and unsafe foods;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Strategies for avoiding exposure to unsafe foods;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Symptoms of allergic reactions;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">How and when to tell an adult about a possible allergic response;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">How to read a food label, especially those at the camp candy store, if age appropriate. For young campers, plan with camp how to handle this.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">How to use an epinephrine auto-injector (such as EpiPen&#174;).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Camper responsibility</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Camper should:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">NEVER trade food with other campers.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Not eat anything with unknown ingredients.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Read every label and check with a counselor (if age appropriate).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Be proactive in the management of mild reactions, such as seeking help if a reaction is suspected</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Tell an adult if a reaction seems to be starting, even if there is no visible appearance of allergic response.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">NOT go off alone if symptoms are beginning.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Camp responsibility</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Be informed of the availability of emergency care.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Know: How to contact EMT/ambulance</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">How much time is needed for an emergency crew to arrive</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">How far it is to the nearest hospital</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">If the hospital has an M.D. present at all times</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Camps located in non-urban settings must understand that rural ambulance and emergency crews may be volunteers. Therefore, additional plans and additional medications may be required.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">On trips away from the campsite, a communication device (ie, cell phone, 2-way radio) should be carried.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Review the health records submitted by parents and physicians.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Establish prevention protocols for your camp.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Make plans so that the camper with food allergies may be safely included in all activities.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Be certain that all food service or kitchen personnel are aware of, and can identify the child with food allergies.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Discuss meal plans with parents/camper and alternative plans if necessary.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Plan how a camper with food allergies will participate in meals. A camper with food allergies should go first in a buffet line to avoid cross-contact or may need a place to sit apart in a special allergen-free space.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Assure that all who will be in contact with camper know of the allergy and can recognize the symptoms of allergic response.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Maintain an appropriate sense of confidentiality and respect for individual privacy.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Identify the camp core emergency response team. This should include, but not be limited to appropriate staff.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Arrange to have this team meet with parents and camper prior to the opening activity, on or before the first day of camper's participation.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Assure that the nurse has the required authorizations and appropriate medications to use in the event of inadvertent contact.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Assure that appropriate personnel are familiar with EpiPen&#174; usage, where medication is located, and protocol.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Arrange a training session before the start of camp. Allow participants to become familiar with the usage of epinephrine auto-injectors.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">If there are planned field trips or out of camp activities:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Be certain any emergency medications and authorizations accompany the camper and the counselor.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Be certain there is a way to contact emergency assistance.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Enforce a \"no eating\" policy in the vehicle.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Medications must be stored in the correct temperature range. Be certain travel personnel understand the importance of this. Many medications are rendered ineffective if left in the sunshine or inside a closed vehicle, or refrigerated. Refer to the manufacturer's instructions for proper storage.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Food Allergy &amp; Anaphylaxis Network can be contacted at: (800) 929-4040, www.foodallergy.org</td>\n\t\t\t\t</tr>\n\t\t\t\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">1.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">10/18/2006  perm requested afurlong@foodallergymail.org\r\n10/19/2006 granted</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=631&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Food_allergy_camp.htm</title></head></div><div class=\"graphic_reference\">These guidelines were developed with input from the following: Helen Rebull, R.N., Virginia Congressional Schools; Cassie Piper, Director of the Early Childhood Program, Virginia Congressional Schools; Greg Cronin, Camp Director; Association of Camp Nurses; The Food Allergy &amp; Anaphylaxis Network.<br>Reproduced with permission from the Food Allergy and Anaphylaxis Network. Copyright © Food Allergy and Anaphylaxis Network.</div><div id=\"graphicVersion\">Graphic 71557 Version 1.0</div></div></div>"},"71558":{"type":"graphic_figure","displayName":"Normal adrenal steroidogenesis","title":"Normal adrenal steroidogenesis","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Normal adrenal steroidogenesis</div><div class=\"cntnt\"><img style=\"width:601px; height:383px;\" src=\"images/ENDO/71558_Norm_adren_steroid_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACTH: corticotropin.</div><div id=\"graphicVersion\">Graphic 71558 Version 4.0</div></div></div>"},"71563":{"type":"graphic_diagnosticimage","displayName":"Plain xray solitary bone met","title":"Solitary bone metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solitary bone metastasis</div><div class=\"cntnt\"><img style=\"width:287px; height:357px;\" src=\"images/ONC/71563_Plain_xray_solitary_bone_me.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metastatic lesions are usually but not always multiple. In this case, a solitary metastasis from a renal cell carcinoma presented following a pathological fracture.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 71563 Version 2.0</div></div></div>"},"71564":{"type":"graphic_picture","displayName":"Severe varicose veins PI","title":"Severe varicose veins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe varicose veins</div><div class=\"cntnt\"><img style=\"width:216px; height:294px;\" src=\"images/PI/71564_Severe_varicose_veins_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a picture of varicose veins, which are swollen and twisted veins in the legs.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 71564 Version 2.0</div></div></div>"},"71565":{"type":"graphic_diagnosticimage","displayName":"Chondromyxoid fibroma tibia","title":"Chondromyxoid fibroma of the proximal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondromyxoid fibroma of the proximal tibia</div><div class=\"cntnt\"><img style=\"width:420px; height:540px;\" src=\"images/PEDS/71565_Chondromyxoid_fibroma_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the eccentric, metaphyseal, geographic lesion in the proximal third of the tibia. Endosteal scalloping (arrows), along with bone expansion, is noted (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71565 Version 3.0</div></div></div>"},"71566":{"type":"graphic_waveform","displayName":"Loss of capture BiV pacing","title":"Loss of LV capture with BiV pacing","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Loss of LV capture with BiV pacing</div><div class=\"cntnt\"><img style=\"width:468px; height:162px;\" src=\"images/CARD/71566_Loss_of_capture_BiV_pacing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top line of this tracing shows one lead from the surface electrocardiogram (ECG). The middle portion of the tracing shows the pacemaker event markers obtained by telemetry. The bottom line of the tracing shows the intracardiac electrogram. The arrow above the tracing indicates the time point at which capture of the left ventricle (LV) by the biventricular (BiV) pacemaker is lost. The changes with loss of capture are subtle in the surface ECG tracing. The event markers and the intracardiac electrogram document the loss of capture.</div><div id=\"graphicVersion\">Graphic 71566 Version 2.0</div></div></div>"},"71567":{"type":"graphic_diagnosticimage","displayName":"Acute eosinophilic pneumonia CT","title":"Acute eosinophilic pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute eosinophilic pneumonia</div><div class=\"cntnt\"><img style=\"width:305px; height:227px;\" src=\"images/PULM/71567_Acute_eosinophilic_pneumoni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT scan of a patient with idiopathic acute eosinophilic pneumonia demonstrating bilateral patchy ground-glass opacities.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 71567 Version 3.0</div></div></div>"},"71570":{"type":"graphic_figure","displayName":"High- and low-flux HEMO","title":"Survival curves for high and low flux","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival curves for high and low flux</div><div class=\"cntnt\"><img style=\"width:395px; height:271px;\" src=\"images/NEPH/71570_HighandlowfluxHEMO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graph showing that mortality in the high- and low-flux dialysis membrane groups were the same in the HEMO study. There was a nonsignificant 8% lower mortality in the high-flow group compared with the low-flux group.</div><div class=\"graphic_footnotes\">HEMO: Hemodialysis study.</div><div class=\"graphic_reference\">Redrawn from Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.</div><div id=\"graphicVersion\">Graphic 71570 Version 3.0</div></div></div>"},"71574":{"type":"graphic_figure","displayName":"Lung transplant procedures","title":"Number of lung transplant procedures reported by year and procedure type","html":"<div class=\"graphic\"><div style=\"width: 864px\" class=\"figure\"><div class=\"ttl\">Number of lung transplant procedures reported by year and procedure type</div><div class=\"cntnt\"><img style=\"width:844px; height:472px;\" src=\"images/PULM/71574_Lung_transplnt_procdrs_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: This figure includes both transplants reported to the International Society for Heart and Lung Transplantation (ISHLT) Registry from organ-exchange organizations in countries with a data-sharing agreement, as well as transplants reported voluntarily from centers in countries without a specific data-sharing agreement. Therefore, this figure may not fully represent the total number of procedures worldwide or the trend in activity.</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1264. Illustration used with the permission of Elsevier Inc. All rights reserved. For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" at: <a href=\"https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\" target=\"_blank\">https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry</a>.</div><div id=\"graphicVersion\">Graphic 71574 Version 3.0</div></div></div>"},"71575":{"type":"graphic_figure","displayName":"Atlanto axial dislocation","title":"Atlanto-axial dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atlanto-axial dislocation</div><div class=\"cntnt\"><img style=\"width:371px; height:441px;\" src=\"images/EM/71575_Atlanto_axial_disloc.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71575 Version 4.0</div></div></div>"},"71576":{"type":"graphic_table","displayName":"Pathogenesis diabetic neuropathy","title":"Potential mechanisms linking metabolic, vascular, and neural defects in diabetic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential mechanisms linking metabolic, vascular, and neural defects in diabetic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Initiator</td> <td class=\"subtitle1\">Metabolic defect</td> <td class=\"subtitle1\">Metabolic mediator</td> <td class=\"subtitle1\">Functional mediator</td> <td class=\"subtitle1\">Consequence</td> </tr> <tr> <td rowspan=\"12\">&#8593; Glucose</td> <td rowspan=\"5\">Glycation/AGE</td> <td>Protein cross-linking</td> <td>Matrix defects</td> <td> <p>Endoneurial fibrosis</p> &#8595; Neurotrophic SAM</td> </tr> <tr> <td>Protein inactivation</td> <td>Receptor-ligand defects</td> <td>&#8595; Neurotrophism</td> </tr> <tr> <td>NO quenching</td> <td>Vasoconstriction</td> <td>Ischemia/hypoxia</td> </tr> <tr> <td>Macrophage activation</td> <td>Cytokines, &#8593; TGF</td> <td> <p>Cytotoxicity*</p> Endoneurial fibrosis</td> </tr> <tr> <td>Free radical formation</td> <td>Oxidative stress</td> <td>Cytotoxicity</td> </tr> <tr> <td>Autooxidation</td> <td>Free radical formation</td> <td>Oxidative stress</td> <td>Cytotoxicity*</td> </tr> <tr> <td rowspan=\"5\">&#8593; Sorbitol pathway</td> <td>&#8595; NADPH</td> <td> <p>Oxidative stress &#8595;</p> NO synthesis</td> <td> <p>Cytotoxicity*</p> Ischemia/hypoxia</td> </tr> <tr> <td>NADH/lactate</td> <td>Pseudohypoxia</td> <td>Cytotoxicity*</td> </tr> <tr> <td>&#8593; Glycation</td> <td>(See above)</td> <td>(See above)</td> </tr> <tr> <td>&#8595; Taurine</td> <td>Oxidative stress</td> <td>Cytotoxicity*</td> </tr> <tr> <td>&#8595; MI/&#8595; PI/&#8595; PKC</td> <td> <p>Signal transduction</p> Eicosanoid defects</td> <td> <p>&#8595; Neurotrophism</p> Ischemia/hypoxia</td> </tr> <tr> <td>&#8593; DAG</td> <td>&#8593; PKC</td> <td>Signal transduction</td> <td>Ischemia</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">FA defects</td> <td>&#8593; Free FA</td> <td>&#8593; Long-chain acyl-Co's</td> <td>Mitochondrial defects</td> <td>Cytotoxicity</td> </tr> <tr> <td>&#8595; 3-&#946;-dehydrog</td> <td>&#8595; GLA</td> <td>Eicosanoid defects</td> <td>Ischemia/hypoxia</td> </tr> <tr class=\"divider_top\"> <td>&#8595; Insulin</td> <td>?&#8595; GF expression</td> <td>?IGF/NGF/BDNF/NT3</td> <td>Neurotrophic factors</td> <td>&#8595; Neurotrophism</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AGE: advanced glycosylation end-products; BDNF: brain-derived neurotrophic factor; DAG: diacylglycerol; FA: fatty acid; GLA: gamma linoleic acid; IGF: insulin-like growth factors; MI: myoinositol; NO: nitric oxide; PI: phosphoinositide; PKC: protein kinase C; NT3: neurotrophin-3; SAM: substrate adhesion molecules; TGF: transforming growth factor.<br />* Cytotoxicity of neural, glial, and vascular components of peripheral nerve.</div><div class=\"graphic_reference\">Adapted from: Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 1995; 12:566.</div><div id=\"graphicVersion\">Graphic 71576 Version 3.0</div></div></div>"},"71577":{"type":"graphic_diagnosticimage","displayName":"Cecal volvulus KUB","title":"Cecal volvulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cecal volvulus</div><div class=\"cntnt\"><img style=\"width:283px; height:374px;\" src=\"images/GAST/71577_Cecal_volvulus_KUB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal radiograph of a 74-year-old man with severe abdominal pain and distension demonstrates a large air-filled cecum oriented transversely across the midabdomen (arrows) extending into the left upper quadrant. These features are consistent with a cecal volvulus. The subtle mural nodularity seen in the wall of the cecum suggests vascular compromise.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 71577 Version 3.0</div></div></div>"},"71579":{"type":"graphic_figure","displayName":"Horizontal arm traction","title":"Horizontal arm traction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Horizontal arm traction</div><div class=\"cntnt\"><img style=\"width:327px; height:258px;\" src=\"images/RHEUM/71579_Horizontal_arm_traction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In horizontal arm traction, the arm is flexed across the anterior chest and steady, prolonged traction is applied in a horizontal direction.</div><div id=\"graphicVersion\">Graphic 71579 Version 3.0</div></div></div>"},"71583":{"type":"graphic_picture","displayName":"Alopecia areata 2","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:380px; height:315px;\" src=\"images/DERM/71583_Alopecia_areata_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hair loss is a round patch. Note the absence of scales or inflammation.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71583 Version 3.0</div></div></div>"},"71587":{"type":"graphic_figure","displayName":"Inferior pontine syndrome","title":"Inferior pontine syndrome","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Inferior pontine syndrome</div><div class=\"cntnt\"><img style=\"width:546px; height:709px;\" src=\"images/NEURO/71587_Inferior_pontine_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 71587 Version 1.0</div></div></div>"},"71588":{"type":"graphic_table","displayName":"Estimate of stillbirth risk for selected maternal risk factors","title":"Estimate of stillbirth risk for selected maternal risk factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimate of stillbirth risk for selected maternal risk factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Prevalence, percent</td> <td class=\"subtitle1\">Estimated rate of stillbirth, per 1000 total births</td> <td class=\"subtitle1\">Odds ratio</td> </tr> <tr> <td>All pregnancies</td> <td>&nbsp;</td> <td>6.4</td> <td>1.0</td> </tr> <tr> <td>Low-risk pregnancies</td> <td>80</td> <td>4.0-5.5</td> <td>0.86</td> </tr> <tr> <td>Nulliparity</td> <td>40</td> <td>7-8</td> <td>1.2-3.0</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Hypertensive disorder</td> </tr> <tr> <td class=\"sublist1\">Chronic hypertension</td> <td class=\"sublist_other\">6-10</td> <td class=\"sublist_other\">6-25</td> <td class=\"sublist_other\">1.5-2.7</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">Pregnancy-induced hypertension</td> </tr> <tr> <td class=\"sublist2\">Mild</td> <td class=\"sublist_other\">5.8-7.7</td> <td class=\"sublist_other\">9-51</td> <td class=\"sublist_other\">1.2-4.0</td> </tr> <tr> <td class=\"sublist2\">Severe</td> <td class=\"sublist_other\">1.3-3.3</td> <td class=\"sublist_other\">12-29</td> <td class=\"sublist_other\">1.8-4.4</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Diabetes</td> </tr> <tr> <td class=\"sublist1\">Treated with diet</td> <td class=\"sublist_other\">2.5-5</td> <td class=\"sublist_other\">6-10</td> <td class=\"sublist_other\">1.2-2.2</td> </tr> <tr> <td class=\"sublist1\">Treated with insulin</td> <td class=\"sublist_other\">2.4</td> <td class=\"sublist_other\">6-35</td> <td class=\"sublist_other\">1.7-7.0</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>&#60;1</td> <td>40-150</td> <td>6-20</td> </tr> <tr> <td>Renal disease</td> <td>&#60;1</td> <td>15-200</td> <td>2.2-30</td> </tr> <tr> <td>Thyroid disorders</td> <td>0.2-2</td> <td>12-20</td> <td>2.2-3.0</td> </tr> <tr> <td>Thrombophilia</td> <td>1-5</td> <td>18-40</td> <td>2.8-5.0</td> </tr> <tr> <td>Cholestasis of pregnancy</td> <td>&#60;0.1</td> <td>12-30</td> <td>1.8-4.4</td> </tr> <tr> <td>Smoking &#62;10 cigarettes</td> <td>10-20</td> <td>10-15</td> <td>1.7-3.0</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Obesity (prepregnancy)</td> </tr> <tr> <td class=\"sublist1\">BMI 25-29.9 kg/m<sup>2</sup></td> <td class=\"sublist_other\">21</td> <td class=\"sublist_other\">12-15</td> <td class=\"sublist_other\">1.9-2.7</td> </tr> <tr> <td class=\"sublist1\">BMI &#62;30</td> <td class=\"sublist_other\">20</td> <td class=\"sublist_other\">13-18</td> <td class=\"sublist_other\">2.1-2.8</td> </tr> <tr> <td>Low educational attainment (&#60;12 years&nbsp;versus 12+ years)</td> <td>30</td> <td>10-13</td> <td>1.6-2.0</td> </tr> <tr> <td>Previous growth-restricted infant (&#60;10 percent)</td> <td>6.7</td> <td>12-30</td> <td>2-4.6</td> </tr> <tr> <td>Previous cesarean section</td> <td>24-28</td> <td>6-13</td> <td>1.0-2.0</td> </tr> <tr> <td>Previous stillbirth</td> <td>0.5-1.0</td> <td>9-20</td> <td>1.4-3.2</td> </tr> <tr> <td class=\"sublist1_start\">Multiple gestation</td> <td class=\"sublist_other_start\">2-3.5</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Twins</td> <td class=\"sublist_other\">2.7</td> <td class=\"sublist_other\">12</td> <td class=\"sublist_other\">1.0-2.8</td> </tr> <tr> <td class=\"sublist1\">Triplets</td> <td class=\"sublist_other\">0.14</td> <td class=\"sublist_other\">34</td> <td class=\"sublist_other\">2.8-3.7</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Advanced maternal age (reference &#60;35)</td> </tr> <tr> <td class=\"sublist1\">35-39</td> <td class=\"sublist_other\">15-18</td> <td class=\"sublist_other\">11-14</td> <td class=\"sublist_other\">1.8-2.2</td> </tr> <tr> <td class=\"sublist1\">40+</td> <td class=\"sublist_other\">2</td> <td class=\"sublist_other\">11-21</td> <td class=\"sublist_other\">1.8-3.3</td> </tr> <tr> <td>Black compared&nbsp;with white</td> <td>15</td> <td>12-14</td> <td>2.0-2.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Adapted with permission from: Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005; 193:1923.</div><div id=\"graphicVersion\">Graphic 71588 Version 7.0</div></div></div>"},"71589":{"type":"graphic_table","displayName":"Dox combos desmoids","title":"Doxorubicin-based combination chemotherapy for desmoid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin-based combination chemotherapy for desmoid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">No of patients</td> <td class=\"subtitle1\">Duration of therapy (cycles)</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Duration of response</td> <td class=\"subtitle1\">Author, year</td> </tr> <tr> <td>DOXO+DTIC</td> <td>11*</td> <td>2-10 cycles (median 5)</td> <td> <p>2 CR</p> <p>4 PR</p> <p>1 MR</p> 2 SD</td> <td>29-235 months</td> <td>Patel, S; 1993</td> </tr> <tr> <td>DOXO+DTIC</td> <td>5</td> <td>4-6 cycles (median 5) preoperatively</td> <td> <p>2 pCR</p> 3 PR</td> <td>21-72 months<sup>&#182;</sup></td> <td>Goepfert, H; 1982</td> </tr> <tr> <td>DOXO+DTIC+Meloxicam</td> <td>7</td> <td>4-5 (median 5) cycles</td> <td> <p>3 CR</p> 4 PR</td> <td>32.5-107.5 (median 74)</td> <td>Gega, M; 2006</td> </tr> <tr> <td>DOXO+DTIC (7cycles) followed by CARBO+DTIC</td> <td>5</td> <td>6-19 cycles</td> <td> <p>1 CR</p> <p>3 PR</p> 1 SD<sup>&#916;</sup></td> <td>10-30 months</td> <td>Schnitzler, M; 1997</td> </tr> <tr> <td>DOXO+Cy or IF+VP-16 or IF+VP-16+MITO+DOXO+P</td> <td>7</td> <td>2-8 cycles (median 6)</td> <td>3 OR<sup>&#9674;</sup></td> <td>3-180 months</td> <td>Okuno, S; 2003</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DOXO: doxorubicin; DTIC: dacarbazine; CARBO: carboplatin; Cy: cyclophosphamide; IF: ifosfamide; VP-16: etoposide; MITO: mitomycin; pCR: pathological CR; CR: complete response; PR: partial response; SD: stable disease; OR: objective response; MR: minor response.<br />* 9 out of 11 patients were evaluable, 2 patients were treated in 1970s could not be evaluated objectively but reported to have responses that enabled the resection of axillary and pelvic disease.<br />¶ All patients received chemotherapy preoperatively, only 1 patient recurred after surgery at 21 months. All others remain NED.<br />Δ Patient progressed rapidly after cessation of chemotherapy.<br /><FONT class=lozenge>◊</FONT> All patients on chemotherapy showed some form of clinical benefit such as objective response or stable disease or symptomatic improvement.</div><div id=\"graphicVersion\">Graphic 71589 Version 2.0</div></div></div>"},"71590":{"type":"graphic_figure","displayName":"Biomechanic loading models","title":"Types of stress on bone and resulting fractures","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Types of stress on bone and resulting fractures</div><div class=\"cntnt\"><img style=\"width:457px; height:488px;\" src=\"images/EM/71590_Biomechanic_loading_models.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71590 Version 2.0</div></div></div>"},"71593":{"type":"graphic_picture","displayName":"Osteoblasts and osteoid","title":"Bone biopsy showing osteoblasts and osteoid formation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone biopsy showing osteoblasts and osteoid formation</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/71593_Osteoblasts_and_osteoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin, eosin, and saffron stain (x 100) of a bone biopsy showing the anatomy of the osteoblasts and osteoid.</div><div class=\"graphic_reference\">Courtesy of CJ Menkes, MD.</div><div id=\"graphicVersion\">Graphic 71593 Version 2.0</div></div></div>"},"71594":{"type":"graphic_figure","displayName":"RET TK receptor mutations","title":"RET tyrosine kinase receptor mutations in MEN2, FMTC, and SMTC","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">RET tyrosine kinase receptor mutations in MEN2, FMTC, and SMTC</div><div class=\"cntnt\"><img style=\"width:583px; height:496px;\" src=\"images/ENDO/71594_RET_TK_rcptr_mutations_Edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MEN2: multiple endocrine neoplasia type 2; FMTC: familial medullary thyroid cancer; SMTC: sporadic medullary thyroid cancer; HSCR: Hirschsprung disease; MEN2A: multiple endocrine neoplasia type 2A; MEN2B: multiple endocrine neoplasia type 2B;&nbsp;TK: tyrosine kinase.</div><div id=\"graphicVersion\">Graphic 71594 Version 4.0</div></div></div>"},"71595":{"type":"graphic_table","displayName":"Causes of lactose malabsorption","title":"Major causes of lactose malabsorption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of lactose malabsorption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary</td> </tr> <tr> <td>Racial or ethnic</td> </tr> <tr> <td>Developmental</td> </tr> <tr> <td>Congenital lactase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary</td> </tr> <tr> <td>Small intestinal bacterial overgrowth</td> </tr> <tr> <td class=\"sublist1_start\">Infectious enteritis</td> </tr> <tr> <td class=\"sublist1\">Giardiasis</td> </tr> <tr> <td class=\"sublist1_start\">Mucosal injury</td> </tr> <tr> <td class=\"sublist1\">Celiac disease</td> </tr> <tr> <td class=\"sublist1\">Inflammatory bowel disease (especially Crohn disease)</td> </tr> <tr> <td class=\"sublist1\">Drug- or radiation-induced enteritis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71595 Version 2.0</div></div></div>"},"71599":{"type":"graphic_picture","displayName":"Low grade spleen laceration","title":"Low grade splenic laceration","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Low grade splenic laceration</div><div class=\"cntnt\"><img style=\"width:504px; height:422px;\" src=\"images/SURG/71599_Low_grade_spleen_lac.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Lewis J Kaplan, MD</div><div id=\"graphicVersion\">Graphic 71599 Version 3.0</div></div></div>"},"71604":{"type":"graphic_algorithm","displayName":"Headache in ER I","title":"Management of headache in the emergency department-I","html":"<div class=\"graphic\"><div style=\"width: 703px\" class=\"figure\"><div class=\"ttl\">Management of headache in the emergency department-I</div><div class=\"cntnt\"><img style=\"width:683px; height:467px;\" src=\"images/NEURO/71604_Headache_in_ER_I_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71604 Version 4.0</div></div></div>"},"71608":{"type":"graphic_table","displayName":"Incision and drainage procedure","title":"Procedure summary: Incision and drainage of skin abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure summary: Incision and drainage of skin abscess</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preparation</td> </tr> <tr> <td class=\"indent1\">1. Explain the procedure to the patient and/or caretaker and obtain informed consent.</td> </tr> <tr> <td class=\"indent1\">2. Provide prophylaxis for bacterial endocarditis, if indicated.</td> </tr> <tr> <td class=\"indent1\">3. Provide procedural sedation and analgesia in addition to local anesthesia.</td> </tr> <tr> <td class=\"subtitle1_single\">Incision and drainage</td> </tr> <tr> <td class=\"indent1\">1. Identify the area of maximal fluctuance.</td> </tr> <tr> <td class=\"indent1\">2. Using a scalpel with either an 11 or 15 blade, make a simple linear incision at the point of maximal fluctuance and through the length of the abscess; a stab incision may be used in a cosmetic area.</td> </tr> <tr> <td class=\"indent1\">3. Obtain culture of drainage fluid, if indicated*.</td> </tr> <tr> <td class=\"indent1\">4. Bluntly probe the abscess cavity with a curved hemostat to remove any identified foreign body and to break up loculations.</td> </tr> <tr> <td class=\"indent1\">5. Copiously irrigate the abscess cavity with normal saline until all visible pus is removed.</td> </tr> <tr> <td class=\"indent1\">6. Pack large abscesses (&#62;5 cm in diameter) and pilonidal abscesses with sterile packing gauze or iodoform. Some physicians may choose to pack all abscesses that will accept packing strips.</td> </tr> <tr> <td class=\"indent1\">7. We suggest that abscesses be left open to heal by secondary intention.</td> </tr> <tr> <td class=\"indent1\">8. Provide antibiotic therapy to selected patients<sup>&#182;</sup>.</td> </tr> <tr> <td class=\"indent1\">9. Provide tetanus prophylaxis, as indicated.</td> </tr> <tr> <td class=\"subtitle1_single\">Follow-up</td> </tr> <tr> <td class=\"indent1\">1. Schedule the patient for a wound check within 24 to 48 hours.</td> </tr> <tr> <td class=\"indent1\">2. At the follow-up visit, remove packing (if present) in patients whose drainage has stopped and initiate warm wet soaks (mild saline solution or soapy water).</td> </tr> <tr> <td class=\"indent1\">3. If drainage persists at the follow-up visit, remove the old packing material and repack with new packing strips. Continue evaluation every 24 to 48 hours with repacking until the drainage stops.</td> </tr> <tr> <td class=\"indent1\">4. If the patient underwent primary closure, remove sutures if pus has reaccumulated. Otherwise, instruct the patient to keep the wound clean and arrange for suture removal seven days after initial incision and drainage.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on skin abscesses, furuncles, and carbuncles.<br />¶ We suggest that patients with multiple lesions, extensive surrounding cellulitis, immunosuppression, risk for MRSA or systemic signs of infection be managed with incision and drainage as well as antimicrobial therapy.</div><div id=\"graphicVersion\">Graphic 71608 Version 7.0</div></div></div>"},"71610":{"type":"graphic_diagnosticimage","displayName":"Phrenic nerve invasion","title":"Phrenic nerve invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phrenic nerve invasion</div><div class=\"cntnt\"><img style=\"width:396px; height:314px;\" src=\"images/PULM/71610_Phrenic_nerve_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal multiplanar reformation of a CT of the thorax shows a left upper lobe tumor with extension to the hilum and mediastinum. There is involvement of the left phrenic nerve with elevation of the left hemidiaphragm.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71610 Version 3.0</div></div></div>"},"71612":{"type":"graphic_picture","displayName":"Malrotation metacarpal fracture","title":"Malrotation due to metacarpal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malrotation due to metacarpal fracture</div><div class=\"cntnt\"><img style=\"width:429px; height:321px;\" src=\"images/EM/71612_Metacarpal_fx_with_malrotat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axes of the fingers normally converge when the MCP and PIP joints are both flexed. In this photograph, while the second, third, and fourth fingers converge as they should, the fifth does not. The divergence of the fifth digit is the result of a fifth metacarpal shaft fracture complicated by malrotation.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal; PIP: proximal interphalangeal.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD</div><div id=\"graphicVersion\">Graphic 71612 Version 6.0</div></div></div>"},"71614":{"type":"graphic_picture","displayName":"Telangiectasia nose","title":"Telangiectasias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectasias</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71614_Telangiectasia_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple telangiectasias are present on the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71614 Version 4.0</div></div></div>"},"71616":{"type":"graphic_table","displayName":"Causes of hypophosphatemia","title":"Major causes of hypophosphatemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypophosphatemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Internal redistribution</td> </tr> <tr> <td class=\"indent1\">Increased insulin secretion, particularly during refeeding</td> </tr> <tr> <td class=\"indent1\">Acute respiratory alkalosis</td> </tr> <tr> <td class=\"indent1\">Hungry bone syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased intestinal absorption</td> </tr> <tr> <td class=\"indent1\">Inadequate intake</td> </tr> <tr> <td class=\"indent1\">Inhibition of phosphate absorption (eg, antacids, phosphate binders, niacin)</td> </tr> <tr> <td class=\"indent1\">Steatorrhea and chronic diarrhea</td> </tr> <tr> <td class=\"indent1\">Vitamin D deficiency or resistance</td> </tr> <tr> <td class=\"subtitle1_single\">Increased urinary excretion</td> </tr> <tr> <td class=\"indent1\">Primary and secondary hyperparathyroidism</td> </tr> <tr> <td class=\"indent1\">Vitamin D deficiency or resistance</td> </tr> <tr> <td class=\"indent1\">Hereditary hypophosphatemic rickets</td> </tr> <tr> <td class=\"indent1\">Oncogenic osteomalacia</td> </tr> <tr> <td class=\"indent1\">Fanconi syndrome</td> </tr> <tr> <td class=\"indent1\">Other - acetazolamide, tenofovir, IV iron, chemotherapeutic agents</td> </tr> <tr> <td class=\"subtitle1_single\">Removal by renal replacement therapies</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71616 Version 9.0</div></div></div>"},"71620":{"type":"graphic_table","displayName":"Causes of headache","title":"Causes of headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Migraine</td> </tr> <tr> <td>Tension-type headache</td> </tr> <tr> <td>Cluster headache</td> </tr> <tr> <td>Medication rebound and withdrawal headache</td> </tr> <tr> <td>Carotid or vertebral artery&nbsp;dissection</td> </tr> <tr> <td>Intracranial hemorrhage (eg, arteriovenous malformation, aneurysm, trauma)</td> </tr> <tr> <td>Cerebral&nbsp;venous sinus thrombosis</td> </tr> <tr> <td>Preeclampsia/eclampsia</td> </tr> <tr> <td>Benign intracranial hypertension</td> </tr> <tr> <td>Post&nbsp;dural puncture&nbsp;headache</td> </tr> <tr> <td>Mass lesion/tumor</td> </tr> <tr> <td>Primary thunderclap headache&nbsp;</td> </tr> <tr> <td>Pituitary apoplexy</td> </tr> <tr> <td>Meningioma</td> </tr> <tr> <td>Reversible cerebral vasoconstriction syndrome </td> </tr> <tr> <td>Reversible posterior encephalopathy syndrome&nbsp;</td> </tr> <tr> <td>Primary angiitis of the central nervous system</td> </tr> <tr> <td>Infection (eg, sinusitis, meningitis, encephalitis)</td> </tr> <tr> <td>Stroke</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71620 Version 4.0</div></div></div>"},"71621":{"type":"graphic_figure","displayName":"Misoprostol lvls oral v vaginal","title":"Misoprostol levels over time with oral versus vaginal administration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Misoprostol levels over time with oral versus vaginal administration</div><div class=\"cntnt\"><img style=\"width:439px; height:404px;\" src=\"images/OBGYN/71621_Misoprostol_lvls_oral_v_vag.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Khan, RU, El-Refaey, H, Sharma, S, et al. Obstet Gynecol 2004; 103:866.</div><div id=\"graphicVersion\">Graphic 71621 Version 1.0</div></div></div>"},"71622":{"type":"graphic_table","displayName":"Causes of tachycardia in children","title":"Causes of tachycardia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of tachycardia in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Life threatening cardiac conditions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Supraventricular tachycardia (SVT)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Ventricular tachycardia (VT)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Other arrhythmias (eg, torsades de pointes, atrial flutter)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Hypertrophic cardiomyopathy (HCM)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Myocarditis, cardiomyopathy</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Pericardial effusion</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Life threatening non-cardiac conditions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Substrate deficiency (hypoxemia, hypoglycemia)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Hypovolemic shock</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Anaphylaxis</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Toxic exposure</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Sepsis</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Electrolyte imbalance (hyperkalemia, hypocalcemia, hypomagnesiumia)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"red\">Pheochromocytoma</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Common conditions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Fever</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Exercise</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Crying</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Pain</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Anxiety, hyperventilation syndrome</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Anemia</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><span class=\"green\">Drug-induced (caffeine, herbal medications, dietary supplements, illicit drugs)</span></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Other conditions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Kawasaki disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute rheumatic fever</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperthyroidism</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">Red = life threatening condition; Green = common condition</div><div id=\"graphicVersion\">Graphic 71622 Version 2.0</div></div></div>"},"71625":{"type":"graphic_diagnosticimage","displayName":"Lymphomatoid gran CT III","title":"59-year-old man who presented with abnormal findings on chest radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">59-year-old man who presented with abnormal findings on chest radiography</div><div class=\"cntnt\"><img style=\"width:446px; height:357px;\" src=\"images/PULM/71625_Lymphomatoid_gran_CT_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image at level of lung apex shows several small thin-walled cysts, 1 to 2 cm in diameter. Histopathology revealed extensive confluent coagulative necrosis, often with presence of pulmonary vessels infiltrated by lymphoma. Areas of necrosis were surrounded by lymphoepithelioid infiltrate with focal formation of poorly formed granulomas.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">From: Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: Radiologic features and pathologic correlations. Am J Roentgenol 2000; 175:1335. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 71625 Version 12.0</div></div></div>"},"71626":{"type":"graphic_table","displayName":"Pleural effusions in HIV II","title":"Pleural effusions in HIV: Differential diagnosis and diagnostic testing (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pleural effusions in HIV: Differential diagnosis and diagnostic testing (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">History/physical exam/lab findings</td> <td class=\"subtitle1\">Pleural fluid characteristics</td> <td class=\"subtitle1\">Additional tests of pleural fluid</td> <td class=\"subtitle1\">Other helpful tests</td> </tr> <tr> <td>Kaposi sarcoma (KS) associated effusion</td> <td> <p>Skin lesions of KS</p> <p>No pleuritic pain</p> </td> <td> <p>Large to massive, bilateral effusion(s)</p> <p>Hemorrhagic fluid</p> </td> <td>Cytology is negative</td> <td> <p>Chest radiograph: diffuse pulmonary opacities</p> <p>Endobronchial lesions of KS</p> <p>Pleural biopsy is negative</p> </td> </tr> <tr> <td>Multicentric Castleman disease</td> <td> <p>Fever</p> <p>Cough, dyspnea in 60 percent</p> <p>Peripheral lymphadenopathy</p> <p>Anemia</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Chest radiograph: reticular or nodular opacities</p> <p>Chest CT: mediastinal adenopathy as disease progresses</p> <p>Lymph node biopsy</p> </td> </tr> <tr> <td>Systemic lymphoma</td> <td> <p>Low CD4 level</p> <p>Serum LDH high</p> </td> <td> <p>Large, serosanguinous exudative effusion (may have mass effect)</p> <p>Pleural LDH high</p> <p>Cytology positive (60 percent)</p> </td> <td>Flow cytometry</td> <td>Pleural biopsy</td> </tr> <tr> <td>Primary effusion lymphoma</td> <td> <p>Low CD4 count</p> <p>Preexisting KS in 30 percent</p> </td> <td>Pleural fluid cytology usually diagnostic</td> <td> <p>LANA-1 (HHV8) +</p> <p>Lymphocytes often:</p> <p>CD45 +/CD30 +/EMA -/T cell antigen -/LMP1 usually -</p> <p>Monoclonal B cell population by Southern blot</p> </td> <td> <p>Chest CT: adjacent parietal pleural thickening and absent lymphadenopathy</p> <p>Pericardial effusion and ascites (common)</p> </td> </tr> <tr> <td>Thromboembolism</td> <td>Risk factor(s) for thromboembolism</td> <td>Exudative, may be serous or serosanguinous</td> <td>&nbsp;</td> <td> <p>d-Dimer (positive)</p> <p>CT pulmonary angiogram</p> </td> </tr> <tr> <td>Hypoalbuminemia</td> <td>Bilateral peripheral edema</td> <td>Transudative</td> <td>&nbsp;</td> <td>Serum albumin (low)</td> </tr> <tr> <td>Heart failure</td> <td> <p>Chronic dyspnea</p> <p>Bilateral peripheral edema</p> </td> <td>Transudative</td> <td>&nbsp;</td> <td> <p>Serum BNP (elevated)</p> <p>Echocardiogram</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMA: epithelial membrane antigen; LANA-1: as latency-associated nuclear antigen, a latent HHV8 gene product; LMP1: latent membrane protein 1 of Epstein Barr virus.</div><div id=\"graphicVersion\">Graphic 71626 Version 2.0</div></div></div>"},"71629":{"type":"graphic_diagnosticimage","displayName":"GB adenomatous polyp US","title":"Gallbladder adenomatous polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gallbladder adenomatous polyp</div><div class=\"cntnt\"><img style=\"width:317px; height:317px;\" src=\"images/GAST/71629_GB_adenomatous_polyp_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gallbladder ultrasonography showing an adenomatous polyp. Note its homogeneous appearance and density that is similar to the surrounding liver tissue.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 71629 Version 2.0</div></div></div>"},"71630":{"type":"graphic_picture","displayName":"Verrucous lesion in blasto","title":"Disseminated blastomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated blastomycosis</div><div class=\"cntnt\"><img style=\"width:360px; height:227px;\" src=\"images/ID/71630_Verrucous_lesion_in_blasto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous plaque on the upper cheek due to disseminated blastomycosis.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders, CV, Nesbitt, LT Jr (Eds) Williams and Wilkins, Baltimore 1995. p.174.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 71630 Version 4.0</div></div></div>"},"71631":{"type":"graphic_diagnosticimage","displayName":"Chagas heart disease Echo","title":"Chronic Chagas' heart disease","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Chronic Chagas' heart disease</div><div class=\"cntnt\"><img style=\"width:539px; height:220px;\" src=\"images/CARD/71631_Chagas_heart_disease_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram in a patient with chronic Chagas' heart disease. Apical long axis (left panel) and four-chamber (right panel) views show left ventricular dilation and a large apical thrombus.</div><div id=\"graphicVersion\">Graphic 71631 Version 2.0</div></div></div>"},"71634":{"type":"graphic_picture","displayName":"Omphalitis II","title":"Omphalitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Omphalitis</div><div class=\"cntnt\"><img style=\"width:432px; height:268px;\" src=\"images/PEDS/71634_Omphalitis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Omphalitis with induration and erythema surrounding the umbilicus in a newborn.</div><div class=\"graphic_reference\">Courtesy of Martin I Lorin, MD.</div><div id=\"graphicVersion\">Graphic 71634 Version 3.0</div></div></div>"},"71635":{"type":"graphic_picture","displayName":"Gerbers test","title":"Push off or Gerber's test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Push off or Gerber's test</div><div class=\"cntnt\"><img style=\"width:432px; height:387px;\" src=\"images/EM/71635_Gerber_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The subscapularis is the rotator cuff muscle primarily responsible for internal rotation. Its strength can be assessed using the push-off, or Gerber's, test. This test is performed by having the patient place one hand behind his back and push posteriorly against resistance.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD</div><div id=\"graphicVersion\">Graphic 71635 Version 2.0</div></div></div>"},"71636":{"type":"graphic_algorithm","displayName":"Diagnosis of acromegaly","title":"Algorithm for the diagnosis of acromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of acromegaly</div><div class=\"cntnt\"><img style=\"width:401px; height:366px;\" src=\"images/ENDO/71636_Diagnosis_of_acromegaly.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor-1; OGTT: oral glucose tolerance test; GH: growth hormone; MRI: magnetic resonance imaging; CT: computed tomography: GHRH: growth hormone-releasing hormone.</div><div class=\"graphic_reference\">Adapted from: Melmed S, Anterior pituitary. In: Current Practice of Medicine, Korenman S (Ed), 1996.</div><div id=\"graphicVersion\">Graphic 71636 Version 7.0</div></div></div>"},"71638":{"type":"graphic_table","displayName":"Ankle foot orthosis","title":"Semi-rigid ankle foot orthosis (AFO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Semi-rigid ankle foot orthosis (AFO)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Type</td>\n\n      <td class=\"subtitle1\">Description</td>\n\n      <td class=\"subtitle1\">Brands</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hinged ankle strap</td>\n\n      <td>Modified orthotic footplate provides critical foot and arch support while resisting inversion and eversion</td>\n\n      <td>Active Ankle, Bledsoe Ultimate Ankle Brace, Atom Ankle by Swede-O</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ankle gauntlet</td>\n\n      <td>Removable plastic stabilizers insert into pockets on either side to help protect against inversion and eversion</td>\n\n      <td>Swede-O, Royce ExoForm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Flexible stirrup</td>\n\n      <td>Standard ankle brace allows for unobstructed motion in plantar and dorsiflexion</td>\n\n      <td>AirCast</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71638 Version 1.0</div></div></div>"},"71640":{"type":"graphic_figure","displayName":"Mortality men women AF","title":"Atrial fibrillation increases mortality in men and women","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation increases mortality in men and women</div><div class=\"cntnt\"><img style=\"width:406px; height:260px;\" src=\"images/CARD/71640_Mortality_men_women_AF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 5209 subjects in the Framingham Heart Study, the mortality after a 10-year follow-up was higher in both men and women, aged 55 to 74, who had atrial fibrillation (AF) compared to those without AF (p &lt;0.001) A similar relationship was seen in subjects between the ages of 75 and 94 (not shown).</div><div class=\"graphic_reference\">Data from Benjamin EJ, Wolf PA, D'Agostino RB, et al. Circulation 1998; 98:946.</div><div id=\"graphicVersion\">Graphic 71640 Version 2.0</div></div></div>"},"71641":{"type":"graphic_table","displayName":"Respiratory disease and RA","title":"Respiratory disease in rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Respiratory disease in rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Interstitial</td> </tr> <tr> <td class=\"sublist2_start\">Interstitial pneumonitis/fibrosis (RA-ILD)</td> </tr> <tr> <td class=\"sublist2\">Usual interstitial pneumonitis (UIP)</td> </tr> <tr> <td class=\"sublist2\">Organizing pneumonia (OP)</td> </tr> <tr> <td class=\"sublist2\">Nonspecific interstitial pneumonitis (NSIP)</td> </tr> <tr> <td class=\"sublist2\">Lymphoid interstitial pneumonitis (LIP)</td> </tr> <tr> <td class=\"sublist2\">Desquamative interstitial pneumonitis (DIP)</td> </tr> <tr> <td class=\"sublist2\">Mixed morphology</td> </tr> <tr> <td class=\"indent1\">Rheumatoid nodules</td> </tr> <tr> <td class=\"indent1\">Rheumatoid pneumoconiosis (Caplan's syndrome)</td> </tr> <tr> <td class=\"indent1\">Apical fibrobullous disease</td> </tr> <tr> <td class=\"subtitle1_single\">Airway</td> </tr> <tr> <td class=\"indent1\">Cricoarytenoid arthritis/central airway obstruction</td> </tr> <tr> <td class=\"indent1\">Obliterative bronchiolitis</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Chronic small airway obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Pleural</td> </tr> <tr> <td class=\"indent1\">Pleuritis</td> </tr> <tr> <td class=\"indent1\">Pleural effusion</td> </tr> <tr> <td class=\"indent1\">Pleural thickening</td> </tr> <tr> <td class=\"indent1\">Cholesterol (chyliform) effusions</td> </tr> <tr> <td class=\"indent1\">Lung entrapment and trapped lung</td> </tr> <tr> <td class=\"subtitle1_single\">Chest wall</td> </tr> <tr> <td class=\"indent1\">Thoracic cage immobility</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary vascular</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Drug-related</td> </tr> <tr> <td class=\"indent1\">? Lung cancer</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71641 Version 4.0</div></div></div>"},"71642":{"type":"graphic_table","displayName":"Curth postulates","title":"Curth's postulates*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Curth's postulates*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Postulates</td> <td class=\"subtitle1\">Definitions</td> </tr> <tr> <td>1. Concurrent onset</td> <td>The dermatosis and malignancy occur concurrently</td> </tr> <tr> <td>2. Parallel course</td> <td>If the malignancy is treated successfully or recurs, the dermatosis follows a similar course</td> </tr> <tr> <td>3. Uniformity</td> <td>A specific malignancy is consistently associated with a specific dermatosis</td> </tr> <tr> <td>4. Statistical significance</td> <td>There is a statistically significant association between the malignancy and the dermatosis based upon case-control studies</td> </tr> <tr> <td>5. Genetic basis</td> <td>There is a genetic association between the malignancy and dermatosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Curth's postulates are criteria used to identify a consistent relationship between an internal malignancy and a cutaneous disorder. All criteria do not have to be met.</div><div class=\"graphic_reference\">Adapted from: Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin 2009; 59:73.</div><div id=\"graphicVersion\">Graphic 71642 Version 1.0</div></div></div>"},"71643":{"type":"graphic_picture","displayName":"Herpetic whitlow blister","title":"Herpetic whitlow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpetic whitlow</div><div class=\"cntnt\"><img style=\"width:405px; height:540px;\" src=\"images/SURG/71643_Herpetic_whitlow_blister.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with herpetic whitlow usually present with tingling and burning pain of the hand that is followed by the development of erythema, swelling, and 1- to 2-mm vesicles containing clear fluid. Note the small, clear vesicles on the palmar aspect of the middle finger.</div><div id=\"graphicVersion\">Graphic 71643 Version 3.0</div></div></div>"},"71644":{"type":"graphic_figure","displayName":"Diagram showing AV fistula for hemodialysis PI","title":"Diagram showing AV fistula for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram showing AV fistula for hemodialysis</div><div class=\"cntnt\"><img style=\"width:266px; height:616px;\" src=\"images/PI/71644_AV_fistula_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows an AV fistula in a person's arm. An AV fistula is under the skin. A doctor makes an AV fistula by doing surgery to connect an artery directly to a vein. It is usually done in the lower arm but can be done in the upper arm. During hemodialysis,&nbsp;two needles are put into the access to remove and return blood to the body.</div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">AV: arteriovenous (this means involving an artery and a vein).</SPAN></div><div id=\"graphicVersion\">Graphic 71644 Version 10.0</div></div></div>"},"71646":{"type":"graphic_picture","displayName":"Neonate with omphalocele","title":"Omphalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Omphalocele</div><div class=\"cntnt\"><img style=\"width:296px; height:252px;\" src=\"images/OBGYN/71646_Neonate_with_omphalocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midline abdominal wall defect covered by amnion and peritoneum and containing abdominal contents. The defect is at the base of the umbilical cord, with the cord inserting at its apex.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 71646 Version 3.0</div></div></div>"},"71648":{"type":"graphic_figure","displayName":"Mortality in Hodgkin lymphoma","title":"Disease-related and non-Hodgkin mortality in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Disease-related and non-Hodgkin mortality in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:465px; height:304px;\" src=\"images/ONC/71648_Mortality_in_Hodgkin_lymph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial risk of death from Hodgkin lymphoma or other causes in 2498 patients treated for Hodgkin lymphoma at Stanford University from 1960 to 1995. Most of the early mortality is due to Hodgkin lymphoma, while almost all deaths after 10 to 15 years were due to other causes, mostly second malignancy and cardiovascular and pulmonary disease.</div><div class=\"graphic_reference\">Modified from: Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8(Suppl 1):S115.</div><div id=\"graphicVersion\">Graphic 71648 Version 3.0</div></div></div>"},"71649":{"type":"graphic_table","displayName":"Risk assignment childhood ALL","title":"Clinical risk assignment and suggested therapies in childhood acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical risk assignment and suggested therapies in childhood acute lymphoblastic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk group</td> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Percent</td> <td class=\"subtitle1\">Recommended therapy</td> <td class=\"subtitle1\">Projected five-year event-free survival</td> </tr> <tr class=\"divider_bottom\"> <td>Low</td> <td> <p><strong>ALL</strong> of the following:</p> <ol> <li> <p>NCI standard risk group*</p> </li> <li> <p>Lesser risk cytogenetics: <br /> Trisomies 4 and 10<br /> <strong>or<br /> </strong>ETV-RUNX1 (United States)<br /> <strong>or</strong> <br /> Hyperdiploid (Europe)</p> </li> <li> <p>Rapid response to therapy<sup>&#182;</sup></p> </li> </ol> </td> <td>15 percent</td> <td>Conventional antimetabolite-based therapy</td> <td>&#62;95 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Average</td> <td> <p><strong>EITHER </strong>of the following:</p> <ol> <li> <p>NCI standard risk group*<br /> <strong>and<br /> </strong>Rapid response to therapy<sup>&#182;</sup></p> </li> <li> <p>NCI standard risk group*<br /> <strong>and<br /> </strong>Lesser risk cytogenetics<br /> <strong>and<br /> </strong>Slow response to therapy<sup>&#916;</sup></p> </li> </ol> </td> <td>36 percent</td> <td>Intensified antimetabolite therapy</td> <td>90 to 95 percent</td> </tr> <tr class=\"divider_bottom\"> <td>High</td> <td> <p><strong>ANY </strong>of the following:</p> <ol> <li> <p>NCI high risk group<sup>&#9674;<br /> </sup><strong>and<br /> </strong>Rapid response to therapy<sup>&#182;</sup></p> </li> <li> <p>NCI standard risk group*<br /> <strong>and<br /> </strong>Slow response to therapy<sup>&#916;&#167;</sup></p> </li> <li> <p>CNS positive leukemia</p> </li> <li> <p>Testicular leukemia</p> </li> </ol> </td> <td>25 percent</td> <td>Intensive multi-agent chemotherapy</td> <td>88 to 90 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Very high</td> <td> <p><strong>ANY</strong> of the following:</p> <ol> <li> <p>MRD+ at day 29<sup>&#167;</sup></p> </li> <li> <p>Induction failures</p> </li> <li> <p>MLL rearrangements <br /> <strong>or<br /> </strong>iAMP21 amplification</p> </li> <li> <p>Age &#60;1 year (or &#62;13 years if treated on a COG protocol)</p> </li> </ol> </td> <td>24 percent</td> <td> <p>Consider allogeneic hematopoietic cell transplantation in first remission</p> <p>Allogeneic transplant <strong>not</strong> recommended for infants</p> </td> <td>&#60;80 percent</td> </tr> <tr> <td rowspan=\"2\">Special groups</td> <td> <p>T cell ALL</p> </td> <td>&nbsp;</td> <td> <p>Intensive multi-agent chemotherapy</p> </td> <td> <p>66&nbsp;to 80 percent<sup> [1,2]</sup></p> <p><sup></sup></p> </td> </tr> <tr> <td>&nbsp; <p>Philadelphia chromosome<br /> [t (9; 22)]</p> </td> <td>&nbsp;</td> <td>&nbsp; <p>Intensive multi-agent chemotherapy containing a BCR-ABL tyrosine kinase inhibitor</p> </td> <td>&nbsp; <p>70&nbsp;percent<sup> [3]</sup></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cell count; NCI: National Cancer Institute; MRD: minimal residual disease; CNS: central nervous system; MLL: mixed lineage leukemia gene; iAMP21: intrachromosomal amplification of chromosome 21; COG: Children's Oncology Group; ALL: acute lymphoblastic leukemia.<br />* NCI standard risk group: WBC &lt;50,000/microL <STRONG>AND </STRONG>age&nbsp;one to &lt;10 years.<br />¶&nbsp;MRD negative at days 8 and 29 (rapid response to therapy).<br />Δ&nbsp;MRD positive at day 8 and negative at day 29 (slow response to therapy).<br />◊ NCI high risk group: WBC ≥50,000 microL <STRONG>OR</STRONG> age ≥10 years (up to 13 years if treated on a COG protocol).<br />§&nbsp;With some exceptions.<br /></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:2753.</LI>&#xD;&#xA;<LI>Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011; 118:874.</LI>&#xD;&#xA;<LI>Schultz KR,&nbsp;Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology group study AALL0031. Leukemia 2014; 28:1467.</LI></OL></div><div id=\"graphicVersion\">Graphic 71649 Version 5.0</div></div></div>"},"71650":{"type":"graphic_table","displayName":"Valve surgery congenital MR","title":"ACC/AHA guideline summary: Mitral valve surgery (repair or valve replacement) in adolescents or young adults with congenital mitral regurgitation (MR)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Mitral valve surgery (repair or valve replacement) in adolescents or young adults with congenital mitral regurgitation (MR)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class I - There is evidence and/or general agreement mitral valve surgery is indicated in adolescents or young adults with congenital MR in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Symptomatic severe MR with NYHA class III-IV symptoms.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Asymptomatic severe MR and left ventricular dysfunction, defined as a left ventricular ejection fraction (LVEF) &#8804;60 mmHg.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIa - The weight of evidence or opinion is in favor of the usefulness of mitral valve surgery in adolescents or young adults with congenital MR in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Mitral valve repair in experienced surgical centers in asymptomatic severe MR and preserved left ventricular function (LVEF &#62;60 percent) if the estimated likelihood of successful repair without residual MR is greater than 90 percent.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIb - The weight of evidence or opinion is less well established for the usefulness of mitral valve surgery in adolescents or young adults with congenital MR in the following setting:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Asymptomatic severe and preserved left ventricular function (LVEF &#62;60 percent) if valve replacement is highly likely.</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Data from: Bonow RO, Carabello BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.</div><div id=\"graphicVersion\">Graphic 71650 Version 2.0</div></div></div>"},"71651":{"type":"graphic_diagnosticimage","displayName":"Pelvic vertical shear injury","title":"Pelvic vertical shear injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic vertical shear injury</div><div class=\"cntnt\"><img style=\"width:396px; height:368px;\" src=\"images/EM/71651_Pelvic_vertical_shear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical shear injury with left sacral fracture, rami fractures, and associated left transverse acetabulum fracture.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 71651 Version 3.0</div></div></div>"},"71652":{"type":"graphic_picture","displayName":"Traumatic cataract","title":"Traumatic cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic cataract</div><div class=\"cntnt\"><img style=\"width:427px; height:286px;\" src=\"images/EM/71652_Traumatic_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A photograph of a patient following blunt trauma showing traumatic cataract. Retroillumation of the lens demonstrates posterior-subcapsular opacification of the lens.</div><div class=\"graphic_reference\">Photo courtesy of Kathryn A. Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.</div><div id=\"graphicVersion\">Graphic 71652 Version 3.0</div></div></div>"},"71653":{"type":"graphic_picture","displayName":"Balloon dilat stricture Endosc","title":"Balloon dilation of a peptic stricture in the esophagus","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Balloon dilation of a peptic stricture in the esophagus</div><div class=\"cntnt\"><img style=\"width:565px; height:178px;\" src=\"images/GAST/71653_Balloon_dilat_stricture_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic images demonstrate a stricture in the distal esophagus (first panel) that was dilated with a balloon (second panel) with a resulting larger esophageal lumen (third panel).</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 71653 Version 2.0</div></div></div>"},"71654":{"type":"graphic_table","displayName":"MDS classification WHO","title":"World Health Organization (WHO) classification system for myelodysplastic syndrome (MDS) ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification system for myelodysplastic syndrome (MDS) </div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Disease\n   </td>\n   <td  class=\"subtitle1\">\n   Marrow blasts\n   </td>\n   <td  class=\"subtitle1\">\n   Clinical presentation\n   </td>\n   <td  class=\"subtitle1\">\n   Cytogenetic abnormalities\n   </td>\n   </tr>\n   <tr>\n   <td>Refractory anemia (RA)</td>\n   <td>&#60;5 percent</td>\n   <td>Anemia</td>\n   <td>25 percent</td>\n   </tr>\n   <tr>\n   <td>RA with ring sideroblasts (RARS)</td>\n   <td>&#60;5 percent</td>\n   <td>Anemia, &#8805;15 percent ringed sideroblasts in erythroid precursors</td>\n   <td>5 to 20 percent</td>\n   </tr>\n   <tr>\n   <td>MDS with isolated del(5q) (5q- syndrome)</td>\n   <td>&#60;5 percent</td>\n   <td>Anemia, normal platelets</td>\n   <td>100 percent</td>\n   </tr>\n   <tr>\n   <td>Refractory cytopenia with multilineage dysplasia (RCMD)</td>\n   <td>&#60;5 percent</td>\n   <td>\t<p>Bicytopenia or pancytopenia</p>\n\t<p>&#177;15 ring sideroblasts</p>\n</td>\n   <td>50 percent</td>\n   </tr>\n   <tr>\n   <td>Refractory anemia with excess blasts-1</td>\n   <td>5 to 9 percent</td>\n   <td>Cytopenias +/- peripheral blood blasts (&#60;5 percent)</td>\n   <td>30 to 50 percent</td>\n   </tr>\n   <tr>\n   <td>Refractory anemia with excess blasts-2</td>\n   <td>10 to 19 percent</td>\n   <td>Cytopenias, peripheral blood blasts present</td>\n   <td>50 to 70 percent</td>\n   </tr>\n   <tr>\n   <td>Myelodysplastic syndrome, unclassified</td>\n   <td>&#60;5 percent</td>\n   <td>Neutropenia or thrombocytopenia</td>\n   <td>50 percent</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">MDS: myelodysplastic syndrome.</div><div class=\"graphic_reference\">Source: Vardiman, JW, Brunning, RD, Arber, DA, et al. Introduction and overview of the classification of myeloid neoplasms. In: WHO classification of tumors of hematopoietic and lymphoid tissues, Swerdlow, SH, Campo, E, Harris, NL, et al. (Eds), WHO Press, 2008. p.18.</div><div id=\"graphicVersion\">Graphic 71654 Version 2.0</div></div></div>"},"71655":{"type":"graphic_figure","displayName":"Quantitative PCR","title":"Example of quantitative real-time polymerase chain reaction","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Example of quantitative real-time polymerase chain reaction</div><div class=\"cntnt\"><img style=\"width:546px; height:570px;\" src=\"images/HEME/71655_Quantitative_PCR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The polymerase chain reaction (PCR) can be quantitated in its early exponential phase. Panel A: If there are many targets in the starting sample (eg, curves on the left), the generated fluorescent signal will cross a predetermined threshold value (C<sub>T</sub>) early in the PCR cycling process. If there are few targets (eg, curves on the right), the signal will rise more slowly and will cross C<sub>T</sub> at a later PCR cycle. Panel B: When C<sub>T</sub> is plotted versus the starting quantity of target DNA, the relationship is linear over more than 8 logarithms. To establish the amount of targets in a sample, one can simply determine the cycle number at which C<sub>T</sub> is crossed and use the standard curve to infer the number of targets present in the sample. Panel C: In an example of a cancer patient with t(14;18), the initially large number of targets present (red curve) is markedly reduced after treatment (blue curve).</div><div id=\"graphicVersion\">Graphic 71655 Version 1.0</div></div></div>"},"71656":{"type":"graphic_diagnosticimage","displayName":"MRI of the airway in a child with OSA","title":"MRI of the airway in a child with obstructive sleep apna","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of the airway in a child with obstructive sleep apna</div><div class=\"cntnt\"><img style=\"width:432px; height:404px;\" src=\"images/PEDS/71656_T1-weighted_midsagit_axial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted midsagittal and axial magnetic resonance&nbsp;imaging (MRI)&nbsp;of a control subject (C) and a subject with&nbsp;obstructive sleep apnea&nbsp;(OSA). Note that the&nbsp;subject with OSA has a narrow nasopharyngeal (top right) and oropharyngeal (lower right) airway.</div><div class=\"graphic_footnotes\">C: control; OSAS: obstructive sleep apnea.</div><div class=\"graphic_reference\">Reproduced with permission from Arens, R, McDonough, JM, Costarino, A, et al. Magnetic resonance imaging of the upper airway structure of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2001; 164:698. Official Journal of the American Thoracic Society. Copyright ©2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 71656 Version 3.0</div></div></div>"},"71657":{"type":"graphic_picture","displayName":"Mature cataract","title":"Mature cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mature cataract</div><div class=\"cntnt\"><img style=\"width:365px; height:252px;\" src=\"images/PC/71657_Mature_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of the red reflex signifies the presence of a mature cataract.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 71657 Version 1.0</div></div></div>"},"71659":{"type":"graphic_table","displayName":"ARA criteria for RA","title":"1987 American College of Rheumatology (formerly American Rheumatism Association) revised classification criteria for rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">1987 American College of Rheumatology (formerly American Rheumatism Association) revised classification criteria for rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criterion</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>Morning stiffness</td> <td>Morning stiffness in and around the joints, lasting at least one hour before maximal improvement.</td> </tr> <tr> <td>Arthritis of&nbsp;three or more joint areas</td> <td>At least&nbsp;three joint areas (out of 14 possible areas; right or left PIP, MCP, wrist, elbow, knee, ankle, MTP joints) simultaneously have had soft tissue swelling or fluid (not bony overgrowth alone) as observed by a physician.</td> </tr> <tr> <td>Arthritis of hand joints</td> <td>At least one area swollen (as defined above) in a wrist, MCP, or PIP joint.</td> </tr> <tr> <td>Symmetric arthritis</td> <td>Simultaneous involvement of the same joint areas (as defined above) on both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs, without absolute symmetry is acceptable).</td> </tr> <tr> <td>Rheumatoid nodules</td> <td>Subcutaneous nodules over bony prominences or extensor surfaces, or in juxta-articular regions as observed by a physician.</td> </tr> <tr> <td>Serum rheumatoid factor</td> <td>Demonstration of abnormal amounts of serum rheumatoid factor by any method for which the result has been positive in less than 5 percent of normal control subjects.</td> </tr> <tr> <td>Radiographic changes</td> <td>Radiographic changes typical of rheumatoid arthritis on posteroanterior hand or wrist radiographs, which must include erosions or unequivocal bony decalcification localised in, or most marked adjacent to, the involved joints (osteoarthritis changes alone do not qualify).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: For classification purposes, a patient has RA if at least four of these criteria are satisfied (the first four must have been present for at least six weeks).</div><div id=\"graphicVersion\">Graphic 71659 Version 5.0</div></div></div>"},"71661":{"type":"graphic_figure","displayName":"Redundant sigmoid colon","title":"Redundant sigmoid colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Redundant sigmoid colon</div><div class=\"cntnt\"><img style=\"width:398px; height:552px;\" src=\"images/SURG/71661_Redundant-sigmoid-colon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a redundant sigmoid colon.</div><div id=\"graphicVersion\">Graphic 71661 Version 2.0</div></div></div>"},"71663":{"type":"graphic_table","displayName":"DDx of rash by appearance 3","title":"Differential diagnosis of fever and rash based upon appearance of the rash","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fever and rash based upon appearance of the rash</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Macules, papules, nodules, or plaques</td> <td class=\"subtitle1\">Vesicles, bullae, or pustules</td> <td class=\"subtitle1\">Purpuric macules, purpuric papules, or purpuric vesicles</td> <td class=\"subtitle1\">Widespread erythema with or without edema followed by desquamation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Protozoal/parasitic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p><em>Leishmania braziliensis</em></p> <p><em>Leishmania mexicana</em></p> <p><em>Leishmania tropica</em></p> <p><em>Necator americanus</em></p> <p><em>Onchocerca volvulus</em></p> <p><em>Schistosoma</em></p> <p><em>Strongyloides stercoralis</em></p> <p><em>Toxoplasma gondii </em>(toxoplasmosis)</p> <p><em>Trichinella spiralis</em> (trichinosis)</p> <p><em>Trypanosoma </em>spp</p> </td> <td>&nbsp;</td> <td> <p><em>Plasmodium falciparum</em> (blackwater fever)*</p> <p><em>Trichinella spiralis</em> (trichinosis)</p> <p><em>Toxoplasma gondii</em></p> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Noninfectious</td> </tr> <tr> <td class=\"indent1\"> <p>Erythema multiforme</p> <p>Systemic lupus erythematosus</p> <p>Dermatomyositis</p> <p>Drug hypersensitivities</p> <p>Gianotti-Crosti syndrome</p> <p>Inflammatory bowel disease</p> <p>Pityriasis rosea (fever rare)</p> <p>Sarcoidosis</p> <p>\"Serum sickness\"<sup>&#182;</sup></p> <p>Sweet syndrome (acute febrile neutrophilic dermatosis)</p> <p>Still's disease (juvenile idiopathic arthritis)</p> </td> <td> <p>Erythema multiforme bullosum</p> <p>Toxic epidermal necrolysis</p> <p>Dermatitis from plants</p> <p>Drug hypersensitivities</p> </td> <td> <p>\"Allergic\" vasculitis<sup>&#182;</sup></p> <p>Erythroderma</p> <p>Cholesterol embolization</p> <p>Disseminated intravascular coagulation (purpura fulminans)<sup>&#916;</sup></p> <p>Drug hypersensitivities</p> <p>Fat embolism</p> <p>Henoch-Sch&#246;nlein purpura</p> <p>Immune thrombocytopenic purpura</p> <p>Granulomatosis with polyangiitis (Wegener's)</p> </td> <td> <p>Erythroderma</p> <p>Drug hypersensitivities</p> <p>Graft-versus-host reaction</p> <p>Stevens-Johnson syndrome</p> <p>Toxic epidermal necrolysis</p> <p>von Zumbusch pustular psoriasis</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reportable disease.<br />&para; May have arthralgia or musculoskeletal pain.<br />&Delta; Often present as infarcts.</div><div class=\"graphic_reference\">Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from: Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.</div><div id=\"graphicVersion\">Graphic 71663 Version 10.0</div></div></div>"},"71665":{"type":"graphic_table","displayName":"IDSA ATS CAP guidelines","title":"IDSA/ATS guidelines: Recommended empiric antibiotics for community-acquired pneumonia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">IDSA/ATS guidelines: Recommended empiric antibiotics for community-acquired pneumonia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Outpatient treatment</td> </tr> <tr> <td class=\"sublist2_start\">1. Previously healthy and no use of antimicrobials within the previous three months:</td> </tr> <tr> <td class=\"sublist2\"> <p>A macrolide (azithromycin, clarithromycin, or erythromycin)</p> <p><strong>OR</strong></p> Doxycyline*</td> </tr> <tr> <td class=\"sublist2_start\">2. Presence of comorbidities such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; or use of antimicrobials within the previous three months (in which case an alternative from a different class should be selected):</td> </tr> <tr> <td class=\"sublist2\"> <p>A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])</p> <p><strong>OR</strong></p> A beta-lactam (first-line agents: high-dose amoxicillin, amoxicillin-clavulanate; alternative agents: ceftriaxone, cefpodoxime, or cefuroxime) <strong>PLUS</strong> a macrolide (azithromycin, clarithromycin, or erythromycin)*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3. In regions with a high rate (&#62;25 percent) of infection with high-level (MIC &#8805;16 mcg/mL) macrolide-resistant <em>Streptococcus pneumoniae</em>, consider use of alternative agents listed in (2) above.</td> </tr> <tr> <td class=\"subtitle1_single\">Inpatients, non-ICU treatment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])</p> <p><strong>OR</strong></p> An antipneumococcal beta-lactam (preferred agents: cefotaxime, ceftriaxone, or ampicillin-sulbactam; or ertapenem for selected patients)<sup>&#182;</sup> <strong>PLUS</strong> a macrolide (azithromycin, clarithromycin, or erythromycin)*<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Inpatients, ICU treatment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>An antipneumococcal beta-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) <strong>PLUS</strong> azithromycin</p> <p><strong>OR</strong></p> <p>An antipneumococcal beta-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) <strong>PLUS</strong> a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])</p> <p><strong>OR</strong></p> For penicillin-allergic patients, a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg]) <strong>PLUS</strong> aztreonam</td> </tr> <tr> <td class=\"subtitle1_single\">Special concerns</td> </tr> <tr> <td class=\"sublist2_start\">If <em>Pseudomonas</em> <em>aeruginosa</em> is a consideration:</td> </tr> <tr> <td class=\"sublist2\"> <p>An antipneumococcal, antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) <strong>PLUS</strong> either ciprofloxacin or levofloxacin (750 mg)</p> <p><strong>OR</strong></p> <p>The above beta-lactam <strong>PLUS</strong> an aminoglycoside <strong>PLUS</strong> azithromycin</p> <p><strong>OR</strong></p> The above beta-lactam <strong>PLUS</strong> an aminoglycoside <strong>PLUS</strong> a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg]); for penicillin-allergic patients, substitute aztreonam for above beta-lactam</td> </tr> <tr> <td class=\"sublist2_start\">If CA-MRSA is a consideration:</td> </tr> <tr> <td class=\"sublist2\">Add vancomycin or linezolid</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides the 2007 recommendations of the Infectious Diseases Society of America and the American Thoracic Society for reference purposes. Refer to the UpToDate text for information about choosing between the different guidelines and about the preferred doses and durations of the individual antibiotics.</div><div class=\"graphic_footnotes\">IDSA: Infectious Diseases Society of America; ATS: American Thoracic Society; CAP: community-acquired pneumonia; CA-MRSA: community-acquired methicillin-resistant <EM>Staphylococcus aureus</EM>; ICU: intensive care unit; MIC: minimum inhibitory concentration.<br />* Doxycycline may be used as an alternative to a macrolide, but there is stronger evidence to support the use of a macrolide than doxycycline for CAP.<br />¶ Ceftaroline can be used as an alternative to these agents. It is a fifth-generation cephalosporin that was not included in the 2007 IDSA/ATS guidelines for the management of CAP since it was not US Food and Drug Administration (FDA) approved for CAP until 2010. Ceftaroline has a spectrum of activity like that of ceftriaxone, including good in vivo activity against <EM>Streptococcus pneumoniae</EM>. It is also active against MRSA, unlike older cephalosporins. However, it is not FDA approved for CAP involving MRSA since patients with MRSA were excluded from the trials. Ceftaroline is more expensive (average wholesale price 82 USD per day) compared with the alternative agents, which are all off patent.<SUP>[1]</SUP><br />Δ Monotherapy with tigecycline may be used in patients who cannot take either a beta-lactam or a fluoroquinolone. Tigecycline was not included in the 2007 IDSA/ATS guidelines for the management of CAP because it was not FDA approved for CAP until 2009. It has been associated with increased mortality, as discussed further in the UpToDate&nbsp;topic review.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.</LI></OL>Modified with permission from: Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27. Copyright © 2007 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 71665 Version 18.0</div></div></div>"},"71667":{"type":"graphic_picture","displayName":"Trichomonas vaginalis","title":"Trichomonas vaginalis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichomonas vaginalis</div><div class=\"cntnt\"><img style=\"width:360px; height:431px;\" src=\"images/OBGYN/71667_Trichomonas_vaginalis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power microscopy revealing Trichomonas vaginalis with easily identified flagella.</div><div class=\"graphic_reference\">Courtesy of Jack D. Sobel, MD and William E. Secor.</div><div id=\"graphicVersion\">Graphic 71667 Version 1.0</div></div></div>"},"71669":{"type":"graphic_table","displayName":"IOM DRIs for calcium and vitamin D","title":"Institute of Medicine Dietary Reference Intakes for calcium and vitamin D","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Institute of Medicine Dietary Reference Intakes for calcium and vitamin D</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"7\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Life stage group</td> <td class=\"subtitle1\" colspan=\"3\">Calcium</td> <td class=\"subtitle1\" colspan=\"3\">Vitamin D</td> </tr> <tr> <td class=\"subtitle2\">Estimated average requirement<br /> (mg/day)</td> <td class=\"subtitle2\">Recommended dietary allowance<br /> (mg/day)</td> <td class=\"subtitle2\">Upper level intake<br /> (mg/day)</td> <td class=\"subtitle2\">Estimated average requirement<br /> (international units/day)</td> <td class=\"subtitle2\">Recommended dietary allowance<br /> (international units/day)</td> <td class=\"subtitle2\">Upper level intake<br /> (international units/day)</td> </tr> <tr> <td>Infants 0 to 6 months</td> <td>*</td> <td>*</td> <td>1000</td> <td>&#182;</td> <td>&#182;</td> <td>1000</td> </tr> <tr> <td>Infants 6 to 12 months</td> <td>*</td> <td>*</td> <td>1500</td> <td>&#182;</td> <td>&#182;</td> <td>1500</td> </tr> <tr> <td>1 to 3 years old</td> <td>500</td> <td>700</td> <td>2500</td> <td>400</td> <td>600</td> <td>2500</td> </tr> <tr> <td>4 to 8 years old</td> <td>800</td> <td>1000</td> <td>2500</td> <td>400</td> <td>600</td> <td>3000</td> </tr> <tr> <td>9 to 13 years old</td> <td>1100</td> <td>1300</td> <td>3000</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>14 to 18 years old</td> <td>1100</td> <td>1300</td> <td>3000</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>19 to 30 years old</td> <td>800</td> <td>1000</td> <td>2500</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>31 to 50 years old</td> <td>800</td> <td>1000</td> <td>2500</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>51 to 70 year old males</td> <td>800</td> <td>1000</td> <td>2000</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>51 to 70 year old females</td> <td>1000</td> <td>1200</td> <td>2000</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>&#62;70 years old</td> <td>1000</td> <td>1200</td> <td>2000</td> <td>400</td> <td>800</td> <td>4000</td> </tr> <tr> <td>14 to 18 years old, pregnant/lactating</td> <td>1100</td> <td>1300</td> <td>3000</td> <td>400</td> <td>600</td> <td>4000</td> </tr> <tr> <td>19 to 50 years old, pregnant/lactating</td> <td>800</td> <td>1000</td> <td>2500</td> <td>400</td> <td>600</td> <td>4000</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For infants, adequate intake is 200 mg/day for 0 to 6 months of age and 260 mg/day for 6 to 12 months of age.<br />¶ For infants, adequate intake is 400 international units/day for 0 to 6 months of age and 400 international units/day for 6 to 12 months of age.</div><div class=\"graphic_reference\">Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Modified with permission from the National Academies Press, Copyright &copy; 2006, National Academy of Sciences.<br />Sources: Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Panthothenic acid, Biotin, and Choline (1998); Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000); Dietary Reference Intake reports of the Food and Nutrition Board, Institute of Medicine (2010). These reports may be accessed via <a href=\"http://www.nap.edu/\" style=\"font-style: italic;\" target=\"_blank\">www.nap.edu</a>.</div><div id=\"graphicVersion\">Graphic 71669 Version 15.0</div></div></div>"},"71670":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step three","title":"Standard cricothyrotomy step three","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step three</div><div class=\"cntnt\"><img style=\"width:372px; height:324px;\" src=\"images/EM/71670_Cric_standard_step_three.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incise the cricothyroid membrane transversely.</div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 71670 Version 3.0</div></div></div>"},"71671":{"type":"graphic_figure","displayName":"Embryology of annular pancreas","title":"Embryology of annular pancreas","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Embryology of annular pancreas</div><div class=\"cntnt\"><img style=\"width:543px; height:622px;\" src=\"images/GAST/71671_Embryology_of_annular_pancr.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71671 Version 3.0</div></div></div>"},"71672":{"type":"graphic_picture","displayName":"Gastric cancer Endosc","title":"Endoscopic appearances of gastric cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearances of gastric cancer</div><div class=\"cntnt\"><img style=\"width:345px; height:468px;\" src=\"images/GAST/71672_Gastric_cancer_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows different appearances of a gastric adenocarcinoma. Upper panel: Adenocarcinoma in the antrum manifested by a friable, ulcerated, and circumferential mass. Lower panel: Adenocarcinoma of the cardia. This large, lobulated, ulcerated mass was seen only by retroflexed views of the gastroesophageal junction.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 71672 Version 1.0</div></div></div>"},"71673":{"type":"graphic_picture","displayName":"Serous cystadenoma PAS Light","title":"Pancreatic serous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic serous cystadenoma</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/GAST/71673_Serous_cystadenoma_PAS_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periodic Acid Schiff (PAS) staining of pancreatic serous cystadenoma. Note positive staining identifying glycogen-rich cells lining cystic spaces.</div><div class=\"graphic_reference\">Courtesy of Mike Steer, MD.</div><div id=\"graphicVersion\">Graphic 71673 Version 2.0</div></div></div>"},"71674":{"type":"graphic_algorithm","displayName":"Eval irreg heart rate child","title":"Evaluation of child with an irregular heart rate","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Evaluation of child with an irregular heart rate</div><div class=\"cntnt\"><img style=\"width:494px; height:487px;\" src=\"images/PEDS/71674_Eval_irreg_heart_rate_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram performed if there is a suspicion for structural heart disease.</div><div class=\"graphic_footnotes\">HR: heart rate; DX: diagnosis; ECG: electrocardiogram; APB: atrial premature beats; WPW: Wolff-Parkinson-White syndrome; VPBs: ventricular premature beats; SND: sinus node dysfunction; AV: atrioventricular; Sx: symptoms; NS VT: nonsustained ventricular tachycardia; SVT: supraventricular tachycardia; EPS: electrophysiology study; RX: therapy.</div><div class=\"graphic_reference\">Courtesy of Andrew D Blaufox, MD.</div><div id=\"graphicVersion\">Graphic 71674 Version 2.0</div></div></div>"},"71676":{"type":"graphic_table","displayName":"TIA symptoms and vascular territories","title":"Symptoms of transient ischemic attacks and the vascular territories involved","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of transient ischemic attacks and the vascular territories involved</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">ICA/MCA</td> <td class=\"subtitle1\">VA/BA</td> <td class=\"subtitle1\">PCA</td> <td class=\"subtitle1\">Lacunes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Visual abnormalities</td> </tr> <tr> <td class=\"indent1\">Transient monocular blindness</td> <td>++++</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hemianopia</td> <td>+</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Blindness</td> <td>&nbsp;</td> <td>++</td> <td>++</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Motor abnormalities</td> </tr> <tr> <td class=\"indent1\">Hemiparesis</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Quadriparesis</td> <td>&nbsp;</td> <td>++++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Single part weakness</td> </tr> <tr> <td class=\"sublist2\">Face</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+ </td> </tr> <tr> <td class=\"sublist2\">Arm/hand</td> <td class=\"sublist_other\">+++</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+ </td> </tr> <tr> <td class=\"sublist2\">Thigh/leg/foot</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+ </td> </tr> <tr> <td class=\"indent1\">Crossed weakness*</td> <td>&nbsp;</td> <td>++++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Limb ataxia/weakness</td> <td>&nbsp;</td> <td>++</td> <td>&nbsp;</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Gait ataxia</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Sensory abnormalities</td> </tr> <tr> <td class=\"indent1\">Hemisensory</td> <td>+</td> <td>&nbsp;</td> <td>++</td> <td>++</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Single part sensory</td> </tr> <tr> <td class=\"sublist2\">Face</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">++</td> </tr> <tr> <td class=\"sublist2\">Arm/hand</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+</td> </tr> <tr> <td class=\"sublist2\">Thigh/leg/foot</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> </tr> <tr> <td class=\"indent1\">Crossed sensory*</td> <td>&nbsp;</td> <td>++++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cognitive abnormalities</td> </tr> <tr> <td class=\"indent1\">Aphasia</td> <td>++++</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Amnesia</td> <td>&nbsp;</td> <td>+</td> <td>+++</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Alexia</td> <td>+++</td> <td>&nbsp;</td> <td>+++</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Abulia</td> <td>++</td> <td>+</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Brainstem and cranial nerve symptoms</td> </tr> <tr> <td class=\"indent1\">Dizziness/vertigo</td> <td>+</td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Diplopia</td> <td>&nbsp;</td> <td>++++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dysarthria</td> <td>+</td> <td>++</td> <td>&nbsp;</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Dysphagia</td> <td>&nbsp;</td> <td>++</td> <td>&nbsp;</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Tinnitus/hearing loss</td> <td>&nbsp;</td> <td>++++</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICA: internal carotid arteries; MCA: middle cerebral arteries; VA: vertebral arteries; BA: basilar artery; PCA: posterior cerbral arteries.<br />* Crossed weakness or crossed sensory refers to one side of the cranial structures and the opposite side limbs and trunk.</div><div id=\"graphicVersion\">Graphic 71676 Version 4.0</div></div></div>"},"71677":{"type":"graphic_diagnosticimage","displayName":"EGPA (Churg-Strauss) PA","title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) chest radiograph","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:298px;\" src=\"images/PULM/71677_Churg_Strauss_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior chest radiograph of a patient with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 71677 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"71678":{"type":"graphic_table","displayName":"Fat embolism syndrome settings","title":"Conditions associated with fat embolism syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with fat embolism syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Trauma-related</td> </tr> <tr> <td class=\"subtitle2_single\">Orthopedic (common)</td> </tr> <tr> <td class=\"indent2\">Long bone fractures (especially femur)</td> </tr> <tr> <td class=\"indent2\">Pelvic fractures</td> </tr> <tr> <td class=\"indent2\">Fractures of other marrow-containing bones (eg, ribs)</td> </tr> <tr> <td class=\"indent2\">Orthopedic procedures</td> </tr> <tr> <td class=\"indent2\">Intraosseous access or infusions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lung transplantation</td> </tr> <tr> <td class=\"subtitle2_single\">Nonorthopedic (uncommon)</td> </tr> <tr> <td class=\"indent2\">Soft tissue injuries</td> </tr> <tr> <td class=\"indent2\">Chest compressions with or without rib fractures</td> </tr> <tr> <td class=\"indent2\">Burns</td> </tr> <tr> <td class=\"indent2\">Liposuction, lipoinjection, fat grafting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Bone marrow harvesting and transplant</td> </tr> <tr> <td class=\"subtitle1_single\">Nontrauma-related (rare)</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis and panniculitis</td> </tr> <tr> <td class=\"indent1\">Bone tumor lysis</td> </tr> <tr> <td class=\"indent1\">Prolonged steroid therapy</td> </tr> <tr> <td class=\"indent1\">Sickle cell hemoglobinopathies</td> </tr> <tr> <td class=\"indent1\">Fatty liver disease</td> </tr> <tr> <td class=\"indent1\">Lipid infusion</td> </tr> <tr> <td class=\"indent1\">Cyclosporin A solvent</td> </tr> <tr> <td class=\"indent1\">Intraoperative cell salvage</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary bypass</td> </tr> <tr> <td class=\"indent1\">Metastases from fatty tumors</td> </tr> <tr> <td class=\"indent1\">Osteonecrosis</td> </tr> <tr> <td class=\"indent1\">Bone marrow necrosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71678 Version 4.0</div></div></div>"},"71679":{"type":"graphic_table","displayName":"Management of intrapartum fetal heart rate tracings","title":"Management of intrapartum fetal heart rate tracings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of intrapartum fetal heart rate tracings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Fetal heart rate tracing</td> <td class=\"subtitle1\">Possible etiologies and interpretation</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Category I</td> </tr> <tr> <td class=\"indent1\">Baseline 110 to 160 beats per minute with moderate variability and no late or variable decelerations. Accelerations and early decelerations may be present or absent.</td> <td>This is a normal tracing.</td> <td>Intermittent or continuous fetal monitoring based on clinical status and underlying risk factors. Review every 30 minutes in the first stage and every 15 minutes in the second stage of labor.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Category II</td> </tr> <tr> <td class=\"indent1\">Intermittent variable decelerations (&#60;50 percent of contractions)</td> <td>Common finding usually associated with normal outcome.</td> <td>No intervention required.</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" rowspan=\"2\">Recurrent variable decelerations (&#62;50 percent of contractions)</td> <td rowspan=\"2\">Umbilical cord compression. May be associated with impending acidemia, especially if progressive increase in depth, duration, and frequency. Moderate variability and/or accelerations suggest fetus is not currently acidemic.</td> <td>Reposition mother to left or right lateral. Amnioinfusion is an option. Adjunctive measures to promote fetal oxygenation (oxygen supplementation, intravenous fluid bolus, reduce uterine contraction frequency) may be useful. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic.</td> </tr> <tr> <td>Delivery is indicated if tracing does not improve and acidemia suspected.</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" rowspan=\"2\">Recurrent late decelerations</td> <td rowspan=\"2\">Transient or chronic uteroplacental insufficiency, such as from hypotension, tachystole, or maternal hypoxia. Accelerations and/or moderate variability suggest fetus is not currently acidemic.</td> <td>Reposition mother to left or right lateral. Adjunctive measures to promote fetal oxygenation include oxygen supplementation, intravenous fluid bolus, reduce uterine contraction frequency. Persistent late decelerations with minimal variability and absent accelerations suggest fetal acidemia; this is even more likely if variability is absent (category III). Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic.</td> </tr> <tr> <td>Delivery is indicated if tracing does not improve.</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" rowspan=\"2\">Fetal tachycardia (baseline heart rate greater than 160 beats per minute for at least 10 minutes)</td> <td rowspan=\"2\">Infection, medication, maternal medical disorders, obstetric complications, fetal tachyarrhythmia (typically rate over 200 beats per minute). Fetal acidemic more likely when associated with minimal or absent variability, absent accelerations, and/or recurrent decelerations.</td> <td>Treat underlying cause, if known. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic.</td> </tr> <tr> <td>Delivery is indicated if tracing does not improve and acidemia suspected.</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\">Bradycardia (baseline heart rate less than 110 beats per minute for at least 10 minutes)</td> <td rowspan=\"2\">Acute onset may be due to hypotension, umbilical cord occlusion, rapid fetal descent, tachysystole, abruption, uterine rupture. Fetal acidemic more likely when associated with minimal or absent variability and absent accelerations during baseline periods.</td> <td rowspan=\"2\">Treat underlying cause, if known. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic. Delivery is indicated if tracing does not improve and acidemia suspected.</td> </tr> <tr> <td class=\"indent1\">Prolonged decelerations (15 beats per minute drop below baseline for more than 2 and less than 10 minutes)</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" rowspan=\"2\">Minimal variability</td> <td rowspan=\"2\">Fetal sleep, medication, fetal acidemia. If due to fetal sleep, should recover in 20 to 60 minutes. If due to maternal medication, should recover as medication wears off.</td> <td>If decreased fetal oxygenation suspected, reposition mother to left or right lateral. Adjunctive measures to promote fetal oxygenation include oxygen supplementation, intravenous fluid bolus, reduce uterine contraction frequency. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic.</td> </tr> <tr> <td>If no improvement and no accelerations, delivery is indicated if acidemia suspected or confirmed by scalp pH.</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" rowspan=\"2\"> <p>Tachysystole (more than 5 contractions in 10 minutes, averaged over 30 minutes) with fetal heart rate changes.</p> <p>Tachysystole that is spontaneous and associated with a normal fetal heart rate pattern does not require treatment, but the possibility of placental abruption as the underlying etiology should be considered.</p> </td> <td>Spontaneous labor: Tachysystole may be associated with fetal acidemia if accompanied by recurrent fetal heart rate decelerations.</td> <td> <p>Reposition mother to left or right lateral, oxygen supplementation, intravenous fluid bolus. If ineffective, reduce uterine contraction frequency with a tocolytic.</p> <p>Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic.</p> </td> </tr> <tr> <td>Induction or augmentation.</td> <td>Decrease or stop uterotonic medications. Reposition mother to left or right lateral, oxygen supplementation, intravenous fluid bolus. If ineffective, reduce uterine contraction frequency with a tocolytic. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Category III</td> </tr> <tr> <td class=\"indent1\">Absent baseline variability and recurrent late decelerations, recurrent variable decelerations, or bradycardia</td> <td>Increased risk of fetal acidemia.</td> <td>Prepare for delivery and reposition mother to left or right lateral, oxygen supplementation, intravenous fluid bolus. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic. If no improvement after conservative measures and scalp stimulation does not result in acceleration, delivery is advisable.</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\">Sinusoidal</td> <td>Increased risk of hypoxemia. Risk of acidemia increased if prolonged or amplitude of 15 beats per minute or more.</td> <td>Prepare for delivery and reposition mother to left or right lateral, oxygen supplementation, intravenous fluid bolus. Initiate scalp stimulation to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic. If no improvement after conservative measures and scalp stimulation does not result in acceleration, delivery is advisable.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This chart represents a suggested approach to the interpretation and management of fetal heart rate patterns. It is not intended as a standard of care. Patient-specific factors need to be considered in the evaluation and management of individual patients.</div><div class=\"graphic_reference\">Modified from: American College of Obstetricians and Gynecologists Practice Bulletin. Management of intrapartum fetal heart rate tracings. Obstet Gynecol 2010; 116:1232.</div><div id=\"graphicVersion\">Graphic 71679 Version 6.0</div></div></div>"},"71680":{"type":"graphic_figure","displayName":"Leishmania life cycle","title":"Life cycle of <em>Leishmania</em>","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Life cycle of <em>Leishmania</em></div><div class=\"cntnt\"><img style=\"width:612px; height:432px;\" src=\"images/ID/71680_Leishmania_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leishmaniasis is transmitted by the bite of infected female phlebotomine sandflies. The sandfly injects the infective stage (ie, promastigotes) from its proboscis during blood meals <STRONG>(1)</STRONG>. Promastigotes that reach the puncture wound are phagocytized by macrophages and other types of mononuclear phagocytic cells <STRONG>(2)</STRONG>. In these cells, progmastigotes transform into the tissue stage of the parasite (ie, amastigotes) <STRONG>(3)</STRONG>, which multiply by simple division and proceed to infect other mononuclear phagocytic cells <STRONG>(4)</STRONG>. Parasite, host, and other factors affect whether the infection becomes symptomatic and whether cutaneous or visceral leishmaniasis results. Sandflies become infected by ingesting infected cells during blood meals <STRONG>(5,6)</STRONG>. In sandflies, amastigotes transform into promastigotes, develop in the gut (in the hindgut for leishmanial organisms in the <EM>Viannia</EM> subgenus; in the midgut for organisms in the <EM>Leishmania</EM> subgenus) <STRONG>(7)</STRONG> and migrate to the proboscis <STRONG>(8)</STRONG>.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention, DPDx. <A href=\"http://www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm\">http://www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm</A>. </div><div id=\"graphicVersion\">Graphic 71680 Version 3.0</div></div></div>"},"71686":{"type":"graphic_table","displayName":"Treatment of uncomplicated vaginal candidiasis","title":"Treatment of uncomplicated vaginal candidiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of uncomplicated vaginal candidiasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug and trade name(s)</td> <td class=\"subtitle1\">Requires a prescription in US</td> <td class=\"subtitle1\">Preparation</td> <td class=\"subtitle1\">Intravaginal* dose for adult</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clotrimazole</td> </tr> <tr> <td class=\"indent1\">Gyne-Lotrimin<sup>&#182;</sup></td> <td>No</td> <td>1% cream</td> <td>1 applicatorful (approximately 5 g) daily for&nbsp;seven days</td> </tr> <tr> <td class=\"indent1\">Gyne-Lotrimin 3<sup>&#182;</sup></td> <td>No</td> <td>2% cream</td> <td>1 applicatorful (approximately 5 g) daily for&nbsp;three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gyne-Lotrimin<sup>&#916;</sup></td> <td>Not applicable (not available in US)</td> <td>100 mg vaginal tablet<sup>&#916;</sup></td> <td>Insert 1 vaginal tablet daily for&nbsp;seven days or 2 tablets daily for&nbsp;three days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Miconazole</td> </tr> <tr> <td class=\"indent1\">Monistat 7<sup>&#182;</sup></td> <td>No</td> <td> <p>2% cream</p> (combination kit may include 2% miconazole cream for external use)</td> <td>1 applicatorful (approximately 5 g) daily for&nbsp;seven days</td> </tr> <tr> <td class=\"indent1\">Monistat 3<sup>&#182;</sup></td> <td>No</td> <td>4% cream</td> <td>1 applicatorful (approximately 5 g) daily for&nbsp;three days</td> </tr> <tr> <td class=\"indent1\">Monistat 7<sup>&#182;</sup></td> <td>No</td> <td>100 mg vaginal suppository</td> <td>1 suppository daily for seven days</td> </tr> <tr> <td class=\"indent1\">Monistat 3<sup>&#182;</sup>, Vagistat-3</td> <td> <p>No (combination kit)</p> Yes (generic suppository)</td> <td>200 mg vaginal suppository (combination kit may include 2% miconazole cream for external use)</td> <td>1 suppository daily for&nbsp;three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Monistat 1</td> <td>No</td> <td>1200 mg vaginal suppository (combination kit may include 2% miconazole cream for external use)</td> <td>1 suppository for&nbsp;one day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Nystatin<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nystatin vaginal<sup>&#916;</sup> (former US trade name Mycostatin)</td> <td>Not applicable (not available in US)</td> <td>100,000 unit vaginal tablet</td> <td>Insert 1 vaginal tablet daily for 14 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Terconazole<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Terazole 7, Zazole<sup>&#182;</sup></td> <td>Yes</td> <td>0.4% cream</td> <td>1 applicatorful (approximately 5 g) daily at bedtime for&nbsp;seven days</td> </tr> <tr> <td class=\"indent1\">Terazole 3, Zazole<sup>&#182;</sup></td> <td>Yes</td> <td>0.8% cream</td> <td>1 applicatorful (approximately 5 g) daily at bedtime for&nbsp;three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Terazole 3, Zazole<sup>&#182;</sup></td> <td>Yes</td> <td>80 mg vaginal suppository</td> <td>1 suppository daily at bedtime for&nbsp;three days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Tioconazole</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vagistat-1, 1-Day (from Monistat)<sup>&#182;</sup></td> <td>No</td> <td>6.5% ointment</td> <td>1 applicatorful (approximately 5 g) at bedtime as a single dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Butoconazole</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gynazole-1</td> <td>Yes</td> <td>2% cream</td> <td>1 applicatorful (approximately 5 g) as a single dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fluconazole oral administration<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Diflucan<sup>&#182;</sup></td> <td>Yes</td> <td>150 mg oral tablet</td> <td>Single dose by mouth</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There are no significant differences in efficacy among topical and systemic azoles (cure rates &gt;80% for uncomplicated vulvovaginal candidiasis).</div><div class=\"graphic_footnotes\">US: United States.<br />* Except fluconazole (oral administration).<br />¶ Generic equivalent preparation(s) are available in US.<br />Δ Not available in US.<br /><FONT class=lozenge>◊</FONT> Cure rate with nystatin is 70 to 80%.<br />§ Itraconazole is another oral antifungal that appears to be effective<SUP>[1]</SUP>.<br />¥ Rare cases of anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pitsouni E, Iavazzo C, Falagas ME. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2008; 198:153.</LI></OL><br />Data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 71686 Version 18.0</div></div></div>"},"71687":{"type":"graphic_picture","displayName":"Angiolupoid sarcoidosis","title":"Angiolupoid sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiolupoid sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71687_Angiolupoid_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiolupoid sarcoidosis. Well demarcated, erythematous plaques on the cheek with numerous telangiectasias are characteristic of this clinical variant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71687 Version 3.0</div></div></div>"},"71688":{"type":"graphic_table","displayName":"Assessment for allo-HCT eligibility","title":"Assessment for allogeneic hematopoietic cell transplantation eligibility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment for allogeneic hematopoietic cell transplantation eligibility</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Detailed history and physical examination</td> </tr> <tr> <td class=\"sublist1\">Including Karnofsky performance status and dental examination</td> </tr> <tr> <td class=\"sublist1_start\">Laboratory studies</td> </tr> <tr> <td class=\"sublist1\">Complete blood count with differential; chemistries with liver and renal function and electrolytes; pregnancy test; ABO typing; serology for HIV, hepatitis B, hepatitis C, herpes simplex and varicella, cytomegalovirus, Epstein Barr virus, and human T-lymphotropic virus type I and II; urine for micro-analysis and macro-analysis</td> </tr> <tr> <td>Bone marrow aspiration and biopsy</td> </tr> <tr> <td class=\"sublist1_start\">Imaging</td> </tr> <tr> <td class=\"sublist1\">Chest radiograph, an electrocardiogram, and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA)</td> </tr> <tr> <td>Pulmonary function test, including DLCO</td> </tr> <tr> <td>Disease-specific restaging studies</td> </tr> <tr> <td>Donor search</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MUGA: multiple gated cardiac blood pool imaging; DLCO: diffusing capacity of the lungs for carbon monoxide.</div><div id=\"graphicVersion\">Graphic 71688 Version 1.0</div></div></div>"},"71690":{"type":"graphic_picture","displayName":"Bleeding Mallory Weiss Endosc","title":"Mallory-Weiss tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallory-Weiss tear</div><div class=\"cntnt\"><img style=\"width:216px; height:270px;\" src=\"images/GAST/71690_Bleeding_Mallory_Weiss_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows an actively bleeding Mallory-Weiss tear at the gastroesophageal junction.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 71690 Version 1.0</div></div></div>"},"71691":{"type":"graphic_table","displayName":"Modified Spigelmans score and classification","title":"Modified Spigelman's score and classification of duodenal polyposis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Spigelman's score and classification of duodenal polyposis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Factor</td> <td class=\"subtitle1\" colspan=\"3\">Score</td> </tr> <tr> <td class=\"subtitle2\">1 point</td> <td class=\"subtitle2\">2 points</td> <td class=\"subtitle2\">3 points</td> </tr> <tr> <td>Number of polyps</td> <td>1-4</td> <td>5-20</td> <td>&#62;20</td> </tr> <tr> <td>Polyp size, mm</td> <td>1-4</td> <td>5-10</td> <td>&#62;10</td> </tr> <tr> <td>Histology</td> <td>Tubulous</td> <td>Tubulovillous</td> <td>Villous</td> </tr> <tr> <td>Dysplasia</td> <td>Low grade</td> <td>--</td> <td>High grade</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Classification: no polyp: stage 0; 1 to 4 points: stage I; 5 to 6 points: stage II; 7 to 8 points: stage III; 9 to 12 points: stage IV.</div><div class=\"graphic_reference\">Reproduced with permission from: Saurin J, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22:493. Copyright &copy; 2004 American Society of Clinical Oncology (ASCO).</div><div id=\"graphicVersion\">Graphic 71691 Version 4.0</div></div></div>"},"71692":{"type":"graphic_table","displayName":"Hysteroscopy distend media","title":"Distending media for hysteroscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distending media for hysteroscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category </td> <td class=\"subtitle1\">Medium </td> <td class=\"subtitle1\">Hysteroscopic procedure </td> <td class=\"subtitle1\">Biochemical properties </td> <td class=\"subtitle1\">Complications or adverse effects </td> <td class=\"subtitle1\">Safety measures<sup>[1,2]</sup> </td> </tr> <tr> <td>Gaseous</td> <td>Carbon dioxide</td> <td>Diagnostic</td> <td>Colorless gas</td> <td> <p>Gas embolism</p> <p>Shoulder pain</p> </td> <td> <p>Use hysteroscopic insufflator</p> <p>Safety thresholds: </p> <p>Flow &#60;100 mL/min</p> <p>Intrauterine pressure &#60;100 mmHg</p> </td> </tr> <tr> <td rowspan=\"2\">Electrolyte fluid </td> <td> <p>Saline </p> <p>0.9 percent</p> </td> <td> <p>Diagnostic OR</p> <p>Operative:&nbsp;</p> <ul> <li>Bipolar electrocautery </li> <li>Mechanical morcellation device </li> <li>Mechanical tissue removal </li> <li>Laser</li> </ul> </td> <td> <p>Water and sodium chloride</p> <p>Isotonic</p> </td> <td> <p>Volume overload</p> </td> <td rowspan=\"2\"> <p>Fluid deficit thresholds:</p> <p>750 mL: Plan completion of procedure</p> <p>2500 mL: Stop procedure (or earlier in patients who are elderly or have comorbidities)</p> </td> </tr> <tr> <td>Lactated Ringer's solution</td> <td> <p>Diagnostic OR</p> <p>Operative: </p> <ul> <li>Bipolar electrocautery</li> <li>Mechanical morcellation device</li> <li>Mechanical tissue removal</li> <li>Laser</li> </ul> </td> <td> <p>&nbsp;Water and sodium chloride, lacatate, potassium, calcium</p> <p>Isotonic</p> </td> <td> <p>Volume overload</p> </td> </tr> <tr> <td rowspan=\"3\">Electrolyte-poor fluids </td> <td> <p>Mannitol </p> <p>5 percent</p> </td> <td>Operative: monopolar electrocautery only</td> <td> <p>Six-carbon sugar</p> <p>Cleared by kidneys; acts as its own diuretic</p> <p>Elimination half-life: &#8805;100 min<sup>[3]</sup> </p> <p>Isoosmolar</p> </td> <td> <p>Volume overload</p> <p>Hyponatremia</p> </td> <td rowspan=\"3\"> <p>Fluid deficit thresholds:</p> <p>750 mL: Plan completion of procedure <strong>OR</strong> </p> <p>Stop procedure in patients who are elderly or have comorbidities</p> <p>1000 mL: Stop procedure</p> </td> </tr> <tr> <td> <p>Sorbitol</p> <p>3 percent</p> </td> <td>Operative: monopolar electrocautery only</td> <td> <p>Six-carbon sugar</p> <p>Metabolized in the liver to fructose and glucose</p> <p>Elimination half-life: &#8805;33 min<sup>[3]</sup> </p> <p>Hypoosmolar</p> </td> <td> <p>Volume overload</p> <p>Hyponatremia</p> <p>Hypoosmolality</p> <p>Hyperglycemia</p> <p>Peritonitis<sup>[4]</sup></p> </td> </tr> <tr> <td> <p>Glycine </p> <p>1.5 percent</p> </td> <td>Operative: monopolar electrocautery only</td> <td> <p>Amino acid</p> <p>Metabolized into serine and ammonia</p> <p>Elimination half-life: &#8805;40 min<sup>[3]</sup> </p> <p>Hypoosmolar</p> </td> <td> <p>Volume overload</p> <p>Hyponatremia</p> <p>Hypoosmolality</p> <p>Hyperammonemia</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>ACOG technology assessment in obstetrics and gynecology, number 4, August 2005: hysteroscopy. Obstet Gynecol 2005; 106:439.</LI>&#xD;&#xA;<LI>Loffer FD, Bradley LD, Brill AI, et al. Hysteroscopic fluid monitoring guidelines. The ad hoc committee on hysteroscopic training guidelines of the American Association of Gynecologic Laparoscopists. J Am Assoc Gynecol Laparosc 2000; 7:167.</LI>&#xD;&#xA;<LI>Hahn RG. Fluid absorption in endoscopic surgery. Br J Anaesth 2006; 96:8.</LI>&#xD;&#xA;<LI>Phillips AJ. Peritonitis from sorbitol distending medium after hysteroscopy. Obstet Gynecol 2003; 102:1148.</LI></OL></div><div id=\"graphicVersion\">Graphic 71692 Version 2.0</div></div></div>"},"71694":{"type":"graphic_table","displayName":"Annual bariatric procedures US","title":"Estimated number of bariatric operations performed in the United States, 1992-2003","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated number of bariatric operations performed in the United States, 1992-2003</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">2011</td> <td class=\"subtitle1\">2012</td> <td class=\"subtitle1\">2013</td> <td class=\"subtitle1\">2014</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Total</strong></td> <td><strong>158,000</strong></td> <td><strong>173,000</strong></td> <td><strong>179,000</strong></td> <td><strong>193,000</strong></td> </tr> <tr> <td class=\"indent1\">RNY</td> <td>36.7%</td> <td>37.5%</td> <td>34.2%</td> <td>26.8%</td> </tr> <tr> <td class=\"indent1\">Band</td> <td>35.4%</td> <td>20.2%</td> <td>14%</td> <td>9.5%</td> </tr> <tr> <td class=\"indent1\">Sleeve</td> <td>17.8%</td> <td>33%</td> <td>42.1%</td> <td>51.7%</td> </tr> <tr> <td class=\"indent1\">BPD/DS</td> <td>0.9%</td> <td>1%</td> <td>1%</td> <td>0.4%</td> </tr> <tr> <td class=\"indent1\">Revisions</td> <td>6%</td> <td>6%</td> <td>6%</td> <td>11.5%</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>3.2%</td> <td>2.3%</td> <td>2.7%</td> <td>0.1%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ASMBS total bariatric procedures numbers from 2011, 2012, 2013, and 2014 are based on the best estimation from available data (BOLD, ASC/MBSAQIP, national inpatient sample data and outpatient estimations).</div><div class=\"graphic_footnotes\">RNY: Roux-en-Y; BPD/DS: biliopancreatic diversion with duodenal switch; ASMBS: American Society for Metabolic and Bariatric Surgery; BOLD: Bariatric Outcomes Longitudinal Database; ACS/MBSAQIP: American College of Surgeons/Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program.</div><div class=\"graphic_reference\">Reprinted with permission of American Society for Metabolic and Bariatric Surgery, Copyright &copy; 2015, all rights reserved.</div><div id=\"graphicVersion\">Graphic 71694 Version 2.0</div></div></div>"},"71695":{"type":"graphic_table","displayName":"Hemoperfusion in poisons","title":"Common agents for which hemoperfusion may enhance elimination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common agents for which hemoperfusion may enhance elimination</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"sublist1_start\">Barbiturates&nbsp;&nbsp;</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Phenobarbital</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Primidone</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Sedative-hypnotics</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Meprobamate</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Methaqualone</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Glutethimide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Ethchlorvynol</td></tr>\n\t\t\t\t\t\t<tr><td>Phenytoin</td></tr>\n\t\t\t\t\t\t<tr><td>Theophylline</td></tr>\n\t\t\t\t\t\t<tr><td>Disopyramide</td></tr>\n\t\t\t\t\t\t<tr><td>Chloramphenicol</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td>Amanita mushrooms</td></tr>\n\t\t\t\t\t\t<tr><td>Carbamazepine</td></tr>\n\t\t\t\t\t\t<tr><td>Valproate</td></tr>\n\t\t\t\t\t\t<tr><td>Procainamide + N-acetylprocainamide</td></tr>\n\t\t\t\t\t\t<tr><td>Caffeine</td></tr>\n\t\t\t\t\t\t<tr><td>Chloral hydrate</td></tr>\n\t\t\t\t\t\t<tr><td>Dapsone</td></tr>\n\t\t\t\t\t\t<tr><td>Methotrexate</td></tr>\n\t\t\t\t\t\t<tr><td>Phenylbutazone</td></tr>\n\t\t\t\t\t\t<tr><td>Carbon tetrachloride</td></tr>\n\t\t\t\t\t\t<tr><td>Paraquat</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71695 Version 1.0</div></div></div>"},"71696":{"type":"graphic_table","displayName":"Nebulizer technique","title":"Technique for use of medication nebulizer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of medication nebulizer</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Place patient in a comfortable position (preferably sitting up or partially supine, since there is some risk of spillage if the patient is lying flat).</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Assemble apparatus.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Add medication to nebulizer.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Use a fill volume of 3 to 6 mL.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Attach a&nbsp;compressor or a pressurized gas supply&nbsp;(eg, compressed air or oxygen) with a flow of 6 to 8 L/min.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Instruct patient to breathe through the mouth whether using a mask or mouthpiece. If using a mouthpiece, the patient can rest teeth on mouthpiece and close lips around it.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Encourage patient to breathe with a slow inspiratory flow and an occasional deep breath.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Periodically tap nebulizer to return impacted&nbsp;droplets to reservoir.</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Stop&nbsp;treatment when the nebulizer sputters despite tapping.</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 71696 Version 6.0</div></div></div>"},"71698":{"type":"graphic_picture","displayName":"Candidal onychomycosis in a patient with CMCC","title":"Candidal onychomycosis in a patient with chronic mucocutaneous candidiasis (CMCC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidal onychomycosis in a patient with chronic mucocutaneous candidiasis (CMCC)</div><div class=\"cntnt\"><img style=\"width:298px; height:215px;\" src=\"images/ALLRG/71698_Candidal_onychomycosis_in_a_patient_with_CMCC.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71698 Version 1.0</div></div></div>"},"71699":{"type":"graphic_picture","displayName":"Cross wall PM","title":"Cross wall PM","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Cross wall PM</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/ID/71699_Cross_wall_PM_edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gomori methenamine silver staining of skin biopsy (original magnification, x1000).</div><div id=\"graphicVersion\">Graphic 71699 Version 2.0</div></div></div>"},"71701":{"type":"graphic_diagnosticimage","displayName":"MRI HSV encephalitis","title":"MRI findings in a patient with herpes simplex encephalitis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">MRI findings in a patient with herpes simplex encephalitis</div><div class=\"cntnt\"><img style=\"width:514px; height:616px;\" src=\"images/ID/71701_MRI_abnormal_signals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Upper panels) Magnetic resonance (MR) images of the brain of a patient with herpes simplex virus encephalitis at two day after admission. Abnormal signals were seen in the right temporal lobe and insular cortex.<br />(Lower panels) MR images showing that abnormal signals had spread to the left side at 15 days after admission.</div><div class=\"graphic_reference\">Reproduced with permission from: The Department of Neurology, Obihiro Kosei General Hospital, Obihiro. Received for publication March 24, 2003. Copyright &copy; Hideki Houzen, MD.</div><div id=\"graphicVersion\">Graphic 71701 Version 4.0</div></div></div>"},"71702":{"type":"graphic_picture","displayName":"MPGN in mixed cryo light","title":"Membranoproliferative pattern in mixed cryoglobulinemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Membranoproliferative pattern in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/71702_CryoglobulinemiaLight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in mixed cryoglobulinemia showing a membranoproliferative pattern with increased cellularity and thickening of the glomerular capillary walls. The pathognomonic finding is PAS-positive microthrombi composed of precipitated cryoglobulins that are occluding some of the capillary loops (arrows).</div><div class=\"graphic_footnotes\">PAS: periodic acid Schiff.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 71702 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"71705":{"type":"graphic_figure","displayName":"Plat 2nd messenger production","title":"Fate of phosphatidylinositol 4,5-biphosphate (PIP2) in platelets and second messenger production","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fate of phosphatidylinositol 4,5-biphosphate (PIP2) in platelets and second messenger production</div><div class=\"cntnt\"><img style=\"width:367px; height:347px;\" src=\"images/HEME/71705_Plat_2nd_messenger_producti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the outcome of agonist activation of platelet phospholipase C beta (PLC) via the G alpha-q subunit and activation of phosphoinositol 3-kinase gamma (PI3K) via the G beta-gamma subunit. In both cases, the substrate is membrane-associated phosphatidylinositol 4,5-biphosphate (PIP2), shown in the top center of the figure. The green arrows point to the number 1 and 3 carbons in the inositol ring. Hydrolysis of PIP2 by PLC yields 1,4,5-inositol triphosphate (IP3), which raises the cytosolic Ca++ concentration by releasing sequestered Ca++ from the dense tubular system and diacylglycerol (DAG), which activates protein kinase C. Phosphorylation of the number 3 inositol carbon of PIP2 by PI3K generates the second messenger phosphoinositol 3,4,5-triphosphate (PIP3), important for stable platelet aggregation.</div><div id=\"graphicVersion\">Graphic 71705 Version 2.0</div></div></div>"},"71706":{"type":"graphic_picture","displayName":"Brow ptosis","title":"Brow ptosis","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Brow ptosis</div><div class=\"cntnt\"><img style=\"width:507px; height:228px;\" src=\"images/DERM/71706_Brow_ptosis_edt_eyes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lowering of the brow can occur as a natural feature of aging. Note the difference in brow position between the younger individual on the left and the middle-aged person on the right.</div><div id=\"graphicVersion\">Graphic 71706 Version 5.0</div></div></div>"},"71707":{"type":"graphic_diagnosticimage","displayName":"Mycoplasma pneumonia lung imaging B","title":"Acute bronchiolitis caused by <em>Mycoplasma pneumoniae</em>","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Acute bronchiolitis caused by <em>Mycoplasma pneumoniae</em></div><div class=\"cntnt\"><img style=\"width:597px; height:203px;\" src=\"images/ID/71707_MycoplasmapneulungimgB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Magnified view of the right lower lung zone from a posteroanterior chest radiograph shows a reticulonodular pattern. (B) High-resolution computed tomography (CT) scan (1 mm collimation) at the level of the inferior pulmonary veins shows multiple bilateral centrilobular nodular and branching linear opacities (\"tree-in-bud\" pattern; arrows) in both lower lobes. The patient was a previously healthy 24-year-old man. Immunofluorescent microscopy of sputum revealed <EM>M. pneumoniae </EM>organisms.</div><div class=\"graphic_reference\">Reproduced with permission from: Pulmonary infection: Basic concepts. In: Imaging of Pulmonary Infections, Müller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71707 Version 10.0</div></div></div>"},"71708":{"type":"graphic_table","displayName":"Monitoring the NHL survivor for long-term complications","title":"Monitoring the non-Hodgkin lymphoma (NHL) survivor for long-term complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring the non-Hodgkin lymphoma (NHL) survivor for long-term complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Cancer screening</td> </tr> <tr> <td colspan=\"2\">NHL survivors should be advised of their increased risk of developing a malignancy following treatment, encouraged to participate in routine age-appropriate cancer surveillance, and to report any concerning symptoms to their physician.</td> </tr> <tr> <td class=\"indent1\">Breast cancer</td> <td>Starting at age 40 years (or if chest irradiated, eight years after radiation or age 25, whichever is later): <ul> <li>Annual screening mammogram</li> <li>Consider annual breast MRI in addition to mammogram for women who received radiation to the chest between the age of 10 and 35 years</li> <li>Consider referral to high-risk breast clinic for discussion of chemoprevention</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lung cancer</td> <td> <ul> <li>Smoking cessation</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Skin cancer</td> <td> <ul> <li>Annual complete skin examination</li> <li>Sun safety practice</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Cardiovascular health</td> </tr> <tr> <td colspan=\"2\">Screening and counseling techniques are similar to those used for other high risk populations. At a minimum, patients should be instructed not to ignore persistent troubling symptoms and to bring such symptoms to the attention of their physician without delay.</td> </tr> <tr> <td class=\"indent1\">Cardiac disease</td> <td> <ul> <li>Referral to cardiologist for baseline evaluation after treatment</li> <li>Resting and stress echocardiogram (frequency depending on baseline findings and existence of other cardiac risk factors)</li> <li>Traditional risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension)</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Non-coronary vascular disease</td> <td> <ul> <li>Annual examination for carotid bruits; obtain carotid ultrasound if suspicious clinical findings</li> <li>Traditional risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension)</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Endocrine assessment</td> </tr> <tr> <td class=\"indent1\">Infertility</td> <td> <ul> <li>Referral to reproductive endocrinologist as needed</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> <td> <ul> <li>Annual thyroid examination and thyroid function tests (ie, TSH) for NHL survivors whose treatment included radiation to the neck or mediastinum</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Neurologic and psychiatric evaluation</td> </tr> <tr> <td colspan=\"2\">Annual evaluation should include a discussion of psychiatric health including an assessment of symptoms of depression and posttraumatic stress disorder. All patients at increased risk (eg, history of cranial irradiation, intrathecal therapy) should undergo screening for neurocognitive impairment.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71708 Version 1.0</div></div></div>"},"71709":{"type":"graphic_figure","displayName":"Recombination","title":"Recombination","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Recombination</div><div class=\"cntnt\"><img style=\"width:488px; height:354px;\" src=\"images/ALLRG/71709_Recombination.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">V: variable segment; RSS: recombination signal sequence; J: joining segment; RAG1: recombinase activating gene 1; RAG2: recombinase activating gene 2.</div><div id=\"graphicVersion\">Graphic 71709 Version 2.0</div></div></div>"},"71710":{"type":"graphic_picture","displayName":"AIP duct sclerosis Light HP","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/71710_AIP_duct_sclerosis_Light_HP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power (200x) view of a pancreas biopsy in a patient with autoimmune pancreatitis showing a small pancreatic duct with a lymphoplasmacytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of Russell Dorer, MD.</div><div id=\"graphicVersion\">Graphic 71710 Version 1.0</div></div></div>"},"71711":{"type":"graphic_table","displayName":"Female sexual history","title":"Female sexual dysfunction: Taking a sexual history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Female sexual dysfunction: Taking a sexual history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Questions about sexual activity should be specific. Assumptions should not be made about the gender or number of a patient's sexual partners or about how the patient interprets \"sexual activity.\"</td> </tr> <tr> <td class=\"subtitle2_single\">For each complaint, it is important to assess:</td> </tr> <tr> <td class=\"indent1\">Is it new, chronic, or intermittent?</td> </tr> <tr> <td class=\"indent1\">Does it cause personal distress or interpersonal difficulty?</td> </tr> <tr> <td class=\"indent1\">Is it generalized or does it occur only in certain settings or with a specific partner?</td> </tr> <tr> <td class=\"subtitle2_single\">Useful questions:</td> </tr> <tr> <td class=\"indent1\">What is your principle sexual concern (eg, low desire, difficulty with orgasm, dyspareunia)?</td> </tr> <tr> <td class=\"indent1\">When were you last satisfied with your sex life? Describe the frequency of sexual activity and your level of desire, arousal and response at that time versus now.</td> </tr> <tr> <td class=\"indent1\">When did you start to notice a change that was bothersome to you? Do you have any idea what may have occurred at that time that contributed to the problem (eg, infertility, birth of child, depression, new medication, cancer diagnosis, menopause, issue with partner)?</td> </tr> <tr> <td class=\"indent1\">Do you believe stress, fatigue, or limited privacy are contributing to your sexual problem?</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 10px;\"></span> <p>Have you and/or your partner tried anything to improve your sex life, for example vacation, erotic films or books, devices, counseling, or sex therapy? Were any of the interventions helpful?</p> </td> </tr> <tr> <td class=\"subtitle2_single\">If the patient has a partner:</td> </tr> <tr> <td class=\"indent1\">Describe your partner (age, general health, duration of relationship), including his/her level of sexual interest and function [eg, erectile dysfunction]).</td> </tr> <tr> <td class=\"indent1\">Describe your relationship with your partner (eg, caring, communicative, loving, strained). How often do you spend time together as a couple, without family or friends present? Describe your last vacation together; was the sexual problem still present? Improved?</td> </tr> <tr> <td class=\"indent1\">Is your sexual problem causing stress in the relationship? Do you and your partner talk about sexuality? Have you ever met with a counselor or sex therapist to discuss sexual problems?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71711 Version 4.0</div></div></div>"},"71712":{"type":"graphic_table","displayName":"Down syndrome milestones PI","title":"Differences in reaching milestones for children with Down syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences in reaching milestones for children with Down syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Milestone</td> <td class=\"subtitle1\">Typical age</td> <td class=\"subtitle1\">Average age of child with Down syndrome</td> </tr> <tr> <td>Sit</td> <td>6 months</td> <td>11 months</td> </tr> <tr> <td>Creep</td> <td>9 months</td> <td>17 months</td> </tr> <tr> <td>Walk</td> <td>13 months</td> <td>26 months</td> </tr> <tr> <td>Utter first meaningful word(s)</td> <td>10 months</td> <td>18 months</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71712 Version 5.0</div></div></div>"},"71713":{"type":"graphic_figure","displayName":"Femoral vein cannulation","title":"Femoral vein cannulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral vein cannulation</div><div class=\"cntnt\"><img style=\"width:393px; height:414px;\" src=\"images/PEDS/71713_Femoral_vein_cannulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The landmarks for the cannulation of the femoral vein are identified. The patient is placed in a frog-leg position with the hip externally rotated and abducted. The femoral vein is located by feeling for the femoral pulse. The vein is found medial to the pulse. In the patient without a pulse, the vein can be approximately located midway between the pubic symphysis and the anterior superior iliac spine, distal to the inguinal ligament.</div><div id=\"graphicVersion\">Graphic 71713 Version 1.0</div></div></div>"},"71714":{"type":"graphic_table","displayName":"One way sensitivity analysis","title":"Sensitivity analysis on the life expectancy of Outcome 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity analysis on the life expectancy of Outcome 1</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Value of V<sub>1</sub> (life expectancy of Outcome 1)</td>\n<td class=\"subtitle1\">Expected value of Choice 1</td>\n<td class=\"subtitle1\">Expected value of Choice 2</td>\n<td class=\"subtitle1\">Preferred strategy</td>\n</tr>\n<tr>\n<td>8.0</td>\n<td>10.2</td>\n<td>11.5</td>\n<td>Choice 2</td>\n</tr>\n<tr>\n<td>9.0</td>\n<td>10.7</td>\n<td>11.5</td>\n<td>Choice 2</td>\n</tr>\n<tr>\n<td>10.0</td>\n<td>11.1</td>\n<td>11.5</td>\n<td>Choice 2</td>\n</tr>\n<tr>\n<td>11.0</td>\n<td>11.6</td>\n<td>11.5</td>\n<td>Choice 1</td>\n</tr>\n<tr>\n<td>12.0</td>\n<td>12.0</td>\n<td>11.5</td>\n<td>Choice 1</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71714 Version 1.0</div></div></div>"},"71716":{"type":"graphic_table","displayName":"Advantages and disadvantages of central vein approaches","title":"Advantages and disadvantages of central vein approaches","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of central vein approaches</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Approach</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>External jugular</td> <td> <p>Superficial vessel that is often visible</p> <p>Coagulopathy not prohibitive</p> <p>Minimal risk of pneumothorax (especially with US guidance)</p> <p>Head-of-table access</p> <p>Prominent in elderly patients</p> <p>Rapid venous access</p> </td> <td> <p>Not ideal for prolonged venous access</p> <p>Poor landmarks in obese patients</p> <p>High rate of malposition</p> <p>Catheter may be difficult to thread</p> </td> </tr> <tr class=\"divider_top\"> <td>Internal jugular</td> <td> <p>Minimal risk of pneumothorax (especially with US guidance)</p> <p>Head-of-table access</p> <p>Procedure-related bleeding amenable to direct pressure</p> <p>Lower failure rate with novice operator</p> <p>Excellent target using US guidance</p> </td> <td> <p>Not ideal for prolonged access</p> <p>Risk of carotid artery puncture</p> <p>Uncomfortable</p> <p>Dressings and catheter difficult to maintain</p> <p>Thoracic duct injury possible on left</p> <p>Poor landmarks in obese/edematous patients</p> <p>Potential access and maintenance issues with concomitant tracheostomy</p> <p>Vein prone to collapse with hypovolemia</p> <p>Difficult access during emergencies when airway control being established</p> </td> </tr> <tr class=\"divider_top\"> <td>Subclavian</td> <td> <p>Easier to maintain dressings</p> <p>More comfortable for patient</p> <p>Better landmarks in obese patients</p> <p>Accessible when airway control is being established</p> </td> <td> <p>Increased risk of pneumothorax</p> <p>Procedure-related bleeding less amenable to direct pressure</p> <p>Decreased success rate with inexperience</p> <p>Longer path from skin to vessel</p> <p>Catheter malposition more common (especially right SCV)</p> <p>Interference with chest compressions</p> </td> </tr> <tr class=\"divider_top\"> <td>Femoral</td> <td> <p>Rapid access with high success rate</p> <p>Does not interfere with CPR</p> <p>Does not interfere with intubation</p> <p>No risk of pneumothorax</p> <p>Trendelenburg position not necessary during insertion</p> </td> <td> <p>Delayed circulation of drugs during CPR</p> <p>Prevents patient mobilization</p> <p>Difficult to keep site sterile</p> <p>Difficult for PA catheter insertion</p> <p>Increased risk of iliofemoral thrombosis</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: ultrasound; SCV: subclavian vein; CPR: cardiopulmonary resuscitation; PA: pulmonary artery.</div><div class=\"graphic_reference\">With permission from: Factor P, Sznajder JI. Vascular cannulation. In: Principles of Critical Care, Hall JB, Schmidt GA, Wood LDH (Eds), McGraw-Hill, New York, 1992. Copyright 1992 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 71716 Version 6.0</div></div></div>"},"71717":{"type":"graphic_table","displayName":"Pediatric headache history","title":"Important components of the headache history for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important components of the headache history for children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Possible significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Headache history</td> </tr> <tr> <td class=\"indent1\">Age at onset</td> <td> <ul> <li>Migraine headaches frequently begin in the first decade of life. </li> <li>Chronic nonprogressive headaches begin in adolescence. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mode of onset</td> <td class=\"indent1\">Abrupt onset of severe headache (\"thunderclap headache\" or \"worst headache of my life\") may indicate intracranial hemorrhage.</td> </tr> <tr> <td class=\"indent1\">What is the headache pattern: acute, acute recurrent, chronic progressive, nonprogressive daily, or mixed?</td> <td class=\"indent1\">Helps to determine the cause (refer to the UpToDate topic on evaluation of headache in children)</td> </tr> <tr> <td class=\"indent1\">How often does the headache occur?</td> <td> <ul> <li>Migraines typically occur two to four times per month; almost never daily. </li> <li>Chronic nonprogressive headaches may occur five to seven days per week. </li> <li>Cluster headaches typically occur two to three times per day for several months. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">How long does the headache last?</td> <td> <ul> <li>Migraines typically last&nbsp;two to three hours in young children and may last longer (48 to 72 hours) in adolescents. </li> <li>The duration of tension headaches is variable; they may last all day. </li> <li>Cluster headaches usually last 5 to 15 minutes but may last for 60 minutes. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Is there an aura or prodrome?</td> <td class=\"indent1\">Aura or prodrome is suggestive of migraine headaches; if the warning symptoms are focal and repeatedly located to the same side of the body, a seizure or vascular or structural cause should be suspected.</td> </tr> <tr> <td class=\"indent1\">When do the headaches occur?</td> <td> <ul> <li>Headaches that wake the child from sleep or occur on waking may indicate increased intracranial pressure/space-occupying lesion. </li> <li>Tension-type headaches typically occur late in the day. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">What is the headache quality (throbbing/pulsating, dull aching, squeezing, etc)?</td> <td> <ul> <li>Migraine headaches have a throbbing/pulsating quality. </li> <li>Chronic nonprogressive headaches have a squeezing pressure or tightness that waxes and wanes. </li> <li>Cluster headaches have a deep continuous pain. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Where is the pain?</td> <td> <ul> <li>Occipital location may indicate posterior fossa neoplasms but also may occur in basilar migraine. </li> <li>Cluster headaches are usually temporal or retro-orbital. </li> <li>Localized pain may suggest a specific secondary etiology (eg, sinusitis, otitis, dental abscess). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">What brings the headache on or makes it worse?</td> <td> <ul> <li>Headache in the recumbent position or with straining/Valsalva may indicate an intracranial process. </li> <li>Migraines may be triggered by certain foods, odors, bright lights, noise, lack of sleep, menses (in girls), and strenuous activity. </li> <li>Tension-type headaches may worsen with stress, bright lights, noise, strenuous activity. </li> <li>Cluster headaches may be worsen with lying down or resting. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">What makes the headache go away?</td> <td> <ul> <li>Migraines typically respond to analgesic medications, dark, quiet room, cool compress, or sleep. </li> <li>Chronic tension-type headaches may respond to sleep (but not to analgesic medications). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Are there associated symptoms?</td> <td> <ul> <li>Neurologic deficits (eg, ataxia, altered mental status, binocular horizontal diplopia) may indicate increased intracranial pressure and/or a space-occupying lesion. </li> <li>Fever may indicate infection, or rarely intracranial hemorrhage. </li> <li>Stiff neck may indicate meningitis, complicated pharyngitis, or intracranial hemorrhage. </li> <li>Localized pain may indicate localized infection (eg, otitis media, pharyngitis, sinusitis, dental abscess). </li> <li>Autonomic symptoms (eg, nausea, vomiting, pallor, chills, flushing, fever, dizziness, syncope, etc) may indicate migraine or cluster headache. </li> <li>Dizziness, numbness, and/or weakness may occur with idiopathic intracranial hypertension. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Do symptoms continue between headaches?</td> <td> <ul> <li>Persistence of symptoms (neurologic symptoms or nausea/vomiting) between headache episodes is suggestive of increased intracranial pressure and/or mass lesions. </li> <li>Resolution of symptoms between episodes is characteristic of migraine headaches. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Headache burden</td> </tr> <tr> <td class=\"indent1\">Do the headaches impair normal functioning (eg, school attendance, activity) and quality of life?</td> <td class=\"indent1\">Children with chronic nonprogressive headaches have frequent school absences; impaired function may warrant referral.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Additional information</td> </tr> <tr> <td class=\"indent1\">Past medical history</td> <td class=\"indent1\">Certain underlying conditions increase the likelihood of intracranial pathology (eg, sickle cell disease, immune deficiency, malignancy or history of malignancy, coagulopathy, cardiac disease with right-to-left intracardiac shunt, head trauma, neurofibromatosis type 1, tuberous sclerosis complex).</td> </tr> <tr> <td class=\"indent1\">Medications and vitamins</td> <td class=\"indent1\">Medications that may cause headache include oral contraceptives, glucocorticoids, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors, among others. Medications associated with idiopathic intracranial hypertension include growth hormone, tetracyclines, vitamin A (in excessive doses), and withdrawal of glucocorticoids.</td> </tr> <tr> <td class=\"indent1\">Recent change in weight or vision</td> <td class=\"indent1\">May be associated with intracranial process (eg, pituitary tumor, craniopharyngioma, idiopathic intracranial hypertension).</td> </tr> <tr> <td class=\"indent1\">Recent changes in sleep, exercise, or diet</td> <td class=\"indent1\">May precipitate headaches; may be associated with mood disorder.</td> </tr> <tr> <td class=\"indent1\">Change in school or home environment</td> <td class=\"indent1\">May be a source of psychosocial stress.</td> </tr> <tr> <td class=\"indent1\">Family history of headache or neurologic disorder</td> <td class=\"indent1\">Migraine headaches and some tumors and vascular malformations are heritable.</td> </tr> <tr> <td class=\"indent1\">What do child and parents think is causing the pain?</td> <td class=\"indent1\">Indicates their levels of anxiety about the headache.</td> </tr> <tr> <td class=\"indent1\">Mental health history/symptoms, psychosocial stressors</td> <td class=\"indent1\">Chronic nonprogressive headaches may be associated with depression or anxiety.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Information compiled from:<br /><OL>&#xD;&#xA;<LI>Lewis DW, Koch T. Headache evaluation in children and adolescents: When to worry? When to scan? Pediatr Ann 2010; 39:399. </LI>&#xD;&#xA;<LI>Rothner AD. The evaluation of headaches in children and adolescents. Semin Pediatr Neurol 1995; 2:109. </LI>&#xD;&#xA;<LI>Strasburger VC, Brown RT, Braverman PK, et al. Headache. In: Adolescent Medicine: A Handbook for Primary Care, Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.25. </LI></OL></div><div id=\"graphicVersion\">Graphic 71717 Version 8.0</div></div></div>"},"71719":{"type":"graphic_picture","displayName":"American dog tick","title":"An adult female <EM>Dermacentor variabilis</EM> (American dog tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female <EM>Dermacentor variabilis</EM> (American dog tick)</div><div class=\"cntnt\"><img style=\"width:221px; height:225px;\" src=\"images/ID/71719_American_dog_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 71719 Version 3.0</div></div></div>"},"71721":{"type":"graphic_figure","displayName":"CDC weight for age boys 2 to 20 years","title":"Weight-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Weight-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:566px; height:688px;\" src=\"images/PEDS/71721_Weight_age_boys_more_2y_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 71721 Version 6.0</div></div></div>"},"71723":{"type":"graphic_picture","displayName":"Angular cheilitis (perlèche)","title":"Angular cheilitis (perlèche)","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Angular cheilitis (perlèche)</div><div class=\"cntnt\"><img style=\"width:480px; height:315px;\" src=\"images/PEDS/71723_Perleche_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angular cheilitis (perlèche). This patient has scaling, fissuring, and crusting at the corners of her mouth. She has atopic dermatitis elsewhere on her skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2<SUP>nd</SUP> Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71723 Version 2.0</div></div></div>"},"71724":{"type":"graphic_table","displayName":"Infection risk by type of neutropenia","title":"Infection risk by type of neutropenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infection risk by type of neutropenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Marrow reserve</td> <td class=\"subtitle1\">T/B immunity</td> <td class=\"subtitle1\">Relation to ANC</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Low to no risk</td> <td>Chronic benign</td> <td>Normal</td> <td>Normal</td> <td>No</td> </tr> <tr> <td>Ethnic</td> <td>Normal</td> <td>Normal</td> <td>No</td> </tr> <tr> <td>Post infectious</td> <td>Normal/mild decrease</td> <td>Normal</td> <td>Yes/no</td> </tr> <tr class=\"divider_bottom\"> <td>Hypersplenism</td> <td>Normal/increased</td> <td>Depends on cause of hypersplenism</td> <td>No</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Moderate risk</td> <td>Transient neonatal neutropenia</td> <td>Variable</td> <td>Normal</td> <td>Yes</td> </tr> <tr> <td>Post infectious</td> <td>Decreased</td> <td>Normal</td> <td>Yes/no</td> </tr> <tr> <td>Drug induced</td> <td>Decreased/normal</td> <td>Normal</td> <td>Yes</td> </tr> <tr> <td>Cyclic</td> <td>Variable</td> <td>Normal</td> <td>Yes</td> </tr> <tr> <td>Nutritional</td> <td>Variable</td> <td>Normal/variable</td> <td>Yes</td> </tr> <tr> <td>Immune (antibody mediated)</td> <td>Normal</td> <td>Abnormal</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Immune (SLE, CVID)</td> <td>Variable</td> <td>Abnormal T/B</td> <td>No/yes</td> </tr> <tr> <td rowspan=\"7\">High risk</td> <td>LDLGL, PWCA</td> <td>Very decreased to absent</td> <td>Abnormal T cells</td> <td>Yes</td> </tr> <tr> <td>Shwachman</td> <td>Decreased</td> <td>Normal/?</td> <td>Yes</td> </tr> <tr> <td>Kostmann</td> <td>Decreased</td> <td>Normal/?</td> <td>Yes</td> </tr> <tr> <td>Drug induced</td> <td>Very decreased to absent</td> <td>Abnormal</td> <td>Yes</td> </tr> <tr> <td>Antineoplastic chemotherapy</td> <td>Very decreased to absent</td> <td>Abnormal T/B</td> <td>Yes</td> </tr> <tr> <td>Aplastic anemia</td> <td>Decreased/absent</td> <td>Probably abnormal T cells</td> <td>Yes</td> </tr> <tr> <td>Marrow infiltration/MDS/leukemia</td> <td>Decreased/absent</td> <td>Probably abnormal</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; SLE: systemic lupus; CVID: common variable immunodeficiency; LDLGL: lymphoproliferative disorders of large granular lymphocytes; PWCA: pure white cell aplasia; MDS: myelodysplastic syndrome.</div><div id=\"graphicVersion\">Graphic 71724 Version 3.0</div></div></div>"},"71725":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis on arm","title":"Linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71725_Line_IgA_bull_derma_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense vesicles and inflammatory plaques are present on the arm. Some lesions demonstrate an annular configuration.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71725 Version 3.0</div></div></div>"},"71726":{"type":"graphic_figure","displayName":"Components of Paragard IUD A","title":"Components of Paragard IUD A","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Components of Paragard IUD A</div><div class=\"cntnt\"><img style=\"width:504px; height:124px;\" src=\"images/OBGYN/71726_Components_of_Paragard_IUD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: FEI Women's Health. Copyright &#169;FEI Women's Health.</div><div id=\"graphicVersion\">Graphic 71726 Version 1.0</div></div></div>"},"71731":{"type":"graphic_table","displayName":"Symptoms pineal tumors","title":"Signs and symptoms of pineal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of pineal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Symptoms</td>\n</tr>\n<tr>\n<td>Headaches (73 percent)</td>\n</tr>\n<tr>\n<td>Vision abnormalities (47 percent)</td>\n</tr>\n<tr>\n<td>Nausea and vomiting (40 percent)</td>\n</tr>\n<tr>\n<td>Impaired ambulation (37 percent)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Signs</td>\n</tr>\n<tr>\n<td>Papilledema (60 percent)</td>\n</tr>\n<tr>\n<td>Ataxia (50 percent)</td>\n</tr>\n<tr>\n<td>Loss of upward gaze (30 percent)</td>\n</tr>\n<tr>\n<td>Tremor (20 percent)</td>\n</tr>\n<tr>\n<td>Altered pupillary reflexes (17 percent)</td>\n</tr>\n<tr>\n<td>Hyperactive deep tendon reflexes (13 percent)</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Chang, CG, Kegeyama, N, Kobayashi T, et al. Pineal tumors: Clinical diagnosis, with special emphasis on the significance of pineal calcification. Neurosurgery 1981; 8:656.</div><div id=\"graphicVersion\">Graphic 71731 Version 1.0</div></div></div>"},"71732":{"type":"graphic_table","displayName":"Bronchiectasis by distribution","title":"Causes of bronchiectasis in children, based on distribution","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of bronchiectasis in children, based on distribution</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Localized</td> </tr> <tr> <td>Foreign body aspiration</td> </tr> <tr> <td>Intraluminal obstruction (granuloma, tumor)</td> </tr> <tr> <td>Congenital abnormality (intralobar bronchopulmonary sequestration, bronchial stenosis, bronchomalacia, tracheal bronchus)</td> </tr> <tr> <td>Extraluminal compression (lymphadenopathy [eg, tuberculosis], vascular compression, or cardiomegaly)</td> </tr> <tr> <td>Right middle lobe syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Generalized</td> </tr> <tr> <td class=\"subtitle2_single\">Upper lobe predominance</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Aspiration syndrome in non-ambulating children</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Central airways</td> </tr> <tr> <td class=\"indent1\">Allergic bronchopulmonary aspergillosis</td> </tr> <tr> <td class=\"indent1\">Mounier-Kuhn symdrome (may also affect lower lobes if repeated infections)</td> </tr> <tr> <td class=\"subtitle2_single\">Lower lobes predominance</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency (specifically hypogammaglobulinemia)</td> </tr> <tr> <td class=\"indent1\">Chronic aspiration in ambulating children</td> </tr> <tr> <td class=\"indent1\">Interstitial pneumonia</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"subtitle2_single\">Middle lobe and lingual predominance</td> </tr> <tr> <td class=\"indent1\">Primary ciliary dyskinesia</td> </tr> <tr> <td class=\"indent1\">Atypical mycobacterial infection</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Javidan-Nejad C, Bhalla S, Bronchiectasis. Radiol Clin N Am 2009; 47:289.</div><div id=\"graphicVersion\">Graphic 71732 Version 3.0</div></div></div>"},"71733":{"type":"graphic_picture","displayName":"Cobblestoning buccal mucosa","title":"Cobblestone appearance of the buccal mucosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cobblestone appearance of the buccal mucosa</div><div class=\"cntnt\"><img style=\"width:360px; height:262px;\" src=\"images/PEDS/71733_Cobblestoning_buccal_mucosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling of the buccal mucosa in patients with Crohn disease may cause it to appear cobblestoned.</div><div class=\"graphic_reference\">Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 71733 Version 2.0</div></div></div>"},"71734":{"type":"graphic_picture","displayName":"Ileocolonic intussusception","title":"Ileocolonic intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolonic intussusception</div><div class=\"cntnt\"><img style=\"width:379px; height:270px;\" src=\"images/PEDS/71734_Ileocolonic_intussusception.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical view of an ileocolonic intussusception, the most common form of intussusception in infants and young children. The terminal ileum (intussusceptum) is seen extending in to the cecum (intussuscipiens).</div><div class=\"graphic_reference\">Courtesy of David Wesson, MD.</div><div id=\"graphicVersion\">Graphic 71734 Version 2.0</div></div></div>"},"71735":{"type":"graphic_figure","displayName":"Insertion of circular stapler into colon","title":"Insertion of circular stapler into colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of circular stapler into colon</div><div class=\"cntnt\"><img style=\"width:363px; height:413px;\" src=\"images/SURG/71735_Circular-stapler-into-colon.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71735 Version 1.0</div></div></div>"},"71736":{"type":"graphic_figure","displayName":"Overview of iron homeostasis","title":"Iron homeostasis","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Iron homeostasis</div><div class=\"cntnt\"><img style=\"width:633px; height:467px;\" src=\"images/HEME/71736_Overviewironhomeostasis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the pathways involved in iron (Fe) homeostasis. The amount of iron passing from mucosal cells into the body is determined by the rate of erythropoiesis and the state of body iron stores.</div><div class=\"graphic_reference\">Adapted from Scientific American Medicine, Scientific American, New York, 1995.</div><div id=\"graphicVersion\">Graphic 71736 Version 2.0</div></div></div>"},"71737":{"type":"graphic_picture","displayName":"Slapped cheek rash","title":"Slapped cheek rash of parvovirus B19","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slapped cheek rash of parvovirus B19</div><div class=\"cntnt\"><img style=\"width:432px; height:355px;\" src=\"images/PEDS/71737_Slapped_cheek_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A child with the characteristic malar (\"slapped cheek\") rash associated with parvovirus B19 (erythema infectiosum, fifth disease).</div><div class=\"graphic_reference\">Courtesy of Moise L Levy, MD.</div><div id=\"graphicVersion\">Graphic 71737 Version 2.0</div></div></div>"},"71739":{"type":"graphic_figure","displayName":"Apposition of the skin edges following fasciotomy","title":"Apposition of the skin edges following fasciotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apposition of the skin edges following fasciotomy</div><div class=\"cntnt\"><img style=\"width:441px; height:632px;\" src=\"images/SURG/71739_Fasciotomy-skin-apposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Silastic bands or nylon sutures may be used in a &quot;Roman-sandle&quot; configuration to progressively reapproximate the skin edges after fasciotomy. Multiple skin staples are placed along the entire length of the incision on both sides of the wound. Through these staples, silastic bands or heavy gauge nylon sutures are placed in a shoelace or &quot;Roman-sandle&quot; configuration. By gently pulling the ends of the silastic bands (or sutures), the skin edges are pulled together. This procedure may be repeated multiple times over several days to reapproximate the skin edges and narrow or close the wound entirely. Although the skin is reapproximated, the fascia is not closed.</div><div id=\"graphicVersion\">Graphic 71739 Version 2.0</div></div></div>"},"71740":{"type":"graphic_figure","displayName":"Changes in the ductal system with aging and reproduction","title":"Changes in the ductal system with aging and reproduction","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Changes in the ductal system with aging and reproduction</div><div class=\"cntnt\"><img style=\"width:613px; height:749px;\" src=\"images/SURG/71740_Ductal_changes_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extent of the development of the ducts and secretory alveoli in the breasts in both sexes at different stages of activity.</div><div class=\"graphic_reference\">Reproduced with permission from: Snell MD. Clinical Anatomy, 7th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71740 Version 1.0</div></div></div>"},"71741":{"type":"graphic_diagnosticimage","displayName":"Retained surgical sponge on magnetic resonance imaging","title":"Retained surgical sponge on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retained surgical sponge on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:438px; height:514px;\" src=\"images/SURG/71741_Retained_surg_sponge_MRI_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paravertebral gossypiboma in patient with lumbar pain, fever, and palpable mass. Patient had undergone prior laminectomy. Coronal T1-weighted image after IV injection of contrast material shows strong enhancement of peripheral rim (arrows).</div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Reproduced with permission from: Professor Giuseppe D'Ippolito. Originally published in: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol 2009; 193:S94.</div><div id=\"graphicVersion\">Graphic 71741 Version 3.0</div></div></div>"},"71742":{"type":"graphic_table","displayName":"Cell types involved in ACD","title":"Cell types involved in ACD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cell types involved in ACD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cell type</td> <td class=\"subtitle1\">Function in ACD</td> </tr> <tr> <td>Langerhans cells</td> <td>Originally thought to be the primary APC, they may also have a regulatory function. Other APCs such as dermal dendritic cells may be involved in all phases of ACD.</td> </tr> <tr> <td>Keratinocytes </td> <td>Facilitate T cell infiltration into the epidermis by expressing specific receptors that bind to molecules located on T cell surface. They are involved in the initiation phase of ACD by producing cytokines that mobilize LCs to migrate and in the termination of ACD through tolerogenic antigen presentation and production of IL-10 and IL-16, which recruit T regulatory cells.</td> </tr> <tr> <td>CD8+ T cells</td> <td>Major effector cell in ACD and source of IFN-gamma production.</td> </tr> <tr> <td>CD4+ T cells</td> <td>Some experimental data support a role for Th1 memory/effector cells in ACD.</td> </tr> <tr> <td>B-1 cells (a type of B-cells)</td> <td>Produce IgM antibodies in response to IL-4, leading to complement activation and leukocyte chemotaxis.</td> </tr> <tr> <td>Invariant natural killer T cells</td> <td>Respond to unidentified endogenous glycolipids after hapten exposure which leads to IL-4 production to activate B-1 cells.</td> </tr> <tr> <td>T-regulatory cells</td> <td>T cell subsets (CD4+, CD25high, Foxp3 transcription factor, CTLA-4+) that function to suppress the T cell-dependent inflammatory response seen in ACD and are critical to hapten tolerance.</td> </tr> <tr> <td>Natural killer cells</td> <td>Member of the innate immune system recently shown to exhibit memory and antigen specificity in a model of murine ACD.</td> </tr> <tr> <td>Mast cells</td> <td>Produce TNF-alpha, which induces DC migration; promote T cell infiltration through release of IL-3, induce T cell proliferation and activation; release mediators that promote inflammation; and may function in antigen presentation.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Gober MD, Gaspari AA. Allergic contact dermatitis. Curr Dir Autoimmun 2008; 10:1. Copyright &#169; 2008 S. Karger AG, Basel. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71742 Version 1.0</div></div></div>"},"71743":{"type":"graphic_table","displayName":"Path features HCV","title":"Pathologic features in recurrent hepatitis C and acute cellular rejection following orthotopic liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathologic features in recurrent hepatitis C and acute cellular rejection following orthotopic liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Pathologic feature</td>\n\t\t\t\t\t<td class=\"subtitle1\">Acute rejection</td>\n\t\t\t\t\t<td class=\"subtitle1\">Recurrent hepatitis C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lobular necroinflammation</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>+++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Interface hepatitis</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t\t<td>++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bile duct damage</td>\n\t\t\t\t\t<td>+++</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Apoptosis</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>+++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lymphoid aggregates</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cholestasis</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Central vein endotheliitis</td>\n\t\t\t\t\t<td>+++</td>\n\t\t\t\t\t<td>+/-</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Steatosis (fat)</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fibrosis</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>++</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 71743 Version 1.0</div></div></div>"},"71744":{"type":"graphic_table","displayName":"Encephalitis clinical clues","title":"Clinical findings and possible etiologic agent(s) in encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings and possible etiologic agent(s) in encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Possible infectious agent(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General findings</td> </tr> <tr> <td class=\"indent1\">Hepatitis</td> <td>Herpes simplex virus (infant only), enterovirus (in infants), <em>Coxiella burnetii</em>; any severe hepatitis can cause encephalopathy</td> </tr> <tr> <td class=\"indent1\">Lymphadenopathy</td> <td>HIV, Epstein-Barr virus, cytomegalovirus, measles virus, rubella virus, West Nile virus, <em>Treponema pallidum</em>, <em>Bartonella henselae</em> and other bartonella species, <em>Mycobacterium tuberculosis</em>, <em>Toxoplasma gondii</em>, <em>Trypansoma brucei gambiense</em></td> </tr> <tr> <td class=\"indent1\">Parotitis</td> <td>Mumps virus</td> </tr> <tr> <td class=\"indent1\">Rash</td> <td>Herpes simplex virus, varicella zoster virus, herpes B virus, human herpesvirus 6, West Nile virus, rubella virus, some enteroviruses, HIV, <em>Rickettsia rickettsii</em>, <em>Mycoplasma pneumoniae</em>, <em>Borrelia burgdorferi</em>, <em>T. pallidum</em>, <em>Ehrlichia chaffeensis</em>, <em>Anaplasma phagocytophilum</em></td> </tr> <tr> <td class=\"indent1\">Respiratory tract findings</td> <td>Venezuelan equine encephalitis virus, Nipha virus, Hendra virus, influenza virus, adenovirus, <em>M. pneumoniae</em>, <em>C. burnetii</em>, <em>M. tuberculosis</em>, <em>Histoplasma capsulatum</em></td> </tr> <tr> <td class=\"indent1\">Retinitis</td> <td>Cytomegalovirus, <em>T. gondii</em>, West Nile virus, <em>B. henselae</em>, <em>T. pallidum</em></td> </tr> <tr> <td class=\"indent1\">Urinary symptoms (dysuria, urgency, incontinence)</td> <td>St. Louis encephalitis virus (during prodrome)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic findings</td> </tr> <tr> <td class=\"indent1\">Cerebellar ataxia</td> <td>Varicella zoster virus (children), Epstein-Barr virus, mumps virus, St. Louis encephalitis virus, <em>Tropheryma whipplei</em>, <em>T. brucei gambiense</em></td> </tr> <tr> <td class=\"indent1\">Cranial nerve abnormalities</td> <td>Herpes simplex virus, Epstein-Barr virus, <em>Listeria monocytogenes</em>, <em>M. tuberculosis</em>, <em>T. pallidum</em>, <em>B. burgdorferi</em>, <em>T. whipplei</em>, <em>Cryptococcus neoformans</em>, <em>Coccidioides species</em>, <em>H. capsulatum</em></td> </tr> <tr> <td class=\"indent1\">Dementia</td> <td>HIV, human transmissible spongiform encephalopathies (sCJD and vCJD), measles, <em>T. pallidum</em>, <em>T. whipplei</em></td> </tr> <tr> <td class=\"indent1\">Myorhythmia</td> <td><em>T. whipplei</em> (oculomasticatory)</td> </tr> <tr> <td class=\"indent1\">Parkinsonism (bradykinesia, masked facies, cogwheel rigidity, postural instability)</td> <td>Japanese encephalitis virus, St. Louis encephalitis virus, West Nile virus, Nipah virus, <em>T. gondii</em>, <em>T. brucei gambiense</em></td> </tr> <tr> <td class=\"indent1\">Poliomyelitis-like flaccid paralysis</td> <td>Japanese encephalitis virus, West Nile virus, tick-borne encephalitis virus, enteroviruses (enterovirus 71, coxsackieviruses), poliovirus</td> </tr> <tr> <td class=\"indent1\">Rhomboencephalitis</td> <td>Enterovirus 71, herpes simplex virus, West Nile virus, <em>L. monocytogenes</em></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303. Copyright © 2008 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 71744 Version 5.0</div></div></div>"},"71745":{"type":"graphic_table","displayName":"Ischemic forearm exercise test","title":"Ischemic forearm exercise test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ischemic forearm exercise test</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Normal response to ischemic exercise</td> <td class=\"subtitle1\">Lactate</td> <td class=\"subtitle1\">Pyruvate</td> <td class=\"subtitle1\">Ammonia</td> </tr> <tr> <td class=\"subtitle2\">3- to 5-fold increase</td> <td class=\"subtitle2\">3- to 5-fold increase</td> <td class=\"subtitle2\">5- to 10-fold increase</td> </tr> <tr> <td>Glycolytic/glycogenolytic defects</td> <td>No rise or &#60;2-fold increase </td> <td>No rise or &#60;2-fold increase</td> <td>Normal</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Except:</td> </tr> <tr> <td class=\"sublist1\">Phosphorylase b kinase deficiency</td> <td class=\"sublist_other\">Normal - mildly increased</td> <td class=\"sublist_other\">Normal - mildly increased</td> <td class=\"sublist_other\">Normal</td> </tr> <tr> <td class=\"sublist1\">Acid maltase deficiency</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Normal</td> </tr> <tr> <td class=\"sublist1\">Lactate dehydrogenase deficiency</td> <td class=\"sublist_other\">No rise</td> <td class=\"sublist_other\">Normal to markedly increased</td> <td class=\"sublist_other\">Normal</td> </tr> <tr> <td>Fatty acid oxidation defects</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Mitochondrial defects</td> <td>Normal to increased</td> <td>Normal to increased</td> <td>Normal</td> </tr> <tr> <td>Myoadenylate deficiency</td> <td>Normal</td> <td>Normal</td> <td>No rise</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71745 Version 3.0</div></div></div>"},"71746":{"type":"graphic_table","displayName":"Comparison of pneumococcal conjugate and polysaccharide vaccines","title":"Comparison of pneumococcal conjugate and pneumococcal polysaccharide vaccines used in children in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of pneumococcal conjugate and pneumococcal polysaccharide vaccines used in children in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">13-valent pneumococcal conjugate vaccine<br /> (PCV13)</td> <td class=\"subtitle1\">Pneumococcal polysaccharide vaccine<br /> (PPSV23)</td> </tr> <tr> <td><strong>Trade name</strong></td> <td>Prevnar 13</td> <td>Pneumovax 23</td> </tr> <tr> <td><strong>Serotypes contained</strong></td> <td>1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F</td> <td>1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F</td> </tr> <tr> <td><strong>Protein carrier</strong></td> <td>CRM197 (a nontoxic mutant of diphtheria toxin)</td> <td>None</td> </tr> <tr> <td><strong>Adjuvant</strong></td> <td>Aluminum phosphate</td> <td>None</td> </tr> <tr> <td><strong>Contains thimerosal?</strong></td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Dose</strong></td> <td>0.5 mL</td> <td>0.5 mL</td> </tr> <tr> <td><strong>Route</strong></td> <td>Intramuscular</td> <td>Intramuscular or subcutaneous</td> </tr> <tr> <td><strong>Target groups</strong></td> <td>All infants and children younger than five years</td> <td>Individuals &#8805;2 years at increased risk for pneumococcal disease</td> </tr> <tr> <td><strong>Approved age groups</strong></td> <td> <p>&#8805;6 weeks</p> </td> <td>&#8805;2 years</td> </tr> <tr> <td><strong>Number of doses</strong></td> <td>Varies depending on age when series is initiated</td> <td>One or two depending upon risk group</td> </tr> <tr> <td><strong>Recommended schedule</strong></td> <td>2, 4, 6, and 12 to 15 months</td> <td> <p>One dose of PPSV23 at age &#8805;2 years and &#8805;8 weeks after the last indicated dose of PCV13.</p> <p>A second dose (five years after the first) is recommended for children who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia.</p> A second dose is <strong>not</strong> recommended for immunocompetent children with cochlear implants or chronic illness, including chronic heart disease, chronic lung disease, diabetes mellitus, and cerebrospinal fluid leaks.</td> </tr> <tr> <td><strong>May be administered with other vaccines?</strong></td> <td>Yes</td> <td>Yes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71746 Version 14.0</div></div></div>"},"71747":{"type":"graphic_figure","displayName":"Subcuticular suture","title":"Subcuticular suture","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Subcuticular suture</div><div class=\"cntnt\"><img style=\"width:495px; height:429px;\" src=\"images/PEDS/71747_Subcuticular_suture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The suture is anchored at one end of the laceration (A). The plane chosen is either the dermis or just deep to the dermis in the superficial subcutaneous fascia. While maintaining this plane, &quot;mirror image&quot; bites are taken horizontally the full length of the wound (B). The final bite leaves a trailing loop of suture, as shown, so that the knot can be fashioned for final closure (C). This technique is commonly supplemented with wound tapes, particularly if there remains some degree of gapping of the edges.</div><div class=\"graphic_reference\">Reproduced with permission from: Trott, AT. Wounds and lacerations: emergency care and closure, 2nd ed, Mosby Year Book, St. Louis 1997. p.160. Copyright &#169;1997 Elsevier.</div><div id=\"graphicVersion\">Graphic 71747 Version 1.0</div></div></div>"},"71750":{"type":"graphic_table","displayName":"Cytogenetics in AML","title":"Phenotypes and frequencies of leukemias in the presence of various breakpoint sites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenotypes and frequencies of leukemias in the presence of various breakpoint sites</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">FAB subtype</td>\n\n      <td class=\"subtitle1\">Percent all AML</td>\n\n      <td class=\"subtitle1\">Chromosome abnormality</td>\n\n      <td class=\"subtitle1\">Genes involved</td>\n\n      <td class=\"subtitle1\">Prognostic implication</td>\n\n    </tr>\n\n    <tr>\n\n      <td>MO - no maturation</td>\n\n      <td>&plusmn;2</td>\n\n      <td>hypodiploidy</td>\n\n      <td>Not applicable</td>\n\n      <td>Not available</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M1 - minimal maturation</td>\n\n      <td>&plusmn;20</td>\n\n      <td>t(9;22)</td>\n\n      <td>BCR-ABL</td>\n\n      <td>Poor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M2 - limited maturation</td>\n\n      <td>&plusmn;30</td>\n\n      <td>t(8;21)</td>\n\n      <td>ETO-AML1</td>\n\n      <td>Intermediate</td>\n\n    </tr>\n\n    <tr>\n\n      <td>With basophilia</td>\n\n      <td>&#60;1</td>\n\n      <td>t(6;9)</td>\n\n      <td>DEK-CAN</td>\n\n      <td>Poor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M3 - promyelocytic</td>\n\n      <td>&plusmn;10</td>\n\n      <td>t(15;17)</td>\n\n      <td>PML-RARA</td>\n\n      <td>Favorable, present in most patients</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M4 - myelomonocytic</td>\n\n      <td>&plusmn;25</td>\n\n      <td>t(...;11) or t(11;...)</td>\n\n      <td>MLL-other</td>\n\n      <td>Poor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M4E - myelomonocytic with eosinophilia</td>\n\n      <td>&plusmn;10</td>\n\n      <td>t(16;16) or (inv)16</td>\n\n      <td>MYH11- CBFB</td>\n\n      <td>Favorable, present in most patients</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M5 - monocytic</td>\n\n      <td>&#60;2</td>\n\n      <td>t(9;11) t(...;11) or t(11;...)</td>\n\n      <td>AF9-MLL MLL-other</td>\n\n      <td>Favorable Poor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M6 - erythroleukemia</td>\n\n      <td>&#60;2</td>\n\n      <td>t(3;5)</td>\n\n      <td>Not available</td>\n\n      <td>Poor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M7 - megakaryoblastic</td>\n\n      <td>&#60;2</td>\n\n      <td>t(1;22)</td>\n\n      <td>Not available</td>\n\n      <td>Very poor</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">FAB: French American British Classification.</div><div id=\"graphicVersion\">Graphic 71750 Version 1.0</div></div></div>"},"71752":{"type":"graphic_figure","displayName":"Skin abrasion PI","title":"Minor cuts and scrapes","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Minor cuts and scrapes</div><div class=\"cntnt\"><img style=\"width:504px; height:671px;\" src=\"images/PI/71752_Skin-abrasion-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture A shows a scrape (also called an &quot;abrasion&quot;). The scrape doesn't go all the way through the skin, so it does not need stitches. Picture B shows a cut that does go all the way through the skin. This cut is deep, so it needs stitches.</div><div id=\"graphicVersion\">Graphic 71752 Version 4.0</div></div></div>"},"71753":{"type":"graphic_diagnosticimage","displayName":"Pulmonic regurgitation CW Doppler","title":"Pulmonic regurgitation CW Doppler","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Pulmonic regurgitation CW Doppler</div><div class=\"cntnt\"><img style=\"width:572px; height:431px;\" src=\"images/CARD/71753_Pulm_regurg_CW_Doppler_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This echocardiographic frame demonstrates the use of the pulmonary insufficiency jet velocity, measured by continuous wave Doppler from the right ventricular outflow tract, to estimate mean pulmonary artery pressure. The continuous wave Doppler beam is aligned with the pulmonary insufficiency jet. The peak pulmonary artery velocity (v) is 1.5 m/sec, which translates into a mean pulmonary artery pressure of 16 mmHg using the regression equation of 4 (v)<sup>2</sup> = 0.7 [(mean pulmonary arterial pressure) – 2].</div><div id=\"graphicVersion\">Graphic 71753 Version 2.0</div></div></div>"},"71754":{"type":"graphic_table","displayName":"Benzodiazepines for treatment of procedural anxiety","title":"Benzodiazepines for treatment of procedural anxiety in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benzodiazepines for treatment of procedural anxiety in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Benzodiazepine</td> <td class=\"subtitle1\">Oral dose*<sup>&#182;</sup></td> <td class=\"subtitle1\">Initial parenteral dose*<sup>&#182;</sup></td> <td class=\"subtitle1\">Onset (minutes)</td> </tr> <tr> <td>Alprazolam</td> <td>0.5 mg</td> <td>Not available</td> <td>Oral: 15 to 30 (delayed with high fat meal)</td> </tr> <tr> <td>Diazepam</td> <td>2 to 10 mg</td> <td>0.03 to 0.1 mg/kg intravenous (2 to 10 mg per dose)</td> <td> <p>Oral: 15<br /> Intravenous: 2 to 5</p> </td> </tr> <tr> <td>Lorazepam</td> <td>1 to 2 mg</td> <td>0.02 to 0.04 mg/kg intravenous (1 to 4 mg per dose)</td> <td>Oral: 15 to 30 <br /> Intravenous: <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&#8804;10 to 15 </span></td> </tr> <tr> <td>Midazolam</td> <td>Oral midazolam is not recommended due to variable response and limited availability (intranasal dosing is provided in footnote<sup>​&#916;</sup>)</td> <td>0.01 to 0.02 mg/kg intravenous (0.5 to 2 mg per dose)</td> <td>Intranasal: <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&#8804;5<br /> <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Intravenous: 1 to 3</span></span></td> </tr> <tr> <td>Oxazepam</td> <td>15 to 30 mg</td> <td>Not available</td> <td>Oral: 60 to 120</td> </tr> <tr> <td>Temazepam</td> <td>15 to 30 mg</td> <td>Not available</td> <td>Oral: 30 to 60</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Some patients experience mild symptoms such as nausea, lightheadedness, fatigue, unsteadiness, or psychomotor impairment for up to 24 hours after the administration of sedative agents. This should be made clear to the patient and the patient should be warned not to drive until side effects have completely resolved. Refer to UpToDate topic review of procedural sedation in adults.</LI>&#xD;&#xA;<LI>Equipment, medications, and personnel skilled in advanced cardiac life support and with knowledge of the effects of sedatives and reversal agents must be available for intravenous administration of benzodiazepines.</LI>&#xD;&#xA;<LI>The approach to benzodiazepine selection is reviewed in accompanying text; refer to section on medication preferred or indicated.</LI></UL></div><div class=\"graphic_footnotes\"><br />* <STRONG>Individualization of dose</STRONG>: In most adults, a standard (non-weight based) dose at the lower end to middle of dose range shown in table is appropriate. However, patients with regular benzodiazepine or alcohol use leading to tolerance may need a dose in the upper end of the range. Approximately 50% reduction of dose&nbsp;is needed for older (&gt;60 years) or debilitated adults, patients with low cardiac output, or those premedicated with opioid analgesics. If&nbsp;intravenous administration is used, a slow rate of administration (eg over 2 to 5 minutes or more) with frequent assessments of cardiorespiratory and sedative effects is recommended. In patients who are <STRONG>obese</STRONG>, standard, non-weight-based initial dosing is preferred. Standard adult doses are shown in parentheses following intravenous weight-based doses.<br />¶&nbsp;Repeated dose(s) usually equal to one-half of initial dose may be needed 30 to 60 minutes after oral administration or 5 to 30 minutes after intravenous administration, based upon response and duration of procedure.<br />Δ&nbsp;5 mg/mL midazolam injection solution may be administered intranasally at a dose of 1 to 4 mg<SUP>[1]</SUP>. Onset is within 5 minutes. The injection solution is irritating to nasal passages.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hollenhorst J, Munte S, Friedrich L, et al. Using intranasal midazolam spray to prevent claustrophobia induced by MR imaging. AJR 2001; 176:865.</LI></OL>Courtesy of authors with additional data from Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45:855&nbsp;and Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 71754 Version 11.0</div></div></div>"},"71755":{"type":"graphic_figure","displayName":"Gallbladder anatomy","title":"Gallbladder anatomy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Gallbladder anatomy</div><div class=\"cntnt\"><img style=\"width:576px; height:415px;\" src=\"images/SURG/71755_Gallbladder_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71755 Version 2.0</div></div></div>"},"71757":{"type":"graphic_figure","displayName":"Delivery of uterus vaginally","title":"Delivery of the uterine fundus posteriorly during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery of the&nbsp;uterine fundus posteriorly during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:369px; height:456px;\" src=\"images/OBGYN/71757_Delivery_of_uterus_vaginall.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71757 Version 3.0</div></div></div>"},"71758":{"type":"graphic_table","displayName":"Postoperative bile leak studies","title":"Endoscopic management of postoperative bile leak - clinical and cholangiographic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic management of postoperative bile leak - clinical and cholangiographic features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Cholecystectomy, percent</td> <td class=\"subtitle1\">Lapchole, percent*</td> <td class=\"subtitle1\">Cystic</td> <td class=\"subtitle1\">Luschka<sup>&#182;</sup></td> <td class=\"subtitle1\">Other</td> <td class=\"subtitle1\">CBD stones, percent</td> </tr> <tr> <td>Liguory '91</td> <td>52</td> <td>62<sup>&#916;</sup></td> <td>0</td> <td>n/r</td> <td>n/r</td> <td>n/r</td> <td>n/r</td> </tr> <tr> <td>Davids '92</td> <td>55</td> <td>87<sup>&#916;</sup></td> <td>0</td> <td>69</td> <td>7</td> <td>24</td> <td>28</td> </tr> <tr> <td>Bourke '95</td> <td>85</td> <td>100</td> <td>62</td> <td>79</td> <td>6</td> <td>15</td> <td>18</td> </tr> <tr> <td>Barkun '97</td> <td>50</td> <td>100</td> <td>58</td> <td>77</td> <td>15</td> <td>8</td> <td>22</td> </tr> <tr> <td>Ryan '98</td> <td>50</td> <td>100</td> <td>78</td> <td>72</td> <td>8</td> <td>20</td> <td>22</td> </tr> <tr> <td>Hourigan '99</td> <td>53</td> <td>100</td> <td>85</td> <td>68</td> <td>17</td> <td>15</td> <td>11</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Excludes patients who were converted to open cholecystectomy during surgery.<br />¶ In the majority of series both cholecystohepatic (Luschka) and right hepatic duct leaks are included together.<br />Δ Includes patients who underwent hepatobiliary surgery other than cholecystectomy.</div><div id=\"graphicVersion\">Graphic 71758 Version 2.0</div></div></div>"},"71759":{"type":"graphic_picture","displayName":"Salmonella Shigella agglut","title":"Serologic grouping by agglutination with antisera","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serologic grouping by agglutination with antisera</div><div class=\"cntnt\"><img style=\"width:343px; height:240px;\" src=\"images/ID/71759_SalmonellaShigellaagglut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolates of <EM>Salmonella</EM> and <EM>Shigella</EM> can be presumptively identified by agglutination with appropriate antisera. A positive agglutination is on the left, a negative agglutination on the right.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 71759 Version 3.0</div></div></div>"},"71760":{"type":"graphic_table","displayName":"Symptoms of odontogenic infections","title":"Clinical features of odontogenic orofacial and peripharyngeal \"space\" infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of odontogenic orofacial and peripharyngeal &quot;space&quot; infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Space infections</td> <td class=\"subtitle1\" rowspan=\"2\">Usual site of origin</td> <td class=\"subtitle1\" colspan=\"5\">Clinical features</td> </tr> <tr> <td class=\"subtitle2\">Pain</td> <td class=\"subtitle2\">Trismus</td> <td class=\"subtitle2\">Swelling</td> <td class=\"subtitle2\">Dysphagia</td> <td class=\"subtitle2\">Dyspnea</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Masticator</td> </tr> <tr> <td class=\"sublist1\">Masseteric and pterygoid </td> <td class=\"sublist_other\">Molars (especially 3rd) </td> <td class=\"sublist_other\">+ </td> <td class=\"sublist_other\">+++ </td> <td class=\"sublist_other\">May not be evident (deep) </td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td class=\"sublist1\">Temporal </td> <td class=\"sublist_other\">Post. maxillary molars</td> <td class=\"sublist_other\">+ </td> <td class=\"sublist_other\">- </td> <td class=\"sublist_other\">Face, orbit (late) </td> <td class=\"sublist_other\">- </td> <td class=\"sublist_other\">-</td> </tr> <tr> <td>Buccal </td> <td>Bicuspids, molars </td> <td>&#177;</td> <td>&#177; </td> <td>Cheek (marked)</td> <td>- </td> <td>-</td> </tr> <tr> <td>Canine </td> <td>Maxillary canines, incisors </td> <td>++ </td> <td>- </td> <td>Upper lip, canine fossa </td> <td>- </td> <td>-</td> </tr> <tr> <td>Infratemporal </td> <td>Post. maxillary molars</td> <td>+ </td> <td>++</td> <td>Face, orbit (late) </td> <td>&#177; </td> <td>&#177;</td> </tr> <tr> <td>Submental </td> <td>Mandibular incisors</td> <td>++</td> <td>- </td> <td>Chin (firm)</td> <td>- </td> <td>-</td> </tr> <tr> <td>Submandibular </td> <td>Masseteric spaces </td> <td>+++ </td> <td>- </td> <td>Angle of jaw (marked) </td> <td>- </td> <td>-</td> </tr> <tr> <td>Sublingual </td> <td>2nd, 3rd mandibular molars </td> <td>+</td> <td>&#177; </td> <td>Submandibular (brawny) </td> <td>- </td> <td>-</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Lateral pharyngeal</td> </tr> <tr> <td class=\"sublist1\">Anterior</td> <td class=\"sublist_other\">Mandibular incisors</td> <td class=\"sublist_other\">+&nbsp;</td> <td class=\"sublist_other\">&#177;</td> <td class=\"sublist_other\">Floor of mouth (tender)</td> <td class=\"sublist_other\">+ (if bilateral)&nbsp;</td> <td class=\"sublist_other\">+ (if bilateral)</td> </tr> <tr> <td class=\"sublist1\">Posterior </td> <td class=\"sublist_other\">Masticator spaces </td> <td class=\"sublist_other\">+++ </td> <td class=\"sublist_other\">+++ </td> <td class=\"sublist_other\">Angle of jaw </td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">&#177;</td> </tr> <tr> <td rowspan=\"2\">Retropharyngeal (and \"danger\")</td> <td>Masticator spaces </td> <td>&#177;</td> <td>&#177; </td> <td>Post. pharynx </td> <td>+ </td> <td>+++</td> </tr> <tr> <td>Lateral pharyngeal space, distant via lymphatics </td> <td>+</td> <td>&#177; </td> <td>Post. pharynx (midline) </td> <td>+ </td> <td>+</td> </tr> <tr> <td>Pretracheal </td> <td>Retropharyngeal space, anterior esophagus </td> <td>+</td> <td>- </td> <td>Hypopharynx </td> <td>+ </td> <td>+++</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">±: minimal or occasional; +: present; ++: moderate; +++: prominent or severe.</div><div id=\"graphicVersion\">Graphic 71760 Version 3.0</div></div></div>"},"71761":{"type":"graphic_figure","displayName":"Stroke risk medical treatment","title":"Predicted five-year risk of ipsilateral ischemic stroke in patients with recently symptomatic carotid stenosis on medical treatment","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Predicted five-year risk of ipsilateral ischemic stroke in patients with recently symptomatic carotid stenosis on medical treatment</div><div class=\"cntnt\"><img style=\"width:543px; height:612px;\" src=\"images/NEURO/71761_Stroke_risk_medical_treatme.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Derived from Cox model based on five clinically important patient characteristics in men and women. Stroke/TIA/Ocular refers to the most severe symptomatic ipsilateral ischemic event in the past six months: Stroke&gt; Cerebral TIA&gt; Ocular events only.</div><div class=\"graphic_reference\">Reproduced with permission from: Rothwell, PM, Mehta, Z, Howard, SC, et al. From subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005; 365:256. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 71761 Version 1.0</div></div></div>"},"71762":{"type":"graphic_picture","displayName":"Kleihauer-Betke stain for fetal hemoglobin","title":"Kleihauer-Betke stain for fetal hemoglobin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kleihauer-Betke stain for fetal hemoglobin</div><div class=\"cntnt\"><img style=\"width:396px; height:327px;\" src=\"images/OBGYN/71762_Kleihauer_betke_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to the typical dark pink fetal red blood cell. Note the &quot;ghost&quot; maternal red cells in the background, a result of the instability of hemoglobin A at acidic pH.</div><div id=\"graphicVersion\">Graphic 71762 Version 2.0</div></div></div>"},"71763":{"type":"graphic_figure","displayName":"Cervical spinal cord anatomy","title":"Cervical spinal cord","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Cervical spinal cord</div><div class=\"cntnt\"><img style=\"width:495px; height:339px;\" src=\"images/PEDS/71763_Cervical_spinal_cord_anatom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spinal cord originates from the medulla oblongota and continues caudally through the vertebral foramina until it terminates in the lumbar area. The spinal cord possesses three main tracts: the posterior columns, corticospinal tract, and the spinothalamic tract. The posterior columns carry fine touch, vibration sense, proprioception, and pressure from the ipsilateral side. The corticospinal tract carries motor fibers to the ipsilateral side of the body. The spinothalamic tract carries pain and temperature fibers from the contralateral side of the body.</div><div id=\"graphicVersion\">Graphic 71763 Version 1.0</div></div></div>"},"71764":{"type":"graphic_picture","displayName":"Herpes simplex - oral","title":"Herpes simplex virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex virus infection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71764_Herpes_simplex_oral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions and vesicular lesions are present in the mouth.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71764 Version 3.0</div></div></div>"},"71765":{"type":"graphic_figure","displayName":"Normal hip rotation","title":"Normal hip rotation according to age (years)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal hip rotation according to age (years)</div><div class=\"cntnt\"><img style=\"width:416px; height:604px;\" src=\"images/PEDS/71765_Normalhiprotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hip rotation is assessed with the child prone. The mean and normal range (two standard deviations) for internal rotation (upper panel) and external rotation (lower panel) are depicted above.</div><div class=\"graphic_reference\">Reproduced with permission from: Staheli LT. Lower limb. In: Fundamentals of Pediatric Orthopedics, 4<sup>th</sup> ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 71765 Version 10.0</div></div></div>"},"71766":{"type":"graphic_figure","displayName":"Blood supply to the face and mouth","title":"Blood supply to the face and mouth","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Blood supply to the face and mouth</div><div class=\"cntnt\"><img style=\"width:520px; height:414px;\" src=\"images/EM/71766_BloodsupplyfacemouthPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Attia MW, Loiselle J. Management of soft-tissue injuries of the mouth. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71766 Version 7.0</div></div></div>"},"71768":{"type":"graphic_table","displayName":"Etiology acute UGI bleeding in adults","title":"Etiology of acute upper gastrointestinal bleeding in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of acute upper gastrointestinal bleeding in adults</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Ulcerative or erosive</td> </tr> <tr> <td class=\"sublist1_start\">Peptic ulcer disease</td> </tr> <tr> <td class=\"sublist1\">Idiopathic</td> </tr> <tr> <td class=\"sublist1\">Drug induced</td> </tr> <tr> <td class=\"sublist2\">Aspirin</td> </tr> <tr> <td class=\"sublist2\">Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td class=\"sublist1\">Infectious</td> </tr> <tr> <td class=\"sublist2\">Helicobacter pylori</td> </tr> <tr> <td class=\"sublist2\">Cytomegalovirus</td> </tr> <tr> <td class=\"sublist2\">Herpes simplex virus</td> </tr> <tr> <td class=\"sublist1\">Stress-induced ulcer</td> </tr> <tr> <td class=\"sublist1\">Zollinger-Ellison syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Esophagitis</td> </tr> <tr> <td class=\"sublist1\">Peptic</td> </tr> <tr> <td class=\"sublist1\">Infectious</td> </tr> <tr> <td class=\"sublist2\">Candida albicans</td> </tr> <tr> <td class=\"sublist2\">Herpes simplex virus</td> </tr> <tr> <td class=\"sublist2\">Cytomegalovirus</td> </tr> <tr> <td class=\"sublist2\">Miscellaneous</td> </tr> <tr> <td class=\"sublist1\">Pill-induced</td> </tr> <tr> <td class=\"sublist2\">Alendronate</td> </tr> <tr> <td class=\"sublist2\">Tetracycline</td> </tr> <tr> <td class=\"sublist2\">Quinidine</td> </tr> <tr> <td class=\"sublist2\">Potassium chloride</td> </tr> <tr> <td class=\"sublist2\">Aspirin</td> </tr> <tr> <td class=\"sublist2\">Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td class=\"subtitle1_single\">Portal hypertension</td> </tr> <tr> <td>Esophageal varices</td> </tr> <tr> <td>Gastric varices</td> </tr> <tr> <td>Duodenal varices</td> </tr> <tr> <td>Portal hypertensive gastropathy</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Arterial, venous, or other vascular malformations</td> </tr> <tr> <td>Idiopathic angiomas</td> </tr> <tr> <td>Hereditary hemorrhagic telangectasia (Osler-Weber-Rendu syndrome)</td> </tr> <tr> <td>Dieulafoy's lesion</td> </tr> <tr> <td>Watermelon stomach (gastric antral vascular ectasia)</td> </tr> <tr> <td>Radiation-induced telangiectasia</td> </tr> <tr> <td>Blue rubber bleb nevus syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Traumatic or post-surgical</td> </tr> <tr> <td>Mallory-Weiss tear</td> </tr> <tr> <td>Foreign body ingestion</td> </tr> <tr> <td>Post-surgical anastomosis</td> </tr> <tr> <td>Aortoenteric fistula</td> </tr> <tr> <td>Post gastric/duodenal polypectomy</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors</td> </tr> <tr> <td class=\"sublist1_start\">Benign</td> </tr> <tr> <td class=\"sublist1\">Leiomyoma</td> </tr> <tr> <td class=\"sublist1\">Lipoma</td> </tr> <tr> <td class=\"sublist1\">Polyp (hyperplastic, adenomatous, hamartomatous)</td> </tr> <tr> <td class=\"sublist1_start\">Malignant</td> </tr> <tr> <td class=\"sublist1\">Adenocarcinoma</td> </tr> <tr> <td class=\"sublist1\">Mesenchymal neoplasm</td> </tr> <tr> <td class=\"sublist1\">Lymphoma</td> </tr> <tr> <td class=\"sublist1\">Kaposi's sarcoma</td> </tr> <tr> <td class=\"sublist1\">Carcinoid</td> </tr> <tr> <td class=\"sublist1\">Melanoma</td> </tr> <tr> <td class=\"sublist1\">Metastatic tumor</td> </tr> <tr> <td class=\"sublist1_start\">Miscellaneous</td> </tr> <tr> <td class=\"sublist1\">Hemobilia</td> </tr> <tr> <td class=\"sublist1\">Hemosuccus pancreaticus</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71768 Version 5.0</div></div></div>"},"71769":{"type":"graphic_picture","displayName":"Patchy lesions Crohn Endosc","title":"Asymmetric distribution of lesions in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asymmetric distribution of lesions in Crohn disease</div><div class=\"cntnt\"><img style=\"width:366px; height:183px;\" src=\"images/GAST/71769_Patchy_lesions_Crohns_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy in Crohn disease demonstrates the characteristic patchy erythema (left panel) and ulceration (right panel) that occur next to areas of normal mucosa.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 71769 Version 4.0</div></div></div>"},"71770":{"type":"graphic_picture","displayName":"LIP lung biopsy","title":"Lymphocytic interstitial pneumonitis (LIP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonitis (LIP)</div><div class=\"cntnt\"><img style=\"width:389px; height:261px;\" src=\"images/PEDS/71770_LIP_lung_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A representative field of a lung biopsy specimen from a child with LIP, demonstrating a diffuse infiltrate of mature and immature lymphocytes, plasma cells, and histiocytes in the alveolar septae and pulmonary interstitium. Nodular formation of lymphocytes is also seen. Although fibrosis is not a typical feature, widening of the pleura with fibrous tissue is seen.</div><div class=\"graphic_reference\">Courtesy of Cynthia Epstein, MD and Leland L Fan, MD.</div><div id=\"graphicVersion\">Graphic 71770 Version 2.0</div></div></div>"},"71771":{"type":"graphic_figure","displayName":"Seldinger technique for central venous access","title":"Seldinger technique for central venous access","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Seldinger technique for central venous access</div><div class=\"cntnt\"><img style=\"width:542px; height:450px;\" src=\"images/PEDS/71771_Seldinger_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The needle, attached to a syringe, is inserted into the femoral vein. Once the needle is through the skin, the plunger of the syringe is gently pulled back. The needle is in the vessel when blood flows freely into the syringe. <br />(B) The syringe is removed and the flexible end of the guidewire is inserted through the needle into the vessel. <br />(C) The needle is removed, leaving the guidewire in place. The catheter is advanced with a twisting motion over the guidewire into the vessel. The guidewire is then removed as the catheter is held in place. <br />(D) The catheter should flush easily with fluid.</div><div id=\"graphicVersion\">Graphic 71771 Version 3.0</div></div></div>"},"71772":{"type":"graphic_figure","displayName":"SNAQ","title":"Simplified nutritional appetite questionnaire (SNAQ)","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Simplified nutritional appetite questionnaire (SNAQ)</div><div class=\"cntnt\"><img style=\"width:562px; height:568px;\" src=\"images/PC/71772_SNAQ_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Wilson, MG, Thomas, PR, Rubenstein, LZ, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005; 82:1074. Copyright &#169; 2005 American Society for Nutrition.</div><div id=\"graphicVersion\">Graphic 71772 Version 3.0</div></div></div>"},"71773":{"type":"graphic_figure","displayName":"mBODE after LVRS","title":"Changes in mBODE after lung volume reduction surgery","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Changes in mBODE after lung volume reduction surgery</div><div class=\"cntnt\"><img style=\"width:532px; height:280px;\" src=\"images/PULM/71773_mBODE_after_LVRS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The percentage of patients (x axis) experiencing changes in mBODE (<strong>m</strong>odified <strong>B</strong>ody mass index, airflow <strong>O</strong>bstruction, <strong>D</strong>yspnea, and <strong>E</strong>xercise capacity) (y axis) six months after randomization to medical therapy or bilateral lung volume reduction surgery (LVRS). Patients who had died or were not able to provide data to calculate mBODE at each time point are also illustrated.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &#169; 2008 American Thoracic Society. Martinez, FJ, Han, MK, Andrei, AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. American Journal of Respiratory and Critical Care Medicine 2008; 178:491. Official journal of the American Thoracic Society. Diane Gern, Publisher.</div><div id=\"graphicVersion\">Graphic 71773 Version 2.0</div></div></div>"},"71775":{"type":"graphic_figure","displayName":"Pressures tricuspid regurg ","title":"Tricuspid regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/CARD/71775_Pressures_tricuspid_regurg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel: Right atrial (RA) and right ventricular (RV) pressure tracings, obtained simultaneously, show elevated RA and RV pressures. A large &quot;V&quot; wave is seen in the RA during ventricular systole. Bottom panel: The venous pulse of the regurgitation can be detected in the femoral vein. The femoral vein pressure is slightly higher than that of the right atrium, a pressure gradient that maintains normal blood flow.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.</div><div id=\"graphicVersion\">Graphic 71775 Version 2.0</div></div></div>"},"71776":{"type":"graphic_picture","displayName":"Lepromatous leprosy lesions","title":"Skin lesions of lepromatous leprosy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin lesions of lepromatous leprosy</div><div class=\"cntnt\"><img style=\"width:504px; height:275px;\" src=\"images/ID/71776_Lepromatous_leprosy_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Schmiedel S, Ehrhardt S, Moll I, Burchard GD. A Thai patient with generalised inflammatory skin disease 18 years after migration to Europe. Lancet 2006; 367:1458. Copyright &#169; 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 71776 Version 2.0</div></div></div>"},"71777":{"type":"graphic_diagnosticimage","displayName":"Septic cavernous sinus MRI","title":"Septic cavernous sinus magnetic resonance imaging (MRI)","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Septic cavernous sinus magnetic resonance imaging (MRI)</div><div class=\"cntnt\"><img style=\"width:511px; height:256px;\" src=\"images/ID/71777_Septic_cavernous_sinus_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These T1-weighted MRI scans with contrast show multiple irregular defects within the enhancing cavernous sinus on the left side (arrowhead). (Panel A) Axial view. (Panel B) Coronal view.</div><div class=\"graphic_reference\">Reproduced with permission from: Yoshida T, Kasai T, Kondo M, et al. Septic cavernous sinus thrombosis caused by penicillin-resistant Streptococcus. Infections in Medicine 2008; 25:20. Copyright ©2008, Infections in Medicine, CMPMedica. All rights reserved.</div><div id=\"graphicVersion\">Graphic 71777 Version 3.0</div></div></div>"},"71779":{"type":"graphic_figure","displayName":"Internal podalic version2","title":"Internal podalic version","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Internal podalic version</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/OBGYN/71779_Internal_podalic_version2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upward pressure on head is applied as downward traction is exerted on feet.</div><div class=\"graphic_reference\">Modified&nbsp;from: Pritchard JA, MacDonald PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980.</div><div id=\"graphicVersion\">Graphic 71779 Version 2.0</div></div></div>"},"71781":{"type":"graphic_picture","displayName":"Short term tubes","title":"Short-term tympanostomy tubes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short-term tympanostomy tubes</div><div class=\"cntnt\"><img style=\"width:432px; height:353px;\" src=\"images/PEDS/71781_Shorttermtubes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-term tympanostomy tubes are intended to remain in the eardrum for 8 to 18 months. They include Armstrong grommet tubes (A), Reuter-bobbin (R), Sheehy (S), and Paparella (P).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright © 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 71781 Version 13.0</div></div></div>"},"71782":{"type":"graphic_table","displayName":"Management of women with previous PTD or 2nd trimester loss","title":"Management of women with previous preterm delivery or second trimester loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of women with previous preterm delivery or second trimester loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Patient population</td> <td class=\"subtitle1\">Interventions to be considered</td> <td class=\"subtitle1\">Options in next pregnancy if history-indicated cerclage was not successful (ie, preterm birth &#60;33 weeks)</td> </tr> <tr> <td>Women with:<br /> <ul> <li>&#8805;2 consecutive prior second-trimester losses*, <strong>or</strong> </li> <li>&#8805;3 early (&#60;34 weeks) preterm births </li> </ul> </td> <td> <p>Transvaginal cerclage at 12 to 14 weeks and</p> <p>Hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks</p> </td> <td> <p>Transabdominal cerclage</p> <p>Hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks</p> </td> </tr> <tr class=\"divider_top\"> <td>Women with:<br /> <ul> <li>One prior second-trimester loss*, <strong>or</strong> </li> <li>One or two preterm births&nbsp; </li> </ul> </td> <td> <p>Hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks</p> <p>Serial measurement of cervical length beginning at 14 to 16 weeks and ending at 24 weeks </p> <p>If cervical length <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&#8804;</span>25 mm before 24 weeks, place transvaginal cerclage</p> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Usually a spontaneous pregnancy loss between 16 and 27 6/7ths weeks of gestation.</div><div class=\"graphic_reference\">Data from: Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol 2010; 203:89.</div><div id=\"graphicVersion\">Graphic 71782 Version 5.0</div></div></div>"},"71783":{"type":"graphic_figure","displayName":"Saphenous cutdown site and immobilization","title":"Saphenous cutdown site and immobilization","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Saphenous cutdown site and immobilization</div><div class=\"cntnt\"><img style=\"width:540px; height:396px;\" src=\"images/EM/71783_Saphenous_cutdown_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A saphenous cutdown is best performed where the vein courses anterior to the medial malleolus of the tibia. An incision (about 2 cm in length) through the skin is made perpendicular to the long axis of the vein.</div><div id=\"graphicVersion\">Graphic 71783 Version 5.0</div></div></div>"},"71784":{"type":"graphic_table","displayName":"Guidelines for BMD testing in premenopausal women","title":"Guidelines for bone mineral density testing in premenopausal women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for bone mineral density testing in premenopausal women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">International Society for Clinical Densitometry</td> </tr> <tr> <td>History of fragility fracture</td> </tr> <tr> <td>Diseases, conditions, or medications associated with low bone mass or bone loss</td> </tr> <tr> <td>Considering pharmacologic therapy for osteoporosis</td> </tr> <tr> <td>Monitoring drug therapy for osteoporosis</td> </tr> <tr> <td>Women in the menopausal transition if there is a specific risk factor for fracture (eg, low body weight, prior low-trauma fracture, or high-risk medication)&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: 2013 ISCD Official Positions - Adult.&nbsp;<A href=\"http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/\">www.iscd.org/official-positions/2013-iscd-official-positions-adult/</A> (Accessed on February 28, 2014).<br />Courtesy of Carolyn Becker, MD and Adi Cohen, MD.</div><div id=\"graphicVersion\">Graphic 71784 Version 6.0</div></div></div>"},"71787":{"type":"graphic_picture","displayName":"Sialolith","title":"Salivary gland stones: Sialolith","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salivary gland stones: Sialolith</div><div class=\"cntnt\"><img style=\"width:350px; height:273px;\" src=\"images/PC/71787_Sialolith.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.</div><div id=\"graphicVersion\">Graphic 71787 Version 2.0</div></div></div>"},"71790":{"type":"graphic_table","displayName":"Features of Clostridium difficile infection in children","title":"Features suggestive of <em>Clostridium difficile</em> infection in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features suggestive of <em>Clostridium difficile</em> infection in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Severe diarrhea (volume, frequency [&#62;6 stools/day], abdominal pain)</td> </tr> <tr> <td class=\"indent1\">Fever (&#8805;102&#176;F [38.9&#176;C])</td> </tr> <tr> <td class=\"indent1\">Leukocytosis (&#8805;15,000 white blood cells/microL)</td> </tr> <tr> <td class=\"indent1\">Fecal leukocytes or occult blood</td> </tr> <tr> <td class=\"indent1\">Hypoalbuminemia</td> </tr> <tr> <td class=\"indent1\">Acidosis</td> </tr> <tr> <td class=\"indent1\">Acute abdomen with no passage of stool due to ileus</td> </tr> <tr> <td class=\"sublist2_start\">Radiographic evidence of colitis:</td> </tr> <tr> <td class=\"sublist2\">a. Plain film: Bowel wall thickening, dilatation, thumb-printing, ascites</td> </tr> <tr> <td class=\"sublist2\">b. Ultrasound: Bowel wall thickening, ascites</td> </tr> <tr> <td class=\"sublist2\">c. CT: Bowel wall thickening, dilatation, accordion sign, mural enhancement, fat stranding, ascites</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pseudomembranous colitis</td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors and predisposing conditions</td> </tr> <tr> <td class=\"indent1\">Antibiotic exposure&nbsp;in the past 10 weeks</td> </tr> <tr> <td class=\"indent1\">Recent hospitalization</td> </tr> <tr> <td class=\"indent1\">Acid suppressant exposure (proton pump inhibitors or histamine-2 receptor antagonists)</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal feeding tubes</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency (malignancy, solid organ or hematopoietic transplantation)</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Hirschsprung enterocolitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 71790 Version 5.0</div></div></div>"},"71791":{"type":"graphic_table","displayName":"Warfarin dosing protocol","title":"Suggested protocol for initiating warfarin therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested protocol for initiating warfarin therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Days of warfarin treatment</td> <td class=\"subtitle1\">INR &#60;1.5</td> <td class=\"subtitle1\">INR 1.5 to 1.9</td> <td class=\"subtitle1\">INR 2.0 to 3.0</td> <td class=\"subtitle1\">INR &#62;3.0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Suggested initial dose for days 1 and 2</td> </tr> <tr> <td class=\"indent1\">Normal adult</td> <td>5 mg*</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> </tr> <tr> <td class=\"indent1\">Frail adult, malnourished, elderly, liver disease</td> <td>2.5 mg*</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Dosing for day 3 and beyond</td> </tr> <tr> <td class=\"indent1\">Day 3</td> <td>5 to 10 mg</td> <td>2.5 to 5 mg</td> <td>0 to 2.5 mg</td> <td>No dose</td> </tr> <tr> <td class=\"indent1\">Day 4</td> <td>10 mg</td> <td>5 to 7.5 mg</td> <td>0 to 5 mg</td> <td>No dose</td> </tr> <tr> <td class=\"indent1\">Day 5</td> <td>10 mg</td> <td>7.5 to 10 mg</td> <td>0 to 5 mg</td> <td>No dose</td> </tr> <tr> <td class=\"indent1\">Day 6</td> <td>7.5 to 12.5 mg</td> <td>5 to 10 mg</td> <td>0 to 7.5 mg</td> <td>No dose</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In this protocol, which is provided for guidance only, suggested doses of warfarin after day 2 are given as ranges. The clinician must judge the rapidity and magnitude of INR changes for the individual patient and make dosage adjustments accordingly. An algorithm for monitoring and adjustment of maintenance warfarin is presented separately. Refer to UpToDate topics on use of warfarin and table on suggested protocol for adjustment of maintenance warfarin.</div><div class=\"graphic_footnotes\">n/a: not applicable.<br />* This table assumes that the patient has started with an INR in the normal range.</div><div class=\"graphic_reference\">See text for details concerning the source for this protocol and relevant references.</div><div id=\"graphicVersion\">Graphic 71791 Version 8.0</div></div></div>"},"71792":{"type":"graphic_picture","displayName":"Lupus erythematosus tumidus on face","title":"Lupus erythematosus tumidus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lupus erythematosus tumidus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/71792_Lupus_eryth_tumidus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory plaques consistent with lupus erythematousus tumidus (tumid lupus erythematosus) are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71792 Version 3.0</div></div></div>"},"71793":{"type":"graphic_diagnosticimage","displayName":"Arteriogram in RA stenosis","title":"Aortogram showing renal artery stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram showing renal artery stenosis</div><div class=\"cntnt\"><img style=\"width:384px; height:288px;\" src=\"images/NEPH/71793_Arteriogram_in_RA_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortogram shows a focal stenosis of the left renal artery with poststenotic dilatation (arrow). The right renal artery has a normal caliber and is delivering contrast to the right kidney well before the left kidney receives contrast.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 71793 Version 4.0</div></div></div>"},"71796":{"type":"graphic_waveform","displayName":"ECG bidirectional VT","title":"Single-lead electrocardiogram (ECG) showing bidirectional ventricular tachycardia (VT)","html":"<div class=\"graphic normal\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing bidirectional ventricular tachycardia (VT)</div><div class=\"cntnt\"><img style=\"width:465px; height:128px;\" src=\"images/CARD/71796_Bidirectional_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythm strip showing bidirectional ventricular tachycardia (VT) which may be a manifestation of digoxin toxicity. This rare, life-threatening tachyarrhythmia is characterized by beat-to-beat changes in the polarity of consecutive premature ventricular complexes.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 71796 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"71798":{"type":"graphic_table","displayName":"Medication overuse headache criteria","title":"Medication overuse headache diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medication overuse headache diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Description:</strong> Headache occurring on 15 or more days per month developing as a consequence of regular overuse of acute or symptomatic headache medication (on 10 or more, or 15 or more days per month, depending on the medication) for more than 3 months. It usually, but not invariably, resolves after the overuse is stopped.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>A.</strong> Headache occurring on 15 or more days per month in a patient with a pre-existing headache disorder.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>B.</strong> Regular overuse for more than three months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache:</td> </tr> <tr> <td class=\"indent1\">Regular intake for &#8805;10 days per month for &#62;3 months of ergotamines, triptans, opioids, or combination analgesics, <strong>or</strong> any combination of ergotamines, triptans, simple analgesics, NSAIDs and/or opioids without overuse of any single drug or drug class alone or when the pattern of overuse cannot be reliably established.</td> </tr> <tr> <td class=\"indent1\">Regular intake for &#8805;15 days per month for &#62;3 months of simple analgesics (ie, acetaminophen, aspirin, or NSAID).</td> </tr> <tr> <td class=\"sublist1_start\"><strong>C.</strong> Not better accounted for by another ICHD-3 diagnosis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: International Classification of Headache Disorders, 3rd edition; NSAID: nonsteroidal antiinflammatory drug.</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 71798 Version 9.0</div></div></div>"},"71799":{"type":"graphic_figure","displayName":"Elbow radiograph position","title":"Elbow radiograph position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow radiograph position</div><div class=\"cntnt\"><img style=\"width:315px; height:504px;\" src=\"images/EM/71799_Elbowxrayposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic positioning. The correct method of taking a lateral view is with the upper extremity directed anteriorly rather than externally rotated.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71799 Version 13.0</div></div></div>"},"71800":{"type":"graphic_figure","displayName":"Sellick maneuver","title":"Cricoid pressure (Sellick maneuver)","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Cricoid pressure (Sellick maneuver)</div><div class=\"cntnt\"><img style=\"width:525px; height:362px;\" src=\"images/EM/71800_Sellickmaneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cricoid pressure (Sellick maneuver). Posterior displacement of the airway cartilages occludes the compliant esophagus. In infants and young children, the tracheal cartilage is also very compliant, and excessive force while applying cricoid pressure may impair airway patency.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71800 Version 13.0</div></div></div>"},"71801":{"type":"graphic_figure","displayName":"MAPK signal cascade","title":"MAPK signaling cascade in papillary thyroid carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MAPK signaling cascade in papillary thyroid carcinoma</div><div class=\"cntnt\"><img style=\"width:130px; height:441px;\" src=\"images/ENDO/71801_MAP_kinase_signal_cascade.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the MAPK signaling cascade in papillary thyroid carcinoma.&nbsp;MAPK, also known as&nbsp;ERK, translocates to the nucleus and promotes cell division when it is phosphorylated by MEK, a serine/threonine kinase. Constitutive activation of this process is tumorigenic. MAPK phosphorylation is a relatively distal step in a sequential phosphorylation cascade that can begin with the activation of a tyrosine kinase, is followed by phosphorylation of RAS which activates BRAF, a serine/threonine kinase followed by MEK and MAPK phosphorylation. In papillary thyroid carcinoma, somatic genetic alterations at three of these steps activate this linear signaling cascade. A gene rearrangement creating a chimeric RET or TRK activates the initial tyrosine kinase step. Activating point mutations of either RAS or BRAF constitutively activates these proteins. The tyrosine kinase, RAS, and BRAF genetic alterations are usually mutually exclusive, suggesting that any single alteration is sufficient to play an early role in tumorigenesis.<SUP>[1,2]</SUP></div><div class=\"graphic_footnotes\">MAPK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinase.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Melillo RM, Castillone D, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068.</LI>&#xD;&#xA;<LI>Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007; 148:936.</LI></OL></div><div id=\"graphicVersion\">Graphic 71801 Version 4.0</div></div></div>"},"71802":{"type":"graphic_diagnosticimage","displayName":"SIS endometrial polyp2","title":"Sonohysterogram of an endometrial polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonohysterogram of an endometrial polyp</div><div class=\"cntnt\"><img style=\"width:387px; height:265px;\" src=\"images/OBGYN/71802_SIS_endometrial_polyp2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An endometrial polyp measuring 1.9 x 1.2cm is clearly visible. The stalk of the polyp can be seen extending toward the fundus.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 71802 Version 3.0</div></div></div>"},"71803":{"type":"graphic_table","displayName":"Normal values for lipid levels","title":"Reference values for lipid levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reference values for lipid levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Total cholesterol (90)</td> <td class=\"subtitle1\">LDL cholesterol (90)</td> <td class=\"subtitle1\">Triglycerides (90)</td> <td class=\"subtitle1\">HDL cholesterol (10)</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"6\">White men</td> <td>20 to 34</td> <td>236</td> <td>165</td> <td>199</td> <td>34</td> </tr> <tr> <td>35 to 44</td> <td>258</td> <td>176</td> <td>241</td> <td>30</td> </tr> <tr> <td>45 to 54</td> <td>268</td> <td>187</td> <td>228</td> <td>31</td> </tr> <tr> <td>55 to 64</td> <td>274</td> <td>194</td> <td>280</td> <td>31 </td> </tr> <tr> <td>65 to 74</td> <td>270</td> <td>185</td> <td>256</td> <td>31</td> </tr> <tr> <td>&#8805;75</td> <td>257</td> <td>186</td> <td>219</td> <td>32</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"6\">White women</td> <td>20 to 34</td> <td>229</td> <td>155</td> <td>164</td> <td>38</td> </tr> <tr> <td>35 to 44</td> <td>242</td> <td>155</td> <td>209</td> <td>37</td> </tr> <tr> <td>45 to 54</td> <td>279</td> <td>182</td> <td>212</td> <td>38</td> </tr> <tr> <td>55 to 64</td> <td>291</td> <td>189</td> <td>213</td> <td>37</td> </tr> <tr> <td>65 to 74</td> <td>290</td> <td>192</td> <td>253</td> <td>37</td> </tr> <tr> <td>&#8805;75</td> <td>287</td> <td>197</td> <td>248</td> <td>39</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-Hispanic white men<br /> </td> <td>260</td> <td>179</td> <td>248</td> <td>30</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-Hispanic white women<br /> </td> <td>271</td> <td>176</td> <td>228</td> <td>37</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mexican-American men<br /> </td> <td>257</td> <td>172</td> <td>266 </td> <td>33</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mexican-American women<br /> </td> <td>258</td> <td>166</td> <td>240</td> <td>37</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-Hispanic black men<br /> </td> <td>252 </td> <td>186</td> <td>171</td> <td>35</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-Hispanic black women<br /> </td> <td>262</td> <td>174</td> <td>162 </td> <td>40</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Reference values in the United States for the ninetieth percentile for total and LDL-cholesterol and triglycerides and for the tenth percentile for HDL-cholesterol. Values are shown according to age for white men and women, and mean values are given for different groups. (Units are mg/dL; divide cholesterol values by 38.5 to convert to mmol/L; divide triglyceride values by 88.5 to convert to mmol/L.) </div><div class=\"graphic_reference\">Data from: National Health and Nutrition Examination Survey (NHANES) III.</div><div id=\"graphicVersion\">Graphic 71803 Version 2.0</div></div></div>"},"71804":{"type":"graphic_picture","displayName":"Erythema marginatum close up","title":"Erythema marginatum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema marginatum</div><div class=\"cntnt\"><img style=\"width:427px; height:333px;\" src=\"images/RHEUM/71804_Erythema_marginatum_close_u.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A closer view of erythema marginatum in a patient with acute rheumatic fever.</div><div class=\"graphic_reference\">Reproduced with permission from: Binotto MA, Guilherme L, Tanaka AC. Rheumatic fever. Images Paediatr Cardiol 2002; 11:12. Copyright © 2002 Images in Paediatric Cardiology.</div><div id=\"graphicVersion\">Graphic 71804 Version 2.0</div></div></div>"},"71805":{"type":"graphic_figure","displayName":"Velpeau xray technique","title":"Velpeau view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Velpeau view</div><div class=\"cntnt\"><img style=\"width:213px; height:332px;\" src=\"images/RHEUM/71805_Velpeau_xray_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient's arm is held in internal rotation and the film is taken superior to inferior with the patient leaning backward.</div><div id=\"graphicVersion\">Graphic 71805 Version 2.0</div></div></div>"},"71806":{"type":"graphic_table","displayName":"Cystic echinococcus classification and treatment","title":"World Health Organization classification of cystic echinococcosis and treatment stratified by cyst stage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization classification of cystic&nbsp;echinococcosis and treatment stratified by cyst stage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">WHO stage</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Size</td> <td class=\"subtitle1\">Preferred treatment</td> <td class=\"subtitle1\">Alternate treatment</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">CE1</td> <td rowspan=\"2\">Unilocular unechoic cystic lesion with double line sign</td> <td rowspan=\"2\">Active</td> <td>&#60;5 cm</td> <td>Albendazole alone</td> <td>PAIR</td> </tr> <tr> <td>&#62;5 cm</td> <td>Albendazole + PAIR</td> <td>PAIR</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">CE2</td> <td>Multiseptated, \"rosette-like\" \"honeycomb\" cyst</td> <td>Active</td> <td>Any</td> <td>Albendazole + either modified catheterization or surgery</td> <td>Modified catheterization</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"2\">CE3a</td> <td rowspan=\"2\">Cyst with detached membranes (water-lily sign)</td> <td rowspan=\"2\">Transitional</td> <td>&#60;5 cm</td> <td>Albendazole alone</td> <td>PAIR</td> </tr> <tr> <td>&#62;5 cm</td> <td>Albendazole + PAIR</td> <td>PAIR</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">CE3b</td> <td>Cyst with daughter cysts in solid matrix</td> <td>Transitional</td> <td>Any</td> <td>Albendazole + either modified catheterization or surgery</td> <td>Modified catheterization</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">CE4</td> <td>Cyst with heterogenous hypoechoic/hyperechoic contents; no daughter cysts</td> <td>Inactive</td> <td>Any</td> <td>Observation</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">CE5</td> <td>Solid plus calcified wall</td> <td>Inactive</td> <td>Any</td> <td>Observation</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Albendazole is dosed 10 to 15 mg/kg per day in two divided doses; the usual dose for adults is 400 mg twice daily. Duration of therapy is discussed in the text.</div><div class=\"graphic_footnotes\">WHO: World Health Organization; CE: cystic echinocococcis; PAIR: puncture, aspiration, injection, reaspiration.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>Junghanss T, da Silva AM, Horton J, et al. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 2008; 79:301.</li>&#xD;&#xA;    <li>Brunetti E, Kern P, Vuitton DA, Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71806 Version 6.0</div></div></div>"},"71807":{"type":"graphic_picture","displayName":"Blepharochalasis","title":"Blepharochalasis","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Blepharochalasis</div><div class=\"cntnt\"><img style=\"width:452px; height:339px;\" src=\"images/ALLRG/71807_Blepharochalasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient had recurrent bouts of upper lid swelling. Chronic changes of distended and thinned \"cigarette-paper\" skin remain.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd&nbsp;ed, Lippincott Williams &amp; Wilkins, Philadelphia&nbsp;2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71807 Version 2.0</div></div></div>"},"71808":{"type":"graphic_diagnosticimage","displayName":"Coronary artery with dissection","title":"Coronary artery with dissection","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Coronary artery with dissection</div><div class=\"cntnt\"><img style=\"width:513px; height:514px;\" src=\"images/CARD/71808_Coronary_artery_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross sectional view of the coronary artery, a dissection flap is separated from the coronary artery wall and protruding into the lumen (arrow). (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 71808 Version 2.0</div></div></div>"},"71809":{"type":"graphic_picture","displayName":"Lung cancer clubbing","title":"Clubbing","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Clubbing</div><div class=\"cntnt\"><img style=\"width:494px; height:216px;\" src=\"images/ONC/71809_Lung_cancer_clubbing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Side and B) top view of nail bed hypertrophy causing a distal enlargement of the fingers in a patient with lung cancer.</div><div class=\"graphic_reference\">Reproduced with permission from: Midthun, DE, et al. Clinical presentation of lung cancer. Lung Cancer 1996; :421. Copyright © Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 71809 Version 2.0</div></div></div>"},"71810":{"type":"graphic_picture","displayName":"TRAM breast reconstruction","title":"Transverse rectus abdominis muscle (TRAM) reconstruction","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Transverse rectus abdominis muscle (TRAM) reconstruction</div><div class=\"cntnt\"><img style=\"width:535px; height:383px;\" src=\"images/ONC/71810_TRAM_breast_reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right single pedicle TRAM flap reconstruction following mastectomy for breast cancer. Left panel, preoperative appearance; right panel, postoperative appearance.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 71810 Version 2.0</div></div></div>"},"71811":{"type":"graphic_figure","displayName":"Exercise diastolic dysfunction","title":"PCWP increases during exercise in patients with diastolic heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PCWP increases during exercise in patients with diastolic heart failure</div><div class=\"cntnt\"><img style=\"width:324px; height:296px;\" src=\"images/CARD/71811_Exercise_diastolic_dysfunct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During symptom-limited upright exercise, normal subjects have an increase in left ventricular end diastolic volume (LVEDV), associated with a modest increase in pulmonary capillary wedge pressure (PCWP) which remains within a normal range (red arrow). In contrast, patients with normal systolic function who have left ventricular hypertrophy, diastolic dysfunction, and a stiff, nondistensible left ventricle have a marked increase in PCWP with exercise, often to levels associated with pulmonary edema (blue arrow), but no change in LVEDV. This is consistent with exercise-induced ischemia and an exaggerated impairment of diastolic relaxation of the hypertrophied myocardium.</div><div class=\"graphic_reference\">Data from: Kitzman DW, Higginbotham MB, Cobb FR, et al, J Am Coll Cardiol 1991; 17:1065.</div><div id=\"graphicVersion\">Graphic 71811 Version 3.0</div></div></div>"},"71813":{"type":"graphic_table","displayName":"Neonatal ETT size","title":"Endotracheal tube sizes for neonatal resuscitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endotracheal tube sizes for neonatal resuscitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tube size, mm, inside diameter</td> <td class=\"subtitle1\">Gestational age, weeks</td> <td class=\"subtitle1\">Weight, grams</td> </tr> <tr> <td>2.5</td> <td>&#60;28</td> <td>&#60;1000</td> </tr> <tr> <td>3</td> <td>28 to 34</td> <td>1000 to 2000</td> </tr> <tr> <td>3.5</td> <td>34 to 38</td> <td>2000 to 3000</td> </tr> <tr> <td>3.5 to 4</td> <td>&#62;38</td> <td>&#62;3000</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Use No. 0 laryngoscope blade for preterm infants, and No. 1 for term infants.</div><div id=\"graphicVersion\">Graphic 71813 Version 3.0</div></div></div>"},"71814":{"type":"graphic_picture","displayName":"Instruments","title":"Instruments for corneal culturing and specimen staining","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Instruments for corneal culturing and specimen staining</div><div class=\"cntnt\"><img style=\"width:509px; height:216px;\" src=\"images/PC/71814_Instruments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Kimura spatulas (on marking pen), glass slides, alcohol lamp to sterilize spatulas, and culture media.<br />(B) Microscope and specimen staining setup.<br />(C) Specimen staining trough for wash.</div><div id=\"graphicVersion\">Graphic 71814 Version 2.0</div></div></div>"},"71815":{"type":"graphic_figure","displayName":"Diet modification to facilitate antihypertensive drug withdrawal","title":"Ability of dietary modification to maintain normotension after discontinuation of chronic antihypertensive therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ability of dietary modification to maintain normotension after discontinuation of chronic antihypertensive therapy</div><div class=\"cntnt\"><img style=\"width:367px; height:251px;\" src=\"images/NEPH/71815_Diet_drug_cessation_in_HTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ability of combined nutritional intervention (weight loss, salt restriction, and avoidance of excess alcohol [squares]) to maintain normotension as compared&nbsp;with a control group without dietary modification (circles) after cessation of previously successful antihypertensive therapy. Hypertension recurred in over 90% of control patients but in only 60% with dietary modification.</div><div class=\"graphic_reference\">Data from Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program.&nbsp;JAMA 1987; 257:1484.</div><div id=\"graphicVersion\">Graphic 71815 Version 4.0</div></div></div>"},"71816":{"type":"graphic_waveform","displayName":"Basic case 6 with answer","title":"Atrial bigeminy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Atrial bigeminy</div><div class=\"cntnt\"><img style=\"width:540px; height:125px;\" src=\"images/CARD/71816_Basic_case_6_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial bigeminy in which each sinus beat is followed by a premature atrial complex. The premature P waves (arrows) appear to be inverted in lead II, suggesting that they originate from a low atrial ectopic focus. The tall peaked P waves of the sinus beats are consistent with right atrial abnormality (overload).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 71816 Version 2.0</div></div></div>"},"71817":{"type":"graphic_figure","displayName":"Determinants of plasma sodium","title":"Determinants of the plasma sodium concentration","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Determinants of the plasma sodium concentration</div><div class=\"cntnt\"><img style=\"width:714px; height:680px;\" src=\"images/NEPH/71817_DtrmnntsplasmaNacncntrtn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among both normal subjects and patients with a variety of diseases, there is a very close correlation between the plasma water sodium concentration and the ratio of total body exchangeable solutes (primarily Na salts in the extracellular fluid + K salts in the cells) to the TBW. The exchangeable portion is used since approximately 30% of the body Na and a smaller fraction of the body K are bound in areas such as bone where they are \"nonexchangeable\" and therefore osmotically inactive.</div><div class=\"graphic_footnotes\">Na: sodium; K: potassium; TBW: total body water.</div><div class=\"graphic_reference\">Adapted from Edelman I, Leibman J, O'Meara MP, et al. J Clin Invest 1958; 37:1236, by copyright permission of the American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 71817 Version 4.0</div></div></div>"},"71819":{"type":"graphic_figure","displayName":"Time to sustained disability in MS","title":"Time to sustained disability (use of a cane) with multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Time to sustained disability (use of a cane) with multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:553px; height:476px;\" src=\"images/NEURO/71819_Time_sustained_EDSS_6.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan–Meier survival curve of time to use of a cane (sustained Expanded Disability Status Scale score 6) from birth by age at onset of multiple sclerosis (n = 2319)</div><div class=\"graphic_reference\">Reproduced with permission from: Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66:172. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71819 Version 11.0</div></div></div>"},"71820":{"type":"graphic_picture","displayName":"Light microscopy ITGCNU","title":"Germ cell neoplasia in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Germ cell neoplasia in situ</div><div class=\"cntnt\"><img style=\"width:333px; height:299px;\" src=\"images/ONC/71820_Light_microscopy_ITGCNU.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of germ cell neoplasia in situ (GCNIS). The seminoma-like cells of GCNIS are seen in two seminferous tubules. These cells have a \"fried egg\" appearance with clear cytoplasm surrounding a round, dark nucleus.</div><div class=\"graphic_reference\">Courtesy of Michael Weinstein, MD, PhD.</div><div id=\"graphicVersion\">Graphic 71820 Version 2.0</div></div></div>"},"71821":{"type":"graphic_diagnosticimage","displayName":"Esophageal perforation in Boerhaave syndrome UGI","title":"Esophageal perforation in Boerhaave syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal perforation in Boerhaave syndrome</div><div class=\"cntnt\"><img style=\"width:321px; height:377px;\" src=\"images/GAST/71821_Esophageal_perforation_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Water-soluble contrast esophagram shows a distal esophageal perforation (arrow) with extravasation of contrast material into the mediastinum and left pleural space.</div><div class=\"graphic_reference\">Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.</div><div id=\"graphicVersion\">Graphic 71821 Version 3.0</div></div></div>"},"71822":{"type":"graphic_table","displayName":"EUS FNA submucosal lesions","title":"Diagnostic characteristics of endoscopic ultrasound-guided fine-needle aspiration (EUS FNA) for gastrointestinal wall lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic characteristics of endoscopic ultrasound-guided fine-needle aspiration (EUS FNA) for gastrointestinal wall lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Sensitivity (percent)</td> <td class=\"subtitle1\">Specificity (percent)</td> <td class=\"subtitle1\">Accuracy (percent)</td> </tr> <tr> <td>Giovannini, 1995</td> <td class=\"centered\">7</td> <td class=\"centered\">60</td> <td class=\"centered\">100</td> <td class=\"centered\">72</td> </tr> <tr> <td>Gress, 1997</td> <td class=\"centered\">27</td> <td class=\"centered\">--</td> <td class=\"centered\">--</td> <td class=\"centered\">81</td> </tr> <tr> <td>Wiersema, 1997</td> <td class=\"centered\">103</td> <td class=\"centered\">61</td> <td class=\"centered\">79</td> <td class=\"centered\">67</td> </tr> <tr> <td>Williams, 1999</td> <td class=\"centered\">8</td> <td class=\"centered\">50</td> <td class=\"centered\">25</td> <td class=\"centered\">38</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography, Gress F, Bhattacharya I (Eds), Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 71822 Version 5.0</div></div></div>"},"71824":{"type":"graphic_table","displayName":"Adhesion molecules in leukocyte migration","title":"Adhesion molecules in leukocyte migration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adhesion molecules in leukocyte migration</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Adhesion molecule</td>\n<td class=\"subtitle1\">Cellular expression for leukocyte migration</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">Integrins</td>\n\n</tr>\n<tr>\n<td class=\"indent1\">LFA-1 (CD11a/CD18b)</td>\n<td>Present on lymphocytes</td>\n</tr>\n<tr>\n<td class=\"indent1\">Mac-1 (CR3, CD11b/CD18b)</td>\n<td>Present on neutrophils and monocytes</td>\n</tr>\n<tr>\n<td class=\"indent1\">gp 150/95 (CD11c/CD18b)</td>\n<td>Present on neutrophils and monocytes</td>\n</tr>\n<tr>\n<td class=\"indent1\">VLA-4 (very late antigen-4)</td>\n<td>Present on lymphocytes, monocytes, and eosinophils</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">Immunoglobulin superfamily</td>\n\n</tr>\n<tr>\n<td class=\"indent1\" colspan=\"1\" rowspan=\"2\">ICAM-1</td>\n<td>Low level constitutive endothelial cell expression</td>\n</tr>\n<tr>\n\n<td>Increased endothelial cell expression with stimulation</td>\n</tr>\n<tr>\n<td class=\"indent1\" colspan=\"1\" rowspan=\"2\">ICAM-2</td>\n<td>High level constitutive endothelial cell expression</td>\n</tr>\n<tr>\n\n<td>No increase with stimulation</td>\n</tr>\n<tr>\n<td class=\"indent1\" colspan=\"1\" rowspan=\"2\">VCAM-1</td>\n<td>No constitutive endothelial cell expression</td> \n</tr>\n<tr>\n\n<td>Increased endothelial cell expression with stimulation</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">Selectins</td>\n\n</tr>\n<tr>\n<td class=\"indent1\">P-selectin</td>\n<td>Platelet and endothelial cell surface expression after stimulation</td>\n</tr>\n<tr>\n<td class=\"indent1\">E-selectin</td>\n<td>Exclusively expressed on stimulated endothelial cells</td>\n</tr>\n<tr>\n<td class=\"indent1\" colspan=\"1\" rowspan=\"2\">L-selectin</td>\n<td>Constitutively expressed on neutrophils, monocytes, and a T cell subset</td>\n</tr>\n<tr>\n\n<td>Shed from neutrophils after stimulation with chemoattractants</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">15.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=70948&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Expression_adhesion_molecul.htm</title></head></div><div class=\"graphic_footnotes\">LFA-1: lymphocyte function associated antigen-1; CD: cluster of differentiation; Mac-1: macrophage antigen-1, also known as CD11b/CD18; CR: complement receptor; gp: glycoprotein; VLA-4: very late antigen-4; ICAM: intracellular adhesion molecule; VCAM: vascular cell adhesion molecule.</div><div id=\"graphicVersion\">Graphic 71824 Version 4.0</div></div></div>"},"71825":{"type":"graphic_movie","displayName":"Machine set up and scanning strategy","title":"Machine set up and scanning strategy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Machine set up and scanning strategy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/71825_Machinesetupconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:442px; height:341px;\" src=\"images/PULM/71825_Machinesetup.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71825 Version 2.0</div></div></div>"},"71826":{"type":"graphic_table","displayName":"Metropolitan Life Insurance Company height-weight tables","title":"Metropolitan Life Insurance Company height-weight tables","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metropolitan Life Insurance Company height-weight tables</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Height-weight for women, according to height</td> </tr> <tr> <td class=\"subtitle2_left\">Height wearing shoes (feet and inches)*</td> <td class=\"subtitle2_left\">Weight range (pounds)<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">4'10\"</td> <td class=\"indent1\">109-121</td> </tr> <tr> <td class=\"indent1\">4'11\"</td> <td class=\"indent1\">111-123</td> </tr> <tr> <td class=\"indent1\">5'0\"</td> <td class=\"indent1\">113-126</td> </tr> <tr> <td class=\"indent1\">5'1\"</td> <td class=\"indent1\">115-129</td> </tr> <tr> <td class=\"indent1\">5'2\"</td> <td class=\"indent1\">118-132</td> </tr> <tr> <td class=\"indent1\">5'3\"</td> <td class=\"indent1\">121-135</td> </tr> <tr> <td class=\"indent1\">5'4\"</td> <td class=\"indent1\">124-138</td> </tr> <tr> <td class=\"indent1\">5'5\"</td> <td class=\"indent1\">127-141</td> </tr> <tr> <td class=\"indent1\">5'6\"</td> <td class=\"indent1\">130-144</td> </tr> <tr> <td class=\"indent1\">5'7\"</td> <td class=\"indent1\">133-147</td> </tr> <tr> <td class=\"indent1\">5'8\"</td> <td class=\"indent1\">136-150</td> </tr> <tr> <td class=\"indent1\">5'9\"</td> <td class=\"indent1\">139-153</td> </tr> <tr> <td class=\"indent1\">5'10\"</td> <td class=\"indent1\">142-156</td> </tr> <tr> <td class=\"indent1\">5'11\"</td> <td class=\"indent1\">145-159</td> </tr> <tr> <td class=\"indent1\">6'0\"</td> <td class=\"indent1\">148-162</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"2\">Height-weight for men, according to height</td> </tr> <tr> <td class=\"subtitle2_left\">Height wearing shoes (feet and inches)*</td> <td class=\"subtitle2_left\">Weight range (pounds)<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">5'2\"</td> <td class=\"indent1\">131-141</td> </tr> <tr> <td class=\"indent1\">5'3\"</td> <td class=\"indent1\">133-143</td> </tr> <tr> <td class=\"indent1\">5'4\"</td> <td class=\"indent1\">135-145</td> </tr> <tr> <td class=\"indent1\">5'5\"</td> <td class=\"indent1\">137-148</td> </tr> <tr> <td class=\"indent1\">5'6\"</td> <td class=\"indent1\">139-151</td> </tr> <tr> <td class=\"indent1\">5'7\"</td> <td class=\"indent1\">142-154</td> </tr> <tr> <td class=\"indent1\">5'8\"</td> <td class=\"indent1\">145-157</td> </tr> <tr> <td class=\"indent1\">5'9\"</td> <td class=\"indent1\">148-160</td> </tr> <tr> <td class=\"indent1\">5'10\"</td> <td class=\"indent1\">151-163</td> </tr> <tr> <td class=\"indent1\">5'11\"</td> <td class=\"indent1\">154-166</td> </tr> <tr> <td class=\"indent1\">6'0\"</td> <td class=\"indent1\">157-170</td> </tr> <tr> <td class=\"indent1\">6'1\"</td> <td class=\"indent1\">160-174</td> </tr> <tr> <td class=\"indent1\">6'2\"</td> <td class=\"indent1\">164-178</td> </tr> <tr> <td class=\"indent1\">6'3\"</td> <td class=\"indent1\">167-182</td> </tr> <tr> <td class=\"indent1\">6'4\"</td> <td class=\"indent1\">171-187</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In shoes with 1\" heels.<br />¶ Weight (pounds), at age 25 to 59 years, wearing indoor clothing weighing 5 pounds for men, 3 pounds for women.<br />Δ Listed weight ranges represent ideal body weight. Minimally acceptable weights are generally calculated as 85 to 90 percent of ideal.</div><div class=\"graphic_reference\">Adapted from: Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64:1.</div><div id=\"graphicVersion\">Graphic 71826 Version 4.0</div></div></div>"},"71831":{"type":"graphic_table","displayName":"Fast v slow conduction","title":"Fast versus slow response cardiac tissues","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fast versus slow response cardiac tissues</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr><td class=\"subtitle1\">Properties</td><td class=\"subtitle1\">Fast response times</td><td class=\"subtitle1\">Slow response times</td></tr><tr>\n<td class=\"subtitle2_left\">Location</td>\n<td>Atria, specialized infranodal conducting system, ventricles, AV bypass tracts</td>\n<td>Sinoatrial and atrioventricular nodes, depolarized fast response tissues in which phase 0 depends upon calcium current</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Passive cellular properties</td>\n\n\n</tr>\n<tr>\n<td class=\"indent1\">Normal resting potential</td>\n<td>-80 to -95 mV</td>\n<td>-40 to -65 mV</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Active cellular properties</td>\n\n\n</tr>\n<tr><td class=\"indent1\">Phase 0 current</td><td>Sodium</td><td>Primarily calcium</td></tr><tr><td class=\"indent1\">Phase 0 channel kinetics</td><td>Fast</td><td>Slow activation; inactivation depends upon voltage and cell calcium concentration</td></tr><tr>\n<td class=\"indent1\">Peak overshoot</td>\n<td>+20 to +40 mV</td>\n<td>-5 to + 20 mV</td>\n</tr>\n<tr>\n<td class=\"indent1\">Action potential amplitude</td>\n<td>90 to 135 mV</td>\n<td>30 to 70 mV</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Properties dependent upon active and passive properties</td>\n\n\n</tr>\n<tr>\n<td class=\"indent1\">Threshold voltage</td>\n<td>-60 to -75 mV</td>\n<td>-40 to -60 mV</td>\n</tr>\n<tr><td class=\"indent1\">Conduction velocity</td><td>0.5 to 5 m/sec</td><td>0.01 to 0.1 m/sec</td></tr><tr><td class=\"indent1\">Conducive to reentry</td><td>Only with inactivation of sodium channels with marked slowing of conduction velocity</td><td>Present in normal tissue</td></tr><tr>\n<td class=\"subtitle2_left\">Automaticity</td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Comparison of the major electrophysiologic characteristics of &quot;fast&quot; and &quot;slow&quot; response tissues.</div><div id=\"graphicVersion\">Graphic 71831 Version 1.0</div></div></div>"},"71834":{"type":"graphic_picture","displayName":"Irritant contact dermatitis","title":"Irritant contact dermatitis of the hands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant contact dermatitis of the hands</div><div class=\"cntnt\"><img style=\"width:341px; height:216px;\" src=\"images/PC/71834_Irritant_contact_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hands are the usual site for irritant contact dermatitis. The dermatitis is characterized by erythema, chapped skin, dryness, and fissuring.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 71834 Version 2.0</div></div></div>"},"71835":{"type":"graphic_picture","displayName":"Mediastinal benign schwannoma 2","title":"Mediastinal benign schwannoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal benign schwannoma</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/PULM/71835_Mediastinal_benign_schwan1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spindle cells may demonstrate nuclear atypia, but mitotic figures are rare. (Hematoxylin and eosin, magnification 100x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 71835 Version 1.0</div></div></div>"},"71837":{"type":"graphic_table","displayName":"Contraindications to breastfeed","title":"Contraindications to breastfeeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to breastfeeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Maternal</td> </tr> <tr> <td class=\"indent1\">Abuse of street drugs or alcohol</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus infection</td> </tr> <tr> <td class=\"indent1\">T-cell lymphotropic virus infection</td> </tr> <tr> <td class=\"indent1\">Untreated miliary tuberculosis (breastfeeding may be initiated approximately two weeks after initiation of antituberculous therapy)</td> </tr> <tr> <td class=\"indent1\">Antimetabolite chemotherapy and ongoing radiation therapy</td> </tr> <tr> <td class=\"indent1\">Active herpetic breast lesions</td> </tr> <tr> <td class=\"subtitle1_single\">Infant</td> </tr> <tr> <td class=\"indent1\">Galactosemia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Pediatric Nutrition Handbook. 7th edition, 2014. </LI>&#xD;&#xA;<LI>Policy statement on Breastfeeding and the use of Human Milk. Pediatrics 2012; 129:e827.</LI></OL></div><div id=\"graphicVersion\">Graphic 71837 Version 5.0</div></div></div>"},"71838":{"type":"graphic_figure","displayName":"Woods corkscrew maneuver","title":"Wood's corkscrew maneuver","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Wood's corkscrew maneuver</div><div class=\"cntnt\"><img style=\"width:539px; height:616px;\" src=\"images/OBGYN/71838_Woods_corkscrew_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The posterior shoulder is rotated counterclockwise until (B) it becomes anterior. The anterior shoulder rotates out from under the symphysis pubis and descends during this process.</div><div id=\"graphicVersion\">Graphic 71838 Version 2.0</div></div></div>"},"71839":{"type":"graphic_table","displayName":"Pediatric anatomic variants C-spine","title":"Normal anatomic variants of the cervical spine in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal anatomic variants of the cervical spine in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Lordosis may be absent in normal children up to the age of 15 years and in children in a cervical spine collar.</td> </tr> <tr> <td>The posterior arch of C1 fuses by 3 years.</td> </tr> <tr> <td>The anterior arch of C1 fuses by 10 years.</td> </tr> <tr> <td>The epiphyseal plate at the base of the odontoid fuses with the body of C2 by 6 years, but a fusion line may be evident in normal children up to the age of 10 years.</td> </tr> <tr> <td>Anterior vertebral wedging due to secondary growth centers may be confused with compression fractures up to the age of 7 years.</td> </tr> <tr> <td>Posterior laminar fusion lines may be confused with fractures up to the age of 6 years.</td> </tr> <tr> <td>Pseudosubluxation of C2 anterior to C3 is seen in approximately 40 percent of children under the age of 8 years.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71839 Version 3.0</div></div></div>"},"71840":{"type":"graphic_table","displayName":"Diabetes education checklist","title":"Diabetes education checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diabetes education checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preliminary actions</td> </tr> <tr> <td>New patient folder provided</td> </tr> <tr> <td>Educational materials provided</td> </tr> <tr> <td>Prescriptions given or called in to pharmacy</td> </tr> <tr> <td>Prescriptions filled </td> </tr> <tr> <td class=\"subtitle1_single\">Essentials of diabetes</td> </tr> <tr> <td>What is diabetes: Location/function of pancreas</td> </tr> <tr> <td>Type 1 versus type 2 diabetes: Differences in treatment</td> </tr> <tr> <td>What causes diabetes</td> </tr> <tr> <td>Basic management routine described</td> </tr> <tr> <td>Timing of blood glucose monitoring, meals/snacks, and insulin administration</td> </tr> <tr> <td>Education plan established</td> </tr> <tr> <td class=\"subtitle1_single\">Diabetes skills</td> </tr> <tr> <td class=\"subtitle2_single\">Blood glucose testing</td> </tr> <tr> <td class=\"indent1\">Importance of testing, recording, timing of blood glucose monitoring</td> </tr> <tr> <td class=\"indent1\">Name of meter given </td> </tr> <tr> <td class=\"indent1\">Demonstration of fingerstick and alternate site testing</td> </tr> <tr> <td class=\"indent1\">Need to retest for hypoglycemia</td> </tr> <tr> <td class=\"subtitle2_single\">Insulin administration</td> </tr> <tr> <td class=\"indent1\">Insulin types described: Onset, duration, action</td> </tr> <tr> <td class=\"indent1\">Storage, stability of insulin after opening vial discussed</td> </tr> <tr> <td class=\"indent1\">Procedure: Teaching insulin administration (drawing-up and mixing of insulin, and site rotation) </td> </tr> <tr> <td class=\"indent1\">Proper disposal of syringes</td> </tr> <tr> <td class=\"subtitle2_single\">Ketone testing</td> </tr> <tr> <td class=\"indent1\">What are ketones and when to test</td> </tr> <tr> <td class=\"indent1\">Urine testing for \"ketones\" (acetoacetate) and/or&nbsp;blood testing for ketones (beta hydroxybutyrate)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Demonstration of ketone testing, notifying clinic if moderate to large ketones</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoglycemia</td> </tr> <tr> <td>Sign, symptoms, and causes</td> </tr> <tr> <td>Management of each stage</td> </tr> <tr> <td>Glucagon demonstration</td> </tr> <tr> <td>Medic alert </td> </tr> <tr> <td class=\"subtitle1_single\">Hyperglycemia</td> </tr> <tr> <td>Signs, symptoms, and causes</td> </tr> <tr> <td>Management </td> </tr> <tr> <td>Importance of checking for ketones </td> </tr> <tr> <td>Diabetic ketoacidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Nutritional management</td> </tr> <tr> <td>Consultation with registered dietician</td> </tr> <tr> <td>Importance of consistency and timing of meals, insulin administration, carbohydrate counting</td> </tr> <tr> <td class=\"subtitle1_single\">Adaptation for daily living</td> </tr> <tr> <td class=\"sublist1_start\">School</td> </tr> <tr> <td class=\"sublist1\">School packet given</td> </tr> <tr> <td class=\"sublist1\">Contact school RN and school orders given</td> </tr> <tr> <td>Travel</td> </tr> <tr> <td>Treatment of sick days</td> </tr> <tr> <td>Social issues</td> </tr> <tr> <td>Sports</td> </tr> <tr> <td class=\"subtitle1_single\">Psychosocial support</td> </tr> <tr> <td>Information provided including useful web sites and resources materials </td> </tr> <tr> <td>Contact with the American Diabetes Association and Juvenile Diabetes </td> </tr> <tr> <td>Social worker consultation and phone number provided</td> </tr> <tr> <td class=\"subtitle1_single\">Follow-up </td> </tr> <tr> <td class=\"sublist1_start\">Appointments</td> </tr> <tr> <td class=\"sublist1\">Follow-up appointment made with pediatric endocrine clinic and phone contact information</td> </tr> <tr> <td class=\"sublist1\">Referrals</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71840 Version 2.0</div></div></div>"},"71842":{"type":"graphic_picture","displayName":"Thyroid goiter","title":"Sporadic macrofollicular goiter with normal macrofollicles: Findings on surgical histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sporadic macrofollicular goiter with normal macrofollicles: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/ENDO/71842_Thyroid_goiter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of a sporadic macrofollicular goiter with normal large thyroid follicules filled with colloid. These follicles are disrupted by needle biopsy so that the colloid will smear across the slide or occassionally aggregate into droplets.</div><div id=\"graphicVersion\">Graphic 71842 Version 3.0</div></div></div>"},"71845":{"type":"graphic_picture","displayName":"Thoracostomy tube fixation","title":"Thoracostomy tube fixation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracostomy tube fixation</div><div class=\"cntnt\"><img style=\"width:342px; height:514px;\" src=\"images/SURG/71845_Thoracostomy_tube_fixation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anchor stitch is loosely tied over the tube.<br> (B) The tube is secured to the anchor stitch. Notice the indentation on the tube indicating a snug tie to prevent slippage.</div><div class=\"graphic_reference\">Courtesy of Joseph Friedberg, MD.</div><div id=\"graphicVersion\">Graphic 71845 Version 2.0</div></div></div>"},"71846":{"type":"graphic_diagnosticimage","displayName":"Ultrasound ulnar nerve after elbow fracture","title":"Ultrasound of the ulnar nerve after elbow fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the ulnar nerve after elbow fracture</div><div class=\"cntnt\"><img style=\"width:390px; height:514px;\" src=\"images/NEURO/71846_US_ulnar_nerve_elbow_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial ultrasound images of the ulnar nerve adjacent to the medial epicondyle. The ultrasound on the top (A) is from a patient with long standing symptoms of ulnar neuropathy after an elbow fracture. The diagnosis was confirmed with electrodiagnostic studies showing ulnar motor conduction block, loss of sensory nerve action potentials, and significant motor nerve conduction velocity slowing across this site. The cross sectional area of this nerve is 31 mm<sup>2</sup>, three times the normal size of the nerve as shown in the ultrasound on the bottom (B) from an asymptomatic, age-matched control.</div><div class=\"graphic_footnotes\">1: region of interest (green circle) used to calculate cross-sectional area of ulnar nerve; ME: medial epicondyle; U: ulnar nerve.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 71846 Version 3.0</div></div></div>"},"71847":{"type":"graphic_figure","displayName":"Progression of human coronary atherosclerosis I","title":"Progression of human coronary atherosclerosis I","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Progression of human coronary atherosclerosis I</div><div class=\"cntnt\"><img style=\"width:577px; height:619px;\" src=\"images/CARD/71847_Prog_coronary_athero_I_ed2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of human coronary plaque progression, part 1 of 2.<BR>(A) Intimal thickening is normal in all age groups and is characterized by smooth muscle cell accumulation within the intima.<BR>(B) Intimal xanthoma or so-called fatty streak corresponds to the accumulation of predominantly macrophages within the intima; these lesions have been shown to regress in later adult life.<BR>(C) Pathologic intimal thickening marks the first of the progressive lesions and denotes the accumulation of extracellular lipid in the absence of apparent necrosis.<BR>(D) Fibrous cap atheroma indicates the presence of an encapsulated necrotic core.<BR>(E) The core may eventually become thinned (thin-cap fibroatheroma).<BR>(F) This lesion may rupture, allowing contact of the contents of the necrotic core, causing a luminal thrombosis.</div><div class=\"graphic_footnotes\">EL: extracellular lipid; NC: necrotic core; FC: fibrous cap; Th: thrombus.</div><div class=\"graphic_reference\">Reproduced with permission from: Virmani R, Kolodgie FD, Burke AP. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 71847 Version 10.0</div></div></div>"},"71848":{"type":"graphic_picture","displayName":"Interdigital erythrasma","title":"Interdigital erythrasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interdigital erythrasma</div><div class=\"cntnt\"><img style=\"width:396px; height:279px;\" src=\"images/DERM/71848_Interdigital_erythrasma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scale and maceration were present in this web space of the foot of a patient with interdigital erythrasma. The three lateral web spaces of both feet were involved. The potassium hydroxide preparation was negative; the Wood's lamp examination showed bright coral red fluorescence.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright &#169; 2008 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 71848 Version 2.0</div></div></div>"},"71852":{"type":"graphic_table","displayName":"Topical hemostatic agents for managing bleeding","title":"Topical hemostatic agents for managing bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical hemostatic agents for managing bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">How supplied</td> <td class=\"subtitle1\">Trade names in United States</td> <td class=\"subtitle1\">Absorption time<sup>[1]</sup></td> <td class=\"subtitle1\">Adverse effect*<sup>[2]</sup></td> <td class=\"subtitle1\">Relative expense<sup>&#182;[1,3]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Physical agents</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"7\">Wax-based</td> </tr> <tr> <td class=\"indent2\">Bone wax</td> <td>Beeswax</td> <td>Stick form</td> <td>Not applicable</td> <td>Indefinite</td> <td>Impaired bone healing</td> <td>&#162;</td> </tr> <tr> <td class=\"indent2\">Ostene (soluble copolymer implant material)</td> <td>Synthetic alkaline oxide copolymers</td> <td>Stick form</td> <td>Ostene</td> <td>48 hours</td> <td>&nbsp;</td> <td>&#162;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"7\">Dry matrix</td> </tr> <tr> <td class=\"indent2\">Absorbable gelatin (gelatin matrix)</td> <td>Porcine</td> <td>Sponge, powder</td> <td>Gelfilm, Gelfoam, Surgifoam, Gelfoam hemostasis kit (also contains human thrombin)</td> <td>4 to 6 weeks</td> <td>Infection, abscess or granuloma formation, fibrosis, clot disruption if sponge is removed<sup>[1]</sup></td> <td>$</td> </tr> <tr> <td class=\"indent2\">Oxidized regenerated cellulose</td> <td>Plant</td> <td>Mesh</td> <td>Surgicel (Nu-Knit, Fibrillar, SNoW)</td> <td>1 to 2 weeks<sup>&#916;</sup></td> <td>Foreign body reaction, infection, adhesions<sup>[1]</sup></td> <td>$</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Microfibrillar collagen (collagen hemostat)</td> <td rowspan=\"2\">Bovine</td> <td>Sheets</td> <td>Actifoam, Avitene (Ultrafoam), Endo Avitene, Instat MCH, Helistat Helitene, Syringe Avitene</td> <td rowspan=\"2\">&#62;8 weeks</td> <td rowspan=\"2\">Granuloma formation, allergenic</td> <td rowspan=\"2\">$$</td> </tr> <tr> <td>Powder</td> <td>Avitene Flour</td> </tr> <tr> <td class=\"indent2\">Microporous polysaccharide spheres (MPH)</td> <td>Synthetic</td> <td>Powder</td> <td>Arista AH</td> <td>24 to 48 hours</td> <td>Use of &#62;50 g can alter glucose load in patients with diabetes</td> <td>$</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"7\">External agents</td> </tr> <tr> <td class=\"indent2\">Chitosan</td> <td>Biodegradable complex carbohydrate derived from chitin</td> <td>Adhesive dressing</td> <td>HemCon bandage (Chitoflex)</td> <td>Not applicable</td> <td>Training needed to ensure proper application</td> <td>&#162;</td> </tr> <tr> <td class=\"indent2\">Zeolite</td> <td>Calcium-loaded aluminosilicate mineral</td> <td>Very low moisture granule</td> <td>Quikclot</td> <td>Not applicable</td> <td>Potential for thermal injury</td> <td>&#162;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Biologically active agents</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Topical thrombin</td> <td>Bovine</td> <td rowspan=\"3\">Liquid</td> <td>Thrombin-JMI</td> <td rowspan=\"3\">Not applicable</td> <td rowspan=\"3\"> <p>Intravascular application leads to thrombosis</p> Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td rowspan=\"3\">$$</td> </tr> <tr> <td>Human</td> <td>Evithrom</td> </tr> <tr> <td>Recombinant human (rHuman)</td> <td>Recothrom</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Fibrin sealant (human fibrinogen and human thrombin)<sup>&#9674;</sup></td> <td>Human</td> <td rowspan=\"2\">Liquid</td> <td>Artiss, Tisseel (also contains synthetic aprotinin), Evicel, TachoSil, Evarrest</td> <td rowspan=\"2\">Immediate</td> <td rowspan=\"3\">Potential exposure to blood-borne viruses</td> <td>$$$</td> </tr> <tr> <td>Human autologous</td> <td>CryoSeal Fibrin Sealant System Vitagel (autologous fibrinogen and bovine thrombin)</td> <td>Not available</td> </tr> <tr> <td>Human</td> <td>Powder (spray&nbsp;and direct application;&nbsp;for use with absorbable gelatin sponge)</td> <td>Raplixa</td> <td>(See Absorbable gelatin sponge, above)</td> <td>Not available&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dry Fibrin Sealant Dressing (DFSD)<sup>&#167;</sup></td> <td>Freeze-dried fibrinogen and thrombin applied to gauze substrate</td> <td>Dressing</td> <td>Not applicable</td> <td>Not applicable</td> <td>&nbsp;</td> <td>$$$$</td> </tr> <tr> <td class=\"indent1\">Bovine albumin-glutaraldehyde tissue adhesive</td> <td>Bovine</td> <td>Liquid</td> <td>Bioglue</td> <td>&nbsp;</td> <td>Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td>$$$$</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Combination preparations</td> </tr> <tr> <td class=\"indent1\">Thrombin/gelatin</td> <td>Bovine or porcine</td> <td>Liquid</td> <td>Floseal (bovine), Surgiflo (porcine)</td> <td>6 to 8 weeks</td> <td>Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td>$$$</td> </tr> <tr> <td class=\"indent1\">Thrombin/collagen</td> <td>Bovine</td> <td>Liquid</td> <td>Costasis</td> <td>4 weeks</td> <td>Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td>$$$</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INR: international normalized ratio.<br />* Although rare, use of protein-containing topical hemostatics and fibrin sealants can be associated with&nbsp;severe hypersensitivity reactions and formation of antibodies; such reactions may be seen especially after repeated&nbsp;application.&nbsp;&nbsp;<br />¶ The cost of topical hemostatics is highly variable in United States and subject to institutional contracting. Price range (US dollars): ¢: less than 50 dollars; $: 50 to 100 dollars; $$: 101 to 300 dollars; $$$: 301 to 500 dollars; $$$$: 501 to 750 dollars.<br />Δ&nbsp;The low pH of the oxidized regenerated cellulose can inhibit proteases and elastase, which can delay resorption for more than two weeks.<br />◊ Thrombin and fibrinogen concentrations vary. Fibrinogen concentrations are higher for commercial preparations. As an example, Tisseel and Evicel have fibrinogen concentrations of 70 and 55 to 85 mg/mL, respectively, compared with 2.5 to 25 mg/mL for cryoprecipitate (unmanipulated). When rapid clot formation (5 to 10 seconds) is desired, thrombin concentrations of 500 to 1000 NIH units should be used (eg, Tisseel, 500 IU/mL; Evicel, 800 to 1200 IU/mL).<SUP>[4,5]</SUP><br />§&nbsp;Investigational.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Duenas-Garcia OF, Goldberg JM. Topical hemostatic agents in gynecologic surgery. Obstet Gynecol Surv 2008; 63:389.</LI>&#xD;&#xA;<LI>Gabay M, Boucher B. An essential primer for understanding the role of topical hemostats, surgical sealants, and adhesives for maintaining hemostasis. Pharmacotherapy 2013; 33:935.</LI>&#xD;&#xA;<LI>Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. J Urol 2006; 176:2367.</LI>&#xD;&#xA;<LI>TISSEEL VH Kit. Available at: <A href=\"https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm072968.pdf\">https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm072968.pdf</A></LI>&#xD;&#xA;<LI>(Accessed on October 27, 2017).</LI>&#xD;&#xA;<LI>EVICEL Fibrin Sealant. Available at: <A href=\"https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270787.pdf\">https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270787.pdf</A></LI>&#xD;&#xA;<LI>(Accessed on October 27, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 71852 Version 11.0</div></div></div>"},"71853":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 5","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:371px; height:348px;\" src=\"images/OBGYN/71853_Tx_post_vaginal_wall_def_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a left lateral defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 71853 Version 2.0</div></div></div>"},"71854":{"type":"graphic_picture","displayName":"Acinar cell carcinoma","title":"Histologic appearance of acinar cell carcinoma, moderately differentiated","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of acinar cell carcinoma, moderately differentiated</div><div class=\"cntnt\"><img style=\"width:396px; height:303px;\" src=\"images/ONC/71854_Acinar_cell_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acini are identifiable and some lumens contain eosinophilic secretion (arrow). The tumor has more fibrous stroma than normal acinar tissue. Hematoxylin and Eosin.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 71854 Version 3.0</div></div></div>"},"71855":{"type":"graphic_picture","displayName":"Histol microinvasive melanoma","title":"Microinvasive radial growth phase melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microinvasive radial growth phase melanoma</div><div class=\"cntnt\"><img style=\"width:367px; height:284px;\" src=\"images/ONC/71855_Histol_microinvasive_melano.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light photomicrograph of a microinvasive radial growth phase superficial spreading melanoma. In addition to epidermal involvement, this superficial spreading melanoma is characterized by dermal extension of the tumor cells (white arrow). However, the largest dermal nest is not larger than the largest epidermal nest, and there are no dermal mitoses.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 71855 Version 1.0</div></div></div>"},"71856":{"type":"graphic_table","displayName":"POW and TREE mnemonics","title":"POW and TREE mnemonics for writing strategy instruction for a child with writing disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">POW and TREE mnemonics for writing strategy instruction for a child with writing disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">POW mnemonic*</td> </tr> <tr> <td class=\"centered\"><strong>P</strong></td> <td><strong>Pick</strong> my idea</td> </tr> <tr> <td class=\"centered\"><strong>O</strong></td> <td><strong>Organize</strong> my notes<sup>&#182;</sup>: <ul> <li>Who is the main character? </li> <li>When does the story take place? </li> <li>Where does the story take place? </li> <li>What does the main character do or want to do? What do other characters do? </li> <li>What happens then? What happens with other characters? </li> <li>How does the story end? </li> <li>How does the main character feel? How do other characters feel? </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>W</strong></td> <td><strong>Write</strong> and say more</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">TREE mnemonic<sup>&#916;</sup></td> </tr> <tr> <td class=\"centered\"><strong>T</strong></td> <td><strong>Topic sentence:</strong> Make a statement you believe in</td> </tr> <tr> <td class=\"centered\"><strong>R</strong></td> <td><strong>Reasons:</strong> List three or more reasons why you believe what you wrote in the topic sentence</td> </tr> <tr> <td class=\"centered\"><strong>E</strong></td> <td><strong>Ending:</strong> Wrap it up</td> </tr> <tr> <td class=\"centered\"><strong>E</strong></td> <td><strong>Examine:</strong> Check your work and make sure you completed all of the steps</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Designed for students who are writing a story.<br />¶&nbsp;A graphic organizer can be used to answer the questions in this step.<br />Δ&nbsp;Can be used to write a persuasive essay.</div><div class=\"graphic_reference\">Modified and reproduced with permission from: Harris K, Graham Sl, Mason L. Self-regulated strategy development in the classroom: Part of a balanced approach to writing instruction for students with disabilities. Focus on Exceptional Children 2003; 35:1. Copyright © 2003 Love Publishing Company.</div><div id=\"graphicVersion\">Graphic 71856 Version 4.0</div></div></div>"},"71857":{"type":"graphic_figure","displayName":"Foot anatomy superior view","title":"Foot anatomy superior view","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Foot anatomy superior view</div><div class=\"cntnt\"><img style=\"width:509px; height:521px;\" src=\"images/EM/71857_Foot_anatomy_superior_view.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71857 Version 2.0</div></div></div>"},"71858":{"type":"graphic_picture","displayName":"Traction retinal detachment","title":"Traction retinal detachment: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction retinal detachment: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:333px;\" src=\"images/ENDO/71858_Traction_retinal_detachment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of traction retinal detachment due to contraction of neovascularization with prominent associated fibrous tissue; there are numerous striae indicating tractional retinal elevation of the macula and fovea to the left of the disc.</div><div id=\"graphicVersion\">Graphic 71858 Version 3.0</div></div></div>"},"71859":{"type":"graphic_table","displayName":"ACOG CPP Rx A recs","title":"Summary of recommendations for treatment of chronic pelvic pain from the American College of Obstetricians and Gynecologists","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for treatment of chronic pelvic pain from the American College of Obstetricians and Gynecologists</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Recommendations based on good, consistent scientific evidence (level A)</td> </tr> <tr> <td class=\"subtitle2\">Intervention</td> <td class=\"subtitle2\">Indication</td> </tr> <tr> <td>Combined oral contraceptive pills</td> <td>Primary dysmenorrhea</td> </tr> <tr> <td>GnRH agonists</td> <td>Endometriosis, irritable bowel syndrome (may be given empirically in women with symptoms consistent with endometriosis)</td> </tr> <tr> <td>Nonsteroidal anit-inflammatory drugs</td> <td>Dysmenorrhea, moderate pain</td> </tr> <tr> <td>Progestins (daily, high dose)</td> <td>Endometriosis, pelvic congestion syndrome</td> </tr> <tr> <td>Laparoscopic ablation/resection of endometriosis</td> <td>Stage I-III endometriosis</td> </tr> <tr> <td>Presacral neurectomy</td> <td>Centrally located dysmenorrhea</td> </tr> <tr> <td>Uterine nerve ablation</td> <td>Not indicated<sup>[1]</sup></td> </tr> <tr> <td>Adjunctive psychotherapy</td> <td>CPP</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA 2009; 302:955.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 71859 Version 4.0</div></div></div>"},"71860":{"type":"graphic_picture","displayName":"Livedo reticularis","title":"Livedo reticularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Livedo reticularis</div><div class=\"cntnt\"><img style=\"width:353px; height:319px;\" src=\"images/CARD/71860_Livedo_reticularis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with lupus and anti-phospholipid antibodies with livedo reticularis (manifested by a reddish-cyanotic, reticular pattern of the skin) which has resulted in ulcer formation (arrows).</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 71860 Version 1.0</div></div></div>"},"71862":{"type":"graphic_figure","displayName":"O2 prescription air travel","title":"Oxygen prescription for air travel","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Oxygen prescription for air travel</div><div class=\"cntnt\"><img style=\"width:502px; height:461px;\" src=\"images/PULM/71862_O2_prescription_air_travel.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sample oxygen prescription for air travel. Some airlines request that prescriptions be printed on physician letterhead.</div><div class=\"graphic_reference\">Based on information from the Airline Oxygen Council of America.</div><div id=\"graphicVersion\">Graphic 71862 Version 1.0</div></div></div>"},"71863":{"type":"graphic_figure","displayName":"Peak and plateau pressure","title":"Peak and plateau pressures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peak and plateau pressures</div><div class=\"cntnt\"><img style=\"width:430px; height:505px;\" src=\"images/PULM/71863_Peak_and_plateau_pressure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between tidal volume and airway pressure during mechanical ventilation. The inspiratory plateau in the volume tracing is achieved by temporary occlusion of the expiratory limb of the ventilator circuit. During this period, airway pressure falls from a peak of 20 cmH<sub>2</sub>O to a plateau pressure of 10 cmH<sub>2</sub>O. These measurements allow the calculation of respiratory system (or thoracic) compliance. The static compliance of the respiratory system is equal to the exhaled tidal volume divided by the difference between plateau and positive end-expiratory pressures (Crs = Vt / Plat-PEEP). An increase in the difference between peak and plateau pressures implies increased airway resistance.</div><div class=\"graphic_reference\">Adapted from Tobin, MJ. Respiratory monitoring. JAMA 1990; 264:244.</div><div id=\"graphicVersion\">Graphic 71863 Version 1.0</div></div></div>"},"71864":{"type":"graphic_diagnosticimage","displayName":"Septic pulmonary emboli CT","title":"Septic pulmonary emboli","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Septic pulmonary emboli</div><div class=\"cntnt\"><img style=\"width:349px; height:609px;\" src=\"images/PULM/71864_Septic_pulmonary_emboli_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the chest shows multiple nodules, most in subpleural locations and many with cavitation, in an intravenous drug user with tricuspid endocarditis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71864 Version 3.0</div></div></div>"},"71868":{"type":"graphic_waveform","displayName":"12-lead ECG left posteroseptal WPW","title":"12-lead electrocardiogram (ECG) of a left posteroseptal accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a left posteroseptal accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:498px; height:295px;\" src=\"images/CARD/71868_Left_posteroseptal_WPW.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram during right atrial pacing in a patient with Wolff-Parkinson-White syndrome shows a long stimulus to the P wave with a short PR interval, the appearance of both right and left bundle branch block morphologies, and a negative QRS morphology and delta wave in the inferior leads. This localizes the pathway to the posteroseptal area. The presence of a positive delta wave in lead I, RS ratio in lead V1 of approximately 1, and a negative delta wave in lead II places the pathway on the left side, inside the coronary sinus os or along the middle cardiac vein. This type of accessory pathway may be related to cardiac venous anomalies and aneurysms.</div><div id=\"graphicVersion\">Graphic 71868 Version 4.0</div></div></div>"},"71870":{"type":"graphic_diagnosticimage","displayName":"Subacute HP CT","title":"Subacute hypersensitivity pneumonia (extrinsic allergic alveolitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacute hypersensitivity pneumonia (extrinsic allergic alveolitis)</div><div class=\"cntnt\"><img style=\"width:363px; height:213px;\" src=\"images/PULM/71870_Subacute_EAA_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subacute hypersensitivity pneumonia (extrinsic allergic alveolitis) with multiple so-called acinar nodules permeating the entire lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71870 Version 5.0</div></div></div>"},"71872":{"type":"graphic_table","displayName":"Quick sources of sugar PI","title":"Quick sources of sugar to treat low blood sugar","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quick sources of sugar to treat low blood sugar</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>3 or 4 glucose tablets</td> </tr> <tr> <td>&#189; cup of juice or regular soda (not sugar-free)</td> </tr> <tr> <td>2 tablespoons of raisins</td> </tr> <tr> <td>4 or 5 saltine crackers</td> </tr> <tr> <td>1 tablespoon of sugar</td> </tr> <tr> <td>1 tablespoon of honey or corn syrup</td> </tr> <tr> <td>6 to 8 hard candies</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These sources of sugar act quickly to treat low blood sugar levels. People with diabetes who use insulin or certain other diabetes medicines should carry at least one of these items at all times.</div><div id=\"graphicVersion\">Graphic 71872 Version 3.0</div></div></div>"},"71873":{"type":"graphic_waveform","displayName":"Bifascicular block","title":"Bifascicular block","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Bifascicular block</div><div class=\"cntnt\"><img style=\"width:611px; height:313px;\" src=\"images/CARD/71873_Bifascicular_block.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">By permission: Nathanson LA, McClennen S, Safran C, Goldberger AL. ECG Wave-Maven: Self-Assessment Program for Students and Clinicians. <a href=\"http://ecg.bidmc.harvard.edu/\" target=\"_blank\">http://ecg.bidmc.harvard.edu</a>.</div><div id=\"graphicVersion\">Graphic 71873 Version 3.0</div></div></div>"},"71874":{"type":"graphic_figure","displayName":"TW alternans and arrhythmic events post-MI","title":"Repolarization alternans (RPA) predicts arrhythmic events following myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Repolarization alternans (RPA) predicts arrhythmic events following myocardial infarction</div><div class=\"cntnt\"><img style=\"width:486px; height:356px;\" src=\"images/CARD/71874_TW_alternans_arrhythmic_eve.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 102 patients with a prior myocardial infarction (MI) followed for 13 months, the event-free survival was significantly higher in those without repolarization alternans (RPA negative) compared to those with repolarization alternans (RPA positive). The sensitivity and negative predictive value of RPA for predicting an arrhythmic event were 93 and 98 percent, respectively, but the positive predictive value was only 28 percent.</div><div class=\"graphic_reference\">Data from Ikeda T, Sakata T, Takami M, et al, J Am Coll Cardiol 2000; 35:722.</div><div id=\"graphicVersion\">Graphic 71874 Version 2.0</div></div></div>"},"71877":{"type":"graphic_table","displayName":"Transplant fungal prophylaxis","title":"Suggested approach to antifungal prophylaxis for organ transplant recipients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested approach to antifungal prophylaxis for organ transplant recipients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Transplant organ</td> <td class=\"subtitle1\">Targeted pathogen*</td> <td class=\"subtitle1\">High risk characteristics</td> <td class=\"subtitle1\">Agent<sup>&#182;</sup></td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td>Liver</td> <td><em>Aspergillus</em></td> <td>Poor allograft function; fulminant hepatic failure pretransplantation; reexploration or retransplantation; hemodialysis; isolation of <em>Aspergillus</em> from any site</td> <td>Lipid AmB<sup>&#916; </sup>or an echinocandin</td> <td>1 to 4 weeks</td> </tr> <tr> <td>Liver</td> <td><em>Candida</em></td> <td>Repeated operation; higher intraoperative transfusion requirements; longer operation time; renal failure; ICU stay</td> <td> <p>Fluconazole</p> Alternatives: an echinocandin or lipid AmB<sup>&#916;</sup></td> <td>1 to 4 weeks</td> </tr> <tr> <td>Lung</td> <td><em>Aspergillus</em></td> <td>Airway specimen cultures positive for <em>Aspergillus</em>, particularly for patients with rejection or poor graft function; increased immunosuppression; CMV infection; obliterative bronchiolitis</td> <td> <p>Itraconazole or voriconazole<sup>&#9674;</sup> or lipid AmB<sup>&#916;</sup> (full dose intravenous) &#177; nebulized AmB</p> </td> <td> <p>Depends on CT findings and clearance of sputum cultures, appearance of tracheal anastomosis.</p> 1 to 6 months</td> </tr> <tr> <td>Pancreas</td> <td><em>Candida</em></td> <td> <p>All procedures</p> (Risk increased with enteric drainage, anastamotic leak, pancreas transplantation after kidney transplantation, pancreatitis)</td> <td> <p>Fluconazole</p> <p>Alternatives: an echinocandin or lipid AmB<sup>&#916;</sup></p> </td> <td>4 weeks</td> </tr> <tr> <td>Bowel</td> <td><em>Candida</em></td> <td> <p>All procedures </p> (Risk increased with peritonitis or leaks, reexploration, renal failure, ischemia, CMV infection, parenteral nutrition)</td> <td> <p>Fluconazole</p> <p>May use an echinocandin or lipid AmB<sup>&#916;</sup> as alternatives.</p> </td> <td>2 to 4 weeks</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Lipid AmB: lipid formulation of amphotericin B; ICU: intensive care unit; CMV: cytomegalovirus; CT: computed tomography.<br />* Adjusted for prevalence at center.<br />¶ An echinocandin (eg, caspofungin) might be considered as an alternative to fluconazole for prophylaxis against <EM>Candida</EM> and voriconazole as an alternative to lipid AmB; however, hepatotoxicity and drug interactions may limit their use.<br />Δ A lipid formulation of amphotericin B is preferred over amphotericin B deoxycholate in order to reduce administration-associated side effects and nephrotoxicity.<br />◊ Adjust doses of calcineurin inhibitors and monitor levels carefully when initiating or discontinuing azole antifungal.</div><div id=\"graphicVersion\">Graphic 71877 Version 4.0</div></div></div>"},"71878":{"type":"graphic_figure","displayName":"Solute clearance over time PD","title":"Graphs showing the total solute clearance among CAPD patients as measured by weekly Kt/V and creatinine clearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graphs showing the total solute clearance among CAPD patients as measured by weekly Kt/V and creatinine clearance</div><div class=\"cntnt\"><img style=\"width:417px; height:446px;\" src=\"images/NEPH/71878_Solute_clearance_over_time.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Total solute clearance over time, as measured by weekly Kt/V (top panel) and CCr (lower panel), in patients on continuous peritoneal dialysis. Although peritoneal clearance (middle columns) remains constant, total clearance (left columns) falls because of a progressive loss in RRF (right columns).</div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; RRF: residual renal function; CCr: creatinine clearance.</div><div class=\"graphic_reference\">Data from: Burkart JM, Schreiber M, Korbet SM, et al. Solute clearance approach to adequacy of peritoneal dialysis. Perit Dial Int 1996; 16:457.</div><div id=\"graphicVersion\">Graphic 71878 Version 3.0</div></div></div>"},"71879":{"type":"graphic_table","displayName":"Nonmotor symptoms of Parkinson disease","title":"Nonmotor symptoms of Parkinson disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonmotor symptoms of Parkinson disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Cognitive dysfunction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Psychosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mood disorders (depression, anxiety, apathy/abulia)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sleep disturbances</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fatigue</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Autonomic dysfunction (urinary urgency/frequency, constipation, orthostasis, erectile dysfunction)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Olfactory dysfunction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pain and sensory disturbances</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dermatologic findings (seborrhea)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 71879 Version 2.0</div></div></div>"},"71882":{"type":"graphic_picture","displayName":"Carmustine lung fibrosis Gross","title":"Lung fibrosis due to carmustine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung fibrosis due to carmustine</div><div class=\"cntnt\"><img style=\"width:401px; height:382px;\" src=\"images/PULM/71882_Carmustine_lung_fibrosis_Gr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postmortem slide of cut surface of lungs in a case of late-onset carmustine lung fibrosis from a woman who died 13 years after receiving carmustine for astrocytoma. There is extensive subpleural fibrosis, especially at the lung apices.</div><div class=\"graphic_reference\">Courtesy of Ronan O'Driscoll, MD.</div><div id=\"graphicVersion\">Graphic 71882 Version 1.0</div></div></div>"},"71883":{"type":"graphic_table","displayName":"Ethambutol dosing","title":"Suggested ethambutol doses, using whole tablets, for adults weighing 40 to 90 kilograms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested ethambutol doses, using whole tablets, for adults weighing 40 to 90 kilograms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Weight, kg*</td> </tr> <tr> <td class=\"subtitle2\">40 to 55</td> <td class=\"subtitle2\">56 to 75</td> <td class=\"subtitle2\">76 to 90</td> </tr> <tr> <td><strong>Daily, mg (mg/kg)</strong></td> <td>800 (14.5 to 20)</td> <td>1200 (16 to 21.4)</td> <td>1600<sup>&#182;</sup> (17.8 to 21.1)</td> </tr> <tr> <td><strong>Thrice weekly, mg (mg/kg)</strong></td> <td>1200 (21.8 to 30)</td> <td>2000 (26.7 to 35.7)</td> <td>2400<sup>&#182;</sup> (26.7 to 31.6)</td> </tr> <tr> <td><strong>Twice weekly, mg (mg/kg)</strong></td> <td>2000 (36.4 to 50)</td> <td>2800 (37.3 to 50)</td> <td>4000<sup>&#182;</sup> (44.4 to 52.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on estimated lean body weight.<br />¶ Maximum dose regardless of weight.</div><div class=\"graphic_reference\">Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 71883 Version 10.0</div></div></div>"},"71884":{"type":"graphic_picture","displayName":"Stellate lesions I","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:404px; height:263px;\" src=\"images/PULM/71884_Stellate_lesions_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows stellate lesions (arrows).</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 71884 Version 1.0</div></div></div>"},"71885":{"type":"graphic_table","displayName":"Complement regulatory proteins","title":"Complement regulatory proteins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complement regulatory proteins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"12.5%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">Comment</td> <td class=\"subtitle1\">Disease</td> </tr> <tr> <td>C1INH</td> <td class=\"centered\">P</td> <td>Inactivates C1 and MASPs</td> <td>Binds C1r/C1s, MASPs</td> <td>HAE</td> </tr> <tr> <td>C4BP</td> <td class=\"centered\">P</td> <td>DAA* and CA<sup>&#182;</sup></td> <td>Binds C4b</td> <td>&ndash;</td> </tr> <tr> <td>Factor H</td> <td class=\"centered\">P</td> <td>DAA* and CA<sup>&#182;</sup></td> <td>Binds C3b</td> <td>aHUS, AMD, C3G</td> </tr> <tr> <td>DAF (CD55)</td> <td class=\"centered\">M</td> <td>DAA*</td> <td>Prevents formation of and dissociates C3/C5 convertases</td> <td>CHAPLE syndrome</td> </tr> <tr> <td>MCP (CD46)</td> <td class=\"centered\">M</td> <td>CA<sup>&#182;</sup></td> <td>Binds C3b and C4b so that factor I can cleave them</td> <td>Primarily aHUS</td> </tr> <tr> <td>CR1 (CD35)</td> <td class=\"centered\">M</td> <td>DAA* and CA<sup>&#182;</sup></td> <td>Binds C3b, C4b, C1q, and MBL</td> <td>&ndash;</td> </tr> <tr> <td>CRIg</td> <td class=\"centered\">M</td> <td>Blocks alternative pathway</td> <td>Binds C3b and iC3b</td> <td>&ndash;</td> </tr> <tr> <td>CSDM1</td> <td class=\"centered\">M</td> <td>CA<sup>&#182;</sup></td> <td>Binds C3b</td> <td>&ndash;</td> </tr> <tr> <td>Factor I</td> <td class=\"centered\">P</td> <td>A protease that cleaves C3b and C4b</td> <td>Requires a cofactor, such as MCP or factor H</td> <td>aHUS, AMD</td> </tr> <tr> <td>Anaphylatoxin inactivator (carboxypeptidase N)</td> <td class=\"centered\">P</td> <td>A protease that inactivates anaphylatoxins</td> <td>Binds and cleaves C4a, C3a, and C5a</td> <td>&ndash;</td> </tr> <tr> <td>Vitronectin<sup>&#916;</sup></td> <td class=\"centered\">P</td> <td>Blocks fluid-phase MAC</td> <td>Binds C5b67</td> <td>&ndash;</td> </tr> <tr> <td>CD59</td> <td class=\"centered\">M</td> <td>Blocks MAC on host cells</td> <td>Binds C8/C9</td> <td>PNH</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">C4BP and particularly factor H transfer from plasma to damaged cells and exposed acellular tissue surfaces (basement membranes) to prevent undesirable complement activation. This is particularly important in cases of extracellular debris accumulation, as in AMD.</div><div class=\"graphic_footnotes\">C1INH: C1 inhibitor; P: plasma; MASPs: mannose-binding lectin (MBL)-associated serine proteases; HAE: hereditary angioedema; C4BP: C4b binding protein; DAA: decay-accelerating activity; CA: cofactor activity; aHUS: atypical hemolytic uremic syndrome; AMD: age-related macular degeneration; C3G: C3 glomerulopathy; DAF: decay-accelerating factor or CD55; M: membrane; CHAPLE: complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy; MCP: membrane cofactor protein or CD46; CR1: complement receptor 1 or CD35; CRIg: complement receptor of the immunoglobulin superfamily; CSDM1: CUB and sushi multiple domains protein 1; MAC: membrane attack complex; PNH: paroxysmal nocturnal hemoglobinuria.<br />* DAA refers to the ability to irreversibly dissociate the convertases.<br />¶ CA indicates association of the regulator with the serine protease factor I to cleave and thereby inactivate C3b and/or C4b to prevent further convertase formation.<br />Δ Clusterin is not included due to conflicting data as to its role as plasma MAC inhibitor.</div><div id=\"graphicVersion\">Graphic 71885 Version 7.0</div></div></div>"},"71886":{"type":"graphic_figure","displayName":"Primary and secondary responses","title":"Primary and secondary antibody responses to tetanus and diphtheria antigens","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Primary and secondary antibody responses to tetanus and diphtheria antigens</div><div class=\"cntnt\"><img style=\"width:482px; height:346px;\" src=\"images/RHEUM/71886_Primary_and_second_response.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antigen is administered at the time indicated on the x-axis. Time on the x-axis is not marked with units since the course of the response will vary greatly depending on the dose of antigen, the route of administration, and whether the antigen persists in the body or is rapidly cleared. For many protein or glycoprotein antigens not associated with an ongoing infection, the time course of the response ranges from two to four weeks. In the primary response, there is an initial lag period, and then immunoglobulin M (IgM) is produced initially, followed later by immunoglobulin G (IgG). In the secondary response, there is a much shorter lag period. The initial rise in antibody production is more rapid, and the total amount produced is greater than in the primary response. In addition, there is a predominance of the IgG isotype (although IgM antibodies are produced as well), and the antibodies have higher affinity for antigen.</div><div class=\"graphic_reference\">Legend is modified with permission from: Bona C, Bonilla F. B Cells and Humoral Immunity. In: Textbook of Immunology, 2nd ed, Harwood Academic Publishers 1996. Page 124, figure 5.I4.</div><div id=\"graphicVersion\">Graphic 71886 Version 4.0</div></div></div>"},"71887":{"type":"graphic_figure","displayName":"Adult mosquito bodies","title":"Adult Anopheline and Culicine mosquito bodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adult Anopheline and Culicine mosquito bodies</div><div class=\"cntnt\"><img style=\"width:383px; height:355px;\" src=\"images/ID/71887_Adult_mosquito_bodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anopheline mosquitoes are oriented with head, thorax and abdomen in a straight line at an acute angle to the surface. Culicine mosquitoes rest with the head and body angled, with the abdomen directed back to the surface.</div><div class=\"graphic_reference\">Courtesy of Cheryl Whitehorn, MSc.</div><div id=\"graphicVersion\">Graphic 71887 Version 2.0</div></div></div>"},"71891":{"type":"graphic_picture","displayName":"Acute eosinophilic myocarditis","title":"Acute eosinophilic myocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute eosinophilic myocarditis</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/CARD/71891_Endomyocard_fibrosis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eosinophilic infilitration of the myocardium in a case of acute eosinophilic myocarditis in a 23-year old woman who went to transplant for a rapidly progressive dilated cardiomyopathy.</div><div class=\"graphic_reference\">Reproduced with permission from Bilinska ZT, Bilinska M, Grzybowski J, et al. Unexpected eosinophilic myocarditis in a young woman with rapidly progressive dilated cardiomyopathy. Int J Cardiol 2002; 86:295. Copyright ©2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 71891 Version 3.0</div></div></div>"},"71893":{"type":"graphic_picture","displayName":"Superficial spreading melanoma 4","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/71893_Superficial_spread_melan_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lesion is asymmetric and presents border irregularity, color variegation, and a nodular component.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71893 Version 5.0</div></div></div>"},"71894":{"type":"graphic_table","displayName":"Polarized and non-polarized dermoscopy","title":"Differences between polarized and non-polarized dermoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between polarized and non-polarized dermoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Non-polarized dermoscopy<br /> (NPD)</td> <td class=\"subtitle1\">Polarized dermoscopy<br /> (PD)</td> </tr> <tr> <td><strong>Technique</strong></td> <td>Requires direct contact between the scope and the skin. Requires a liquid interface.</td> <td>Although PD can be used in either the contact or non-contact mode, and can be used with or without a liquid interface, using a liquid interface and direct contact provides superior image clarity.</td> </tr> <tr class=\"divider_top\"> <td><strong>Skin layers</strong></td> <td>Superficial layers are better visualized than deeper layers.</td> <td>Deep layers of epidermis and papillary dermis (depth of polarized light ~60 to 100 micrometers) are better visualized than superficial layers.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Colors and structures</strong></td> <td>Blue white-veil due to orthokeratosis is more conspicuous.</td> <td>Pink and red colors are more conspicuous.</td> </tr> <tr> <td>Milia-like cysts and comedo-like structures are easier to recognize under NPD.</td> <td>Milia-like cysts and comedo-like structures are less conspicuous with PD.</td> </tr> <tr> <td>The steel-blue color seen in blue nevi appears more homogeneous under NPD.</td> <td>The blue color in blue nevi will appear darker with differing hues.</td> </tr> <tr> <td>Regression areas (peppering, blue white areas and gray color) are more conspicuous with NPD. This difference is especially pronounced on thin skin such as facial or sun-damaged skin.</td> <td>The white scar-like areas are more conspicuous under PD.</td> </tr> <tr> <td>The ability to visualize vascular structures is dependent upon the amount of pressure applied to the skin.</td> <td>Vascular structures and collagen are more conspicuous.</td> </tr> <tr> <td>&nbsp;</td> <td>Shiny white structures, including white shiny&nbsp;streaks, also known as crystalline structures, are only seen under PD.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Pan Y, Gareau DS, Scope A, et al. Polarized and nonpolarized dermoscopy: the explanation for the observed differences. Arch Dermatol 2008; 144:828. </li> <li>Benvenuto-Andrade C, Dusza SW, Agero AL, et al. Differences between polarized light dermoscopy and immersion contact dermoscopy for the evaluation of skin lesions. Arch Dermatol 2007; 143:329. </li> </ol></div><div id=\"graphicVersion\">Graphic 71894 Version 6.0</div></div></div>"},"71895":{"type":"graphic_picture","displayName":"PIP flexion","title":"Examination of finger PIP joint flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of finger PIP joint flexion</div><div class=\"cntnt\"><img style=\"width:396px; height:340px;\" src=\"images/EM/71895_PIP_flexion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 71895 Version 1.0</div></div></div>"},"71897":{"type":"graphic_figure","displayName":"Dividing the parametrium","title":"Dividing the parametrium during radical hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dividing the parametrium during radical hysterectomy</div><div class=\"cntnt\"><img style=\"width:440px; height:366px;\" src=\"images/OBGYN/71897_Dividing_the_parametrium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ureters are retracted as far lateral as possible and the parametrium divided at the sidewall.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 71897 Version 2.0</div></div></div>"},"71898":{"type":"graphic_table","displayName":"Rand trials adjuv chemo gast CA","title":"Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"22%\"></colgroup><colgroup width=\"12%\"></colgroup><colgroup span=\"2\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Country</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Chemotherapy</td> <td class=\"subtitle1\">Hazard ratio for survival (95% CI)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Non-anthracycline-containing polychemotherapy</td> </tr> <tr> <td class=\"indent1\">Huguier M; 1980</td> <td>France</td> <td>53</td> <td>5-FU, VBL, CTX</td> <td>No significant survival difference</td> </tr> <tr> <td class=\"indent1\">Schlag P; 1982</td> <td>Germany</td> <td>98</td> <td>5-FU, BCNU</td> <td>0.66 (0.31-1.41)</td> </tr> <tr> <td class=\"indent1\">Douglass H; 1982</td> <td>USA</td> <td>142</td> <td>5-FU, MeCCNU</td> <td>0.58 (0.35-0.95)*</td> </tr> <tr> <td class=\"indent1\">Ochiai T; 1983</td> <td>Japan</td> <td>59</td> <td>MMC, 5-FU, Ara-C</td> <td>1.08 (0.5-2.31)</td> </tr> <tr> <td class=\"indent1\">Higgins G; 1983</td> <td>USA</td> <td>134</td> <td>5-FU, MeCCNU</td> <td>0.94 (0.58-1.53)</td> </tr> <tr> <td class=\"indent1\">Engstrom P; 1985</td> <td>USA</td> <td>180</td> <td>5-FU, MeCCNU</td> <td>0.94 (0.58-1.53)</td> </tr> <tr> <td class=\"indent1\">Jakesz R; 1988</td> <td>Austria</td> <td>87</td> <td>Ara-C, MMC, 5-FU</td> <td>0.65 (0.38-1.13)</td> </tr> <tr> <td class=\"indent1\">Bonfanti G; 1988</td> <td>Italy</td> <td>144</td> <td>5-FU, MeCCNU</td> <td>0.97 (0.61-1.55)</td> </tr> <tr> <td class=\"indent1\">Allum W; 1989</td> <td>UK</td> <td>271</td> <td>MMC, 5-FU</td> <td>0.99 (0.73-1.36)</td> </tr> <tr> <td class=\"indent1\">Allum W; 1989</td> <td>UK</td> <td>270</td> <td>CTX, 5-FU, VCR, MTX<sup>&#182;</sup> then MMC, 5-FU</td> <td>1.01 (0.74-1.38)</td> </tr> <tr> <td class=\"indent1\">Nakajima T; 1999</td> <td>Japan</td> <td>573</td> <td>MMC, 5-FU, UFT</td> <td>0.74 (0.5-1.09)</td> </tr> <tr> <td class=\"indent1\">Cirera L; 1999</td> <td>Spain</td> <td>148</td> <td>MMC, Ftorafur</td> <td>0.60 (0.39-0.93)*</td> </tr> <tr> <td class=\"indent1\">Nashimoto A; 2003</td> <td>Japan</td> <td>252</td> <td>MMC, 5-FU, Ara-C</td> <td>No significant survival difference</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bang Y; 2012</td> <td>Korea</td> <td>1035</td> <td>Capecitabine, oxaliplatin</td> <td>0.72 (0.52-1.00)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Anthracycline-containing polychemotherapy</td> </tr> <tr> <td class=\"indent1\">Coombes R; 1990</td> <td>UK</td> <td>281</td> <td>5-FU, DOX, MMC</td> <td>0.89 (0.66-1.21)</td> </tr> <tr> <td class=\"indent1\">Krook J; 1991</td> <td>USA</td> <td>125</td> <td>5-FU, DOX</td> <td>0.97 (0.62-1.51)</td> </tr> <tr> <td class=\"indent1\">Hallissey M; 1994</td> <td>UK</td> <td>283</td> <td>5-FU, DOX, MMC</td> <td>0.95 (0.74-1.22)</td> </tr> <tr> <td class=\"indent1\">Macdonald J; 1995</td> <td>USA</td> <td>193</td> <td>5-FU, DOX, MMC</td> <td>0.91 (0.65-1.28)</td> </tr> <tr> <td class=\"indent1\">Lise M; 1995</td> <td>Italy</td> <td>294</td> <td>5-FU, DOX, MMC</td> <td>0.86 (0.64-1.14)</td> </tr> <tr> <td class=\"indent1\">Tsavaris N; 1996</td> <td>Greece</td> <td>84</td> <td>5-FU, EPI, MMC</td> <td>0.76 (0.31-1.87)</td> </tr> <tr> <td class=\"indent1\">Neri B; 1996</td> <td>Italy</td> <td>103</td> <td>5-FU, LV, EPI</td> <td>0.46 (0.27-0.77)*</td> </tr> <tr> <td class=\"indent1\">Di Costanzo F; 2008</td> <td>Italy</td> <td>258</td> <td>PELF</td> <td>0.91 (0.64-1.26)</td> </tr> <tr> <td class=\"indent1\">Bouche O; 2005</td> <td>France</td> <td>260</td> <td>Infusional 5-FU, CIS</td> <td>0.74 (0.54-1.02)</td> </tr> <tr> <td class=\"indent1\">Nitti D; 2006</td> <td>EORTC</td> <td>206</td> <td>5-FU, DOX, MTX</td> <td>0.89 (0.51-1.31)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Nitti D; 2006</td> <td>ICCG</td> <td>191</td> <td>5-FU, EPI, MTX</td> <td>1.05 (0.69-1.41)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">De Vita F; 2007</td> <td>GOIM</td> <td>228</td> <td>5-FU, LV, EPI, ETOP</td> <td>0.91 (0.69-1.21)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Kulig J; 2010</td> <td>Poland</td> <td>309</td> <td>EAP</td> <td>0.889 (0.676-1.169)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">S-1 monotherapy</td> </tr> <tr> <td class=\"indent1\">Sasako M; 2011</td> <td>Japan</td> <td>1059</td> <td>S-1</td> <td>0.67 (0.54-0.83)*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">5-FU: fluorouracil; VBL: vinblastine; CTX: cyclophosphamide; BCNU: Carmustine; MeCCNU: Semustine (methyl-CCNU); MMC: mitomycin C;&nbsp;Ara-C: cytarabine; MTX: methotrexate; VCR: vincristine; UFT: ftorafur and uracil; DOX: doxorubicin; EPI: epirubicin; LV: leucovorin; PELF: cisplatin, epirubicin, leucovorin, 5-FU; CIS: cisplatin; EORTC: European Organization for Research and Treatment of Cancer; ICCG: International Collaborative Cancer Group; GOIM: Grupopa Oncologico dell'Italia Meridionale; ETOP: etoposide; EAP: etoposide, doxorubicin, cisplatin.<br />* Statistically significant values for survival.<br />¶ Induction chemotherapy with five days of CTX, 5-FU, VCR, and MTX, followed by MMC and 5-FU.<br />Δ Both trials reported together, neither of which reached its accrual goal (760 for the EORTC and 480 for the ICCG trials).</div><div id=\"graphicVersion\">Graphic 71898 Version 10.0</div></div></div>"},"71900":{"type":"graphic_picture","displayName":"RTT pseudostationary b","title":"Rett syndrome, pseudostationary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, pseudostationary</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/71900_RS_stage_III_pseudostatio1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This girl with RTT demonstrated prominent motor dysfunction but experienced no further cognitive decline.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: Meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 71900 Version 4.0</div></div></div>"},"71901":{"type":"graphic_table","displayName":"Surrogates insulin resistance","title":"Surrogate measures of insulin resistance in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surrogate measures of insulin resistance in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Homeostasis model assessment (HOMA)</td> </tr> <tr> <td>[Fasting insulin concentration (in microU/mL) x fasting glucose concentration (in mmol/L)] &#247; 22.5</td> </tr> <tr> <td>OR</td> </tr> <tr> <td>[Fasting insulin concentration (in milliunits/mL) x fasting glucose concentration (in mg/dL)] &#247; 405</td> </tr> <tr> <td class=\"indent1\">The HOMA value increases with increasing insulin resistance. A threshold value to define insulin resistance in children and adolescents has not been defined. Proposed thresholds range from &#62;3.16<sup>[1]</sup> to &#62;4<sup>[2]</sup>.&nbsp; Other investigators propose cutoffs that vary with pubertal status, with a threshold of &#62;2.5 in prepubertal children (SMR stage I), and&nbsp;&#62;4.0 in pubertal-aged children (SMR stage II and above)<sup>[3]</sup>.&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Fasting glucose/insulin ratio (FGIR)</td> </tr> <tr> <td>Fasting glucose concentration/fasting insulin concentration</td> </tr> <tr> <td class=\"indent1\">The FGIR value decreases with increasing insulin resistance. FGIR &#60;7 suggests insulin resistance<sup>[4]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\">Quantitative insulin sensitivity check index (QUICKI)</td> </tr> <tr> <td>1 &#247; [log fasting insulin concentration (microU/mL) + log glucose concentration (mg/dL)]</td> </tr> <tr> <td class=\"indent1\">The QUICKI value decreases with increasing insulin resistance. The normal range of QUICKI in children and adolescents has not yet been determined. In one study of obese children and adolescents, mean QUICKI was 0.313 and 0.339 in subjects with and without insulin resistance, respectively<sup>[1]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HOMA: homeostasis model assessment; SMR: sexual maturity rating (Tanner stage); FGIR: fasting glucose/insulin ratio; QUICKI: quantitative insulin sensitivity check index.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115:e500. </LI>&#xD;&#xA;<LI>Reinehr T, Andler W. Changes in the atherogenic risk factor profile according to degree of weight loss. Arch Dis Child 2004; 89:419.&nbsp;</LI>&#xD;&#xA;<LI>Valerio G, Licenziati MR, Iannuzzi A et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr Metab Cardiovasc Dis 2006; 16:279.</LI>&#xD;&#xA;<LI>Dimartino-Nardi J. Premature adrenarche: findings in prepubertal African-American and Caribbean-Hispanic girls. Acta Paediatr Suppl 1999; 88:67.</LI></OL></div><div id=\"graphicVersion\">Graphic 71901 Version 5.0</div></div></div>"},"71903":{"type":"graphic_figure","displayName":"Anterior view of proximal humerus","title":"Anterior view of proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior view of proximal humerus</div><div class=\"cntnt\"><img style=\"width:429px; height:430px;\" src=\"images/RHEUM/71903_Anatomy_of_proximal_humerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows pertinent neural and vascular structures that may be compromised by fractures of the proximal humerus. The supraspinatus muscle tendon attaches to the greater tuberosity of the humerus. The subscapularis tendon attaches at the lesser tuberosity. The bicipital tendon (not shown) courses in the groove between the tuberosities along with arterial branches of the anterior circumflex artery.</div><div id=\"graphicVersion\">Graphic 71903 Version 3.0</div></div></div>"},"71904":{"type":"graphic_table","displayName":"HCC aflatoxin","title":"Relation between hepatocellular carcinoma rate and aflatoxin intake","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relation between hepatocellular carcinoma rate and aflatoxin intake</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Location </td>\n\n      <td class=\"subtitle1\"> HCC rate, per 100,000/yr*</td>\n\n      <td class=\"subtitle1\">Aflatoxin B intake, ng/kg per day</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Kenya, high altitude</td>\n\n      <td>1.2</td>\n\n      <td>3.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Kenya, low altitude</td>\n\n      <td>4.0</td>\n\n      <td> 10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thailand</td>\n\n      <td>6.0</td>\n\n      <td>45</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mozambique</td>\n\n      <td>17.7</td>\n\n      <td>131.4</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Based on hospitalized patients.</div><div class=\"graphic_reference\">Adapted from: Van Rensburg SJ, Cook-Mozaffari P, van Schalkwyk DJ, et al. Br J Cancer 1985; 51:713.</div><div id=\"graphicVersion\">Graphic 71904 Version 2.0</div></div></div>"},"71905":{"type":"graphic_movie","displayName":"View through a rigid bronchoscope - mouth to epiglottis","title":"Rigid broncoscopy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigid broncoscopy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/71905_rgdintbiconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:307px; height:228px;\" src=\"images/CARD/71905_rgdintbi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video shows the view through a rigid bronchoscope as it is passed from the mouth to the epiglottis.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 71905 Version 2.0</div></div></div>"},"71906":{"type":"graphic_diagnosticimage","displayName":"Agenesis corpus callosum","title":"Agenesis of the corpus callosum at 28 and 35 postmenstrual weeks","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Agenesis of the corpus callosum at 28 and 35 postmenstrual weeks</div><div class=\"cntnt\"><img style=\"width:513px; height:240px;\" src=\"images/OBGYN/71906_Agenesis_corpus_call_edt3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and B, at 28 weeks showing the lateral ventricles (Lv) pointing up (Viking helmet) and in panel B the third ventricle (arrow) is displaced up coming all the way to the falx cerebri. Panel C, similar section to panel A. Panel D, a normal median section showing the normally developed corpus callosum for comparison. Panel E, a median section showing absence of the corpus callosum, abnormal gyral pattern (arrows) and a prominent third ventricle.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 71906 Version 5.0</div></div></div>"},"71907":{"type":"graphic_figure","displayName":"B-Lynch suture","title":"Anterior uterine wall with B-Lynch suture in place and an enlarged drawing (box) of lower uterine segment with B-Lynch suture in place","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Anterior uterine wall with B-Lynch suture in place and an enlarged drawing (box) of lower uterine segment with B-Lynch suture in place</div><div class=\"cntnt\"><img style=\"width:485px; height:517px;\" src=\"images/OBGYN/71907_B-Lynch_suture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large Mayo needle with #2 chromic catgut is used to enter and exit the uterine cavity at A and B. The suture is looped over the fundus and then reenters the uterine cavity posteriorly at C, which is directly below B. The suture should be pulled very tight at this point. It then enters the posterior wall of the uterine cavity at D, is looped back over the fundus, and anchored by entering the anterior lateral lower uterine segment at E and crossing through the uterine cavity to exit at F. The free ends at A and F are tied down securely to compress the uterus.</div><div class=\"graphic_reference\">Adapted from: Ferguson JE, Bourgeois JF, Underwood PB. B-LYNCH SUTURE FOR POSTPARTUM HEMORRHAGE. Obstetrics &amp; Gynecology 2000; 95(Supp 6):1020.</div><div id=\"graphicVersion\">Graphic 71907 Version 2.0</div></div></div>"},"71910":{"type":"graphic_table","displayName":"DDX PHPT lab result","title":"Differential diagnosis of primary hyperparathyroidism, typical laboratory findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of primary hyperparathyroidism, typical laboratory findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease </td> <td class=\"subtitle1\" colspan=\"5\">Laboratory test </td> </tr> <tr> <td class=\"subtitle2\">Intact PTH </td> <td class=\"subtitle2\">Serum calcium </td> <td class=\"subtitle2\">Urinary calcium (mg/24 hours) </td> <td class=\"subtitle2\">Ca/Cr clearance </td> <td class=\"subtitle2\">25OHD </td> </tr> <tr> <td>PHPT</td> <td>High-normal or elevated</td> <td>Elevated</td> <td>Normal or elevated</td> <td>0.01 to 0.05 (&#62;0.02)</td> <td>Normal, low-normal, or low</td> </tr> <tr> <td>Malignancy</td> <td>Low (&#60;20 pg/mL)</td> <td>Elevated</td> <td>Generally high</td> <td>&nbsp;</td> <td>Depends on malignancy*</td> </tr> <tr> <td>FHH</td> <td>Normal, mildly elevated in 15 to 20 percent</td> <td>Elevated</td> <td>Generally low (&#60;100)</td> <td>&#60;0.01</td> <td>Normal</td> </tr> <tr> <td>PHPT with vitamin D deficiency</td> <td>Elevated</td> <td>Normal or elevated</td> <td>Low-normal or low (&#60;200)</td> <td>&nbsp;</td> <td>Low (&#60;20 ng/mL)</td> </tr> <tr> <td>Normocalcemic&nbsp;PHPT</td> <td>Elevated</td> <td>Normal</td> <td>Normal</td> <td>&nbsp;</td> <td>Normal</td> </tr> <tr> <td>Secondary&nbsp;hyperparathyroidism due to vitamin D deficiency</td> <td>Elevated</td> <td>Normal or low</td> <td>Low</td> <td>&nbsp;</td> <td>Low (&#60;20 ng/mL)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; PHPT: primary hyperparathyroidism; FHH: familial hypocalciuric hypercalcemia; 25OHD: 25-hydroxyvitamin D; Ca/Cr: calcium/creatinine.<br />* 25-hydroxyvitamin D is often normal in malignancy. It could be low in cases of concomitant vitamin D deficiency, due to poor dietary intake and little sun exposure. The 1,25-dihydroxyvitamin D may be elevated, depending upon the malignancy.</div><div id=\"graphicVersion\">Graphic 71910 Version 4.0</div></div></div>"},"71912":{"type":"graphic_table","displayName":"NSAID dose for medical therapy of dysmenorrhea","title":"Suggested nonsteroidal antiinflammatory drug (NSAID) doses in primary dysmenorrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested nonsteroidal antiinflammatory drug (NSAID) doses in primary dysmenorrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Subsequent dose, as needed</td> <td class=\"subtitle1\">Maximum dose per day in short-term use (&#8804;3 days)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Propionic (phenylpropionic) acids</td> </tr> <tr> <td class=\"indent1\">Ibuprofen*</td> <td>400 to 600 mg</td> <td>400 to 600 mg every 4 to 6 hours</td> <td>2400 mg</td> </tr> <tr> <td class=\"indent1\">Naproxen base*</td> <td>500 mg</td> <td>250 mg every 6 to 8 hours</td> <td>1250 mg</td> </tr> <tr> <td class=\"indent1\">Naproxen sodium*</td> <td>550 mg</td> <td>275 every 6 to 8 hours</td> <td>1375 mg</td> </tr> <tr> <td class=\"indent1\">Fenoprofen</td> <td>200 mg</td> <td>200 mg every 4 to 6 hours</td> <td>3200 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketoprofen</td> <td>50 mg</td> <td>25 to 50 mg every 6 to 8 hours</td> <td>300 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fenamates</td> </tr> <tr> <td class=\"indent1\">Mefenamic acid</td> <td>500 mg</td> <td>250 mg every 6 hours</td> <td>1000 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Meclofenamate</td> <td>100 mg</td> <td>50 mg every 4 to 6 hours</td> <td>400 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acetic acids</td> </tr> <tr> <td class=\"indent1\">Indomethacin</td> <td>25 mg</td> <td>25 mg three times daily</td> <td>150 mg</td> </tr> <tr> <td class=\"indent1\">Tolmetin</td> <td>400 mg</td> <td>400 mg three times daily</td> <td>1800 mg</td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> <td>75 to 100 mg</td> <td>50 mg three times daily</td> <td>150 mg (100 mg beginning on day 2 in some countries)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Etodolac</td> <td>400 mg</td> <td>200 to 400 mg every 6 to 8 hours (immediate release)</td> <td>1000 mg (immediate release)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Salicylates (nonacetylated)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diflunisal<sup>&#182;</sup></td> <td>1000 mg</td> <td>500 mg twice daily</td> <td>1500 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Oxicams</td> </tr> <tr> <td class=\"indent1\">Meloxicam<sup>&#916;</sup></td> <td>7.5 mg</td> <td>7.5 mg once daily</td> <td>15 mg</td> </tr> <tr> <td class=\"indent1\">Piroxicam<sup>&#9674;</sup></td> <td>20 mg</td> <td>10 to 20 mg once daily</td> <td>20 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>NSAIDs are taken at the first onset of menses and continued for one to three days or usual duration of painful symptoms. Patients with severe symptoms may begin taking an NSAID one to two days prior to onset of menses. All doses shown are for oral administration in adult or adolescent women. Patients should be well hydrated and without significant kidney disease (CrCl &gt;60 mL/minute).</li>&#xD;&#xA;    <li>Avoid NSAID use in women with a history of gastrointestinal bleeding, coagulopathy, ischemic heart disease, stroke, heart failure, liver disease, or aspirin sensitive asthma.</li>&#xD;&#xA;    <li>Use with caution or avoid in patients receiving co-medication with anticoagulants, systemic glucocorticoids, lithium, loop diuretics, and other interacting drugs. Specific interactions may be checked by using Lexi-Interact program included with UpToDate.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Available without a prescription in United States and other countries. Naproxen sodium is more rapidly absorbed than naproxen base.<br />&para; Minimal or no effect on platelet functioning and generally tolerated by adults with asthma at daily dose of &le;1000 mg.<br />&Delta; Relatively COX-2 selective and minimal effect on platelet functioning at daily dose of 7.5 mg. Rarely associated with serious cutaneous allergic reactions (eg, Stevens-Johnson syndrome).<br /><span class=\"lozenge\">&loz;</span> Risk of serious gastrointestinal complications may be elevated in doses &ge;20 mg per day; consider concurrent pharmacologic gastroprotection. Rarely associated with serious cutaneous allergic reactions (eg, Stevens-Johnson syndrome).</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Anon. Drugs for pain. Treatment guidelines from the Medical Letter; 2013. 11:31.</LI>&#xD;&#xA;<LI>Majoribanks J, Proctor M, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (review). Cochrane Database Systematic Rev (2010). 20:1.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 71912 Version 11.0</div></div></div>"},"71913":{"type":"graphic_picture","displayName":"Allergic contact dermatitis","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:322px; height:216px;\" src=\"images/PC/71913_Allergic_contact_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Allergic contact dermatitis is characterized by an erythematous, papular dermatitis with indistinct margins, distributed in areas of exposure.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 71913 Version 1.0</div></div></div>"},"71918":{"type":"graphic_figure","displayName":"Removal of etonogestrel contraceptive implant","title":"Removal of etonogestrel contraceptive implant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removal of etonogestrel contraceptive implant</div><div class=\"cntnt\"><img style=\"width:349px; height:645px;\" src=\"images/OBGYN/71918_Removetonogestcontraimpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After sonographic localization of the implant, make a 3 mm incision transversely above the implant, open the modified vasectomy forceps over the implant, close the forceps around the implant, and then use the forceps to remove the implant.</div><div class=\"graphic_reference\">Reproduced with permission from: Speroff L, Darney PD. A Clinical Guide for Contraception, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71918 Version 6.0</div></div></div>"},"71920":{"type":"graphic_figure","displayName":"Changes in wheezing prevalence in children","title":"Changes in the percent of children wheezing in different countries (1960 to 2000) from ISAAC and ECRHS data","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Changes in the percent of children wheezing in different countries (1960 to 2000) from ISAAC and ECRHS data</div><div class=\"cntnt\"><img style=\"width:562px; height:448px;\" src=\"images/ALLRG/71920_Chgs_wheezing_prev_kids.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ISAAC: International Studies of Asthma and Allergies in Children; ECRHS: European Community Respiratory Health Survey; IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Courtesy of Drs. Thomas Platts-Mills and Scott Commins.</div><div id=\"graphicVersion\">Graphic 71920 Version 4.0</div></div></div>"},"71921":{"type":"graphic_table","displayName":"Parenteral rx enterococci","title":"Parenteral treatment for susceptible enterococcal infections in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral treatment for susceptible enterococcal infections in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose and route</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Options for monotherapy*</td> </tr> <tr> <td class=\"indent1\">Ampicillin<sup>&#182;</sup></td> <td>1 to 2 g IV every 4 to 6 hours</td> </tr> <tr> <td class=\"indent1\">Penicillin G</td> <td>18 to 30 million units IV per 24 hours either continuously or in six equally divided doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vancomycin<sup>&#916;</sup></td> <td>Initially 15 mg/kg/dose IV every 12 hours, not to exceed 2 g per dose; subsequent dosing guided by serum trough concentration monitoring</td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Options for combination therapy<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Ampicillin<sup>&#182;</sup></td> <td>2 g IV every 4 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><em>PLUS</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftriaxone</td> <td>2 g IV every 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">One of the following agents:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Ampicillin </li> </ul> </td> <td>Doses as above</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Penicillin G </li> </ul> </td> <td>Doses as above</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Vancomycin </li> </ul> </td> <td>Doses as above</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><em>PLUS</em></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">One of the following agents:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Gentamicin<sup>&#167;</sup> </li> </ul> </td> <td>1 mg/kg IV every 8 hours</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Streptomycin<sup>&#165;</sup> </li> </ul> </td> <td>5 mg/kg IV or IM every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adjustment of dose may be required depending upon site and severity of infection and patient kidney function; for additional information, refer to appropriate UpToDate clinical treatment reviews and Lexicomp drug monographs.</div><div class=\"graphic_footnotes\">* Daptomycin, telavancin, tigecycline, and linezolid are also approved for use in complicated skin and skin structure infections due to vancomycin-susceptible <EM>Enterococcus faecalis</EM>; in addition, tigecycline has approval for complicated intraabdominal infections associated with <EM>E. faecalis</EM>.<br />¶ Infections due to beta-lactamase-producing enterococci requiring parenteral therapy may be treated with ampicillin-sulbactam (3 g IV every 6 hours) or vancomycin.<br />Δ Teicoplanin (where available) may be used in place of vancomycin for treatment of infection due to isolates with minimum inhibitory concentration (MIC) ≤2 mg/L; for vancomycin-resistant strains (very common with <EM>E. faecium</EM>), teicoplanin should not be used (even if susceptible in vitro) because of concern about emergence of resistance. Teicoplanin loading and maintenance doses vary depending on the site and severity of infection. Loading doses range from 400 mg (approximately 6 mg/kg per dose) intravenously every 12 hours for 3 doses to 800 mg (approximately 12 mg/kg per dose) every 12 hours for 3 to 5 doses; maintenance doses range from 6 to 12 mg/kg/day. Therapeutic drug monitoring may be warranted; refer to local product information.<br /><FONT class=lozenge>◊</FONT> For treatment of invasive infection (such as endocarditis, meningitis, and bacteremia in the setting of valvulopathy and/or critical illness), bactericidal activity is required. This may be achieved via synergistic activity of a cell wall-active agent (such as ampicillin) in combination with ceftriaxone, gentamicin or streptomycin (if there is no high level aminoglycoside resistance). Ceftriaxone is preferred by many as the second agent to add to ampicillin for synergism. (Refer to the UpToDate topic on antimicrobial therapy of native valve endocarditis, section on <EM>Enterococcus</EM>.)<br />§ In patients with normal renal function, gentamicin dosing should be adjusted to achieve a one-hour post-dose serum concentration of 3 mcg/mL and a trough concentration of &lt;1 mcg/mL.<br />¥ In patients with normal renal function, streptomycin dosing should be adjusted to achieve a one-hour post-dose serum concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.</div><div id=\"graphicVersion\">Graphic 71921 Version 11.0</div></div></div>"},"71926":{"type":"graphic_picture","displayName":"Hypopigmented mycosis fungoides","title":"Hypopigmented mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypopigmented mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/71926_Mycosis_fungoides_hypo_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented patches are present in this patient with mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71926 Version 6.0</div></div></div>"},"71927":{"type":"graphic_table","displayName":"Latex allergens","title":"<em>Hevea brasiliensis</em> latex allergens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><em>Hevea brasiliensis</em> latex allergens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Name </td> <td class=\"subtitle1\">Description </td> <td class=\"subtitle1\">MW (kD) </td> <td class=\"subtitle1\">Plant family </td> <td class=\"subtitle1\">Crossreactivity </td> </tr> <tr> <td>Hev b 1*</td> <td>Rubber elongation factor</td> <td>58/14.6</td> <td>-</td> <td>Papain, fig</td> </tr> <tr> <td>Hev b 2</td> <td>Beta 1/3 glucanase</td> <td>34 to 36</td> <td>PR-2</td> <td>-</td> </tr> <tr> <td>Hev b 3*</td> <td>Prenyltransferase</td> <td>24 to 27</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b 4</td> <td>Microhelix</td> <td>110/115</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b 5*</td> <td>Acidic protein</td> <td>16</td> <td>-</td> <td>Kiwi</td> </tr> <tr> <td>Hev b 6.01</td> <td>Hevein preprotein (prohevein)</td> <td>20</td> <td>PR-3</td> <td>Avocado, banana, chestnut</td> </tr> <tr> <td>Hev b 6.02*</td> <td>Hevein protein (mature hevein)</td> <td>4.7</td> <td>PR-3</td> <td>Avocado, banana, chestnut</td> </tr> <tr> <td>Hev b 6.03</td> <td>Hevein C-terminal fragment</td> <td>15.3</td> <td>PR-3</td> <td>Avocado, banana, chestnut</td> </tr> <tr> <td>Hev b 7</td> <td>Patatin homologue (Hev b 7.01/7.02)</td> <td>43 to 46</td> <td>-</td> <td>Potato (patatin - Sol t 1)</td> </tr> <tr> <td>Hev b 8</td> <td><em>Hevea</em> profilin</td> <td>14 to 14.2</td> <td>Profilin</td> <td>Pollens, celery</td> </tr> <tr> <td>Hev b 9</td> <td><em>Hevea</em> enolase</td> <td>51</td> <td>-</td> <td>Molds</td> </tr> <tr> <td>Hev b 10</td> <td>Mn superoxide dismutase</td> <td>22 to 26</td> <td>-</td> <td>Molds</td> </tr> <tr> <td>Hev b 11</td> <td>Class I chitinase</td> <td>33</td> <td>PR-3</td> <td>Banana, avocado</td> </tr> <tr> <td>Hev b 12</td> <td>Lipid transfer protein</td> <td>9.4</td> <td>PR-14</td> <td>Peach and other stone fruit</td> </tr> <tr> <td>Hev b 13</td> <td>Esterase</td> <td>42</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hev b 14</td> <td>Chitinase, glycosidase hydrolase family 18</td> <td>30.2</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b 15</td> <td>Serine protease inhibitor&nbsp;</td> <td>8&nbsp;</td> <td>PR-6&nbsp;</td> <td>Wheat&nbsp;</td> </tr> <tr> <td>Hev b CitBP</td> <td>Citrate-binding protein</td> <td>27</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b CyP</td> <td>Cyclophilin rotamase</td> <td>18</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b GAPDH</td> <td>Glyceraldehyde 3-phosphate dehydrogenase</td> <td>37</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b HSP80</td> <td>Heat shock protein</td> <td>80</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b IFR</td> <td>Isoflavone reductase</td> <td>35</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b PRS</td> <td>Proteasome subunit</td> <td>2</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b TRX</td> <td>Thioredocin oxidoreductase</td> <td>12</td> <td>-</td> <td>-</td> </tr> <tr> <td>Hev b UDPGP</td> <td>Uridine diphosphate-glucose pyrophosphorylase</td> <td>52</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PR: pathogenesis-related protein; Sol t: <EM>Solanum tuberosum</EM>.<br />* \"Indicator\" proteins useful for assessment of the allergen content of rubber products or as markers of environmental exposure.<br /></div><div id=\"graphicVersion\">Graphic 71927 Version 5.0</div></div></div>"},"71928":{"type":"graphic_figure","displayName":"Mechanism for medial epicondyle fracture","title":"Mechanism for medial epicondyle fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism for medial epicondyle fracture</div><div class=\"cntnt\"><img style=\"width:418px; height:454px;\" src=\"images/EM/71928_Mechepicondylefx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperextension forces. When a person falls on the outstretched upper extremity, the wrist and fingers are forced into hyperextension (solid arrow), which places tension on the forearm flexor muscles. The sudden tension along with the normal valgus carrying angle tends to place a strong avulsion force on the medial epicondyle (open arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71928 Version 14.0</div></div></div>"},"71929":{"type":"graphic_picture","displayName":"Barretts methylene magnify","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:328px; height:315px;\" src=\"images/GAST/71929_Barretts_methylene_magnify.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic image of specialized intestinal metaplasia in Barrett's esophagus with a tubular pit pattern by methylene blue high magnification chromoendoscopy (Olympus 240 Z, magnified 135x).</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 71929 Version 1.0</div></div></div>"},"71931":{"type":"graphic_diagnosticimage","displayName":"ARDS CT","title":"ARDS CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ARDS CT</div><div class=\"cntnt\"><img style=\"width:413px; height:292px;\" src=\"images/PULM/71931_ARDS_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ARDS due to sepsis after pneumococcal pneumonia.</div><div class=\"graphic_footnotes\">ARDS: acute respiratory distress syndrome; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 71931 Version 3.0</div></div></div>"},"71932":{"type":"graphic_table","displayName":"DBP diagnoses with expressive language delay","title":"Developmental-behavioral diagnoses associated with expressive language delay in young children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Developmental-behavioral diagnoses associated with expressive language delay in young children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Functional diagnosis</td> <td class=\"subtitle1\">Approximate prevalence</td> </tr> <tr> <td>Developmental language delay (expressive, receptive, or mixed)</td> <td>10 percent in preschool children; as high as 30 percent in low-income children</td> </tr> <tr> <td>Specific language impairment (expressive, receptive, or mixed)</td> <td>6 percent of school-age children</td> </tr> <tr> <td>Speech sound disorder/phonologic disorder (articulation disorder)</td> <td>8 to 9 percent of children &#60;5 years; 5 percent of children in first grade</td> </tr> <tr> <td>Fluency disorders/stuttering</td> <td>4 to 5 percent of preschool children; 1 percent of children school-age and older</td> </tr> <tr> <td>Autism spectrum disorders</td> <td>Approximately 1 percent (1 in 110)</td> </tr> <tr> <td>Global developmental delay/intellectual disability</td> <td>1.5 to 3 percent</td> </tr> <tr> <td>Selective mutism (an anxiety disorder)</td> <td>0.7 percent</td> </tr> <tr> <td>Verbal apraxia</td> <td>0.1 to 0.2 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Horwitz SM, Irwin JR, Briggs-Gowan MJ, et al. Language delay in a community cohort of young children. J Am Acad Child Adolesc Psychiatry 2003; 42:932.</LI>&#xD;&#xA;<LI>Tomblin JB, Records NL, Buckwalter P, et al. Prevalence of specific language impairment in kindergarten children. J Speech Lang Hear Res 1997; 40:1245.</LI>&#xD;&#xA;<LI>Statistics on voice, speech, and language. <A href=\"http://www.nidcd.nih.gov/health/statistics/vsl/Pages/stats.aspx\" target=_blank>www.nidcd.nih.gov/health/statistics/vsl/Pages/stats.aspx</A>. (Accessed June 17, 2013).</LI>&#xD;&#xA;<LI>McLeod S, Harrison LJ. Epidemiology of speech and language impairment in a nationally representative sample of 4- to 5-year-old children. J Speech Lang Hear Res 2009; 52:1213.</LI>&#xD;&#xA;<LI>Ward D. The aetiology and treatment of developmental stammering in childhood. Arch Dis Child 2008; 93:68.</LI>&#xD;&#xA;<LI>Craig A, Hancock K, Tran Y, et al. Epidemiology of stuttering in the community across the entire life span. J Speech Lang Hear Res 2002; 45:1097.</LI>&#xD;&#xA;<LI>Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009; 58:1.</LI>&#xD;&#xA;<LI>Yeargin-Allsopp M, Boyle C. Overview: the epidemiology of neurodevelopmental disorders. Ment Retard Dev Disabil Res Rev 2002; 8:113.</LI>&#xD;&#xA;<LI>Bergman RL, Piacentini J, McCracken JT. Prevalence and description of selective mutism in a school-based sample. J Am Acad Child Adolesc Psychiatry 2002; 41:938. </LI>&#xD;&#xA;<LI>Shriberg LD, Aram DM, Kwiatkowski J. Developmental apraxia of speech: I. Descriptive and theoretical perspectives. J Speech Lang Hear Res 1997; 40:273. </LI></OL></div><div id=\"graphicVersion\">Graphic 71932 Version 3.0</div></div></div>"},"71933":{"type":"graphic_movie","displayName":"Ultrasound normal median nerve","title":"Ultrasound normal median nerve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound normal median nerve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/71933_USnormmednerveconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:514px; height:291px;\" src=\"images/NEURO/71933_USnormalmediannerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a real-time axial image of the normal median nerve (arrow), initially at the distal wrist crease. The probe is then slowly moved proximally, in the axial plane, to the mid forearm. Note that the median nerve is initially somewhat speckled but that as the probe moves proximally, the nerve acquires the more classic honeycomb appearance with hypoechoic rounded fascicles surrounded by hyperechoic fibrous tissue. The nerve wraps around and dives deep to the flexor digitorum sublimis muscle and superficial to the flexor digitorum profundus muscle; note the shape change of the nerve from oval to round to triangular to cuboidal as the probe moves up the forearm.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 71933 Version 3.0</div></div></div>"},"71934":{"type":"graphic_figure","displayName":"Sotalol after MI","title":"Decreased survival with sotalol in the SWORD trial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decreased survival with sotalol in the SWORD trial</div><div class=\"cntnt\"><img style=\"width:426px; height:308px;\" src=\"images/CARD/71934_Sotalol_after_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results from the Survival With Oral d-Sotalol (SWORD) trial. The administration of d-sotalol to patients with an ejection fraction ≤40 percent after either recent myocardial infarction (MI) or after symptomatic heart failure with a remote (&gt;42 days) MI was associated with increased mortality compared to placebo (5 versus 3.1 percent). The excess number of deaths was presumed to be primarily due to arrhythmias.</div><div class=\"graphic_reference\">Data from: Waldo AL, Camm AJ, DeRuyter H, et al. Lancet 1996; 348:7.</div><div id=\"graphicVersion\">Graphic 71934 Version 2.0</div></div></div>"},"71935":{"type":"graphic_diagnosticimage","displayName":"Long axis scan of needle aspiration of hip effusion","title":"Long axis scan of needle aspiration of hip effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long axis scan of needle aspiration of hip effusion</div><div class=\"cntnt\"><img style=\"width:257px; height:325px;\" src=\"images/RHEUM/71935_Long_axis_scan_need_hip_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal ultrasound scan of needle (arrowheads) puncturing hip joint effusion (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 71935 Version 1.0</div></div></div>"},"71936":{"type":"graphic_picture","displayName":"Pyogenic granuloma histology 1","title":"Pyogenic granuloma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma</div><div class=\"cntnt\"><img style=\"width:504px; height:343px;\" src=\"images/DERM/71936_Pyogenic_granuloma_hist_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pyogenic granuloma from the neck of a 4-year-old boy. Histologic sections of skin show a polypoid lesion with an epidermal collarette. There is a vague lobular architecture to the vascular proliferation, and in this case, not much inflammation.</div><div class=\"graphic_reference\">Copyright © Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 71936 Version 3.0</div></div></div>"},"71937":{"type":"graphic_figure","displayName":"Afferent pupillary defect","title":"Left afferent pupillary defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left afferent pupillary defect</div><div class=\"cntnt\"><img style=\"width:332px; height:439px;\" src=\"images/NEURO/71937_Afferent_pupillary_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left pupil is the same size as the right under all conditions of illumination because the efferent pathways are intact, but both pupils are smaller when light is directed at the right eye than when it is directed at the left eye, because light is detected better by the right eye. Alternate swinging of the light between the two eyes therefore produces dilation each time the light is directed to the left eye.</div><div class=\"graphic_reference\">With permission from: Gelb DJ. The Neurologic Examination. In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.</div><div id=\"graphicVersion\">Graphic 71937 Version 4.0</div></div></div>"},"71938":{"type":"graphic_table","displayName":"Indications for nonobstetric surgery during pregnancy","title":"Indications for nonobstetric surgery during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for nonobstetric surgery during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Incidence</td> </tr> <tr> <td>Appendicitis</td> <td>1:1500 pregnancies</td> </tr> <tr> <td>Cholecystitis</td> <td>1:1500 to 1:10,000 pregnancies</td> </tr> <tr> <td>Bowel obstruction</td> <td>1:1500 to 1:3500 pregnancies</td> </tr> <tr> <td>Adnexal torsion</td> <td>1:3000 to 1:4000 pregnancies</td> </tr> <tr> <td>Breast or cervical disease</td> <td>1:3000 to 1:5000 pregnancies</td> </tr> <tr> <td>Trauma</td> <td>Variable (trauma complicates 4 to 8 percent of all pregnancies, but the incidence of severe life-threatening trauma possibly requiring surgery is 0.3 to 0.4 percent)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 71938 Version 6.0</div></div></div>"},"71940":{"type":"graphic_figure","displayName":"Cross cradle position PI","title":"Cross-cradle position for breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Cross-cradle position for breastfeeding</div><div class=\"cntnt\"><img style=\"width:476px; height:331px;\" src=\"images/PI/71940_Cross_cradle_position_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cross-cradle hold can also be done while the mother sits in a chair. To feed from the left breast, the infant's head and body are supported by the mother's right hand and forearm. Some women use a pillow to support this arm. The baby's stomach should be flat against the mother's chest and the baby's head should be in line with the body (not turned). The mother's free hand (the left hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.</div><div id=\"graphicVersion\">Graphic 71940 Version 4.0</div></div></div>"},"71941":{"type":"graphic_diagnosticimage","displayName":"Defining the bladder","title":"Defining the bladder","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Defining the bladder</div><div class=\"cntnt\"><img style=\"width:501px; height:341px;\" src=\"images/PEDS/71941_Defining_the_bladder.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71941 Version 2.0</div></div></div>"},"71943":{"type":"graphic_picture","displayName":"VWF multimer analysis","title":"VWF multimer analysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">VWF multimer analysis</div><div class=\"cntnt\"><img style=\"width:408px; height:413px;\" src=\"images/HEME/71943_VWF_multimer_analysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Agarose gel electrophoresis (1.0 percent) of plasma followed by fixation and exposure to a monospecific radiolabeled antibody to VWF. The highest molecular weight multimers of VWF are at the top of the gel (arrow). Lane 1 - severe vWD (type 3) plasma, lane 2 - normal pooled plasma, lane 3 - type 2A plasma, lane 4 - type 2B plasma, lane 5 - vWF extracted from platelets.</div><div class=\"graphic_reference\">From Rick, ME, Diagnosis and management of von Willebrand's syndrome, Med Clin North Am 1994; 78:609.</div><div id=\"graphicVersion\">Graphic 71943 Version 2.0</div></div></div>"},"71949":{"type":"graphic_algorithm","displayName":"Eval incompatible crossmatch","title":"Laboratory evaluation and management of incompatible crossmatch","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Laboratory evaluation and management of incompatible crossmatch</div><div class=\"cntnt\"><img style=\"width:525px; height:524px;\" src=\"images/HEME/71949_Eval_incompatible_crossmatc.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71949 Version 2.0</div></div></div>"},"71950":{"type":"graphic_diagnosticimage","displayName":"Sestamibi coronary ischemia","title":"Sestamibi perfusion scan","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Sestamibi perfusion scan</div><div class=\"cntnt\"><img style=\"width:540px; height:189px;\" src=\"images/CARD/71950_Sestamibi_coronary_ischemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myocardial perfusion scan in a patient injected with Tc-99m-sestamibi in the emergency department during an episode of chest pain. The patient's electrocardiogram (ECG) was nondiagnostic but perfusion defects can be seen in the anteroapical region of the heart (arrows). Cardiac catheterization the next day revealed a tight lesion in the proximal portion of the first diagonal branch of the left anterior descending coronary artery.</div><div class=\"graphic_reference\">Courtesy of Thomas A Holly, MD and Robert C Hendel, MD.</div><div id=\"graphicVersion\">Graphic 71950 Version 3.0</div></div></div>"},"71951":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus due to germinal matrix intraventricular hemorrhage","title":"Hydrocephalus due to germinal matrix intraventricular hemorrhage (IVH) of prematurity","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus due to germinal matrix intraventricular hemorrhage (IVH) of prematurity</div><div class=\"cntnt\"><img style=\"width:505px; height:265px;\" src=\"images/PEDS/71951_Hydro_germ_mat_intra_h2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound in an infant with grade IV intraventricular hemorrhage.<br> (Panel A) Coronal view.<br> (Panel B) Sagittal view.</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 71951 Version 2.0</div></div></div>"},"71955":{"type":"graphic_figure","displayName":"Hormone theray and cognitive function","title":"Hormone therapy does not affect cognitive function","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hormone therapy&nbsp;does not affect cognitive function</div><div class=\"cntnt\"><img style=\"width:382px; height:265px;\" src=\"images/ENDO/71955_ERT_and_cognitive_function.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the Nurses' Health Study shows a lack of relationship between use of hormone replacement therapy in non-demented older women and cognitive function as determined by the telephone version of the MMSE.</div><div class=\"graphic_footnotes\">MMSE: Mini-Mental State Examination.</div><div class=\"graphic_reference\">Data from: Grodstein F, Chen J, Pollen DA, et al. Postmenopausal hormone therapy and cognitive function in healthy older women.&nbsp;J Am Geriatr Soc 2000; 48:746.</div><div id=\"graphicVersion\">Graphic 71955 Version 8.0</div></div></div>"},"71956":{"type":"graphic_figure","displayName":"Trans-urethral bladder catheterization boys","title":"Proper position for penis in transurethral bladder catheterization in males","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper position for penis in transurethral bladder catheterization in males</div><div class=\"cntnt\"><img style=\"width:447px; height:254px;\" src=\"images/PEDS/71956_TUBC_boys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The urethra is straightened by using the nondominant hand to hold the penis perpendicular to the lower abdomen. Gentle traction is applied. The catheter is inserted with the dominant hand until urine returns.</div><div class=\"graphic_reference\">Adapted from King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.</div><div id=\"graphicVersion\">Graphic 71956 Version 2.0</div></div></div>"},"71957":{"type":"graphic_figure","displayName":"Relative risk and odds ratio","title":"Relative risk and odds ratio","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Relative risk and odds ratio</div><div class=\"cntnt\"><img style=\"width:489px; height:295px;\" src=\"images/PC/71957_Relative_risk_and_odds_rati.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a cohort study, the relative risk of a disease can be calculated because all patients under study are available for the analysis comparing risk in exposed and unexposed individuals. In contrast, in a case-control study, cases are drawn from a population of patients who have the disease, and controls from a population without the disease. Thus, the relative risk cannot be calculated since the samples do not necessarily reflect the true proportion of patients who have been exposed to a risk factor. Instead, the relative risk can be estimated using the odds ratio.</div><div id=\"graphicVersion\">Graphic 71957 Version 1.0</div></div></div>"},"71958":{"type":"graphic_form","displayName":"Child asthma action plan","title":"Child asthma action plan","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Child asthma action plan</div><div class=\"cntnt\"><img style=\"width:608px; height:789px;\" src=\"images/PULM/71958_Child_asthma_action_plan.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 71958 Version 3.0</div></div></div>"},"71959":{"type":"graphic_diagnosticimage","displayName":"Myocardial perfusion Chagas","title":"Myocardial perfusion SPECT - <sup>201</sup>Thallium","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Myocardial perfusion SPECT - <sup>201</sup>Thallium</div><div class=\"cntnt\"><img style=\"width:504px; height:345px;\" src=\"images/CARD/71959_Myocardial_perfusion_Chagas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myocardial perfusion scan with Thallium-201 from a 54-year-old male, asymptomatic patient with chronic Chagas' heart disease. A large reversible perfusion defect is present in the inferior, inferior-septal, and apical regions. The epicardial coronary arteries were normal.</div><div class=\"graphic_footnotes\">SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jose A Marin-Neto, MD, PhD, FACC, Benedito C Maciel, MD, FACC, and Marcus V Simoes, MD.</div><div id=\"graphicVersion\">Graphic 71959 Version 6.0</div></div></div>"},"71960":{"type":"graphic_diagnosticimage","displayName":"Fibroblast reticulum","title":"Fibroblast reticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibroblast reticulum</div><div class=\"cntnt\"><img style=\"width:439px; height:250px;\" src=\"images/PULM/71960_Fibroblast_reticulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computer generated reconstruction of the complex reticulum that is highly interconnected and extends from the pleura (yellow) into the underlying parenchyma (left: the blood vessels are represented in red). The green zone added (right) represents the fibroblast reticulum.</div><div class=\"graphic_reference\">Reproduced with permission from: Cool, CD, Groshong, SD, Rai, PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 2006; 174:654. Official Journal of the American Thoracic Society. Copyright &copy;2006 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 71960 Version 3.0</div></div></div>"},"71964":{"type":"graphic_figure","displayName":"Location of spinal tumors","title":"Location of spinal tumors","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Location of spinal tumors</div><div class=\"cntnt\"><img style=\"width:501px; height:495px;\" src=\"images/ONC/71964_Spinal_metastases.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71964 Version 2.0</div></div></div>"},"71965":{"type":"graphic_table","displayName":"Etiology third nerve palsy","title":"Etiology of third nerve palsy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of third nerve palsy in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Location\n   </td>\n   <td  class=\"subtitle1\">\n   Cause\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"7\">\n   Nuclear or fascicular\n   </td>\n   <td>Congenital</td>\n   </tr>\n   <tr>\n   <td>Demyelinating</td>\n   </tr>\n   <tr>\n   <td>Ischemic</td>\n   </tr>\n   <tr>\n   <td>Inflammatory</td>\n   </tr>\n   <tr>\n   <td>Vascular</td>\n   </tr>\n   <tr>\n   <td>Neoplastic</td>\n   </tr>\n   <tr>\n   <td>Traumatic</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"5\">\n   Subarachnoid space\n   </td>\n   <td>Aneurysm</td>\n   </tr>\n   <tr>\n   <td>Carcinomatous meningitis</td>\n   </tr>\n   <tr>\n   <td>Inflammatory</td>\n   </tr>\n   <tr>\n   <td>Infectious</td>\n   </tr>\n   <tr>\n   <td>Neoplastic</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"7\">\n   Cavernous sinus\n   </td>\n   <td>Cavernous sinus thrombosis</td>\n   </tr>\n   <tr>\n   <td>Cavernous sinus fistula</td>\n   </tr>\n   <tr>\n   <td>Neoplastic</td>\n   </tr>\n   <tr>\n   <td>Ischemic</td>\n   </tr>\n   <tr>\n   <td>Inflammatory</td>\n   </tr>\n   <tr>\n   <td>Infectious</td>\n   </tr>\n   <tr>\n   <td>Internal carotid artery aneurysm or dissection</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"4\">\n   Orbital\n   </td>\n   <td>Neoplastic</td>\n   </tr>\n   <tr>\n   <td>Inflammatory</td>\n   </tr>\n   <tr>\n   <td>Infectious</td>\n   </tr>\n   <tr>\n   <td>Traumatic</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Modified and reprinted with permission from Lee AG and Brazis PW. Clinical Pathways in Neuro-Ophthalmology: An Evidence-based Approach, 2nd ed,&nbsp;Thieme, New York 2003.</div><div id=\"graphicVersion\">Graphic 71965 Version 3.0</div></div></div>"},"71968":{"type":"graphic_table","displayName":"Empiric abx purulent mening","title":"Recommendations for empiric antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for empiric antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Predisposing factor</td> <td class=\"subtitle1\">Common bacterial pathogens</td> <td class=\"subtitle1\">Antimicrobial therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age</td> </tr> <tr> <td class=\"indent1\">&#60;1 month</td> <td><em>Streptococcus agalactiae</em>, <em>Escherichia coli</em>, <em>Listeria monocytogenes</em></td> <td>Ampicillin plus cefotaxime; OR ampicillin plus an aminoglycoside</td> </tr> <tr> <td class=\"indent1\">1 to 23 months</td> <td><em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em>, <em>S. agalactiae</em>, <em>Haemophilus influenzae</em>, <em>E. coli</em></td> <td>Vancomycin plus a third-generation cephalosporin<sup>&#182;</sup><sup>&#916;</sup><sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">2 to 50 years</td> <td><em>N. meningitidis</em>, <em>S. pneumoniae</em></td> <td>Vancomycin plus a third-generation cephalosporin<sup>&#182;</sup><sup>&#916;</sup><sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;50 years</td> <td><em>S. pneumoniae</em>, <em>N. meningitidis</em>, <em>L. monocytogenes</em>, aerobic gram-negative bacilli</td> <td>Vancomycin plus ampicillin plus a third-generation cephalosporin<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Head trauma</td> </tr> <tr> <td class=\"indent1\">Basilar skull fracture</td> <td><em>S. pneumoniae</em>, <em>H. influenzae</em>, group A beta-hemolytic streptococci</td> <td>Vancomycin plus a third-generation cephalosporin<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Penetrating trauma</td> <td><em>Staphylococcus aureus</em>, coagulase-negative staphylococci (especially <em>Staphylococcus epidermidis</em>), aerobic gram-negative bacilli (including <em>Pseudomonas aeruginosa</em>)</td> <td>Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem</td> </tr> <tr> <td class=\"indent1\">Postneurosurgery</td> <td>Aerobic gram-negative bacilli (including <em>P. aeruginosa</em>), <em>S. aureus</em>, coagulase-negative staphylococci (especially <em>S. epidermidis</em>)</td> <td>Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem</td> </tr> <tr> <td class=\"indent1\">Immunocompromised state</td> <td><em>S. pneumoniae</em>, <em>N. meningitidis</em>, <em>L. monocytogenes</em>, aerobic gram-negative bacilli (including <em>P. aeruginosa</em>)</td> <td>Vancomycin plus ampicillin plus cefepime; OR vancomycin plus ampicillin plus meropenem</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For recommended dosages for adults,&nbsp;refer to&nbsp;the UpToDate table on recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis.<br />¶ Ceftriaxone or cefotaxime.<br />Δ Some experts would add rifampin if dexamethasone is also given.<br /><FONT class=lozenge>◊</FONT> Add ampicillin if meningitis caused by <EM>Listeria monocytogenes</EM> is suspected.</div><div class=\"graphic_reference\">Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 71968 Version 5.0</div></div></div>"},"71970":{"type":"graphic_diagnosticimage","displayName":"Chest x-rays of K pneumoniae","title":"Chest x-rays of Klebsiella pneumoniae","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Chest x-rays of Klebsiella pneumoniae</div><div class=\"cntnt\"><img style=\"width:496px; height:451px;\" src=\"images/ID/71970_K_pneum_chest_x-rays.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A and B) A-43 year-old diabetic man with alcoholism presented with intermittent fever for five days and dyspnea for one day prior to admission. Mild ketoacidosis was observed. Chest film initially demonstrated bilateral patchy infiltration (panel A), followed by rapid extensive consolidation, particularly of right upper lobe three hours later (panel B). Acute respiratory distress syndrome ensued and the patient died within 12 hours of admission despite appropriate antimicrobial therapy and aggressive hemodynamic support in the intensive care unit. Blood and sputum cultures yielded K. pneumoniae.<br />(Panels C and D) A 64-year-old woman with K. pneumoniae bacteremia and right upper lobe pneumonia; the patient died of extensive pneumothorax following two weeks in intensive care unit (panel C). A 52-year-old man with chronic alcoholism presented with K. pneumoniae bacteremia and right upper lobe pneumonia; he developed acute respiratory distress syndrome with profound septic shock and died within 24 hours of admission (panel D). These radiographs demonstrate the predilection for involvement of the posterior segment of the right upper lobe in K. pneumoniae community-acquired pneumonia as well as the bulging fissure sign, characterized by bowing of the fissure downward due to intense consolidation.</div><div class=\"graphic_reference\">Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.</div><div id=\"graphicVersion\">Graphic 71970 Version 4.0</div></div></div>"},"71971":{"type":"graphic_picture","displayName":"SCCA left vestibule","title":"SCCA of the left vestibule","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">SCCA of the left vestibule</div><div class=\"cntnt\"><img style=\"width:533px; height:228px;\" src=\"images/ONC/71971_SCCAleftvestibule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">SCCA of the left vestibule (A) that extended through the septum into the right vestibule (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright © 1994 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 71971 Version 12.0</div></div></div>"},"71972":{"type":"graphic_table","displayName":"Healthy weight exercise tips","title":"Tips for maintaining a healthy weight: exercise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for maintaining a healthy weight: exercise</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Exercise Phase I</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Begin decreasing time spent in sedentary activities.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Identify how many hours per day your family\nspends in sedentary activities such as watching TV, playing video\ngames, and surfing the internet and make efforts to decrease this time\nevery day this week. Explore ways to be physically active on a daily\nbasis.</td>\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Exercise Phase II</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Decrease sedentary time</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Limit television, video games and computer time to no more than 1 hour per day. Limiting sedentary time will encourage children to choose other activities, most of which will generate increased physical activity. Buy active toys rather than computer games or videotapes. Define indoor areas for physical play such as \"Nerf\" balls, bouncy balls or scooter toys.</td>\n\n\n\n    </tr>\n\n\n    \n\n    \n\n    \n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Incorporate physical activity into daily routines.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Walk or ride bike to school. Play outdoors, in the gym or on the playground for 30 minutes before homework every day. Walk with friends instead of talking to them on the telephone.</td>\n\n\n\n    </tr>\n\n\n    \n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Accumulate 1 hour of physical activity during the day.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Both children and adults should be active for 1 hour every day. This activity can be accumulated throughout the day. Consider purchasing a pedometer ($10 - $15) and join the 10,000 steps a day program.</td>\n\n\n\n    </tr>\n\n\n    \n\n    \n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Be physically active as a family.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Plan family activities for the weekend such as bike riding, hiking; trips to the zoo, museum or library; and house or yard projects. Take family walks.</td>\n\n\n\n    </tr>\n\n\n    \n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Consider participating in organized sports or physical activities.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Get involved in team sports or marching band at school. Take classes in activities that you enjoy such as dance, martial arts, swimming or tennis; or buy an aerobics tape and exercise at home.</td>\n\n\n\n    </tr>\n\n\n    \n\n    \n\n  \n  </tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 71972 Version 1.0</div></div></div>"},"71973":{"type":"graphic_table","displayName":"Differential diagnosis of knock-knees in children","title":"Differential diagnosis of knock-knees in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of knock-knees in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition </td> <td class=\"subtitle1\">Possible clues to the diagnosis</td> </tr> <tr> <td>Physiologic valgus</td> <td>Age&nbsp;two to&nbsp;five&nbsp;years; symmetric deformities; normal stature; lack of symptoms.</td> </tr> <tr> <td>Pathologic valgus</td> <td>Short stature; intermalleolar distance of &#62;8 cm with the patellas facing forward and the femoral condyles touching.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Posttraumatic </td> </tr> <tr> <td class=\"sublist2\">Proximal tibial metaphyseal fracture (Cozen fracture) </td> <td class=\"sublist_other\">History of proximal tibial fracture at age &#60;10 years.</td> </tr> <tr> <td class=\"sublist2\">Proximal tibial physeal fracture</td> <td class=\"sublist_other\">History of proximal tibial fracture.</td> </tr> <tr> <td class=\"sublist2\">Distal femoral physeal fracture </td> <td class=\"sublist_other\">History of fracture.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Systemic/metabolic conditions </td> </tr> <tr> <td class=\"sublist2\">Mucopolysaccharidosis type IV (Morquio syndrome) (OMIM #25300 and 253010) </td> <td class=\"sublist_other\">Coarse facies; short stature; stiff joints; corneal opacities; lumbar kyphosis.</td> </tr> <tr> <td class=\"sublist2\">Renal osteodystrophy </td> <td class=\"sublist_other\">Short stature; pallor; polydipsia; polyuria; abnormal BUN/creatinine </td> </tr> <tr> <td class=\"sublist2\">Rickets (with onset during physiologic valgus:&nbsp;two to&nbsp;four years of age) </td> <td class=\"sublist_other\">Decreased serum calcium or phosphorus; increased alkaline phosphatase; widened physes and flared metaphyses.</td> </tr> <tr> <td class=\"sublist2_start\">Skeletal dysplasia </td> <td>Characteristic clinical and radiographic features vary according to the dysplasia. Some examples are provided below.</td> </tr> <tr> <td class=\"sublist2\">Chondroectodermal dysplasia (Ellis-van Creveld syndrome) (OMIM #225500) </td> <td class=\"sublist_other\">Autosomal recessive inheritance; short stature; short limbs; dysplastic nails and teeth; cardiac defects; polydactyly.</td> </tr> <tr> <td class=\"sublist2\">Spondyloepiphyseal dysplasia tarda (OMIM #313400) </td> <td class=\"sublist_other\">X-linked recessive inheritance; short stature with onset between 5 and 10 years; short trunk; corneal opacities.</td> </tr> <tr> <td class=\"sublist2\">Pseudoachondroplasia (OMIM #177170); associated with bow-legs in some patients </td> <td class=\"sublist_other\">Autosomal dominant inheritance; short-limb dwarfism with onset by&nbsp;two years; joint laxity; vertebral anomalies.</td> </tr> <tr> <td class=\"sublist2\">Multiple epiphyseal dysplasia syndrome (OMIM #132400) </td> <td class=\"sublist_other\">Autosomal dominant inheritance; mild short-limb dwarfism; brachydactyly; small irregular epiphyses on radiographs.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Neoplasms </td> </tr> <tr> <td class=\"sublist2\">Multiple hereditary exostoses (OMIM #133700 and 133701) </td> <td class=\"sublist_other\">Autosomal dominant inheritance; protuberances at ends of long bones; exostoses in juxtaepiphyseal regions of long bones. </td> </tr> <tr> <td class=\"sublist2\">Focal fibrocartilaginous dysplasia of distal femoral metaphysis </td> <td class=\"sublist_other\">Progressive, unilateral deformity; radiolucent, well-circumscribed lesion, often with rim of reactive bone.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Other conditions </td> </tr> <tr> <td class=\"sublist2\">Iliotibial band tightness (due to paralytic conditions, such as myelodysplasia, spastic diplegia, or spinal cord injury) </td> <td class=\"sublist_other\">Abnormal Ober test (refer to UpToDate content on the child with knock-knees).</td> </tr> <tr> <td class=\"sublist2\">Arthritis of the knee (rheumatoid, hemophilia) </td> <td class=\"sublist_other\">History of joint swelling, warmth.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OMIM: Online Mendelian Inheritance in Man; BUN: blood urea nitrogen.</div><div class=\"graphic_reference\">Data from: <br />1. Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6<SUP>th</SUP> ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.<br />2. The knee and leg. In: Tachdjian MO. Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management. Appleton &amp; Lange, Stamford, CT 1997. p.87.<br />3. OMIM: Online Mendelian Inheritance in Man (www.ncbi.nlm.nih.gov/omim/).</div><div id=\"graphicVersion\">Graphic 71973 Version 3.0</div></div></div>"},"71974":{"type":"graphic_diagnosticimage","displayName":"Infectious colitis Doppler US","title":"Infectious colitis on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infectious colitis on ultrasound</div><div class=\"cntnt\"><img style=\"width:372px; height:254px;\" src=\"images/GAST/71974_Infectious_colitis_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasonography in a patient with infectious colitis. Color Doppler imaging, reveals hypervascularity especially of the submucosa. The bowel wall is thickened (10 mm). Microbiological examination confirmed salmonella infection.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 71974 Version 4.0</div></div></div>"},"71975":{"type":"graphic_waveform","displayName":"Advanced case 3","title":"Advanced case 3","html":"<div class=\"graphic normal\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Advanced case 3</div><div class=\"cntnt\"><img style=\"width:561px; height:408px;\" src=\"images/CARD/71975_Advanced_case_3.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 71975 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"71978":{"type":"graphic_table","displayName":"Glycemic index and load values","title":"Dietary glycemic indices and glycemic load for the top 20 carbohydrate-contributing foods in the Nurses' Health Study in 1984","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary glycemic indices and glycemic load for the top 20 carbohydrate-contributing foods in the Nurses' Health Study in 1984</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Foods</td>\n\n\n      <td class=\"subtitle1\">Glycemic index*, percent</td>\n\n      <td class=\"subtitle1\">Carbohydrate per serving, g</td>\n\n      <td class=\"subtitle1\">Glycemic load per serving</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Cooked potatoes (mashed or baked) </td>\n\n\n      <td>102</td>\n\n      <td>37</td>\n\n      <td>38</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. White bread</td>\n\n\n      <td>100</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Cold breakfast cereal</td>\n\n\n      <td>Varies by cereal</td>\n\n      <td>Varies by cereal</td>\n\n      <td>Varies by cereal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Dark bread</td>\n\n\n      <td>102</td>\n\n      <td>12</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. Orange juice</td>\n\n\n      <td>75</td>\n\n      <td>20</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6. Banana</td>\n\n\n      <td>88</td>\n\n      <td>27</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7. White rice</td>\n\n\n      <td>102</td>\n\n      <td>45</td>\n\n      <td>46</td>\n\n    </tr>\n\n    <tr>\n\n      <td>8. Pizza</td>\n\n\n      <td>86</td>\n\n      <td>78</td>\n\n      <td>68</td>\n\n    </tr>\n\n    <tr>\n\n      <td>9. Pasta</td>\n\n\n      <td>71</td>\n\n      <td>40</td>\n\n      <td>28</td>\n\n    </tr>\n\n    <tr>\n\n      <td>10. English muffins</td>\n\n\n      <td>84</td>\n\n      <td>26</td>\n\n      <td>22</td>\n\n    </tr>\n\n    <tr>\n\n      <td>11. Fruit punch</td>\n\n\n      <td>95</td>\n\n      <td>44</td>\n\n      <td>42</td>\n\n    </tr>\n\n    <tr>\n\n      <td>12. Cola</td>\n\n\n      <td>90</td>\n\n      <td>39</td>\n\n      <td>35</td>\n\n    </tr>\n\n    <tr>\n\n      <td>13. Apple</td>\n\n\n      <td>55</td>\n\n      <td>21</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>14. Skim milk</td>\n\n\n      <td>46</td>\n\n      <td>11</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>15. Pancake</td>\n\n\n      <td>119</td>\n\n      <td>56</td>\n\n      <td>67</td>\n\n    </tr>\n\n    <tr>\n\n      <td>16. Table sugar</td>\n\n\n      <td>84</td>\n\n      <td>4</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>17. Jam</td>\n\n\n      <td>91</td>\n\n      <td>13</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>18. Cranberry juice</td>\n\n\n      <td>105</td>\n\n      <td>19</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>19. French fries</td>\n\n\n      <td>95</td>\n\n      <td>35</td>\n\n      <td>33</td>\n\n    </tr>\n\n    <tr>\n\n      <td>20. Candy</td>\n\n\n      <td>99</td>\n\n      <td>28</td>\n\n      <td>28</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Standard reference is white bread, which has a glycemic index of 100 percent. All other glycemic index values are relative to white bread.</div><div class=\"graphic_reference\">Adapted from: Liu S, Willett WC. Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 2002; 4:454.</div><div id=\"graphicVersion\">Graphic 71978 Version 2.0</div></div></div>"},"71979":{"type":"graphic_figure","displayName":"Course pulmonary histiocytosis","title":"Clinical course of pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical course of pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:409px; height:234px;\" src=\"images/PULM/71979_Course_pulmonary_histiocyto.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The data shown were extracted from clinical reviews that described the clinical outcome of 195 subjects with pulmonary Langerhans cell histiocytosis. The length of followup varied from 1 to 12 years. Most patients are stable or improved. In one study, for example, 40 patients had essentially no symptoms of residual disease at least six months after diagnosis; 13 of these patients had persistent radiographic abnormalities.</div><div id=\"graphicVersion\">Graphic 71979 Version 1.0</div></div></div>"},"71980":{"type":"graphic_figure","displayName":"Stroke work index surv HF","title":"Left ventricular stroke work predicts outcome in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular stroke work predicts outcome in heart failure</div><div class=\"cntnt\"><img style=\"width:384px; height:248px;\" src=\"images/CARD/71980_StrokeworkindexsurvHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative survival for 219 patients who underwent hemodynamic monitoring during exercise testing is related to peak exercise left ventricular stroke work index (SWI); two-year survival is better in those with a peak exercise SWI &gt;30 gm/m<SUP>2</SUP> (91 versus 54 percent for SWI ≤30 gm/m<SUP>2</SUP>, p&lt;0.0001).</div><div class=\"graphic_reference\">Data from: Metra M, Faggiano P, D'Aloia A, et al, J Am Coll Cardiol 1999; 33:943.</div><div id=\"graphicVersion\">Graphic 71980 Version 2.0</div></div></div>"},"71981":{"type":"graphic_table","displayName":"Genetic disorders surfactant dysfunction","title":"Genetic disorders causing surfactant dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic disorders causing surfactant dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">SFTPB</td> <td class=\"subtitle1\">SFTPC</td> <td class=\"subtitle1\">ABCA3</td> <td class=\"subtitle1\">NKX2.1&nbsp;</td> </tr> <tr> <td><strong>Mode of inheritance</strong></td> <td>Autosomal recessive</td> <td>Autosomal dominant, <em>de novo</em></td> <td>Autosomal recessive</td> <td>Autosomal dominant, <em>de novo</em>&nbsp;</td> </tr> <tr> <td><strong>Pulmonary presentations</strong></td> <td>Neonatal respiratory distress syndrome</td> <td> <p>Childhood interstitial lung disease</p> <p>Adult interstitial lung disease</p> <p>Neonatal respiratory distress syndrome</p> </td> <td> <p>Neonatal respiratory distress syndrome</p> <p>Childhood interstitial lung disease</p> </td> <td> <p>Neonatal respiratory distress syndrome</p> <p>Childhood interstitial lung disease</p> <p>Recurrent infection</p> <p>No pulmonary involvement</p> </td> </tr> <tr> <td><strong>Course</strong></td> <td>Neonatal lethal</td> <td> <p>Highly variable</p> <p>Survival until 6th decade reported</p> </td> <td> <p>Neonatal lethal</p> <p>Variable severity in childhood</p> </td> <td> <p>Neonatal lethal</p> <p>Variable severity in childhood</p> </td> </tr> <tr> <td><strong>Treatment options described in literature</strong></td> <td> <p>Supportive</p> <p>Lung transplant<sup>[1,2]</sup></p> </td> <td> <p>Supportive<sup>[3]</sup></p> <p>Corticosteroids<sup>[4,5]</sup></p> <p>Hydroxychloroquine<sup>[4,5]</sup></p> <p>Azithromycin<sup>[4]</sup></p> <p>Lung transplant<sup>[2]</sup></p> </td> <td> <p>Supportive</p> <p>Corticosteroids<sup>[6]</sup></p> <p>Hydroxychloroquine<sup>[6,7]</sup></p> <p>Lung transplant<sup>[8,9]</sup></p> </td> <td>Supportive</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Comparative features of inheritance, timing of presentation, outcomes, and treatment options described in the literature for the four main causes of genetic surfactant dysfunction. &quot;Supportive&quot; care indicates measures for respiratory, nutritional, and anti-infective care.</div><div class=\"graphic_footnotes\">SFTPB: gene encoding the surfactant protein B; SFTPC: gene encoding surfactant protein C; ABCA3: gene encoding the member A3 of the ATP Binding Cassette family of proteins; NKX2.1: also called thyroid transcription factor 1, or TTF-1.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Hamvas A, Nogee LM, Mallory GB Jr, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997; 130:231. </LI>&#xD;&#xA;<LI>Palomar LM, Nogee LM, Sweet SC, et al. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr 2006; 149:548. </LI>&#xD;&#xA;<LI>Liptzin DR, Patel T, Deterding RR. Chronic ventilation in infants with surfactant protein C mutations: an alternative to lung transplantation. Am J Respir Crit Care Med 2015; 191:1338.</LI>&#xD;&#xA;<LI>Abou Taam R, Jaubert F, Emond S, et al. Familial interstitial disease with I73T mutation: A mid- and long-term study. Pediatr Pulmonol 2009; 44:167. </LI>&#xD;&#xA;<LI>Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95:449. </LI>&#xD;&#xA;<LI>Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63: 366. </LI>&#xD;&#xA;<LI>Williamson M, Wallis C. Ten-year follow up of hydroxychloroquine treatment for ABCA3 deficiency. Pediatr Pulmonol 2014; 49:299.</LI>&#xD;&#xA;<LI>Hamvas A, Nogee LM, Wegner DJ, et al. Inherited surfactant deficiency caused by uniparental disomy of rare mutations in the surfactant protein-B and ATP binding cassette, subfamily a, member 3 genes. J Pediatr 2009; 155:854. </LI>&#xD;&#xA;<LI>Eldridge WB, Zhang Q, Faro A, et al. Outcomes of Lung Transplantation for Infants and Children with Genetic Disorders of Surfactant Metabolism. J Pediatr 2017; 184:157.</LI></OL></div><div id=\"graphicVersion\">Graphic 71981 Version 7.0</div></div></div>"},"71982":{"type":"graphic_diagnosticimage","displayName":"Plain chest radiograph of diaphragmatic injury with herniation","title":"Plain chest radiograph of diaphragmatic injury with herniation","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Plain chest radiograph of diaphragmatic injury with herniation</div><div class=\"cntnt\"><img style=\"width:598px; height:375px;\" src=\"images/SURG/71982_Diaph_injury_herniation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain chest radiograph shows a traumatic disruption of the left hemidiaphragm. The anteroposterior view (A) obtained on primary survey and&nbsp;lateral view (B) obtained in follow-up&nbsp;show&nbsp;gastrointestinal gas shadows occupying about two-thirds of the left hemithorax (arrowhead). Bowel gas can be seeen adjacent the heart border (arrow).</div><div id=\"graphicVersion\">Graphic 71982 Version 2.0</div></div></div>"},"71983":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber MS","title":"Apical four chamber view of mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four chamber view of mitral stenosis</div><div class=\"cntnt\"><img style=\"width:329px; height:252px;\" src=\"images/CARD/71983_Apical_4_chamber_MS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view from a two dimensional echocardiogram of a patient with mitral stenosis shows left (LA) and right atrial (RA) dilation, biatrial thrombi (arrows), calcification of the mitral valve (MV) commissures, and chordal forshortening and thickening. Although the thrombi are well seen, it is unusual to see atrial thrombi without transesophageal echocardiography.</div><div class=\"graphic_footnotes\">LV: left ventricular.</div><div class=\"graphic_reference\">Courtesy of Acuson Corp.</div><div id=\"graphicVersion\">Graphic 71983 Version 3.0</div></div></div>"},"71985":{"type":"graphic_table","displayName":"MICs for other yeasts","title":"In vitro susceptibility of non-candidal yeasts to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">In vitro susceptibility of non-candidal yeasts to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Organism </td> <td class=\"subtitle1\" rowspan=\"2\">Antifungal agent </td> <td class=\"subtitle1\" rowspan=\"2\">Number tested </td> <td class=\"subtitle1\" colspan=\"3\">MIC, mcg/mL</td> </tr> <tr> <td class=\"subtitle2\">Range </td> <td class=\"subtitle2\">50 percent* </td> <td class=\"subtitle2\">90 percent* </td> </tr> <tr> <td rowspan=\"7\"><em>Cryptococcus neoformans</em> </td> <td>Amphotericin B<sup>&#182;</sup></td> <td>661</td> <td>0.03 to 32</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Flucytosine</td> <td>1614</td> <td>0.06 to 128</td> <td>4</td> <td>8</td> </tr> <tr> <td>Fluconazole</td> <td>1615</td> <td>0.007 to 64</td> <td>4</td> <td>8</td> </tr> <tr> <td>Isavuconazole</td> <td>438</td> <td>&#60;0.008 to 0.5&nbsp;</td> <td>0.03</td> <td>0.06</td> </tr> <tr> <td>Itraconazole</td> <td>1615</td> <td>0.007 to 64</td> <td>0.25</td> <td>4</td> </tr> <tr> <td>Posaconazole</td> <td>1437</td> <td>0.007 to 2</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Voriconazole</td> <td>1608</td> <td>0.007 to 2</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td rowspan=\"5\"><em>Trichosporon asahii</em> </td> <td>Amphotericin B<sup>&#182;</sup></td> <td>43</td> <td>1 to 8</td> <td>4</td> <td>4</td> </tr> <tr> <td>Fluconazole</td> <td>43</td> <td>0.25 to 16</td> <td>2</td> <td>8</td> </tr> <tr> <td>Itraconazole</td> <td>43</td> <td>0.06 to 4</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Posaconazole</td> <td>24</td> <td>0.06 to &#62;16</td> <td>0.12</td> <td>N/A</td> </tr> <tr> <td>Voriconazole</td> <td>10</td> <td>0.25 to 2</td> <td>0.5</td> <td>2</td> </tr> <tr> <td rowspan=\"5\">Other <em>Trichosporon</em> spp </td> <td>Amphotericin B<sup>&#182;</sup></td> <td>15</td> <td>0.06 to 1</td> <td>0.25</td> <td>N/A</td> </tr> <tr> <td>Fluconazole</td> <td>15</td> <td>0.5 to 4</td> <td>2</td> <td>N/A</td> </tr> <tr> <td>Itraconazole</td> <td>15</td> <td>0.03 to 0.5</td> <td>0.12</td> <td>N/A</td> </tr> <tr> <td>Posaconazole</td> <td>15</td> <td>0.03 to 0.5</td> <td>0.12</td> <td>N/A</td> </tr> <tr> <td>Voriconazole</td> <td>15</td> <td>0.03 to 0.25</td> <td>0.06</td> <td>N/A</td> </tr> <tr> <td rowspan=\"6\"><em>Rhodotorula</em> spp</td> <td>Amphotericin B<sup>&#182;</sup></td> <td>64</td> <td>0.5 to 2</td> <td>1</td> <td>1</td> </tr> <tr> <td>Flucytosine</td> <td>64</td> <td>0.06 to 0.5</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Fluconazole</td> <td>64</td> <td>32 to &#62;64</td> <td>&#62;64</td> <td>&#62;64</td> </tr> <tr> <td>Itraconazole</td> <td>64</td> <td>0.5 to 16</td> <td>2</td> <td>16</td> </tr> <tr> <td>Posaconazole</td> <td>64</td> <td>0.5 to 16</td> <td>2</td> <td>4</td> </tr> <tr> <td>Voriconazole</td> <td>64</td> <td>0.25 to 16</td> <td>2</td> <td>4</td> </tr> <tr> <td rowspan=\"6\"><em>Saccharomyces cerevisiae</em> </td> <td>Amphotericin B<sup>&#182;</sup></td> <td>74</td> <td>0.12 to 2</td> <td>1</td> <td>1</td> </tr> <tr> <td>Flucytosine</td> <td>74</td> <td>0.25 to 32</td> <td>0.25</td> <td>0.25</td> </tr> <tr> <td>Fluconazole</td> <td>74</td> <td>0.12 to 16</td> <td>2</td> <td>8</td> </tr> <tr> <td>Itraconazole</td> <td>74</td> <td>0.015 to 1</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Posaconazole</td> <td>22</td> <td>0.12 to 1</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>Voriconazole</td> <td>17</td> <td>0.007 to 0.5</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td rowspan=\"6\"><em>Blastoschizomyces capitatus</em> </td> <td>Amphotericin B<sup>&#182;</sup></td> <td>23</td> <td>0.06 to 0.25</td> <td>0.12</td> <td>0.12</td> </tr> <tr> <td>Flucytosine</td> <td>23</td> <td>0.12 to 16</td> <td>0.12</td> <td>4</td> </tr> <tr> <td>Fluconazole</td> <td>23</td> <td>1 to 32</td> <td>8</td> <td>8</td> </tr> <tr> <td>Itraconazole</td> <td>23</td> <td>0.3 to 0.5</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Posaconazole</td> <td>25</td> <td>N/A</td> <td>0.12</td> <td>0.25</td> </tr> <tr> <td>Voriconazole</td> <td>23</td> <td>0.03 to 0.5</td> <td>0.25</td> <td>0.25</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.<br />* MIC encompassing 50 percent and 90 percent of isolates tested, respectively.<br />¶&nbsp;Amphotericin B MICs determined by Etest.</div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Pfaller MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6:929.</LI>&#xD;&#xA;<LI>Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.</LI>&#xD;&#xA;<LI>Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43:2163.</LI>&#xD;&#xA;<LI>Arikan S, Hascelik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis 2002; 43:107.</LI>&#xD;&#xA;<LI>Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144.</LI>&#xD;&#xA;<LI>Serena C, Marine M, Pastor FJ, et al. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48:2724.</LI>&#xD;&#xA;<LI>Asada N, Uryu H, Koseki M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39.</LI>&#xD;&#xA;<LI>Diekema DJ, Petroelje B, Hollis RJ, Pfaller MA, Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005; 43:476.</LI>&#xD;&#xA;<LI>Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996; 34:3031.</LI>&#xD;&#xA;<LI>Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233.</LI>&#xD;&#xA;<LI>Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole, and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22:24.</LI>&#xD;&#xA;<LI>Pfaller MA, Diekema DJ, Merz WG. Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens. Curr Fungal Infect Reports 2007; 1:53.</LI>&#xD;&#xA;<LI>Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 2015; 59:666.</LI></OL></div><div id=\"graphicVersion\">Graphic 71985 Version 4.0</div></div></div>"},"71987":{"type":"graphic_diagnosticimage","displayName":"Hydrocarbon aspiration radiogragh","title":"Hydrocarbon aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydrocarbon aspiration</div><div class=\"cntnt\"><img style=\"width:341px; height:360px;\" src=\"images/PEDS/71987_Hydrocarbon_aspiration_radi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child developed right middle lobe and bilateral lower lobe infiltrates within hours of aspiration of paint thinner.</div><div class=\"graphic_reference\">Courtesy of Patricia Primm, MD.</div><div id=\"graphicVersion\">Graphic 71987 Version 2.0</div></div></div>"},"71989":{"type":"graphic_picture","displayName":"Basophilic stippling","title":"Basophilic stippling of red cells in lead poisoning","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basophilic stippling of red cells in lead poisoning</div><div class=\"cntnt\"><img style=\"width:347px; height:283px;\" src=\"images/HEME/71989_Basophilic_stippling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows basophilic stippling in several red cells from a patient with lead poisoning. The granules represent ribosomal precipitates. A similar picture can be seen in a number of other conditions including thalassemia, megaloblastic anemia, sickle cell anemia, and sideroblastic anemia.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 71989 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"71990":{"type":"graphic_picture","displayName":"Pelger-Huet anomaly","title":"Decreased nuclear lobes in myelodysplasia (pseudo Pelger-Huet anomaly)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decreased nuclear lobes in myelodysplasia (pseudo Pelger-Huet anomaly)</div><div class=\"cntnt\"><img style=\"width:356px; height:245px;\" src=\"images/HEME/71990_Pelger_Huet_anomaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with refractory anemia with excess blasts (RAEB) shows a neutrophil with a bilobed pseudo-Pelger-Huet (Pelgeroid) nucleus. The two lobes are connected by a thin strand (arrow) giving a &quot;pince-nez&quot; appearance. These nuclei look identical to the those seen in the inherited Pelger-Huet anomaly. This neutrophil also has markedly reduced granulation, a finding commonly seen in the myelodysplastic syndromes.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 71990 Version 3.0</div></div></div>"},"71995":{"type":"graphic_picture","displayName":"Subcorneal pustular dermatosis close view","title":"Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/71995_Subcorneal_pust_derm_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple flaccid pustules and areas of crusting are present on the skin. The largest lesion has a somewhat annular configuration.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 71995 Version 7.0</div></div></div>"},"71996":{"type":"graphic_picture","displayName":"SGD neutrophil","title":"Neutrophil in a patient with neutrophil-specific granule deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neutrophil in a patient with neutrophil-specific granule deficiency</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/ALLRG/71996_SGD_neutrophil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leukocytes from a SGD patient showing lack of granules and bilobed nucleus.</div><div class=\"graphic_footnotes\">SGD: specific granule deficiency.</div><div class=\"graphic_reference\">Courtesy of Robert L Roberts, MD, PhD.</div><div id=\"graphicVersion\">Graphic 71996 Version 4.0</div></div></div>"},"71997":{"type":"graphic_picture","displayName":"Charcot Leyden crystals","title":"Charcot-Leyden crystals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Charcot-Leyden crystals</div><div class=\"cntnt\"><img style=\"width:397px; height:298px;\" src=\"images/ID/71997_Charcot_Leyden_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Charcot-Leyden crystals as found in sputum from a patient with ascariasis. These crystals, which are found in all eosinophilic parasitic lung infections consist of lysophospholipase, an eosinophil-derived enzyme.</div><div class=\"graphic_reference\">Courtesy of Peter F Weller, MD.</div><div id=\"graphicVersion\">Graphic 71997 Version 2.0</div></div></div>"},"71998":{"type":"graphic_picture","displayName":"Nail psoriasis PI","title":"Psoriasis of the nails","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psoriasis of the nails</div><div class=\"cntnt\"><img style=\"width:262px; height:172px;\" src=\"images/PI/71998_Nail_psoriasis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail psoriasis usually turns nails tan or brown in color. It also causes tiny pits to form on the nails.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 71998 Version 1.0</div></div></div>"},"71999":{"type":"graphic_table","displayName":"Enzymes gluconeogenesis","title":"Clinical and laboratory features of hepatic enzyme deficiencies of gluconeogenesis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory features of hepatic enzyme deficiencies of gluconeogenesis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Enzyme deficiency</td> <td class=\"subtitle1\">Lactic acid</td> <td class=\"subtitle1\">Uric acid</td> <td class=\"subtitle1\">Ketosis</td> <td class=\"subtitle1\">Serum lipids</td> <td class=\"subtitle1\">Response to glucagon</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td rowspan=\"4\">G6P</td> <td rowspan=\"4\">&#8593;</td> <td rowspan=\"4\">&#8593;</td> <td rowspan=\"4\">&#177;</td> <td rowspan=\"4\">&#8593;</td> <td rowspan=\"4\">&#8595;</td> <td>Hepatomegaly</td> </tr> <tr> <td>Neonatal onset</td> </tr> <tr> <td>Severe fasting hypoglycemia</td> </tr> <tr> <td>Some patients have neutropenia, platelet dysfunction, renal disease or hypertension</td> </tr> <tr> <td rowspan=\"6\">F16DP</td> <td rowspan=\"6\">&#8593;</td> <td rowspan=\"6\">&#8593;</td> <td rowspan=\"6\">+</td> <td rowspan=\"6\">&#8593;</td> <td rowspan=\"6\">&#8593;&nbsp;(when fed, not when fasted)</td> <td>Mild/moderate hepatomegaly</td> </tr> <tr> <td>Moderate hypoglycemia</td> </tr> <tr> <td>Onset in infancy</td> </tr> <tr> <td>Muscular weakness</td> </tr> <tr> <td>Failure to thrive</td> </tr> <tr> <td>Hyperalaninemia</td> </tr> <tr> <td rowspan=\"5\">PEPCK</td> <td rowspan=\"5\">&#8593;</td> <td rowspan=\"5\">Normal</td> <td rowspan=\"5\">&#177;</td> <td rowspan=\"5\">&#8593;</td> <td rowspan=\"5\">&#8595;</td> <td>Onset in infancy</td> </tr> <tr> <td>Severe hypoglycemia</td> </tr> <tr> <td>Elevated transaminases</td> </tr> <tr> <td>Coagulation abnormalities</td> </tr> <tr> <td>Fatty liver, fatty kidneys</td> </tr> <tr> <td rowspan=\"4\">PC </td> <td rowspan=\"4\">&#8593;</td> <td rowspan=\"4\">Normal</td> <td rowspan=\"4\">+</td> <td rowspan=\"4\">Normal or &#8593;</td> <td rowspan=\"4\">&#8595;</td> <td>Onset in infancy, with early death</td> </tr> <tr> <td>Mild hypoglycemia</td> </tr> <tr> <td>Severe mental retardation</td> </tr> <tr> <td>Subacute necrotizing encephalopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G6P: glucose 6 phosphatase; F16DP: fructose 1, 6, diphosphatase; PEPCK: phospholenol pyruvate carboxykinase; PC: pyruvate carboxylase; ↑: increased; ↓: decreased; +: present; ±: may or may not be present.</div><div id=\"graphicVersion\">Graphic 71999 Version 2.0</div></div></div>"}};